%PDF-1.4%‚„œ”
83 0 obj
<</Metadata 85 0 R/PageLabels 25 0 R/Pages 79 0 R/Type/Catalog>>
endobj
85 0 obj
<</Length 1664/Subtype/XML/Type/Metadata>>stream
<?xpacket begin="Ôªø" id="W5M0MpCehiHzreSzNTczkc9d"?>
<x:xmpmeta xmlns:x="adobe:ns:meta/" x:xmptk="Adobe XMP Core 4.2.1-c043 52.389687, 2009/06/02-13:20:35        ">
   <rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
      <rdf:Description rdf:about=""
            xmlns:xmp="http://ns.adobe.com/xap/1.0/">
         <xmp:CreateDate>2009-01-30T16:30:19Z</xmp:CreateDate>
         <xmp:CreatorTool>QuarkXPress(tm) 6.52</xmp:CreatorTool>
         <xmp:ModifyDate>2014-08-25T20:16:11-07:00</xmp:ModifyDate>
         <xmp:MetadataDate>2014-08-25T20:16:11-07:00</xmp:MetadataDate>
      </rdf:Description>
      <rdf:Description rdf:about=""
            xmlns:pdf="http://ns.adobe.com/pdf/1.3/">
         <pdf:Producer>QuarkXPress(tm) 6.52</pdf:Producer>
      </rdf:Description>
      <rdf:Description rdf:about=""
            xmlns:dc="http://purl.org/dc/elements/1.1/">
         <dc:format>application/pdf</dc:format>
         <dc:title>
            <rdf:Alt>
               <rdf:li xml:lang="x-default">Layout 1</rdf:li>
            </rdf:Alt>
         </dc:title>
      </rdf:Description>
      <rdf:Description rdf:about=""
            xmlns:pdfx="http://ns.adobe.com/pdfx/1.3/">
         <pdfx:XPressPrivate>%%DocumentProcessColors: Black&#xA;%%EndComments</pdfx:XPressPrivate>
      </rdf:Description>
      <rdf:Description rdf:about=""
            xmlns:xmpMM="http://ns.adobe.com/xap/1.0/mm/">
         <xmpMM:DocumentID>uuid:72dfcc25-1dd2-11b2-0a00-eb09276dce00</xmpMM:DocumentID>
         <xmpMM:InstanceID>uuid:72dfcc29-1dd2-11b2-0a00-0ef600000000</xmpMM:InstanceID>
      </rdf:Description>
   </rdf:RDF>
</x:xmpmeta>
<?xpacket end="r"?>
endstream
endobj
25 0 obj
<</Nums[0<</S/D/St 251>>]>>
endobj
79 0 obj
<</Count 8/Kids[72 0 R 80 0 R]/Type/Pages>>
endobj
72 0 obj
<</Count 6/Kids[73 0 R 74 0 R 75 0 R 76 0 R 77 0 R 78 0 R]/Parent 79 0 R/Type/Pages>>
endobj
80 0 obj
<</Count 2/Kids[81 0 R 82 0 R]/Parent 79 0 R/Type/Pages>>
endobj
81 0 obj
<</Annots 86 0 R/Contents 87 0 R/MediaBox[0 0 612 792]/Parent 80 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 88 0 R/GS2 89 0 R>>/Font<</T1_0 33 0 R/T1_1 53 0 R/T1_2 29 0 R/T1_3 69 0 R/T1_4 41 0 R/T1_5 45 0 R/T1_6 37 0 R/T1_7 90 0 R>>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
82 0 obj
<</Annots 91 0 R/Contents 92 0 R/MediaBox[0 0 612 792]/Parent 80 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 93 0 R/GS2 94 0 R>>/Font<</T1_0 33 0 R/T1_1 41 0 R/T1_2 37 0 R/T1_3 57 0 R/T1_4 45 0 R/T1_5 69 0 R/T1_6 90 0 R>>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
91 0 obj
[95 0 R]
endobj
92 0 obj
<</Length 12374>>stream
1 g
/GS0 gs
0 792 0 0 re
f
0 0 0 0 k
/GS1 gs
60 162 492 576 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
-0.02 Tc 0.02 Tw 8 0 0 8 60 732.5292 Tm
[(22.)-480 (Parazzini F; Progetto Menopausa Italia Study group. T)35 (rends of deter)-25 (mi)-1 (-)]TJ
-0.00101 Tc 0.00101 Tw 1.6875 -1.25 Td
[(nants of hor)-25 (mone therapy use in Italian women attending menopause)]TJ
-0.0251 Tc 0 -1.25 TD
(c)Tj
-0.02499 Tc 0.013 Tw [(linics, 1997\320)-25 (2003. Menopause 2008;15:164)-75 (-70.)]TJ
0 Tc 0.01801 Tw -1.6875 -1.37499 Td
[(23.)-500 (Faber A, Bouvy ML, Loskamp L, van de Ber)20 (g PB, Egberts TCG, de)]TJ
-0.02499 Tc 0.01199 Tw 1.6875 -1.25 Td
[(Jong-van den Ber)20 (g L)90 (TW)90 (. Dramatic change in prescribing of hor)-25 (mone re-)]TJ
0 Tc 0 Tw T*
(placement therapy in the Netherlands after publication of the Million)Tj
-0.02499 Tc 0.013 Tw T*
[(W)80 (omen Study: a follow-up study)65 (. Br J Clin Phar)-25 (macol 2005;60:641)50 (-7.)]TJ
-0.013 Tc -1.6875 -1.375 Td
[(24.)-487 (W)80 (egienka G, Havstad S, Kelsey JL. Menopausal hor)-25 (mone therapy in a)]TJ
-0.02499 Tc 0.019 Tw 1.6875 -1.25 Td
[(health maintenance or)20 (ganization before and after W)80 (omen\325)55 (s Health Initia-)]TJ
0.013 Tw T*
[(tive hor)-25 (mone trials ter)-25 (mination. J W)80 (omens Health 2006;15:369)-25 (-78.)]TJ
-0.015 Tc 0.015 Tw -1.6875 -1.375 Td
[(25.)-485 (Haas JS, Kaplan CP)110 (, Gerstenber)20 (ger EP)110 (, Kerlikowske K. Changes in the)]TJ
-0.02 Tc 0.02 Tw 1.6875 -1.25 Td
[(use of postmenopausal hor)-25 (mone therapy after the publication of clinical)]TJ
-0.02499 Tc 0.013 Tw T*
[(trial results. Ann Inter)-25 (n Med 2004;140:184)-75 (-)-25 (8.)]TJ
-0.01401 Tc 0.01401 Tw -1.6875 -1.375 Td
[(26.)-486 (Grady D. Management of menopausal symptoms. N Engl J Med 2006;)]TJ
-0.02499 Tc 0 Tw 1.6875 -1.25 Td
[(355:2338)-25 (-)-125 (47.)]TJ
0.01601 Tw -1.6875 -1.375 Td
[(27.)-475 (Kim N, Gross C, Curtis J, et al. The impact of clinical trials on the us\e of)]TJ
-0.006 Tc 0.006 Tw 1.6875 -1.25 Td
[(hor)-25 (mone replacement therapy: a population-based study)65 (. J Gen Inter)-25 (n)]TJ
-0.02499 Tc 0.013 Tw T*
[(Med 2006;20:1026)-25 (-)-25 (31.)]TJ
-0.011 Tc 0.011 Tw -1.6875 -1.375 Td
[(28.)-489 (Modelska K, Cummings S. T)35 (ibolone for postmenopausal women: sys-)]TJ
-0.01401 Tc 0.01401 Tw 1.6875 -1.25 Td
(tematic review of randomized trials. J Clin Endocrinol Metab 2002;87:)Tj
-0.02499 Tc 0 Tw T*
[(16)-25 (-)-25 (23.)]TJ
-0.024 Tc 0.024 Tw -1.6875 -1.375 Td
[(29.)-476 (Cummings SR, Ettinger B, Delmas PD, et al., for the LIFT T)35 (rial Investi-)]TJ
-0.02499 Tc 0.008 Tw 1.6875 -1.25 Td
[(gators. The ef)20 (fects of tibolone in older postmenopausal women. N Engl J)]TJ
0.013 Tw T*
(Med 2008;359:697-708. )Tj
ET
0 0 0 1 K
114 473.029 m
240 473.029 l
S
BT
/T1_0 1 Tf
0.01199 Tw 9 0 0 9 60 448.5293 Tm
[(Uso de T)70 (erapia de Reemplazo Hor)-25 (monal, 1998)-90 (\320)-25 (2007: Impacto)]TJ
0 -1.22222 TD
(Sostenido de los Hallazgos de Iniciativa de Salud de las Mujeres)Tj
ET
BT
/T1_0 1 Tf
0.013 Tw 8 0 0 8 60 423.5293 Tm
[(BG Silver)-25 (man y ES Kokia)]TJ
ET
BT
/T1_1 1 Tf
8 0 0 8 60 407.5293 Tm
(Ann Phar)Tj
0 Tw 3.69799 0 Td
(macother)Tj
ET
BT
/T1_0 1 Tf
8 0 0 8 120.0947 407.5293 Tm
(2009;43:251)Tj
0 Tc 4.7306 0 Td
(-)Tj
-0.02499 Tc [0.3 (8.)]TJ
ET
BT
/T1_0 1 Tf
7.5 0 0 7.5 60 382.0293 Tm
[(EXTRACT)20 (O)]TJ
ET
BT
/T1_2 1 Tf
-0.024 Tc 6 0 0 6 60 368.5293 Tm
(TRASFONDO:)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 100.1778 368.5293 Tm
[(Estudios sobre terapia de reemplazo hor)-25 (monal \(HR)60 (T\) para)]TJ
-4.7268 -1.11764 Td
[(prevenci\227n de enfer)-25 (medad cr\227nica en mujeres postmenop\207usicas)]TJ
0 -1.11764 TD
(sugieren que los riesgos del tratamiento sobrepasan los beneficios. La)Tj
0 -1.11765 TD
(publicaci\227n del estudio Iniciativa de Salud de las Mujeres \(WHI\) en\)Tj
-0.0251 Tc T*
(2002)Tj
-0.02499 Tc 2.13713 0 Td
(provoc\227 un r\207pido descenso en las compras de terapia de)Tj
-2.13713 -1.11764 Td
[(reemplazo hor)-23.9 (monal entre las mujeres norteamericanas.)]TJ
ET
BT
/T1_2 1 Tf
-0.024 Tc 0 Tw 6 0 0 6 60 308.5293 Tm
(OBJETIV)Tj
-0.02299 Tc 4.19462 0 Td
(OS:)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 96.7354 308.5293 Tm
(Examinar el impacto de los hallazgos de WHI sobre patrones)Tj
-4.32181 -1.11764 Td
[(de uso de terapia de reemplazo hor)-25 (monal en mujeres israelitas.)]TJ
ET
BT
/T1_2 1 Tf
-0.0231 Tc 0 Tw 6 0 0 6 60 286.5292 Tm
(M\203T)Tj
-0.02299 Tc 2.1828 0.00001 Td
(ODOS:)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 93.3631 286.5292 Tm
(Comparamos las compras de preparaciones de estr\227geno por)Tj
-3.92507 -1.11764 Td
[(miembros femeninos de or)20 (ganizaciones de mantenimiento de la salud)]TJ
0 -1.11764 TD
[(\(HMO\) de 45 a\226os o m\207s desde 1998)-90 (\320)-25 (2007 con datos sobre membres\222a.)]TJ
0 -1.11765 TD
(Para cada a\226o calculamos el total de compras anuales y la tasa de)Tj
0 -1.11764 TD
[(utilizaci\227n de terapia de reemplazo hor)-25 (monal, caracterizamos las)]TJ
T*
(usuarias nuevas por edad y modalidad terap\216utica, y examinamos los)Tj
0 -1.11765 TD
(cambios entre modalidades terap\216uticas.)Tj
ET
BT
/T1_2 1 Tf
-0.024 Tc 0 Tw 6 0 0 6 60 217.0293 Tm
[(RESUL)91 (T)75 (ADOS:)]TJ
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 102.0434 217.0293 Tm
[(V)110 (einte por ciento de las mujeres de 45 a\226os o m\207s)]TJ
-4.94628 -1.11764 Td
(compraron estr\227genos en 2001, comparado con 10% en 2007 \(p <)Tj
0 Tw T*
(0.001, )Tj
ET
BT
/T1_3 1 Tf
0 Tc 8.5 0 0 8.5 81.9937 198.0293 Tm
(c)Tj
ET
BT
/T1_2 1 Tf
5 0 0 5 86.4462 200.7793 Tm
(2)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 88.8212 198.0293 Tm
(\). Los productos vaginales presentaron un aumento en el)Tj
-3.39073 -1.11764 Td
(porcentaje de compras, de 5% en 1999 a 18% en 2007. Un porcentaje)Tj
0 -1.11764 TD
(creciente de usuarias nuevas de 55 a\226os o m\207s comenzaron con un)Tj
0 -1.11765 TD
(producto vaginal \(62% en 1999, 82% en 2007\). Despu\216s de 2002, las)Tj
-0.0251 Tc 30.35294 66.19508 Td
(u)Tj
-0.02499 Tc (suarias nuevas de terapia oral la descontinuaron m\207s r\207pido que)Tj
-0.00001 -1.11765 Td
[(anterior)-25 (mente. Se atribuye a T)35 (ibolona el porcentaje creciente de)]TJ
0 -1.11764 TD
(medicamentos orales comprados \(12% en 2003, 29% en 2007\).)Tj
ET
BT
/T1_2 1 Tf
-0.024 Tc 0 Tw 6 0 0 6 318 700.6874 Tm
(CONCLUSIONES:)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 368.0652 700.6874 Tm
(Documentamos el impacto r\207pido y sostenido de los)Tj
-5.89002 -1.11764 Td
[(resultados de WHI en la utilizaci\227n de terapia de reemplazo hor)-25 (monal)]TJ
T*
(en una poblaci\227n grande de mujeres israelitas, incluyendo una ca\222d\a)Tj
0 -1.11765 TD
[(marcada en la tasa de uso, particular)-25 (mente de preparaciones orales,)]TJ
-0.0251 Tc 0 -1.11764 TD
(d)Tj
-0.02499 Tc (uraci\227n reducida de la terapia y aumento en uso de preparaciones)Tj
-0.00001 -1.11765 Td
[(vaginales y T)35 (ibolona como primeras selecciones para tratamiento.)]TJ
ET
BT
/T1_0 1 Tf
0.013 Tw 8 0 0 8 468.2831 636.6873 Tm
[(T)35 (raducido por Ana E V\216lez)]TJ
ET
BT
/T1_0 1 Tf
0.01199 Tw 9 0 0 9 318 610.6874 Tm
[(L)90 (\325Utilisation d\325Hor)-25 (monoth\216rapie Substitutive, 1998)-90 (\320)-24 (2007: Impact)]TJ
0 -1.22222 TD
(Prolong\216 des R\216sultats de l\325Initiative Pour la Sant\216 des Fem\mes )Tj
ET
BT
/T1_0 1 Tf
0.013 Tw 8 0 0 8 318 585.6874 Tm
[(BG Silver)-25 (man et ES Kokia)]TJ
ET
BT
/T1_1 1 Tf
8 0 0 8 318 569.6874 Tm
[(Ann Phar)-25 (macother)]TJ
ET
BT
/T1_0 1 Tf
0 Tw 8 0 0 8 378.0947 569.6874 Tm
[(2009;43:251)50 (-)-25 (8.)]TJ
ET
BT
/T1_0 1 Tf
7.5 0 0 7.5 318 544.1874 Tm
(R\203SUM\203)Tj
ET
BT
/T1_2 1 Tf
-0.024 Tc 6 0 0 6 318 530.6874 Tm
(INTRODUCTION:)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 368.0593 530.6874 Tm
[(Les \216tudes portant sur l\325hor)-25 (monoth\216rapie substitutive)]TJ
-5.88933 -1.11764 Td
(\(HTS\) dans le but de pr\216venir certaines complications chez les femm\es)Tj
0 -1.11764 TD
(m\216nopaus\216es, sugg\217rent que les risques sont sup\216rieurs aux b\\216n\216fices.)Tj
0 -1.11765 TD
(La publication des r\216sultats de l\325Initiative pour la Sant\216 des \Femmes)Tj
0 -1.11764 TD
(\(ISF\) en 2002 entra\224na un rapide d\216clin des ventes de ces produi\ts aux)Tj
0 Tw 0 -1.11765 TD
(\203tats-Unis. )Tj
ET
BT
/T1_2 1 Tf
-0.024 Tc 6 0 0 6 318 470.6874 Tm
(OBJECTIFS:)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 353.8536 470.6874 Tm
(Examiner l\325impact des r\216sultats de l\325ISF sur l\325utilisation)Tj
-4.21807 -1.11765 Td
(d\325HTS par les femmes Isra\216liennes.)Tj
ET
BT
/T1_2 1 Tf
-0.024 Tc 0 Tw 6 0 0 6 318 448.6874 Tm
(D)Tj
0.013 Tw [(EVIS EXP\203RIMENT)76 (AL:)]TJ
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 387.6205 448.6874 Tm
(Nous avons analys\216 les achats de pr\216parations)Tj
-8.19065 -1.11764 Td
(d\325estrog\217nes pour la p\216riode de 1998)Tj
0 Tc 14.05162 0 Td
(\320)Tj
-0.02499 Tc [0.1 (2007 par les femmes de 45 ans et)]TJ
-14.05163 -1.11766 Td
[(plus, membres d\325une or)20 (ganisation de gestion des soins de la sant\216, et)]TJ
T*
(reli\216 ces \210 achats \210 l\325ensemble de la population membre de)Tj
0 -1.11764 TD
[(l\325or)20 (ganisation. Pour chaque ann\216e, nous avons calcul\216 le total des ach\ats)]TJ
0 -1.11765 TD
(et le taux d\325utilisation d\325HTS. Nous avons caract\216ris\216 les n\ouvelles)Tj
T*
(utilisatrices selon leur \211ge et le type de traitement et avons examin\\216 les)Tj
0 -1.11764 TD
(changements de th\216rapies. )Tj
ET
BT
/T1_2 1 Tf
-0.024 Tc 0 Tw 6 0 0 6 318 369.6874 Tm
[(R\203SUL)91 (T)75 (A)76 (TS:)]TJ
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 354.7457 369.6874 Tm
[(V)60 (ingt pourcent des femmes de 45 ans et plus ont achet\216 des)]TJ
-4.32302 -1.11765 Td
(estrog\217nes en 2001, contre 10% en 2007 \(p < 0.001, )Tj
ET
BT
/T1_3 1 Tf
0 Tc 0 Tw 8.5 0 0 8.5 487.4508 360.1874 Tm
(c)Tj
ET
BT
/T1_2 1 Tf
5 0 0 5 491.9033 362.9374 Tm
(2)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 494.2783 360.1874 Tm
[(\). L)90 (\325utilisation de)]TJ
-20.73862 -1.11764 Td
(produits pour administration vaginale a augment\216 de 5% en 1999 \210 1\8%)Tj
0 -1.11765 TD
(en 2007. Une proportion plus grande d\325utilisatrices de 55 ans et plus\ ont)Tj
0 -1.11764 TD
(d\216but\216 la th\216rapie par un produit pour administration vaginale \\(62% en)Tj
T*
(1999, 82% en 2007\). Apr\217s 2002, les nouvelles utilisatrices de th\216\rapie)Tj
0 -1.11765 TD
[(orale ont cess\216 la th\216rapie plus rapidement qu\325avant. Par)-23 (mis les produits)]TJ
T*
(oraux, la tibolone est plus utilis\216e qu\325avant \(12% en 2003, 29% e\n)Tj
0 Tw T*
(2007\). )Tj
ET
BT
/T1_2 1 Tf
-0.024 Tc 6 0 0 6 318 281.1874 Tm
(CONCLUSIONS:)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.01199 Tw 8.5 0 0 8.5 364.2133 281.1874 Tm
[(Nous avons document\216 un ef)19.8 (fet rapide et prolong\216 des)]TJ
-5.43685 -1.11765 Td
[(r\216sultats de l\325ISF sur l\325utilisation d\325HTS chez une lar)20 (ge population de)]TJ
0 -1.11764 TD
(femmes Isra\216liennes. Les observations incluent une baisse importante \du)Tj
T*
(taux d\325utilisation, en particulier des pr\216parations orales, une r\216\duction de)Tj
0 -1.11765 TD
(la dur\216e de traitement, et une augmentation de l\325utilisation de pr\oduits)Tj
0 -1.11764 TD
(pour administration vaginale et de tibolone comme premier choix de)Tj
0 Tw T*
(traitement.)Tj
ET
BT
/T1_0 1 Tf
0.013 Tw 8 0 0 8 462.5398 207.6874 Tm
[(T)35 (raduit par Suzanne Laplante )]TJ
ET
0 0 0 0 k
60.5 17.75 378.5 13 re
f
BT
0 0 0 1 k
/T1_2 1 Tf
-0.024 Tc 0 Tw 10 0 0 10 60.5 23.9116 Tm
(258)Tj
ET
BT
/T1_4 1 Tf
0 Tc 5 0 0 5 84.2499 25.4116 Tm
(n)Tj
ET
BT
/T1_1 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 97.431 23.9116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_4 1 Tf
0 Tc 0 Tw 5 0 0 5 230.556 25.4116 Tm
(n)Tj
ET
BT
/T1_1 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 243.737 23.9116 Tm
[(2009 February)55 (, V)110 (olume 43)]TJ
ET
0 0 0 0 k
472.5 17.5 79.5 13 re
f
BT
0 0 0 1 k
/T1_1 1 Tf
0 Tw 10 0 0 10 476.2004 23.6616 Tm
[(www)75.3 (.theannals.com)]TJ
ET
0 0 0 0 k
60 745 234 10 re
f
BT
0 0 0 1 k
/T1_5 1 Tf
0 Tc -0.013 Tw 8 0 0 8 60 749.5293 Tm
[(BG)-250 (Silver)-25 (man and ES Kokia)]TJ
ET
BT
0 g
/GS2 gs
/T1_6 1 Tf
0 Tw 5 0 0 5 285.1575 11 Tm
( at University of Canterbury Library on August 25, 2014)Tj
0 0 1 rg
/GS2 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS2 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
33 0 obj
<</BaseFont/CMRXZL+Times-Roman/Encoding 30 0 R/FirstChar 32/FontDescriptor 32 0 R/LastChar 213/Subtype/Type1/Type/Font/Widths[250 0 0 0 0 833 0 0 333 333 0 0 250 333 250 278 500 500 500 500 500 500 500 500 500 500 278 278 564 564 0 0 0 722 667 667 722 611 556 722 722 333 389 722 611 889 722 722 556 0 667 556 611 722 722 944 722 722 611 0 0 0 0 0 0 444 500 444 500 444 333 500 500 278 278 500 278 778 500 500 500 500 333 389 278 500 500 722 500 500 444 0 0 0 0 0 0 0 0 611 0 0 0 444 444 444 0 0 0 0 444 444 0 0 278 0 278 0 500 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 500 1000 0 0 0 333]>>
endobj
41 0 obj
<</BaseFont/IUQKRZ+Times-Italic/Encoding 38 0 R/FirstChar 32/FontDescriptor 40 0 R/LastChar 121/Subtype/Type1/Type/Font/Widths[250 0 0 0 0 0 0 0 0 0 0 0 250 0 250 0 500 0 500 500 500 0 0 0 0 500 0 0 0 0 0 0 0 611 0 0 0 0 611 0 0 0 0 0 0 0 0 0 611 0 0 0 556 0 611 0 0 0 0 0 0 0 0 0 0 500 500 444 0 444 278 0 500 0 0 0 278 722 500 500 500 0 389 389 278 500 0 667 0 444]>>
endobj
37 0 obj
<</BaseFont/QNCLNF+Times-Bold/Encoding 34 0 R/FirstChar 32/FontDescriptor 36 0 R/LastChar 131/Subtype/Type1/Type/Font/Widths[250 0 0 0 0 0 0 0 0 0 0 0 250 332 0 0 499 499 499 499 499 499 499 499 499 499 332 0 0 0 0 0 0 721 666 721 721 666 610 0 0 388 499 0 666 942 721 776 610 0 721 555 666 721 721 0 721 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 666]>>
endobj
57 0 obj
<</BaseFont/DTWGIJ+Symbol/Encoding 54 0 R/FirstChar 32/FontDescriptor 56 0 R/LastChar 99/Subtype/Type1/Type/Font/Widths[250 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 549]>>
endobj
45 0 obj
<</BaseFont/AGFDFE+ZapfDingbatsITC/Encoding 42 0 R/FirstChar 110/FontDescriptor 44 0 R/LastChar 110/Subtype/Type1/Type/Font/Widths[761]>>
endobj
69 0 obj
<</BaseFont/QOFAPH+Times-BoldItalic/Encoding 66 0 R/FirstChar 32/FontDescriptor 68 0 R/LastChar 213/Subtype/Type1/Type/Font/Widths[250 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 667 0 0 667 667 722 778 389 0 667 0 0 0 0 0 0 667 556 611 0 0 889 0 0 0 0 0 0 0 0 0 500 0 444 500 444 333 500 556 278 0 500 278 778 556 500 500 0 389 389 278 556 444 0 0 444 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 333]>>
endobj
90 0 obj
<</BaseFont/Helvetica/Encoding/WinAnsiEncoding/Subtype/Type1/Type/Font>>
endobj
66 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 66/B 69/E/F/G/H/I 75/K 82/R/S/T 87/W 97/a 99/c/d/e/f/g/h/i 107/k/l/m/n/o/p 114/r/s/t/u/v 121/y 213/quoteright]/Type/Encoding>>
endobj
68 0 obj
<</Ascent 700/CapHeight 669/Descent -204/Flags 262242/FontBBox[-200 -216 992 921]/FontFile3 67 0 R/FontName/QOFAPH+Times-BoldItalic/ItalicAngle -11/StemH 0/StemV 79/Type/FontDescriptor/XHeight 685>>
endobj
67 0 obj
<</Length 4152/Length1 4152/Subtype/Type1C>>stream
  QOFAPH+Times-BoldItalic   C¯ ¯¯¯¯Ä˚\˚l˙t˙-
 ãã
 ãã  	    LØ   }éì002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Turku is a trademark of Stream Technologies Inc.Turku Bold ItalicTurku     # ( 4 J M W F S N B O  E & , P L V T U * Q D G I 8  ) ' H 3 5 Z "   Ü~Î4ìˆH˘q‚ÂpˆÇ >ÕCê‹	]	™
6
Ø3`Òq'∞Äúã´˜∆©˜°´r§¯o˜&Ë˜‰¯ÂÆîñî≠√®iK˚!<s˚ÖÉm˜ä∞p:˚J:.`yï£íåêèö˜}˜ú˜®ƒø„È;º˚/˚§¯r√âùÅmÅàzÉn˚¸U}Y{{ZÖr˜¡˜Nˆ÷˜◊g≤)¨”y±˜±§˜‘Ø†˘?˘:˘BntÄ~Ñzl`©4˚5kG>*6R˚˚˚5˜˚˜G“˜ †§Ωßôª˜Hû“êë¡ë§˚≤râòñäë≠áïÇrp_˚?}{y{f_(N—˜˜/Ë˜∫˜SÂ∏P˚é®Ü-y≠˘Æáw˜˜˜¯˜≈¯@Gø}ü∑Õ±≥À‹µY˚ï¶á¯≥˜\nyÅÑu¯]l®ãA˚26!˚?˜â_ã˚!FVVC!^·Òàmåh˚s©ßóííûØ∑hÊ˜‰€˜ﬁi»˚Ì¸óv¯√˜˜˜˜V˘@fmmff©m∞∞©©∞∞m©f®˚r/zÖä#ÅqπäóÖrÜâÑá{S˚lÄbávã|e¶q¥«√∏ÂøuôjWqoxãÉÑíìîäãîÆã»˜z™˜¸óvç˜≥˜µ˘P3ymá1Çq¢≥èjw}\Ñq'˚ˇ}WÑjãzb§sµ‹º÷«≤uöiUqqyãÇÖíïóí¨ö¿˚bìv¯pw„˜ﬁ˜B‘Ë˜~˜^˜U„˜Ê±p™inqqlË_∂~ãijbN6.à˜VÖ√v‡W}rá=Äqõüå{ïörò0â!ããâ˚âM˚b~À˜´˜l¨ê˜#˚#˜˜>ÁÙ˜(˜j˜´æ‡∫ùîu(AM8v˜<CLegocÏ^uß¡úåîê¢Âî˜:Œ˜Ω`ØO˚'˚"˚<˚13 L‚Ÿ¬≥Ìƒ˚ô†v˜◊˜ v¯-˜w¯cQ|âã˚ ~p∂äñÜw}V~]>˚°˜Ω˜2©Î ˆ•ãúìeãÆÆ£©∑¥u§h\`X˚JÜé˜óv©v¯‘äw¯⁄˜h˜}¯aO~~â˚q∑äïÜwÑåÑk˚ãÉkM˚q˜˜˜Ê˜≠ññíÇ|Çâ~Ü|ãG˚oi˚˜∞˜µ˜·˜πãôïÅ~b3˚Oã8Ë_¢vπ«¥≠Ï√uóeQ|z|ãÇÑíì∞„˜LãÁ∫m®YXL`˚?éú∏ê°®¯¥q§b-D˚H]àç˚*ívç—˜ˇµv˜p˜û¯9¢äôxnIH˚å1rx¢™Ã‹˜çﬁÜ˜PØ˚ÖySâ∑Ös£b˚˚)˚R˚3=µ[Œ«∑≠Á√çåÄbâÉã}dßp≥∏Ω∂ﬁ¡vöfWxx|ãÉÜëïßë®ßÁ-óv©v¯bw˜wp˜Ö¯aS~YÑ.Öp†´åoqj äÜãÉlP˚h˜˜Ë‚Ω•òñÇ~i4˚[ã:b£u∏ƒº¥ÂæuòeP}{zäÉÑíï§„˜iã÷Ωp¢X6N/*Jâç¸$˚*”D“˜˝µv˜p˜¢¯9¢öwkbD˚†/rz£ÆÕ€˜Ä‚˜ä˜´FyWÜ4Öp†ßòÇwÑázÖue˚t£wîpã˚
˚/˚S˚1B∏U«ÃπØÊ¿çÇcäÇ{pd°u±ººµﬂΩuõmZwu{äÖäÜëì¢∫˜:î¨úã´˜∆¨˜ü™s£p˘:ÿ˘˘1¸ØsœÇëánáuÖu˚¸V}X}~WÉr¯º«˜WrêK˚+U˚!ã_uñ°ååñâÜõ≈ƒ˜e˜©xD~äàxßÜ‘˜¶qèe6gp˚ë»˜s¯≠îòïÆ˜Ωf#¶Üúã§¯ˇ§v˘e¯¯$˜l˜Y¥∞óë≥è§˚grüâØçpoMStw˚I˚6Üå«˜qôøüö«è§˚ÀrŒÉíàkÄàzÑq˚¸U}X|}XÉr˜µ§Wê}î®ìãëçë ˜Ñìâ˜ ˚zìzêyãÅ|ÅÜTÖr˜¨§hçzïÄ¢˚*}©¯5®à˜˜`˜˜Ø¯b˚'˚˚3˚;5œKÁ˜%˜˜0˜9ËL….Én©äövaBS˚¨+iy°∑÷ø˜≠ˆÜ˚*É—bv¯=§t¯çp˜±˘OB~oá ~p§≤èhÅàzÜz˚0¸À˜Ω˜O≥ß˚1§ÆI…æ´®Èøuñq\{zxã`s˜Hæ ¬œ«ùîºì§˚brµáîá|p`a˚
0äç-óv¯_w´wö¯p–¯{¯V˚
a˚&wUgGfFZXnã}ãÉîãõãñê°ï¨È˜…EÅI|Bâpªáìáu}ÜsÄf_˚+ÇkÖjãxV£s¿¬≥¶ÿ√ìñèë™∂çâ{\Öopc°w∑ƒ≈∫‹∑vòfUxx|ãÅáëò–ôìØöæ˚ôìvå®¯1´äwπÎ¥Í\˜ﬂ¯ao{ÉÖÜ}|nv°ã^:VZ?TônŒ=≥[õmrlrsjYj∫·~qé¸u˚:•ôììëô|°§xã∑‰»¬Ÿı˚‹ã“ßü¢´∏©c<ò\¶à¸óv¯4∂Ä˜∑˜ã¯ÁhZ>^f2dhæL˚pÇmxFãn`•r∏≈ª≥Î∆uôgStsyãÉÑíìöìØú»»˜oﬁ∂C˚ôã£˘ §k¯H˜õ£Sè|îßôãìô¿ãí¢˜¯.ôæ†ù∫ç§˚ΩrÃÑîÜr~ÜqÜx˚¸W}X{|ZÑr˜ª˚*˚`•˜:Æ¯”˜‘˜˜k¯c*{£é˚|pπäìáwÅÑnÉj˚¸>~X}Ä_äq˜å•Xå}í•ß•Ÿï∫{´õÜ°˜˜"˜J˜<Ÿb∫IZ\p;RâèÔ™£ôxlAD˚à*uzõ†¨¥˜ô¥€ß∫∏≤˚b~Ã¯¨Ü˜˜)˜˜—˜!GYov`_nØƒœƒ˜mÂôîÑÇ}vzãpm§t™≤£¶∂¬^ÆE˚˚%˚:˚//…LÁ◊º≠Ò“˚—˚`˜˚™¯Ÿµ˜˜Çv˜˜	˚˜™˜Ä¯Vù“§Ï©æ≠ãóëáÉÄ{Åãw≤o†u¶©††´ªd´Q˚ @8˚:_BÉaÙ‘|NÑmáwM˚≠,v~-SÄÉêëîõìã§¥ßwûmoutn\≥k≈˜=Ω˜f¯&‹‰îµ-óv©v¯bw˜Ù˜p˜π˘O.zná6Çq£≤èhÅâ}Öv˚.¸À˜¶Ïß›°∏∏Ë ”ØãôãîÖã{ãa3˚Sã8h¶r∞·¥‘…µvõeSrp}ãÉÑíìùÂ˜ã»∏n®^GT^˚4âå˜Éév˘*§Ã˘ˇ¯Œy˜≥¯„§øúô¥ê§˚OræâóÑm{àÅr˚.˚Ÿâj˜πà¶à©ãô±ìí¡ë§˚†r√ÜöwE˚(˚»äc˜ÓäëãëãëÆöó∏è§˚®r ÑêÖïE⁄¸◊®˜y¯{å«¸{˚—†v˘Aw˜j‡˜¯˜πŸÂﬂ√h≤Ybnl`L—êãafZ[Fl˜ã§˜ƒ∑˜£§s˘…˘$§Vvóßòåêó∑ã€˜Ω¥˜)ôøöóøí§˚ær ÑñÜr~árÖu\˚B˚É¡˜\ö¬¢ö…å§˚œr ÑïÖpÄáuÑs˚¸U}W}WÇr˜ª§gègÖºôçïö¿Ω˜H˜ÇK˚||TzFÜr˜—úã§˜Õ¨˜û´s£~˘3ÿ˘&˘1¸ßsÕÇíár|ásÖu˚¸U~[|}WÅr˜ª§Tê{î®öçåô¿¿˜]ıä©xãGäàußÜ’˜•oè\0s}˚ã{«˜r¯Øïñì∑»Ω~sß¶sîpK•Ö˚*˚_≠˜Kv˜4´˜ã™W‚ã˜˜˜ @˜	ˆ˜ÑùÿoÇù•~öwt`_qEC^©ª∑»≥õı˜!¯K®útcWi˚En|ü±æ¨˜–˙˚C¸>+uipSN◊`˜ ˜&Î«Ê«g¨˚™VöiïyôãõõúùòöôÉã†ı˜Í⁄ÌúäíáûŒ√˚•ikìa˚$9*V¶d¿v9]}}emùw¥|úã§¯¯´r§n˘¯A˜Î√ó¶ï´°∫¨©¡ãæãÏ>∫˚3ã˚¶rŒÇëàr}áqÖw˚¸U}W}WÇr˜º§Qê|ì®ôê£î´¬˜Vß˜ ˚ﬂ˜^§Uç}ów≈˚I¯ÑØîîì™√¨iO:bFPysÑjábädã§¯ıÆi≠Ω¯Î˘˘1¸∫e˚?§ÑπÏ…¥˜ë˚'¸Ø|UrzIãr˜ﬂ§CéÄë™òê®ë†˜¯éÓÜ™hì˚¶â˚b˚a‹:˜¯ªw†wÙ˜∑˜KÀ™ò¯0µñâ˚T≤•˚ïJjWQIjÍqmÆãgntsli¶p∞„‰„˜Eı‚˜&æ˜ÕΩiûmÏnqpk˙V¬èãb]I˚ygâ~‘w˜w‰rŸK|vàJÑxû¯Vò˜bõöã˜úñ¸vé§
⁄å
_˜é˘
endstream
endobj
42 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[110/a73]/Type/Encoding>>
endobj
44 0 obj
<</Ascent 1667/CapHeight 1667/Descent -293/Flags 4/FontBBox[0 -143 976 814]/FontFile3 43 0 R/FontName/AGFDFE+ZapfDingbatsITC/ItalicAngle 0/StemH 0/StemV 0/Type/FontDescriptor/XHeight 0>>
endobj
43 0 obj
<</Length 178/Length1 178/Subtype/Type1C>>stream
  AGFDFE+ZapfDingbatsITC   6ã˚πœÉ
 à?ãã
 à?ãã   h   e   kë   ¨ a73    á %<¯
˙0˚π…˝Ã˘7˘Ã˝YV¯Á˙¸Á‰˙!—ç˙s˙sçç¯Õ˘
endstream
endobj
54 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 99/chi]/Type/Encoding>>
endobj
56 0 obj
<</Ascent 921/CapHeight 671/Descent -223/Flags 4/FontBBox[-180 -292 1090 1005]/FontFile3 55 0 R/FontName/DTWGIJ+Symbol/ItalicAngle 0/StemH 0/StemV 41/Type/FontDescriptor/XHeight 684>>
endobj
55 0 obj
<</Length 472/Length1 472/Subtype/Type1C>>stream
  DTWGIJ+Symbol   F¯ ¯¯¯¯)¡˚H˚∏˙÷˙Å
 ãã
 ãã      ™  π éïchigreaterequal002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Simpele is a trademark of Stream Technologies Inc.Simpele   á à wz¶&˚|‰¯≈€ó¯è¯õYxKypn`Svµ˜b[˜a¯	$˚˚Üe˜:~√c≥_ãXcQ6Ügúœõ£™±∂´gMö´˚˚m¸&Ô˜)˜ßí]ïLërñZïkóuõl¨u©ãŒã≥«õ˜¸$&ã√®¯É¯†˜Ó ¸É˜xM¯E˚Z¸E˚ZN¯É˚
√¸ÉSs£¯Üç˜?ò˜Åã˚véØ
¥
_˜é˘
endstream
endobj
34 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 44/comma/hyphen 48/zero/one/two/three/four/five/six/seven/eight/nine/colon 65/A/B/C/D/E/F 73/I/J 76/L/M/N/O/P 82/R/S/T/U/V 88/X 131/Eacute]/Type/Encoding>>
endobj
36 0 obj
<</Ascent 912/CapHeight 676/Descent -203/Flags 262178/FontBBox[-168 -218 998 934]/FontFile3 35 0 R/FontName/QNCLNF+Times-Bold/ItalicAngle 0/StemH 0/StemV 25/Type/FontDescriptor/XHeight 921>>
endobj
35 0 obj
<</Length 3520/Length1 3520/Subtype/Type1C>>stream
  QNCLNF+Times-Bold   @¯ ¯¯¯¯˚<˚n˙z˙:
 ãã
 ãã   ˘   ı  >∞  õ }áå002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Turku is a trademark of Stream Technologies Inc.Turku BoldTurku  !               5 3 " 4 ' 0 / %  # + & * 7 . ≤ 6 - $ 9 1 #   < | ”C]ª&R›CêÁÍ7´çÙHßB«â¡		á

t
ª ©˚+ã§˘+w˜O˜&¯N§1çxõ◊¯Õz˚è˚q†ƒôèô§óu\¸:wz(är¸$öv£v≤˜L‡˜sµÕ`∫O[jj[[©k∑‡ííéãìóìÇ}fkd>Sñt…∞¢û¶©¨±†æª˚+ã˜¯M˜˜Ω˜¯q˜hrEo|Ç(˚*˜3˜.ﬁ€´«ã÷˜@◊˚*DI˚Y¶ƒ•∂´ø–ºV@YwSaN^K]U˚˚s¯3˚+}˜(˚(Ω¯œ€˜≠˜&@˜®¯f˜ã‹b«:Ø∞À±û©«ﬁMø(&@Y$U†Æ«∞§¿ã«≤bMIig,mxË˜ `«P+EdZT®DqÌã7iprlS«gÈ˜9˜˜˜&˚“†v˜@˜∑˜Ü˜≤˜@˜˚Ü˚˚+É«O˜(˜S˜‹˜¯	ÿ∏¯i˘8˚’+˚Ì˜
Å∫ÉªuŒm¥VTU^\X¯DZ„ãBgqrhV»hÂ˜4˜	˜‹fÕH≥V´eì˚î°‹˜©˚+~¶˜˛π˜Ñ•ß¯R¯n˜p˜Aﬁ˚ kxá}e≥˜*—–˜/≤•˚®j˚8˚/˚w˚BÊ˚˜"˜ÊÓ˜˚-K˚nZuyñ°Ä|¶Ç⁄Âµç®ë∫íå†ìùÃ¢Q˚6˚+†v¯Ø˜ú¯^¯o˘8¸3`˚r§Àú£†√˜b˚Z¸ØÍ˚+~™˘ßß˜˚˜˜9˜˚˜
ÿ¯j˜M„b«˚“‘‚£ºΩÃ„A√˚
˚ 6H˚A≥UÔPË"l]X5&·H˜˜Á⁄˜‘˚˜ÙaÇgjeR®Cƒ“∂±±∑¬≠]?ËÖ¸+Gi_XOe¡‡≈ï™≥∆˜C£kD˚+~•˜Ñπ˜˝¶•¯R¯l¯&˜>.˜˚˚1*˚˚’9ˆ∞£êô®]˚0DD˚(kq˜ù§˜C˜8˜v˚1¶häoÉSÜsÖxMt≈˜5˜ó®ª°ùÅxïõoñ62˚+~ß˘ß£¯V¯n˜ﬂ˜b,˜*˚˚,˚+˚a˚ZÎ˚&˜˜Î˜&˜Z˚2˚ ˚'wN\\w»˜'˜y˜&ü»∫∫üN˚&˚+†v˜#˜¯Ew˜ù˜&˚$˜$Ë¯m˜#˜M¯E;dYk_xr˚˚4êë#˚2˚˜ä˚#˜&˜#Ë˚$˜˚c˜a˜ªËç¸$õã§¯ˇ´¨¶˜U˜6˜T¶˘¯oà˜]¸Íá˚]®°˜±≠˜î¸£BÄ6Ñr˜¯§7ê}ò’¯£˜Äæoû˚“ã§¯˛¨r§˜˜5˜K˜>¯˘]§tçÇèÇò˚]˜≤˜∞∂πﬂ˜
,»˚O˚”r‘áô{D¸NBÉÇ<Är˜Â§@ï}ö–˜V•˜c˚ÕY¯à˚dj˚$ä˜î¯´öï∫ﬁ±^)“ã§˜@≤¯Zwî˘9˘B£]èÅóW˜˚s¯¢n˚p¸∏e.ÇYr˜_§Oètó§öò±´Ÿ˜sßQûRt~ÉÅ|àÄàéãYÜrû˜Ä˚VË˜á,x≠v˘:´Æ®w˜˜Ö˜
Ï¯î˜SŸa—G≠˚'÷9µw†ãº»∂≤ Á—I˚≠ß˜mmoÉÖÖxgg≠1˚7<˚1ºO˜PÕlÁ_†rãTHY_?Ù$Bÿ˜on˚å®Ï¢êîïõ≠±iÌ˜(Ô‡˜cã§˜ƒ¨˜≠¨r§Ú˜5˜.§˜£ﬁ¯Ÿ¯o˜]¸…r–áù}W¸zY}CÉr˜˚§2éuô¿˜~ıà¨iô˚	§˜Êrx˚	jk&â˜~˛≤óì«˜#∆\˚ù˜x¨˘¨Æ˘V˘y˜„˜d˚'˜(˚b˚b˚'˚(˚d˚b˜(˚(˜a˜a˜(˜(˜b˚Eå˚hO˚˚˚	P˜˜h˜_À˜˜˜Ã˚˚_“évù§˘§Ú∂¯B∑¯˘N˘§˚kr’ÑûvD˚√â˚Ó¯?˚fr£áô∫S¸oT|}CÅr˜v§>ïxüœ¯%ç¯¯Q¸≤¶¯·ƒòôÃî“ã§rÆ¯Û≠r§Î˜6˜ï˜A‹˘D˜Î˜e˚˜˚}˚√rÃÖú}\¸Å^vzNár˜Œ˜p˜ ˜˜f¸˚A{˚VH)˚a|ö∂¯ä∞òïª˜“˚˚]˚“ìv¯yw›˜<˜é¯πf±]\ee]\±e∫π∞±∫˚—∫f±]\ee\]±e∫π∞±πõã§r´˜ °˜Æ©r§Ú˜3˜L˜?Æ¯˝˜NÂH ˚£ç˜∞≤∞ÿÚ/ƒ˚;˚«rŒàüzX¸yXÅ@Çr˜’˜?˜”˜˛˚[˜Ÿ˚ lp˚à˜tÆöô±—¨`/ß˚›&cZ8`yù∂˜ç©ÙºX˚˚+,¨˘]§é˜"›˜5¯p˘§˚Ûr‹â†}U¸¿Myr_qvòù£¶îã´≤iÆddmj`D’SÍ˜#‘‘˜&¯H‘õõ”çõã™l§˜ƒ¨˜≠¨r§Ú˜5˜6•˜§∑˘˜dp˚QBZ˚Kwòµ˜á˜
Ñ©nô˚•˜Áqz˚kn˚à˜}¥óíœ˜#ƒ`˚†§˜\¸“ˇr–Öù|Y¸wW~ÄAÇr¯€˚öã§˘§˜˜4¯§BétúΩ¯x¿¢ù‘å§˚Òr“â°zV¸xZuzDár“çv˘2§õ˘?˘O˘§˚hr´à¡åa{àÅz]˚˚‹˚˜–pÃàîãõßòë‘è§˚„rΩÇóÅ°X˜î¸Ï¶˜v¯ﬂ£…óñ¡ï˜∏ã§˘§s£Ûµ¯¶˜.¯˙+§<ïÅñ“¯O”ôö‘ê£˚è˚[¸l˚\¯l˚è¯r’ÉôÅW¸pOÄÇ<Är˜~§7ìyù‘¯fç˜é¸‚¶˜ç¯Òç¸çS}@Ñrõ†v˘Mv¯X˜˘˜dd˚d¸€§’îòñø¯wΩyöFë§¯“˚\r˜vR∂˚#GÑb˚}˜é´®ú˜•˚Áq}˜m®˚
í˚áaü~À˜‘º˜≈˚˘1vÅ~mx˚#4T˜˜0õùûïüã§üws“xº˘§Ì˜2˜’∑˘O˘§˚pr€ÉùyB˚ƒ˚*TG˚(]…˜˜·÷úõ€å§˚ÂrÕÜõyF˚·/ù\ø`aºœv‡◊€©∂≤Ø≥üœ·˜”∆ôõÀîõã™l§˘§Û˜6˘˜xn˚*KO\˚Dxó∏¯lÿôó‚ç§˚rŒáù|X¸yXÇÉ?r¯’“y∫˘	≠áwº˜E˚E˘`§Ù˘A˜m§;4Ig;ã˚IÒ˜a˜k»ˆ˜Á€E˚«§Ù˜~pk~}yËoBΩã#˚V˚)˚0˚`˚d˜%˚"˜j˜ŒÆ˜Ó“ã§˘§õ˘<˘L§[çq∫t∞˚I˜Ø˜9˜uéúÌö§˚årÃÜíÑrráÅ˚˚(*˜+ÄùÜñãïüóëœè§˚Ìr∞àñÇ™^˜Z˚∏˚B˚qrkt~TÄr˜ç§Pëuñå§å¢£∑Õ‚≤ΩÒ˚6ôuíxãvÅáEÖrcã§˜™Æ˜ƒ≠r§Ó˜5˜:˜?‹¯È¯Å˜0À˚>˚”rŒÑö{G¸N=záIÄr˜·§>îó”˜M∞ˆ¬ñ¶ª≈≠´¡À˚?à˚gj˚˜†¸•õï±Ÿ≠]!xû¯aó˜_õ˜pî˜üì¸ué§
§å
_˜é˘
endstream
endobj
38 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 44/comma 46/period 48/zero 50/two/three/four 57/nine 65/A 70/F 80/P 84/T 86/V 97/a/b/c 101/e/f 104/h 108/l/m/n/o/p 114/r/s/t/u 119/w 121/y]/Type/Encoding>>
endobj
40 0 obj
<</Ascent 684/CapHeight 654/Descent -205/Flags 98/FontBBox[-169 -217 1009 884]/FontFile3 39 0 R/FontName/IUQKRZ+Times-Italic/ItalicAngle -11/StemH 0/StemV 23/Type/FontDescriptor/XHeight 677>>
endobj
39 0 obj
<</Length 3543/Length1 3543/Subtype/Type1C>>stream
  IUQKRZ+Times-Italic   C¯ ¯¯¯¯Ä˚=˚m˙Ö˙
 ãã
 ãã      ¸  =¨  ∂ }âé002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Turku is a trademark of Stream Technologies Inc.Turku ItalicTurku    5 I F  " O B M T P G 1 S N D U Q Z    ' C V  7   X     Y ÏLO≥Eø|¡>≥ﬁ+ü ≠Z∆	?	§
4
b
∑
˝n7-†v¯ˇÆ∆¯—˘˘"¸ßa˚.ùá°∫ú§•ü§¨¶ë˜˚#¸•}YszFÑ{˜∂õ9ëÇè´ïë•í•˜ ¯á¡÷®rKÅäÇâxúä˚*óv©v¯Ovû¯]¯pÙó_QvwzãÉÑíïñëôçìƒ˜eïÆë©ãò≤pßfKFM˚#-âç˜
¯KÖêL}wÜBÉz§åúå§âãtuj|P˚¸ã÷±˜)õµ≤∆¡‹Õ∆ÆãõãóÄã}ãÜåãÉnW˚S}WÇapú{ßæ∑Æ⁄ª˚bÅ∏¯¢™·˜yÃ¯/¯
∏o¢T˚˚2˚9˚&3æV‡Œ’≤œ…óCQk{`ãSe∞¡ôéüí•®è˜,†Ú◊ã‚Jí7+G˚vù∑∞Êœ‘¿é†åö{t¸$d†v˜vØ¯+vX¯˚¯»õSéÉï”,¯Ãq˚µ¸âA˚}{bÉ{˜Oõ\ê~í¢òì•ó¢≈˜˜pü˚åÅåÇãÅgx~Pä{æ˜ö˚V˜(˜òç˚*óv©v¯Nvô¯`¯nÛ|òUFÅÅyãÇÖíîíê†ï±∑˜4ó∑î¥ãö∞q§e,4˚&H^âçÀ˜eáç˚tëå[Ç{æâòÜx~ÇnÖvãÉl@˚ß÷¥˜$¢√º— „±¨ØãòãïãzãÄÖlÅf`˚7{PäÉ|lõ{´π©§„À˚*Äº[ª¯°úﬁ¯pÔñ~~YSyãÑÜêìïê¶ñµÿ˜∆ÖéLÑÄ[äåÄÆoûdã˚˚1˚J˚-=ÆbŒ—≤©˜„çà{LÜqãwoò®±¨•ﬂÕ˚˜î3,˚z!drß∑ÂÈ˜q˜Æ¢qd¸ïv¥˜Ç˜´˘;ÜêQ{à9{§ç∑ärÑèñv>"¸v;à}ãziõy™¡ß¢Ò—îUCwxuãÅÜëïíéöì©˚ôìv¢v¯A£åv˜ ‘πÿ|¯¯O}}ÇÑá~|nqúãcC[aJ-˜?ã@[nkaRl≥Ïz|¸w˚4öõíëêñ|≠™xã±ﬂ…¬÷Í˚Ÿã‘¨¢ü≠Ω´g=ï|õ˚*ïv¯Yv¶ﬂ˜¶ﬁ¯h˜πËU√2˚(˚*˚0˚-/¬WÎ˜ ˜*˜<˜8´)B˚m˚[k∞¬Ó›˜p˜∂ßfP¸˚Mv¯Ô´˜x°ØÍ¯:¯˙±g¶Xaexdjibu\j#0ÉkÂ3¸9t˚lX_ãÑëïîîêãô†zösw}zsi¨q∑Â–Ï˜Mµ‘˜’˜ ë´ ˜0¶±”¬ôïÜÑäÜÅÄã|sö{°¢ùù°d†v˜≈∞˜Æ©¯âÚ¯¯äÓB¿˚˚åz´Ü±è`}áv`˚
¸={RÑÖPÄ{˜âõSíìßöéóî≠¿˜U∂Ö§â±ã˜,Û€˜	$ë˚OW˚xtçè{—˜ãë†óì®ãÊ¥g;˚ô†v˜ËÒåv∏¯¯0¯™xünX@7(^Çwäçº˜[àéWÅWÇWÇ{éûìåì†òÅy~ÖiÅh:˚π◊∂˜ ö¥Æ–∞’µ¿†ã†fã∂®úû´”óv©v¯ø\∫ó˘Fx˘RÙ}óZOxyzäÉÜêïîåêí£ƒ˜gî≠ë©ãòØsßk24˚Haâç¶„ï±ãúØt£iO?D˚8àéƒ˜[àé$vååPÄ{¿äñázÉçë{M8˚ ÷™üﬂ…„x—º¬ª®òìÇ|Éåç|Tãâ;˚∫◊≤˜,†¬ªœ∫œ¡ª¶ãóãîÇã}ãÜåéÄ^Z˚Z}Qáz~¯oö{¶π∫∞ÿ¿˚bÄØ¯5w©‡¯<˜¸Ωa´H˚%˚ ˚'˚.)øUÎ‘…Æ‘¿{îcZSk[ãSh∏“˜$Ï˜Ò£öÉ{|Çãruõ|£¶ûû•¸ñv¯+¨Ø˜ò˜º¯B;ßÚåçãçãçêàèÖÖääÄÇ\Sbib{mÄáàãÅãÇãîãÇ÷B˚ßt5åéãÇuä†y¶§£ñü¢ùõòú≥ƒ~ërlpj{}ãÅÖëñêåçèõﬂ˜“ﬂ˚*˚Mv˜Wû¯∂¯Â¯i˜…ﬂaºBL[l=TâéßÓáí˚0uéz©é≠àãpÑÜsÇj˚¸N~YÖÖ[Ü|˜bö\yî°©®ìÆ}¶òà®˜!˜0˜=˜+1ì˚(˚ ˚5'ltö°πª˜(ùπÃ§ƒºø≥°mW˚b˚Lv˘v˜‡Èc≥–¯>¯≤u£h‡v{|w–Z¡óãdP,˚/p]w˜Ö¨N˜qyãvE}ÅVzéüìåî¡§Y˚lºöGïV~{Ñ|tmxqplwwÄÖÇãwã}®pãtãz{ãuãpüy™ã∞ãº≤–‡˜	˜#˜˜Éã⁄˚*ã÷¯•‘¯‡¯W¯éÌF‘-*?Q%güÑ≤Õµß…ã“¿WDP`C%˚˚e˚tz˜˜Ω˜zírXv~Uã˚Rê˜U˜U˜
˜
©∫ãœ˚*Ñß˘ß´⁄˜»Ÿ¯Ö¯H˜*OÊ(˚.˚,˚|˚~˚Œ0Í˜1˜&˜j˜y=‚˚*T˚]J5_jjvhUjΩ‹˜Ω˜U¡Ó∆¨∑≠∑ø™\<˚*êv˜äπ¯•–„˜ò÷¯Ä¯[˜E‚˚˚˚˚˚ "…@‰±∑õ©∫èáM˚˚˚˚uy˜úŒ¢÷æ˜Â›˜$ã˜&@≈Tv3wijwWp^Keæ·˜”ı‰Ã≠\0d†v˜€Æ˜ó¨ì˘˘˘"¸Ü{œÖïÜn}ÜpÖt˚¸O{RÉÑRÄ{˜êõQèyñ®ñåèì©…˜s≈ä¡äπéãYxâ|ÖsúÖ◊˜xëZ,ìè˚BàÃ˜}ë¢ïéÕã˜,™~M}ãÇâxüâ˚*Å°¯º¯‡¯n˜‘‘[ºD2V:J^äç¯ÜêUÇêã#|{†â∏ënyfá{˚¸äàr’n…˜)˜:˜B˜06~#˚˚S˚h|ó¶ÏÎ˜â˜µßiW˚*Ä¿mv¯Nv™v˜‡˜∏¯o˜ }î[Nyy|ãÑÖëïóçåòºãê†Ÿ˜ºAa˚rT`HP/XUnãqãç•çìÊ¯ ∏àéQ}zà@Ä}†â≤ílÉãäÇgY˚W\ÜpãzgùxØ–ææ˜O˜çh˚Éhw¯lúy©œØ–ªÆ¸$á˜˜¨≥sßinvxpzíù{ö}êÉrurVgïx‡º∂¡ã∆dév˘4v◊¯¯˘D˘õ˚N{øÑñÖuy|hfK˚^˚ÛáI¯Jäëãëãê´öî…íõ˚Ö{¿ÑëÉô9Á¸√û¯¯˝õ¶ôï•ç˚*†v˜EÕKÀå¯q∞¯r˘:c¸5¸CwG˜ôZ˚G⁄∫˜EÓöÕ,ô˜◊,˚◊˚iç˜≈˜’˚*Ö±¯Ôµ˜Ÿ€p‚–¯e¯Ω—O¡<FKcLlöÜ¥º®ú∑ãæØfU8,I˚$zå{°‡Ù≈N˚3QCDzrñüm•eÑéwpz|rf¥v”˜1˜˜˜#ÿr¥E≠é–˜ª¨´“úév¯`v°v˜’˜: ˜Hª¸˘¯¨v†jt}|xj∂Üãf]_I˚˚&k˜˝ãèáçÜãáâäÉÜ˚S˚ƒâÖÁÉÊzÂ¸ØÑâêÉ¸âàãäà[ÅzáVÇ}°åéããßåìÖìtïmö˚ë#ê4Äåäfôìëî∑§˜:˜∫ç®˚–çqéÖíåëìí¢û…÷˜=˜]Ô¸$Ä˜¶˜˜∑™r§mlrrlm§r™©§§©xû¯Aô˜g¢íã˜°ç¸sé°
¢
_˜é˘
endstream
endobj
30 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 37/percent 40/parenleft/parenright 44/comma/hyphen/period/slash/zero/one/two/three/four/five/six/seven/eight/nine/colon/semicolon/less/equal 65/A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P 82/R/S/T/U/V/W/X/Y/Z 97/a/b/c/d/e/f/g/h/i/j/k/l/m/n/o/p/q/r/s/t/u/v/w/x/y/z 131/Eacute 135/aacute/agrave/acircumflex 142/eacute/egrave 146/iacute 148/icircumflex 150/ntilde/oacute 208/endash/emdash 213/quoteright]/Type/Encoding>>
endobj
32 0 obj
<</Ascent 684/CapHeight 662/Descent -215/Flags 34/FontBBox[-168 -218 1000 899]/FontFile3 31 0 R/FontName/CMRXZL+Times-Roman/ItalicAngle 0/StemH 0/StemV 84/Type/FontDescriptor/XHeight 677>>
endobj
31 0 obj
<</Length 9451/Length1 9451/Subtype/Type1C>>stream
  CMRXZL+Times-Roman   @¯ ¯¯¯¯˚<˚n˙|˙
 ãã
 ãã   ˚   ˜  ®¨  $  }àç002.000Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Turku is a trademark of Stream Technologies Inc.Turku RomanTurku  U  S J P  U    F T H O Q M B D N I Z X E G V W  / C  	 ) 3 5 
 L 1 6 4 "        Y o *   8  R + ' [ . 0  $ %  & - K 7 â    # ( , ; : 9 ÿ » ◊ ” œ ≤ “ ‘ À … W   o  ^ØN¨;z@ŒÕ;≥K√	 	ä	Î

k
Õ
‰"çOêãÒkÃt‚\âXî4k«MÏå‘BÅÎB]∆*c‡&ëÌ(K∞O∆Jâ˜å˛∑v‡i  ú!!∫"p˚—†v¯`w†w÷ﬂ–˜‚¯+¨wühblsH]â‰∞ÜéJqwÑMu{éöìåï§ï{_˚éYÇÉNÅ{˜ÉõKvùƒ˜súò§ûûôòôìîíìáÉîx†ìáõ°õû•¸†v¯^w˜$◊8ﬂ˜E˘ßt¢opttop°tßß¢¢¶÷˝õËKèÅñ”˜˜ÜèWwZyVy|é©åãì¶î{_˚{CÅGà{˚*Ç¶¯4ß®‰˜ö‰¯i˜~˜0È˚˚0+˚˚Á'˜˜ÍÛ˜2h˚^FA8O˜˜*ÁºÃ–ﬂ«*˚¸$¸Åø¯´–ﬂ˜™Õ~ñvrzÅtãg|¶ ˜≥´&˜ñâéÖU<midpÑÜâàãÖãáåâéãø˚¬5©b…∏≤§æ¨˚*ã◊¯§‘˜Â·¯n˜~êmdÜpPã˚Ñ˜=˜D‚Ê≥⁄ã⁄Ì:Ÿ&˚HK˚lüÜØÍ≤Ø”ã›ƒP6?\*95˚F˚P~¯˚*~•˘•£Î˜òÎ¯p˜ﬂ˜c˜E∆§ndò[[d~rnFPb˚˚˚≥˚—Or®≤~ªª≤ò§®—«≥˜˜+˚h`!44`ı˜h˜i∂ı‚‚∂!˚i¸$õv£v√˜ †˜Xñøh≤\jrskl¢wØ`ôêéãîïêáÅäâiogVgïxŒ≠∏»ƒ˚bÅ–˜o´˜Ø§–F“˜cÒÙ¯<˜1{ìW<dpJã.Pﬁ˜Ö˜À˜P…&˚7(˚&˚ —6˜	ÎÕø˜ΩÏ˚˜-˚cŸöÆØ«∆•m7ó˚ôÇ°êv¯Zwí¢æ»˜:—ú˜˜ªt´M∞ Ànú|§ã©Ø≠®∂≈Æd6úõ¨á˜ÉÜáâÖÜÑåéÖúôcçs:QXDO™e·Z≈j≠xùqãn_koYEiØÚs{\˚/òîíêéîìïäàñúÅ¥§á•Ÿ ƒ”˚*˚nƒ˜&÷@‘Ê§˜k≤êßß–nﬁ˜EŸ•®›¿¯i¯≤?u~çìwù]têm*AE-L§h–gCKyvtuö|≤{æ¿FZnfgTÿ`Ô˜˜ŸÊ ]¥@é˚êTçsïãùîòûôòóòôìîúêÜ®ÁœÕ‰®áû|∞P˚Snf_›¿MaÃÌ»¶Æªƒ∏B.Û˚ﬁR?b˚ﬁ¿3M©µ£ïú≤π¨Ñéõâ§àªâ¿âà°Äãi˚*†v¯)¬åw⁄‹:ﬂ˜Eﬂ‘¯xõ]}õº˜yË^ƒB[p|ID€¨ÑçYxà@tyéôëåì¶ì{[˚ãS}z\â{˜göYê{ò≠˜≠Ãª√õî¨ª£kJ˚eN}xZà{˚*˚Vv˜a´¯«åw’ﬂ˜v‡Ï¯i˜à˜F‰*R_sVaâç‘‹ÖéTvää4m{åóéãó´ëÅ[¸gUÑÑMÑ{˜ÖõAå}ó…˜0m´©≤˜Ê˜˜$6f˚YAArmóûs}óÇóï˜äÏØìª™∫’º>˚¸†vÏﬂ˜îõMå~ó√¯ÁáéHwvÖEy{åôíãó∞ìÄY¸pV{}Ná{˚bñvåƒ¯§∞„˜6›x¯O≥•{tÖà}rÖóª˜W˜`π˚ 1CYNrûw¢¢°†°òáòãò®™ü∑π¶lWNOuBqWg]kxjãZãN∑`…ã∏ã∏¢¬Ω∏Tëùx∑™ßõ≠ß˚0ﬂsàÄÉx{yb{sfo≠π»∫µ˜±˚bÅ”¯®§◊¯0˜(}ì`HapQã1K›˜ƒ‘ÿ≤ñÇcóëwïkö|£ã¶ûù•¡E∫<˚+!˚!˚⁄/˜ﬂ∆∫˜¿˜†v¯-øåw·ﬂ˜Lﬂ˜Kﬁ‹˘ôõRåïª˜c˜d∆=SXpSU≈xk§SbvÇXFÜáÉÜÅÉ÷ºÉéZyåã1pyéõêåñ§ïx^˚íV}}Sâ{˜rõYyô∞˜Øéïïóï‹£®´ó™ª°iC˚mU~Sà{˜sõSå|ú»˜ê∏´™ú∫¡ûn9˚gSÑÉPÑ{˚*†v¯+¡”ﬂ˜Nﬂ¯zõXêÇó–˜[ˆa¿9R_rQ`â˜¬Öè\{òè kzåìëãè∞ìÇa¸kFÇUÜ{˜kõTç~úŒ˜Öπµ´ù±∫¶eF˚ZGÄ}Rá{˚*˚m¯Àwô¯`¯n¯Iô˚}ØàóÑzÑéîqB<˚q˚˜êÇûãíãñúííΩëô˚a}®ÜóÑîw˜˚ä¶PÆJ|tpG{rt|z||wuùloxzpk™r¥“µº˜*ƒ˜/¯-ñ©ôò°é”ív°v¯dw†˘4p˘I¯Gõ˚{™àòÅy~áu~l0˚r<˜kt…çÑãò£ôì∂èõ˚^{µäôv≠%/˚\k‚H˜CãÜõäìíüòî¨çõ˚G{¢äîÄüX˜˚Èkòëíëëî©ô˜˜ÉÂ˚∞^úãåíìååªû˜˜Óúµêíûê˚*Åø¯ß¶·˜wﬂ¯µõÉÇäãáfÇó∏¯ÀÜéUx|á=v{åòëãêØìÇa˚0¨crïb˚.˚˚˚◊2˜¿µ†∂™çNêàŸßoÅÎ≠˚+»m^l_9Sﬁ˜˜æ◊‘¬ª\U˚—†v¯7´˜_®Úﬂ7ﬁ¯˘´\ßU˚QA˚2ä:k‹˚œBÅÄBá{˜òõ:çñ÷˜œ˜´Ë˚˜∆ùß≤†îÖoük°îÑú¢ûû¢˚*Åƒ¯(w—ﬂ˜Fﬂ=ŸË¯rØôYäñ∫˜Ï˚2{ÀáïÇY˚ÅràÄÉÅuy^wlcjÆµ˜€˚%{ªàò~[˚è;∫Y◊Ø±õ¶¶Ë∑∂9çàŸßîéæô˚*ív¯ewû¯\¯o¯Gõ˚{´äöÄv|Çoy]=˚[%˜îÜòáúãíúòî¨çõ˚W{üäïÜó§s˜˚ø£NéÇòeîãíãèíù∑˜˜‘¶Œíî©ç¸$Ä˜—˜˜I∑™r§mlrrlm§r™©§§©”ïvñû˘û˜ ∏¯1∑x˘T˘ü˚~wÂÑëk4˚„â¸¯u˚?w∂åñÑµ[¸M%~y8Éw˜ü>éz£¯ç∏¯J¸πú¯§Ôöü⁄ë˚*Å´¯Àœﬂ˜w‰¯h˜á˜?Ë$SWlXpâ˜¡Üéa{U{[~{åïíãèÆîÅc¸úm„i⁄˜Ú˜˜!2b˚	]L5[\££˜ê∂µ¨ƒ◊ø;˚˚—†v˜UÀ≤˜ä˜±˜UÀ˚äK˚—˚1v˘Íwª‡˜ƒ˚6˚·Z˜˜l˜[∂Ò˜ÓÇõ˚@˚@˚ã˚L˚µ#Î%≤aßt≤t”ãû˜º∑˜±ûıÒ˜√Ò˘PüAè~ò”¯Q”òò’èü˚®w’áò~C˚W˚√˜W”òò’èü˚®w’áò~C¸QC~~Aáw˜®üAè~ò”˜b˜√˚bC~~Aáwúãû˜¡§˜ÆØxûÒÒ˜}˜‹˘'üdçvóp¨˚b˜ë˜¢ƒ¿Ë˜/ ˚7˚ßw‘Üó~D¸D4ÖÑ=Éw˜®ü=íó“˜X√é˜Ç˚…N¯"Kc˚=ä˜äÏ®óíΩ˜≈]1dãû¯Ì∂ü°˜gÒ˜|v¯„¯ÅÑ˜>¸ƒÑ˚>§˜°†õ˜¡¸í@~8àw˜∫ü8é~ó÷¯í¡˜†{˚°˚—˚1v˘Íw˜\‡˜±˜ä˜aÛ+Òdµo¢d¢{˜5º˚˚l˚[`%˚(î{˜@˜÷˜ã˜L˚*†v›ﬂ¯çõ`çi°dº˚.˜V®¶ÔËΩÆÃâô˚_}ìêäãè¢äîáå~åÅÉÉ{|˚˚âç¯3ÜéOxzÜ>w{åòïãíØîZ¸uUââBÄ{˜~õMç~î¥˜Iç˜˚LûrçáãÖÉÇÖy{-ãû˜°≥˜Ω±xûÓÚ$Ò˜{˜⁄¯±¯w˜$—˚3˚öw’ÉìÇD¸FCäp9âw˜¨ü<å|ö’˜Hä§¢äû⁄≈ñ°≤»≠Æ«œ˚â!S\˚ÊzÅãçt˜ôßíë≠˜ÕY-”}∑¯˙ûÚÚ˜¸∂˘S˘ü˚{w÷âûr(˚¢=Å`slakTtJO\ùÆnnÆÇ∞€˜‘‘ññ⁄èü˚Æy⁄ÉïÅB˚À˚@›6˜:˜HŸ›˜P˜ôõ†Ÿè-~Ø¯¯¥—·˜~Ô¯~˜<€\ƒ˚’Q≠"º‹¿µ≤∆Â–L˚ ¶§u˜hvsÖÇÅzÑ|éê}üOwëq"?D)9≠a˜C˜>¨hNGZ\C0M¿˜Wu©˚h††çñóùØ´jÁ˜
„ÿÛ”ãû˜[¥¯4wö˘G˘Vü^ç}òl”˚ç¯Ãw˚d¸O˚!}xYáw˜Zü\äuô™ïéïëõπ˜
˜ö¥*ïtîlãpzÉWwÜ˜ó˚{˜˜ß˚*†v˜i·¯ö=åyñ∫¯ÌÇç˚G0~•ïúíúèîã¢ï}j¸m\yÄ=ä|˚*âw˜ó∂¯ß©Á˜ÄÔ+ÎÙ¯^¯!˜5/˜
˚˚4'˚ ˚
‘:ˆ¿ªù±π¯åàm˚%˚˚>qçw˜Öõ˜3˜<ã˜Ù+bváÇÅuod}j>\’˜˜± œ‰∏4˚;˚*~∞¯‚‡Ÿ˜˘—¯J˘?ÇëyuÉáwã˚e˚˚Ääâäàãâáçâëä˜É˜5Y˚.&O?;uÑé´^°l}êpr}~tb∑u›˜5˜ Ú˜.˜@˚ƒ˚)¶µ‡˜Xúéåíé˚*}Ø¯Á∆˜—⁄g“–¯C˜lÍkπ+∑‡œπ§∞≈⁄K¬/,MX˚döá≥÷∏´ ãÃ∏^L^r_cnpwvÅWyû¡¶Üz™–ªp®XO8QICqvì†h£cÇéys}~ug∑v÷˜1˜Î˜˚*ôv¯Ë‘ü¯@¯T˘ö¸|_`%úÉ≤Ã¢õ¡ã˜m˚Z¸ËÃ˜Kìvò™˜óÆö´˜g§œw»◊˜r§Ã÷˜q•¿˘ó˜ö—f≥H˚˚ ˚˚;ªW’ÛÎ˜˜˚¯2eYYbyDd{í†oür{ëo˚ ˚	˚BæQÕıÔ˜˜ôâñáûÉ£óâ£∑ßí†∞çâø¿˚˝∫¿¯Ö˜£˚:˚<du•∑œÀ˜?‚≤™f^¸˜º˚:˚<cu£∏»∞ÊπΩ£°°òúëçäÑíïÅöÑ®Éëéwã}˚*†v˜;À¯Qw˜∑⁄>ÿË¯k˜;À&¯Q_˚Œ¸QK˜≠˚;ÿ˜;<À˚Ñ˜Ç˜Èç˚*†v¯Wwú¯b¯sõhçyòn∑˚˜Xﬂ˜û¶ßõ≠åö˚3}¨áíá}~uU?~üèÖs≥x™Ñöãìãõïë´çô˚b}µäêá∞SÍ˚%˚˚9pd}Ålä{˜%õnÄêóìêóô°€˜‹˚õsãäãÄ{ÄÑrá{˚*†v˜]ºã¯à¯à˜]º¸àZ˚—ãû˘û˜Ò˜Ãü8é~ó÷¯O÷òóﬁéü˚∫wﬁàò@¸O@~8àw¸õv£v˜Û˜€˜ ˚˜h˜T¯)©r§lmrrml§r©™§§™∞ß¸øh≤\jrskl¢wØpïîéãîïêáÅäâiogVgïxŒ≠∏»ƒ˚*~ß˘ß√÷F’˜o–T◊‘¯Q˜0ÿiª˚ÊÿÓ¡ÆµŒﬁC≈#!;H0J¢iÒ4‰˚<ulG&ÿI˜	˜
ÿÕÚÿ1¯PuiCVTØEø‘ƒ∏≥ œ∂_G‰ô¸-G__IAU«›Œû±…æ™tîÑãËE£rN˜∫ñv˘"ûê˙1˙6˘ü˚Zw¬ÜôÇl|ÑkÇs˚˚Ë˚˜Èp–ãäãó§°ï¬ü˚üw áèá≠:≠9 ˚Ø˚%¯É†àïãò°óë¿êü˚àw…Çéá“˚SÃ˚CçÜË˚°ö˜.¯;ëyë|éÇë|°U™;±*ú[™4ôŸ˜Éñ™Ã˜H¶‘ö≥ñ©öµõóªë˚—⁄˜ ˜o¯ﬁøh≤\jrskk¢wØîñèãìîåëÜäÅâhohVgïwŒ≠∏»≈˚*˚Vv˜a…¯ß£‡˜|ﬂ¯|˚kõ]çzö¥¯ÍÜêNgU™|ê_ã˚,˚˚&˚Õ4Ï¿¿§ªπçä˚NT|~AÑ{‰˜ÎkÑ~t~srÖs>W◊˜˜	¡Ÿ‹Õ™kF˚ôív˘&û˜CÒ¯˘ü˚¥w⁄âô}C¸d\Äwq|Üë£Ñ≤|õqqutp_≤n∆˜ »”˜¯”ôô⁄ç-ãû˜»µb¥˜ì≤xûÓ˜î¢¥¢œ¯µ¯úà˜#¸¶w’áò~C¸QC~~Aáw˜´ü@é{ö“˜p˜&âﬂäñÅö7¢˜|t6|Å8˚&˜q∑®êêß˜˜û~0ù˚bã©¯©¶¯¯6˜yèv*|~/ã˚˜¢¯*ö˚Ôà˚ú’ïôö»˜˚ù¸*|¯˜Éãû˘ûˆ∑¯ú˘ÔüFçyù–¯Q”ôô‘éü˚[˚o¸é˚{¯é˚Zw›Üò~D¸+&|x;Ñw˜}ü@éx•Ì¯$ç˜é¸∑ô˜ê¯Œç¸V9Ä~<Üw”}Ø¯˛Ø≠˜¯?˜˘C˜ﬁ˜_˚˜#˚S˚T˚˚#˚_˚]˜˚#˜T˜S˜˜#˜]˚å˚T:˚	˚˚:˜	˜T˜R›˜˜˜ﬁ˚˚R¸ív˘FwÇ˜∫˜±˘8I˚x˝FŒú}∑¯Ov˜M≤ß˜˘˜yú=AOp5ã˚+,˜˜K˜SÂ˜	˜(ˆ“N˚∞°Ç˜tvÉu|wåÅå{éxíbôYìaã˚Zã˚!˚#ã˚]ã˚f˜˚˜_ã˜ã˜ øæ◊”ãûx∞¯·∞xûÚÒ¯˜ú˘?˜‚˜b˚)˜˚é˚†w’áò~C¸QC~~Aáw˜Ø˜Ç˜&˜˜cl˚Ö˚U#)˚a\~î´¯ê≠îë¡˜Q˜	˚˚L¸Ä˜˜ç˜‹˜˜T¯)©r§mlrrml§r™©§§™˚˝™r§mlrrlm§r™©§§©dã±eû˜»µb¥˜ì≤xûÓ˜ú¢¨¢´Ä¯Ë˜>o˚ ^]s˚7#Åè≤˜å˜.âﬂäñÇö6¢˜|t6|Å8˚.˜q®êêß˜˜û~0ù§á˜#¸•WÄw’áò~C¸QC~~Aáw¯Ødã≤dû˘ûÓ∞¯Ë˜Bs˚
Siz˚I0Åè∞¯n”òò’èü˚ßw’áò~C¸QpC~~Aáw¯≠¸˚Xv˘7w˜$Á8ﬂ˜U˘ßt¢pottop¢tß¶¢¢¶Ëå˝¯^ÜèXwXyWy|é©åãì¶î{_¸!Äjg}ÇêóÄ≥iÜéwwwywk≤t¬˜∆÷˜"”ïv˘#ûõ˘;‡˘K˘ü˚`‡x∆ÜôÇm}Ñqm˚&¸˚,˜ÊmÕÅ©ãô§ñê èû˚ù‡wΩàú{±6˜ã¸∫ö˜p¯∆®’õõ∫ç˜Ú†v˜]ºã˙|˙|˜]º˛|Z5óv¯†wß¯è¯´Çœ¸=˜V¯=˜Vœ¸è˚{M5†v˜Õ˜Õ©¯ã¯©˜’Õ¸ãI¯ã˚]Õ¸ãI˚*}ß¯∫˜Çö≠Á˜ë‰¯h˜m˜Bﬂ˚[wÑeL™˜1ÓÍ˜;´áö˚vá˚M˚;˚˚D‰˚˜˜·Í˜2j˚ cME4SÈ˜'≤ê≠îô°ò∑ù¥ÂæC˚úã∞fû˜»≥c≤˜ó±xû˜Ò˜Ü;˜¶Ä¯Â˜D≈oΩ\ßröyíZôçg Ë°≤∂⁄˜.«˚<˚¨wﬁàòA¸QA~8àw˜‚¶Ä˜%Ï“Ùß ˚˜Ã<Yb)äõ -ä˜yßèç√˜»]0¶Ä†˚»*O]˚O|ì¨˜ç˜Vå–d˚”}≥˜…û˜Æ≥´˜¯Î˘W˜„û˚íxŸáïÅ@˚4iOq?˚3'˜
˜O˜KÏ˜˜%Ù–U˚µ£É˜fuuÑ{ÄsÖÄçéÄ°Ejë\˚[˚"˚&˚b˚|˜A!˜K˜˜¬ù˜\≈ôö√é”ãû˘û˜Ò‡˘eüXzñÎ2˚|˜é˜Q˜Q««£óŒêü˚òw«áíàtrxs4:tu∫∂˚@˚0˜W‡ﬁñóŸëû˚¨xŸÖñ8¸;8Ä=Öx˜¨û=ëÄóﬁ˜D•°ı!ÿ>¿Fãt‡yÇàOâwdã±¯ﬂ±î¯ﬁ¯Á˜Dt˚hjq%˚ñ¯C¯ˆö¸°x˚>§Úü∞®˜˜q¸H¸ˆ|¯∆”ãû˘û˜œÒ˘R˘ü˚owæåùÇtÅáÄÅ{˚!˚x˚)˜tÄõÖöãò°ôëƒü˚¨wØâôÑßiüt≤W•e˜˚T˚M>~Ä2âw˜∆ü2ç~ñÿ˜U˜'˜w¡ﬂ®¢¬ë”ãû˘ûï˘H‡˘RüWêwòe¬˚S˜¶˜%˜K≈’§öÃèü˚Äw≈àñÜr|É}kd˚˚`∆CÓ~¶ã¢£öë»ü˚¡w–Ö¢w„˚˜˚5˚0˚U;)~ÅWÜw˜}‡ûVçsñå°åúò§∞∏˜˜(Í˚!´\ùgã}‡uwÉSäw˚*Ç¶¯4ß®‰∆˜rx‰ﬂ˜œ˘ú}ôz|}Ñ||˚'˚)≥˜.Ïûóîôãú¸#˝Ë¯i˜~˜0È˚˚0+˚˚Á'˜˜ÍÛ˜2h˚^FA8O˜˜*ÁºÃ–ﬂ«*˚˚bñvåƒ¯§∞„§˜r6›ƒ˜œ˘ú}ôz|}Ñ||˚'˚)≥˜.Ïûóîôãú¸˝t¯O≥•{tÖà}rÖóª˜W˜`π˚ 1CYNrûw¢¢°†°òáòãò®™ü∑π¶lWNOuBqWg]kxjãZãN∑`…ã∏ã∏¢¬Ω¥Tëùx∑™ßõ≠ß˚0ﬂsàÄÉt{yb{sfo≠π»∫µ˜±˚*†v¯)¬åw⁄‹:ﬂ<˜›Bﬂﬁ˜ﬁ˘mf{~r~tëì{tóvñsëuãUhiI}®™ìùößïòàÑô°ÄØy¢Ö¢ã¡©©÷†¸1˝“¯xõ]}õº˜yË^ƒB[p|ID€™ÑçYxà@tyéôëåì¶ì{[˚ãS}z\â{˜göYê{ò≠˜≠ ª√õî¨ª£kJ˚eN}xZà{¸†v¯bwÃ˜r˚Uﬂo ˜œ˘ú}ôz|}Ñ||˚'˚)≥˜.Ïûóîôãú˚≥˝–˜êõKèÅñ”˜˜ÜèXyWxXx|é©åãì¶î{_˚{CÅGà{˚bÅ–˜o´˜Ø§–F“¿˜rGÒ√˜œ˘ú}ôz|}Ñ||˚'˚)≥˜.Ïûóîôãú¸˝Ú¯<˜1{ìW<dpJã.Pﬁ˜Ö˜À˜P…&˚7(˚&˚ —6˜	ÎÕø˜ΩÍ˚˜-˚cŸöÆØ«∆•m7ódã±eû˜»µb¥˜ì≤xûÓ¨˜rî¢¨¢˜ ˜i ˜œ˘ú}ôz|}Ñ||˚'˚)≥˜.Ïûóîôãú¸[˝™¿¯Ë˜>o˚ ^]s˚7#Åè≤˜å˜.âﬂäñÇö6¢˜|t6|Å8˚.˜q®êêß˜˜û~0ù§á˜#¸•V¿w’áò~C¸QC~~Aáw¯Ø˚bÅ–˜o´˜Ø§–F“v˜rëÒ√˜Ö¯è˚'˜)|ö}í|ãz}}zzî}û˜.*˚ï¸èÚ¯<˜1{ìW<dpJã.Pﬁ˜Ö˜À˜P…&˚7(˚&˚ —6˜	ÎÕø˜ΩÍ˚˜-˚cŸöÆØ«∆•m7ó¸†v¯bw˜|w{˜ ˚\ﬂp0˜’¯ê˚˜:K˚˚:¨˜Ú˜$˚ô¸ê»˜êõKèÅñ”˜˜ÜèXyWxXx|é©åãì¶î{_˚{CÅGà{˚bñvåƒ¯§∞„Y˜rÅ›√˜Ö¯è˚'˜)|ö}í|ãz}}zzî}û˜.*˚ï¸èt¯O≥•{tÖà}rÖóª˜W˜`π˚ 1CYNrûw¢¢°†°òáòãò®™ü∑π¶lWNOuBqWg]kxjãZãN∑`…ã∏ã∏¢¬Ω¥Tëùx∑™ßõ≠ß˚0ﬂsàÄÉt{yb{sfo≠π»∫µ˜±˚bñvåƒ¯§˜hw∞„X˜ *› ˜’¯ê˚˜:K˚˚:¨˜Ú˜$˚Û¸êj¯O≥•{tÖà}rÖóª˜W˜`π˚ 1CYNrûw¢¢°†°òáòãò®™ü∑π¶lWNOuBqWg]kxjãZãN∑`…ã∏ã∏¢¬Ω™Tëùx∑™ßõ≠ß˚0ﬂsàÄÉj{yb{sfo≠π»∫µ˜±u°¯Wñ˜\öíã˜öî¸}é¶
ﬂ
_˜é˘
endstream
endobj
1 0 obj
<</OPM 1/Type/ExtGState>>
endobj
93 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
94 0 obj
<</OP false/OPM 0/op false>>
endobj
95 0 obj
<</A 96 0 R/Border[0 0 0]/Rect[244.413 9.0 286.158 16.0]/Subtype/Link/Type/Annot>>
endobj
96 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
86 0 obj
[97 0 R]
endobj
87 0 obj
<</Length 14698>>stream
1 g
/GS0 gs
0 792 0 0 re
f
0 0 0 0 k
/GS1 gs
60 41.333 492 696.667 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
-0.02499 Tc 0.019 Tw 10.5 0 0 10.5 60 730.8196 Tm
(for the entire study period, the potential underestimation of)Tj
-0.015 Tc 0.015 Tw 0 -1.23809 TD
[(duration of therapy is not likely to have af)20 (fected our find-)]TJ
-0.006 Tc 0.006 Tw 0 -1.2381 TD
(ing that treatment duration declined dramatically in later)Tj
-0.02499 Tc T*
[(cohorts of new users. Finally)65 (, as noted above, our data may)]TJ
-0.01801 Tc 0.017 Tw 0 -1.23809 TD
(underestimate the rate of tibolone use since, unlike the re-)Tj
-0.017 Tc 0 -1.2381 TD
(mainder of the medications studied, this product is not in-)Tj
-0.02499 Tc 0.013 Tw T*
[(cluded in the standard for)-25 (mulary)65 (. )]TJ
-0.021 Tc 0.021 Tw 1 -1.23809 Td
[(W)80 (e documented a rapid drop in the proportion of wom-)]TJ
-0.02499 Tc 0.01401 Tw -1 -1.2381 Td
[(en aged 45 years and older using HR)60 (T following the publi-)]TJ
-0.022 Tc 0.022 Tw T*
(cation of the WHI findings, as well as marked shifts in the)Tj
0 Tc 0.034 Tw 0 -1.23809 TD
[(type of treatment used and the duration of therapy)65 (. Our)]TJ
-0.011 Tc 0.011 Tw 0 -1.2381 TD
[(analysis of a lar)20 (ge stable population allowed longitudinal)]TJ
-0.002 Tc 0.00101 Tw 0 -1.23809 TD
[(analysis of HR)60 (T use, enabling not only a survey of drug)]TJ
-0.01801 Tc 0.01801 Tw 0 -1.2381 TD
(purchasing trends, but also estimates of utilization rates in)Tj
-0.02499 Tc 0.02499 Tw T*
[(the tar)20 (get population over a period of several years. Longi-)]TJ
-0.009 Tc 0.008 Tw 0 -1.23809 TD
(tudinal data also allowed us to characterize new users by)Tj
0 Tc 0.071 Tw 0 -1.2381 TD
(age and mode of therapy)Tj
-0.00011 Tc 10.10265 0.00001 Td
(,)Tj
0 Tc 0.57073 0 Td
(and to examine switches be-)Tj
-0.02 Tc 0.02 Tw -10.67337 -1.2381 Td
(tween modes before and after 2002. The decrease in over-)Tj
-0.02499 Tc 0.01199 Tw 0 -1.23809 TD
[(all HR)60 (T use in our population can be attributed both to dis-)]TJ
-0.013 Tc 0.013 Tw 0 -1.2381 TD
(continuation by current users and a reduction in the num)Tj
0 Tc 21.95285 0 Td
(-)Tj
-0.02499 Tc 0.024 Tw -21.95285 -1.2381 Td
(ber of new users. This reduction was sustained through the)Tj
-0.015 Tc 0.015 Tw 0 -1.23809 TD
(end of December 2007. The finding of increased tibolone)Tj
-0.02299 Tc 0.02299 Tw T*
(use is likely due to patient and provider perceptions of this)Tj
-0.02499 Tc 0.009 Tw 0 -1.2381 TD
[(product as a safer alter)-25 (native to traditional HR)60 (T)75 (. Continued)]TJ
0 Tc 0.058 Tw 0 -1.23809 TD
[(surveillance will be required to deter)-25 (mine whether this)]TJ
-0.013 Tc 0.013 Tw T*
[(trend continues and to assess the long-ter)-25 (m health impact)]TJ
-0.02499 Tc 0 -1.2381 TD
(of tibolone use. )Tj
ET
BT
/T1_1 1 Tf
0.00301 Tc 0.00999 Tw 8.5 0 0 8.5 60 368.8197 Tm
(Barbara G Silverman)Tj
ET
BT
/T1_2 1 Tf
8 0 0 8 147.1593 368.8197 Tm
(MD MPH, Unit Head, Research and Aca-)Tj
0 Tc -0.005 Tw -10.89491 -1.125 Td
(demics, Department of Research and Evaluation, Maccabi Health-)Tj
-0.01401 Tw 0 -1.125 TD
[(care Services, T)111 (el A)17 (viv)74 (, Israel)]TJ
ET
BT
/T1_1 1 Tf
-0.01601 Tc -0.01199 Tw 8.5 0 0 8.5 60 339.8197 Tm
(Ehud S Kokia)Tj
ET
BT
/T1_2 1 Tf
8 0 0 8 114.9503 339.8197 Tm
(MD, Director General, Maccabi Healthcare Services,)Tj
0 Tc -6.86879 -1.125 Td
(T)Tj
-0.00011 Tc 0.5 0 Td
[(el)-264 (A)]TJ
0 Tc 0 Tw 1.69093 0 Td
(viv)Tj
ET
BT
/T1_1 1 Tf
0.01401 Tc 8.5 0 0 8.5 60 319.8197 Tm
(Reprints:)Tj
ET
BT
/T1_2 1 Tf
-0.00101 Tw 8 0 0 8 100.7446 319.8197 Tm
[(Dr)55 (. Silverman, Maccabi Healthcare Services, Rechov)]TJ
0.05 Tc 0.207 Tw -5.09307 -1.125 Td
[(HaMered 27, T)111 (el A)17 (viv 68125, Israel, fax 972-3-514-3795,)]TJ
0 Tc 0 Tw T*
(silver_b@mac.org.il)Tj
ET
BT
/T1_1 1 Tf
-0.02499 Tc 10.5 0 0 10.5 318 730.348 Tm
(References)Tj
ET
BT
/T1_0 1 Tf
0 Tc 0.216 Tw 8 0 0 8 322 712.348 Tm
[(1.)-500 (American College of Physicians. Guidelines for counseling post-)]TJ
-0.024 Tc 0.024 Tw 1.1875 -1.25 Td
[(menopausal women about preventive hor)-25 (mone therapy)65 (. Ann Inter)-25 (n Med)]TJ
-0.02499 Tc 0 Tw 0 -1.25 TD
[(1992;1)35 (17:1038)-25 (-)-125 (41.)]TJ
0 Tc 0.00301 Tw -1.1875 -1.375 Td
[(2.)-500 (US Preventive Services T)70 (ask Force. Guide to clinical preventive ser-)]TJ
-0.02499 Tc 0.02 Tw 1.1875 -1.25 Td
[(vices. 2nd ed. W)80 (ashington, DC: Of)20 (fice of Disease Prevention and Health)]TJ
0.013 Tw T*
(Promotion, 1996.)Tj
-0.022 Tc 0.022 Tw -1.20954 -1.375 Td
[(3.)-478 (Manson JE, Martin KA. Postmenopausal hor)-25 (mone-replacement therapy)65 (.)]TJ
-0.02499 Tc 1.20954 -1.25 Td
(N)Tj
0.013 Tw 0.93441 0 Td
[(Engl J Med 2001;345:34)-75 (-)-125 (40.)]TJ
-0.024 Tc 0.024 Tw -2.14577 -1.375 Td
[(4.)-476 (Grodstein F)80 (, Manson JE, Colditz GA, W)40 (illett WC, Spelzer FE, Stampfer)]TJ
0 Tc 0.04201 Tw 1.21136 -1.25 Td
[(MJ. A prospective, observational study of postmenopausal hor)-25 (mone)]TJ
-0.004 Tc 0.004 Tw T*
[(therapy and primary prevention of cardiovascular disease. Ann Inter)-25 (n)]TJ
-0.02499 Tc T*
(M)Tj
0.013 Tw [(ed 2000;133:933)-24.9 (-)-125.1 (41.)]TJ
-0.015 Tc 0.015 Tw -1.20262 -1.375 Td
[(5.)-485 (Grady D, Rubin SM, Pettiti DB, et al. Hor)-25 (mone therapy to prevent dis-)]TJ
-0.022 Tc 0.021 Tw 1.20261 -1.25 Td
[(ease and prolong life in postmenopausal women. Ann Inter)-25 (n Med 1992;)]TJ
-0.02499 Tc 0 Tw T*
[(1)35 (17:1016)-25 (-)-24 (37. )]TJ
-0.01401 Tc 0.01401 Tw -1.20139 -1.375 Td
[(6.)-486 (Keating NL, Cleary PD, Rossi AS, Zaslavsky AM, A)90 (yanian JZ. Use of)]TJ
-0.01801 Tc 0.01801 Tw 1.20139 -1.25 Td
[(hor)-25 (mone replacement therapy by postmenopausal women in the United)]TJ
-0.02499 Tc 0.013 Tw T*
[(States. Ann Inter)-25 (n Med 1999;130:545)-25 (-53.)]TJ
-0.017 Tc 0.017 Tw -1.20433 -1.375 Td
[(7.)-483 (Hersh AL, Stefanick ML, Staf)20 (ford RS. National use of postmenopausal)]TJ
-0.02299 Tc 0.02299 Tw 1.20433 -1.25 Td
[(hor)-25 (mone therapy: annual trends and response to recent evidence. JAMA)]TJ
-0.02499 Tc 0 Tw T*
(2004;291:47-53.)Tj
0 Tc 0.05499 Tw -1.1875 -1.375 Td
[(8.)-500 (W)60 (ysowski DK, Gover)-25 (nale LA. Use of menopausal hor)-25 (mones in the)]TJ
-0.011 Tc 0.011 Tw 1.1875 -1.25 Td
[(United States, 1992 through June, 2003. Phar)-25 (m)1 (a)1 (c)1 (o)1 (e)1 (p)1 (i)1 (d)1 (e)1 (m)1 (i)1 (o)1 (l)1 ( )1 (D)1 (r)1 (u)1 (g)1 ( )1 (S)1 (a)1 (f)]TJ
-0.02499 Tc 0 Tw T*
[(2005;14:171)50 (-)-75 (6.)]TJ
-0.007 Tc 0.007 Tw -1.19476 -1.375 Td
[(9.)-493 (Merom D, Ifrah A, Cohen-Manheim I, Chinich A, Green MS. Factors)]TJ
-0.006 Tc 0.005 Tw 1.19476 -1.25 Td
[(predicting current use of hor)-25 (mone-replacement therapy among meno-)]TJ
-0.024 Tc 0.024 Tw T*
(pausal Jewish women in Israel. The National W)Tj
0 Tw 18.16127 0 Td
(omen\325)Tj
-0.02431 Tc 2.37853 0 Td
(s)Tj
-0.024 Tc 0.024 Tw 0.61461 0 Td
(Health Interview)Tj
-0.02499 Tc 0.013 Tw -21.15441 -1.25001 Td
[(Survey)65 (, 1998. Isr Med Assoc J 2002;4:671)50 (-)-75 (6.)]TJ
0.02499 Tw -1.6875 -1.375 Td
[(10.)-475 (V)60 (inker S, Kaplan B, Y)100 (aphe J, et al. Use of hor)-25 (mone replacement therapy)]TJ
-0.01199 Tc 0.01199 Tw 1.6875 -1.25 Td
(by menopausal women in six family-practice teaching clinics in Israel.)Tj
-0.02499 Tc 0.013 Tw T*
[(Climacteric 2003;6:75)-25 (-)-25 (80.)]TJ
0.004 Tw -1.6875 -1.375 Td
[(1)35 (1.)-475 (W)40 (riting Group for the W)80 (omen\325)55 (s Health Initiative Investigators. Risks and)]TJ
-0.00999 Tc 0.00999 Tw 1.6875 -1.25 Td
(benefits of estrogen plus progestin in healthy postmenopausal women.)Tj
-0.02499 Tc 0.013 Tw T*
(JAMA 2002;288:321)Tj
0 Tw 8.06477 0 Td
[(-)-25 (33.)]TJ
-0.019 Tc -9.75227 -1.375 Td
(12.)Tj
0.019 Tw 1.67486 0 Td
[(US Preventive Services T)68.1 (ask Force. Hor)-25 (mone therapy for prevention of)]TJ
-0.011 Tc 0.00999 Tw 0.01264 -1.25001 Td
(chronic conditions in postmenopausal women: recommendations from)Tj
-0.03999 Tc 0.013 Tw T*
[(the US Preventive Services T)70 (ask Force. Ann Inter)-25 (n Med 2005;142:855)-25 (-)-75 (60.)]TJ
-0.02 Tc 0 Tw -1.6875 -1.375 Td
(13.)Tj
0.02 Tw 1.66912 0 Td
(National Institutes of Health State of the Science Panel. Management of)Tj
-0.02499 Tc 0.013 Tw 0.01838 -1.25001 Td
[(menopause-related symptoms. Ann Inter)-25 (n Med 2005;142:1003)-25 (-13.)]TJ
-0.008 Tc 0 Tw -1.6875 -1.375 Td
(14.)Tj
-0.009 Tc 0.008 Tw 1.71606 0 Td
(Recommendations for estrogen and progestogen use in peri- and post-)Tj
0 Tc 0.11301 Tw -0.02856 -1.25 Td
(menopausal women: October 2004 position statement of the North)Tj
-0.022 Tc 0.022 Tw 5.81267 -1.25 Td
(American Menopause Society)Tj
-0.0217 Tc 11.46642 0.00001 Td
(.)Tj
-0.022 Tc 0.47828 0 Td
[(Menopause 2004;1)35 (1:589)-25 (-)]TJ
-0.02499 Tc 0 Tw -11.94471 -1.25 Td
(600.)Tj
-0.02299 Tc 0.02299 Tw -1.6875 -1.34375 Td
[(15.)-477 (ACOG T)70 (ask Force on Hor)-25 (mone Therapy)65 (. Hor)-25 (mone ther-)]TJ
0 Tc 0.08701 Tw 1.6875 -1.21875 Td
[(apy: executive summary)65 (. Obstet Gynecol 2004;104\(4)]TJ
-0.02499 Tc 0 Tw 0 -1.21875 TD
[(suppl\):1S-)-125 (4S.)]TJ
-0.01801 Tc 0.01801 Tw -1.6875 -1.34375 Td
[(16.)-482 (Hartsfield CL, Connelly MT)75 (, Newton KM, Andrade SE,)]TJ
0 Tc 1.6875 -1.21875 Td
(W)Tj
-0.006 Tc 0.006 Tw 0.85771 0.00001 Td
(ei F)Tj
-0.0061 Tc 1.42934 0.00001 Td
(,)Tj
-0.006 Tc 0.49378 0 Td
[(Buist DS. Health system responses to the W)80 (om-)]TJ
-0.02 Tc 0 Tw -2.78083 -1.21876 Td
[(en\325)55.1 (s)]TJ
0.02 Tw 1.78081 0.00001 Td
(Health Initiative findings on estrogen and progestin:)Tj
0 Tc 0.19 Tw -1.78081 -1.21876 Td
[(or)20 (ganizational response. J Natl Cancer Inst Monogr)]TJ
-0.02499 Tc 0 Tw T*
[(2005;35:1)35.6 (13)-24.9 (-5. )]TJ
-0.002 Tc -1.6875 -1.34375 Td
(17.)Tj
0.002 Tw 1.74316 0.00001 Td
(Grady D, Barrett-Connor E. Postmenopausal hor)Tj
0 Tw 19.47778 0.00001 Td
(mone)Tj
-0.02499 Tc 0.013 Tw -19.53344 -1.21876 Td
[(therapy)65 (. Br Med J 2007;334:860)-75 (-1.)]TJ
-0.01199 Tc 0.01199 Tw -1.6875 -1.34375 Td
[(18.)-488 (Majumdar SR, Almasi EA, Staf)20 (ford RS. Promotion and)]TJ
-0.007 Tc 0.006 Tw 1.6875 -1.21875 Td
[(prescribing of hor)-25 (mone therapy after report of har)-25 (m)-1 ( )-1 (b)-1 (y)]TJ
-0.02499 Tc 0.013 Tw T*
[(the W)80 (omen\325)55 (s Health Initiative. JAMA 2004;292:1983)-25 (-)-25 (8.)]TJ
0 Tw -1.6875 -1.34375 Td
(19.)Tj
0.01601 Tw 1.64999 0.00001 Td
[(Hing E, Brett KM. Changes in US prescribing patter)-23 (ns of)]TJ
0 Tc 0.01401 Tw 0.03751 -1.21875 Td
[(menopausal hor)-25 (mone therapy)65 (, 2001)50 (\320)-25 (2003. Obstet Gy-)]TJ
-0.02499 Tc 0.013 Tw T*
(necol 2006;108:33)Tj
0 Tw 7.08356 0.00001 Td
[(-)-125 (40.)]TJ
-8.77106 -1.34376 Td
(20.)Tj
0.01199 Tw 1.64999 0.00001 Td
(Buist DSM, Newton KM, Miglioretti DL, et al. Hor)Tj
0 Tw 19.64066 0.00001 Td
(mone)Tj
-0.01401 Tc 0.004 Tw -19.60315 -1.21876 Td
[(t)-10 (h)-10 (e)-10 (r)-10 (a)-10 (p)-10 (y)-10 ( )-10 (p)-10 (r)-10 (e)-10 (scribing patter)-25 (ns in the United States. Obstet)]TJ
-0.035 Tc 0.013 Tw T*
(Gynecol 2004;104:1042-50.)Tj
0 Tc 0.131 Tw -1.6875 -1.34375 Td
[(21.)-500 (Menon U, Bur)-25 (nell M, Shar)-25 (ma A, et al.; UKCT)20 (OCS)]TJ
-0.004 Tc 0.004 Tw 1.6875 -1.21875 Td
[(group. Decline in use of hor)-25 (mone therapy among post-)]TJ
-0.02 Tc 0.02 Tw T*
(menopausal women in the United Kingdom. Menopause)Tj
-0.02499 Tc 0 Tw T*
(2007;14:462-7.)Tj
ET
0 0 0 0 k
173 745 379 10 re
f
BT
0 0 0 1 k
/T1_3 1 Tf
0.013 Tw 8 0 0 8 251.5303 749.5293 Tm
[(Sustained Impact of the W)75 (omen\325)75 (s Health Initiative Findings on Hor)-25 (mone Replacement Therapy)]TJ
ET
0 0 0 0 k
167 17.75 385 13 re
f
BT
0 0 0 1 k
/T1_4 1 Tf
10 0 0 10 267.483 23.9116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 5 0 0 5 400.608 25.4116 Tm
(n)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 413.7891 23.9116 Tm
[(2009 February)55 (, V)110 (olume 43    )]TJ
ET
BT
/T1_5 1 Tf
0 Tc 0 Tw 5 0 0 5 524.3189 25.4116 Tm
(n)Tj
ET
BT
/T1_6 1 Tf
-0.024 Tc 10 0 0 10 537.5 23.9116 Tm
(257)Tj
ET
0 0 0 0 k
60 17.5 79.5 13 re
f
BT
0 0 0 1 k
/T1_4 1 Tf
-0.02499 Tc 10 0 0 10 60 23.6616 Tm
[(www)75.2 (.theannals.com)]TJ
ET
0 0 0 0.10001 k
59 165.854 275.492 12.644 re
f
59 141.273 275.492 12.645 re
f
59 117.401 275.492 12.644 re
f
59 93.528 275.492 12.644 re
f
59 67.498 275.492 15.279 re
f
BT
0 0 0 1 k
/T1_1 1 Tf
0.011 Tw 9 0 0 9 110.4972 248.7909 Tm
[(T)74 (able 1.)]TJ
ET
BT
/T1_2 1 Tf
9 0 0 9 144.0128 248.7909 Tm
(Switches to Other Hormone Therapy )Tj
ET
0 0 0 1 K
0.5 w 
59.5 232.041 m
334.001 232.041 l
S
BT
/T1_2 1 Tf
9 0 0 9 111.4296 237.7908 Tm
[(Among W)18 (omen Discontinuing Oral Estrogen)]TJ
ET
BT
/T1_1 1 Tf
0 Tc 0 Tw 5 0 0 5 279.4172 240.5409 Tm
(a)Tj
ET
BT
/T1_1 1 Tf
5.528 Tw 7.5 0 0 7.5 126.63 221.7909 Tm
(Pts.)Tj
7.895 0 Td
(Pts. Pts.)Tj
15.534 0 Td
(Pts.)Tj
-0.01401 Tw -31.42975 -1.06667 Td
[(Y)55 (ear of)-2265 (Discontinuing)-1597 (Switching to )-1446 (Switching to)-1965 (Switching to)]TJ
-0.49976 -1.06666 Td
(Last Oral)Tj
0 Tw 8.417 0.00001 Td
[(Oral )-4864.6 (V)55 (aginal)-2916 (T)55 (ransdermal)-2847 (T)18 (ibolone)]TJ
ET
59.5 193.541 m
334.001 193.541 l
S
BT
/T1_1 1 Tf
7.5 0 0 7.5 62.1961 197.7909 Tm
(Purchase)Tj
-0.01401 Tw 6.84923 0.00001 Td
[(Product \(n\))-2435.9 (Product \(%\))-2042.3 (Product \(%\))]TJ
0 Tw 25.30862 0.00003 Td
(\(%\))Tj
ET
BT
/T1_2 1 Tf
7.5 0 0 7.5 64.752 181.7909 Tm
(1999)Tj
7.748 0 Td
(1,347)Tj
8.631 0 Td
(0.7)Tj
7.703 0 Td
(5.0)Tj
7.864 0 Td
(0.0)Tj
-31.946 -1.6 Td
(2000)Tj
7.74791 0.00001 Td
(2,212)Tj
8.62993 0.00001 Td
(1.1)Tj
7.703 0 Td
(3.8)Tj
7.864 0 Td
(0.0)Tj
-31.94484 -1.60002 Td
(2001)Tj
7.748 0 Td
(2,509)Tj
8.631 0 Td
(1.0)Tj
7.703 0 Td
(5.2)Tj
7.864 0 Td
(0.0)Tj
-31.946 -1.6 Td
(2002)Tj
7.748 0 Td
(4,033)Tj
8.631 0 Td
(1.3)Tj
7.703 0 Td
(9.3)Tj
7.864 0 Td
(0.3)Tj
-31.946 -1.6 Td
(2003)Tj
7.74791 0.00001 Td
(2,181)Tj
8.62993 0.00001 Td
(1.6)Tj
7.703 0 Td
(6.2)Tj
7.864 0 Td
(8.8)Tj
-31.94484 -1.60002 Td
(2004)Tj
7.748 0 Td
(1,350)Tj
8.631 0 Td
(1.5)Tj
7.703 0 Td
(4.4)Tj
7.864 0 Td
(5.8)Tj
-31.946 -1.6 Td
(2005)Tj
7.748 0 Td
(1,225)Tj
8.631 0 Td
(0.9)Tj
7.703 0 Td
(5.5)Tj
7.864 0 Td
(5.3)Tj
-31.946 -1.6 Td
(2006)Tj
7.74791 0.00001 Td
(1,176)Tj
8.62993 0.00001 Td
(1.2)Tj
7.703 0 Td
(4.1)Tj
7.864 0 Td
(4.0)Tj
-31.94484 -1.60002 Td
(2007)Tj
7.748 0 Td
(2,654)Tj
8.631 0 Td
(0.3)Tj
7.703 0 Td
(1.0)Tj
7.864 0 Td
(0.9)Tj
ET
59.5 67.541 m
334.001 67.541 l
S
BT
/T1_2 1 Tf
-0.01401 Tw 7.5 0 0 7.5 64.752 73.7909 Tm
[(All years)-3373 (18,687)]TJ
16.37899 0 Td
(1.1)Tj
7.704 0 Td
(5.3)Tj
7.863 0 Td
(2.2)Tj
ET
BT
/T1_1 1 Tf
0 Tw 5 0 0 5 62.5 56.5409 Tm
(a)Tj
ET
BT
/T1_2 1 Tf
-0.01401 Tw 7.5 0 0 7.5 65.2795 53.7909 Tm
(Maccabi Healthcare Services, 1999\3202007.)Tj
ET
59.25 48.25 275.001 210.998 re
h
S
BT
0 g
/GS2 gs
/T1_7 1 Tf
0 Tw 5 0 0 5 285.1575 11 Tm
( at University of Canterbury Library on August 25, 2014)Tj
0 0 1 rg
/GS2 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS2 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
53 0 obj
<</BaseFont/DJTMWX+Helvetica-Bold/Encoding 50 0 R/FirstChar 32/FontDescriptor 52 0 R/LastChar 119/Subtype/Type1/Type/Font/Widths[278 0 0 0 0 889 0 0 333 333 0 0 0 0 278 278 0 556 556 556 556 0 0 0 0 0 333 0 0 0 0 0 0 722 722 722 722 667 611 778 722 278 556 722 611 833 722 778 667 0 722 667 611 722 667 944 0 667 0 0 0 0 0 0 0 556 611 556 611 556 333 611 611 278 0 556 278 889 611 611 611 0 389 556 333 611 556 778]>>
endobj
29 0 obj
<</BaseFont/ITNCSN+Helvetica/Encoding 26 0 R/FirstChar 32/FontDescriptor 28 0 R/LastChar 213/Subtype/Type1/Type/Font/Widths[278 0 0 0 0 889 0 0 333 333 0 0 278 333 278 278 556 556 556 556 556 556 556 556 556 556 278 278 584 0 0 0 1015 667 667 0 722 667 611 778 722 278 0 667 556 833 0 778 667 0 722 667 611 722 667 944 0 0 0 0 0 0 0 556 0 556 556 500 556 556 278 556 556 222 0 500 222 833 556 556 556 556 333 500 278 556 500 722 500 500 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 556 0 0 0 0 222]>>
endobj
26 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 37/percent 40/parenleft/parenright 44/comma/hyphen/period/slash/zero/one/two/three/four/five/six/seven/eight/nine/colon/semicolon/less 64/at/A/B 68/D/E/F/G/H/I 75/K/L/M 79/O/P 82/R/S/T/U/V/W 95/underscore 97/a/b/c/d/e/f/g/h/i 107/k/l/m/n/o/p/q/r/s/t/u/v/w/x/y/z 208/endash 213/quoteright]/Type/Encoding>>
endobj
28 0 obj
<</Ascent 717/CapHeight 687/Descent -194/Flags 32/FontBBox[-166 -224 1000 931]/FontFile3 27 0 R/FontName/ITNCSN+Helvetica/ItalicAngle 0/StemH 0/StemV 88/Type/FontDescriptor/XHeight 737>>
endobj
27 0 obj
<</Length 5268/Length1 5268/Subtype/Type1C>>stream
  ITNCSN+Helvetica   @¯ ¯¯¯¯˚:˚t˙|˙7
 ãã
 ãã   Û   Ô  ~¨  s Äà002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Helsinki is a trademark of Stream Technologies Inc.Helsinki  D  1 # B S C  ( 4 J M W F N O E & I V , P L " U G Q Y  5 T D Z 	 ) 3 
 X H   8  *     [   '     7  R    0 %  - . o 6 @ ! F   D ∞<uœ“<ΩﬂÙyÿyûÿGé¡˚,e…3≠ˇLÖ¥		R	ê

l
≥
˜(=a÷Vè∂ÎBeî<uûuÔ#wº◊ÓI_öÆeú†v˜¬ﬁ˜é›·Ì˜ÁÓ˘¯ò˜6€˚˚◊˝aÌ˜¬˜u˜··˜(â6Y_+˚U˜é˜XÈºb;úãﬁ˜êŸ˜r›‘Ï˜ÿÎMÎ¯˘˜l‡gª-±Õ≠©ª–ˆ:”˚˚Œ˝a˜ Ù˜%Î·˜¯˚˜À?Ye(˚C˜r˜CÔºgCÙ≠˚Õ7U\*˚c˜ê˜R˜≈b;-|‘[v˜âÕ˜8‘Ø‰L€˜Ö„6‡µ¯§Àá~ÉäÑvÉî°˜¡Ê@¬˚˚HT˚
Ñ€—ï∞©Ÿ÷∑kSi{wlá˚$yπ$~SQ.0ÕOÌ◊√§«ƒˆQë§t√ûñçî°∫˚%˜HK>Q5Qf´ø¿Ø©ÿî˜òÜä≥ü˚—†v¯PÈ|wÿ›9„˜ﬂ¯PÊç~ÑåáQamB]â„9¸üË„˜ƒ‹√∆Ÿ-{ÿcv¯`Ÿ˜Gw≈„3ﬂ˜±Âz¯ô˜®˜24Û˚MZqTcâ˜ò3˝aﬁÃçˆN∏ØwŒ˜Â˜˜D1É˚W?13T“˜˜Ω◊ÊÍºI˚¸˜xﬁ`v˜¡ﬁ˜ü‡ªÔ¯eÂ|˘S¯˚Œ8˜tà@Ågqf¸PcJm8˚09Ò˜V˜EÈ˜˜'˜ –Y&´Ë˜(o˚„˚7˚b˚˚,˚˚o˜˚)˜TˆÿÆÿ…|£.úxﬁ˜ãŸ`Â˜nﬁºÊGË˜ÍÊCË’¯ˇ˜YÔQœ#£ˆ˚a∫Qòn¨ãΩ÷ ∫˜«Z*îÊ˜/Ä3’˚B˚2,7˚3øSÒsŸ˜&h˜
oØpãN4L_˚˚D∆ˆà0åçDïe©dGøŸi˜ ˜Kˆ€˜¸@†v¯üw˜ÌŒ„˜/¯ˇÌ3)„¸ˇ¯ü3¸ü¸@†v˘awŒ„˜/˘a3˝a˚*†v¯üwì¯w¯¯ü+˚(¸=âä˚¯>'˜R¸üË-|◊˜@—˜/€≥Ë˜¥‚8ÊÙ¯ò˜}˜V:˜˚%˚1.˚ ˚K˚6Á'˜*¯˜ÿ»˜
ß4J{YeC.W√˜ÜÙ˜∏—˚∏Ïî«≈›Ô∞@;è˜K†v¯_⁄|wÃﬁ8„˜q„˜n„ˆ˘î˜˛˜KŒ%Lp|EJ≈o^¶IGYoNcâˆ’8¸üÓ„˜±Ù¡–ﬂæ´fO˚˛„˜”Ÿ¡…ŒÃ´c:˚Ê-†v¯^€|wÃﬁ8‰˜è‚Ù¯Ä˜˜˜IŒ˚EZpM_âÙ’8¸üÏ‰˜∞˜¿ÃÂ’≠`.˚÷-|◊cv¯_Ÿ˜HwÆÂ˜±„4‚:‹y¯Ü˘a˙4˚°âŒ[d°E˚7&˚5˚E‰˚˜!œªß≈≠yçD¸Ñ˜â˚TD24Uÿ˜˜∫ÀÍÊø>˚úã·˜Ö‡˜p‡·Ï¯¸·¸E˜Ö¯‡¸˜p¯<‡¸ù˝a-†v¯_€˜FwÃ„˜è‚¯˜˜˜
KÕ˚HbtLYâ˜ú3˝a„˜±˜¬ Î–™f:˚È-|◊cv¯üwœ‚˜â„8ﬁÙ¯|¯ü¯3˚¥ TH2Hi≤◊˜Ô4¸%…Oˆ€¥¢—∏Ùç=ú†v˘aw÷Ï˘)˚«¯@˜æ˜µ˚˚Ô˚˜*˝aÏ˜è˜˜˜è˚¸-}◊¯$◊ÆÊ˜ƒÊ¯ù˜ö˜7'˜˚#˚#'˚˚7˚8Ó˚˜$˜$Ó˜˜80˚P=..PŸ˜˜∆ŸËË∆=˚˚*†v¯üw˜jwŒ‡¯â˚h˜€˜\˜X˚˚v˚q¯36˝a‡˜Z‘Õ˜7˚úú†v˜d‚¯:wô˘˘ ˚ò˘a˚˚†˝aÓ÷˜d˜≥“˚d!˜ª˚r˜˜–ç¸Ñ◊¯’ﬂ„˜ï–mezó®˜Áﬂ’7˜&3˚&EA—˚Ï?¨g–úôåë≥¸†v¯U’˜awﬂ„˜ò¯U’3Ã∂õû∞ìîäâù⁄åwÄåÇ/_f=1EA—¸U„¯U-˚Lv˜R◊¯#⁄{w≈ﬁ8„3ﬂ˜±ÂÈ¯ô˜®˜24Ù˚H^qL`â˘‘8˝lÂ„˜òçWµÆy»˜#„˜˜H1Ö˚X?0„2U–˜˜!º’ÁÍºJ˚˚*†v¯üwò¯r¯˚L˜†˜E˜ì˚ ˚˚M˚˜M˚˜B˚ì˚K˚†˜˜˜Y˜˚Y¸ãı‚Û˜Sı#!d†v˘‡˜ïÎ¯Á˘‡¸Ÿ6˜á˝Î˘˚*|÷˜2ŸV÷˜$◊´ﬂGﬂ˜y‡D„’¯c˜2‘c± ¶ˆ4°<üyòã±∑µ® ‹±pNê‡˜ ÇF√˚˚=J%I≥a›wŸrﬁv†}ãdW]k@2d©ŸÅ7éTíqùp´\”oÊã˜ãﬁ–ãÛ˚*{ÿ¯"⁄©È˜†‡7ﬂË¯q˜L7<y]_I1Z“˜˜¬’Áœ±h>ö‡˜}GÃ˚˚)*˚˚?˚8Á ˜"˜€÷˜ô˚*˚j⁄˘&wñ¯q¯|¯ü+˚!¸?â˚¯?(˜V¸¨b˚Çdãv|éëv<ÖõóàúÚõ†˜_ÿÔ˜úêñﬁ˜Ç˚—˚Mv˙>wœË˜ø˚b<˜2P˜˜J˜D≥˜Î˜;O˚˚B]˚˚=˚V—˚Ú˚0”†v˜·‚˜ΩwÿÏ*Ì¯
ÏÙ˘˘a*˚Ω¸˜Ω*˝aÏÌ˜·¯
˚·”†v˜«ﬁ˜ä‹„Î¯Ó˘>õoöÖóâ∏Ö˜á◊y©Kß÷π§∂ã‡ã˜6–˚*ã˚ﬂ˝aÎ˜«˜ÊÆi.çé˚å}òRÇ¯ô6[a*˚v˜ä˜áﬁ∏a>˚—˚Nv˙>w˜@Ë˜ù˜ù˜VE˜$˜0Q⁄˚2∆˚˚J˚Dc˚+˚;«˜˜Bπ˜˜=”†v¯üwõ˘I˘Y¯ü4 ¸.â&¯.)&¸.â'¯.,˜+¸üÂÒ¯)çÙ¸)Ê-˚n”˜◊¯!€|w≥Ê@„˜ü„7ﬂ9›‘Ä¯á∂¯t9@˘ âÃ^^§H˚4"˚0˚D‰˚˜“µ†¿´ˆ çu˚cZ˚Hg§ƒ}3"úÕZ˜˜7’›˜G˘ 7˜b˚WH/5Uÿ˜˜ªŒÁÈΩC˚-ã›¯±⁄•Ó:‚˜ØÁË¯é›¸òÀª≥∆´‘≥Ô¬„º˜˜3ﬁ˚ÿ˚3?$˚)‚˜ë∏¡Â‡ƒW=Dmk&Q/VË˚Fc5Ö˚-w€¯«⁄∞Ë˜∫Ë¯ô˜È˜}6˜˚/˚/6˚˚}˚z‚˚˜-˜-‚˜˜z.˚KX)++XÌ˜K˜OΩÍÏÏΩ+˚N˜∫†v˘awõ˙"˙2˘a ˚¸€â˚4¯€"˚6¸€â˚¯€#˜O˝a˜:¯Áéå˜7¸ËÒ¸@†v¯¯Ù¿ÛXæ–˜1˘ Ï‡#"–¿‡äHscÅ]”õ´ªÊ¸†v˘awÊÏ˜P˘a*˝a-†v¯Ü“˜w˜úÍ¯Ü˜7¸ÜÍ˘REp$qx˚Ä-x‘˜I⁄˜ÀŸµÂ9‚˜¶Ò4‚Ú¯ï¯˜k7˜˚6˚1+˚%˚‡2˜Ÿ¡¶ƒÆçân˚X`H)ãÍEa¥’Ñ4˚î‘I˜÷∆®≈µΩŒ®˜˜Ù%Ì#XR.6Y¡ÁÒø ﬂ‚√P0-x⁄˜¢◊˜oŸ±ËEÊ˜åÊGËÍ¯ò˜`Ÿh¿;≤ÏÀ¨•¥Œ˜5’˚˚7?˚I®aÕmÚ5ck[/˚Ó4˜!˜$È„˜Ï˚˜—HV[BEWªÃÃπ¥—‹æcKÚ¢˚⁄5XZ1.Q¡‚◊«¿‡ÂƒV9-†v¯Ì·˜Í¯û¯ˆÿ¸y5¯@1W:U˚O˚l/}#Í≠˜4¢“¡˜ ƒ˜¿⁄–ÿ˚*ã”¯’™¯I¯h”˚’˜Õ¯’¸)A˜∂˚Œ¸F-†v˜>◊¯]w˜ﬂ„¯ù˜>◊%¯]B˚’¸R4˜∆˚>„˜>3◊˚u˜t˜‘å-x◊˜–⁄˜*·´Â˜ΩË¯î˜x˜(Î˚Tfk^™˜V˜Ω·˚ˇW¸÷ÜµºÆù¿ãÊÃK1*LJ/;\≤Ÿ|1˚ú◊K˜˜1ÏÈ˜-d†v˜Ÿ·˜p··Ï¯⁄˘·¸Ñ˝aÏ˜Ÿ˜Ù·˚Ù˜p¸ãı6v‚ÛXæ–˜SìÌ‡#!–¿‡äHscÅ]”õ´ªÊ˜Éçvò—˜\—°—˜]—≤—˜]—˜—˜]—Ä˘Â˜8È?◊,-??--◊?ÈÍ◊◊È˚J¯∞UˇÄ¸˝g¡ˆ¯µÍ?◊-,??,-◊?ÍÈ◊◊ÈÄ¯#˚˛T^^ST^∏¬¬∏∏¬√∏^T¸i˜˛T^^TS^∏¬√∏∏√¬∏^SIª¯{¯´ñ€¸˜6¯˜6€¸{˚dE¸†v¯/ı‚ÛXæ–˜S¯/ı‡#!Û¸'Ì#!–¿‡äHscÅ]”õ´ªÊú†v˘awü˘˘˘a˚˚^¸˜â˚b¯˜ ˜ö˝aÚ-x⁄˜…⁄˜E⁄±‰2Ú˜ß‡AÂÚ¯ô˜q˜1Ë˚@VpOdàçï˜?«ÊÒãÏÀ≥fCò‡Ü«~´i≠e≤Q¢Rã˚5ã*˚#ã˚ã˚v·˚˜7ãÍ˜ÏÒ˜1Ü0RJ94OÀÁÁƒ»‡„√P--˚Nv˜T◊¯"⁄|wÆÊ˜≠‚7ﬂ8ﬁŸ¯Ç˚c˘n8Aâ¸…a\¶G˚4"˚1˚G„˚˜!»≥üº≥ç˚ô˙é¯Y˚UF14Vÿ˜˜∫ÕÁÈæA˚-x⁄˜ú‘˜w⁄≠Á˜™ÂIÈÙ¯û˜bﬁiª8≠ç¯√†¨øŒ˜6’˚˚(FD˚3É·˜ ì≤∂„›Ω`DAYd,~Öãçz?åõìãéÙ˜¬c39MU+*`π˜á/˚6ô”C˜(˜/Ó„˜¸ãı˜≈ı‚Û˜S¯/ı#!Û¸/ı#!˚—†v˜{Â∑˜à˜¥˜{Â˚à1˜x‚¯‹‡≤Ó¯âÓ˘v˜˚˜u˚!˜-˚d˚d˚"˚-˚u˚v˜ ˚,˜f˜e˜ ˜,˜v(˚A%˚
˚(˚)%˜
˜A˜EÔ˜˜+˜*Ô˚	˚D”ã›¯Ω›‹Ì¯Ó˘5¯˜g˚˜˚J˚∑˝a˜≥˜R˜˜˜z(Ö˚A< ˚˚O¯Ω˜I˜5¿˚˚¸çv˘áwz˜Ã˜ª˘tI˚ä˝áŒ-ã·˘w◊Ï¯¨·˚ˇ˘*˝a˜K†v˘aw‘Ë.Ê¯äÈ/Á‰˘å˘a˚˚_¸Òâ˚a¯Ò˚˝aË¯<‘«â∆ã«Ëç˜_¸ÔÎ˜]¯‰çËä˚	ä∫;ããã¸Z-†v˜É’ã¯¿¯¿˜É’¸¿A”x·˘w⁄Ï¯Î˘˜ë¯d+¸Y˚FC˚˚I”˜¯V*¸r˚1˜ &˜<˜F˜Ú˜=-˚Ωã¯¿¯¿˚Ω¸¿Y¯x…ËÃJ‘˜∏”Ò»˜'‘◊ﬁ¯:Ãﬂ˘ˆ¯>˜C˚*˜˚V˚e˚:˚:˚d˚k˜:˚:˜l˜˜Œ˜ I@H8d/˚B˚˜˜C˜K˜˜˜A˜3˜˚˚$ F˚Cyäöö§ßÈ»˜cGwMlƒj†Wã˚$˚˚,5ÕAÿ∂¨òΩªçaè†v±Æ¿¢¨¥“∆±›Ëˇ˚ìy*>%A[j≥ƒÏ’Ì‘π≤`Yu°¯üö˜)õôü˜°ñ¸}ö◊
„
_˜™˘
endstream
endobj
50 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 37/percent 40/parenleft/parenright 46/period/slash 49/one/two/three/four 58/colon 65/A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P 82/R/S/T/U/V/W 89/Y 97/a/b/c/d/e/f/g/h/i 107/k/l/m/n/o/p 114/r/s/t/u/v/w]/Type/Encoding>>
endobj
52 0 obj
<</Ascent 750/CapHeight 717/Descent -205/Flags 262176/FontBBox[-170 -227 1001 963]/FontFile3 51 0 R/FontName/DJTMWX+Helvetica-Bold/ItalicAngle 0/StemH 0/StemV 140/Type/FontDescriptor/XHeight 737>>
endobj
51 0 obj
<</Length 4381/Length1 4381/Subtype/Type1C>>stream
  DJTMWX+Helvetica-Bold   @¯ ¯¯¯¯˚>˚w˙}˙W
 ãã
 ãã      u≤  ˆ Äçï002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Helsinki is a trademark of Stream Technologies Inc.Helsinki BoldHelsinki  6  # " $ , ( 3 0 6 / %  + & 5 * 7 . ) 4 -  : 8 F U I P E T V M  1 ' J H S    D O   B C W N L Q G X 	 
  8   | ∑	;°XéΩ+cè±»Ú2\ÈYÖRé’~Ë/FIé∑ﬂ	X	ù	À	‡	˝
K
ì[€;f◊wØÛ8Ä”ã˜˜U˜˜0˜◊˜$˜Æ˜#˚˜)Ù˘0˜m‡m∫:±¯ Æ§¥Œ˜5”˚˚˝a˜≈ﬁ»ïû≠Ùœ±¥—€¯˚:˜¡XdmG˚C˜0˜?◊ÆtWÙú˚∫KafC˚M˜U˜Sœ≥iQ”†v˜'˜¯Qwü˘;˘O˚ë˘a˚A˚ë˝a˜1Ω˜'˜ùπ˚'3˜§˚LÁ˜∞ç”x˜¯É˜∑˘˘?˜â˚)*n_f6˚HÁ˜,˜4ÕÊ˜
ﬁµi1ß˜(˜-~˚˚A˚]˚˚'˚|˚|˜˚$˜^˜;ˆÊ˜A∞”†v˘aw‚˘˘e˚»¯=˜∑˜∏˚U˚•˚µ˜µ˚+˝a˜+˜á—”˜q˚œ˜x˜4v˜û˜˜u˜¯◊˜x˘[¯˚Ω˚˜9¯˚ oQY*˚AÁ˜0˜4ŸÏ˜◊∆_B°˜(˜)x˚Ê˚C˚i˚˚(˚z˚v˜˚+˜YÌÃ´Ÿ»xô0”†v˜Æ˜˜T˜◊˜(˜∏˜(˘9ûsîÑù¿˜HÄ©:Ø’©Øƒﬂ˜3⁄˚˚ˇå˝a˜'˜Æ˜/Óöy˚
çåFéoòZè¯ÜIgn:˚C˜T˜OŒ±hM˜x˜¯ä˜∑˘F˘r˜˙˜m˚˜6˚v˚u˚˚4˚o˚n˜	˚3˜x˜t˜˜4˜m˚*å˚0A,˚˚AÍ˜0˜/÷Î˜˜÷+˚/”x˜¯ˆw”¯÷˘˜é¯g˚,¸m/[^*;[¬Â¯e˚-¸p˚7ı*˜F˜TÒË˜D”†v˘aw–˜ ˜ƒ˜ ˘!˘a˚ ¸àâ˚±¯à˚1˝a˜ ¯îç˜∏¸î”ã˜¯i˜◊˜'˜»˜,˘?¯˜n'˜˚S˚–˝a˜À˜J˜˜%˜{˚,˚(M0'˚&¯i˜$˜¿@˚/˚—ã˜%˜r˜%Á˜*˜Ü¯˜%˚*˚%˜*¸˜%˚*˚%-y˜¯˙w°˜˜A˜*¯w˜d¯ë˚*¸ë?snNKs±Ú¶˚l˚OÃD˜A˜'◊ÿ˜)úã˜˜O˜˜+˜◊˜'˘ ˜¸!˜O˜˜˚˜+¯˜¸¢˝ad†v¯„˜˜z˜+¯Ë¯„˜¸⁄˚˜l¸„˜+¯„¸†v˘awÀ˜*˜j˘a˚*˝aú†v˘awû˘˘˘a˚/˚0¸≥âä˚.¯¥˚4˜Ü˝a˜#˜K†v˘aw–˜ ¯4˜˘ê˘a˚l˚¸…à˚¯…˚o˝a˜ ¯Ïç˜¸Ï˜(˜¯Ïç¸Ï”†v˜’˜˜§w“¯◊˘˘a˚*˚§˚´˜§˚*˝a˜*˜’˜´˚’úw˜˜I˜$˜'˜6˜≤˜"˚˜˜•˜#˚˜%’˘	˜lÚS√˚¨ˆ˚C∑Sôv†ã¥¿º¨◊Ê∫hBï˜#˜$Ñ ‚˚;˚A&8˚"˚*ıo˜nŸÿyÓt™vã^NYl&,Z∞ŸÉ˚"çCôd±aøSÂk˜ã˜@ã˜Áã˜$dã˜¯ﬂw◊¯é¯⁄˜˚¯¯ﬂ˚*˝a-ã˜¯h˜
´˜˜]˜ ¯í˜˚»®ƒ˜œ ≈¿ª®¬ã⁄ã˜(„˚'ã˚'ã<6Ü˚9˜Óè•¨“«≥bL4Gk˚4˚*jSÑ˚ú†v˘awö˘˘˘a˚=˚!˚À˚*˜À˚D˜å¸S˚¢˜+˜°˜∫†v˘aw˜∑œ¨Ÿç⁄¨‘˙4˘a˚+b˚Cb˚Bg˚Dâh˜UçÉB˜Ë˚3N˚æîøZ˚´âh˜Sêt7˜˘˚3˜_˝a˜ ±˜N∂˜N©˜Pç™˚O≥˚P¥˚M˜#-}˜˜Ê˜˜¢˜#˚#˜ ˜p˜#Ù¯¢˜x§˜P2Ù˚5˚4.%˚D˚IÁ&˜9˜⁄¬˜Ø˚#cyny\ÏAdµ‰ÑÙ˜pÊ˚m⁄ò´¨  Øf@ï˚—Öı˜ﬂÔ›˜ ˜»àıâ|Ñä^Ñë±˜≥·Ô5˜%˚ ˚%C'”˚’7≥kÚùûôåç´d†v¯@˜˜>wÃ˜˚˜ ˜]˜Ù¯µ¯˜C—˚CVnUoà˜ë˚˝aÏ˜ ˜≈ﬂ≥≤’∆ßjC˚◊d}˜	˜Ÿ˜
≠˜#˜ï˜#¯’˜û˜?!˜˚9˚:!˚˚?˚AÛ ˜<˜;Û˜ ˜@˚# _S76_√ˆÙ∏ƒﬂﬁ∏R"d}˜;v¯<˜˜?w≠˜$˜|˜˚˜z¯∏˘a¸˚˚ìâ ^d†D˚5˚ ˚;˚@‰˚˜œæ¶¡ÆçzH˙é˜ò&^Q=E^ ÏÛµ∆÷⁄µR -}ı˜ı©˜#˚˜˚˜˜a˜ ‘¯ö˜9˜d˚·?ãÍ©´ù¿«®uZë˜˜Ñ;≈˚-˚;D ˚X˜› ã3ggxVÃ=h¢¬à‰˚#˚çÎE˜0˜#Ê–˜d}˜
8v¯ßwÕ˜ ˜[˜˚˜Ù¯≥¯ß¯˚˚«B`\IOm¨Ã˜›˚ ˚Ò˚ÕC˜÷æß»ØÙç@¸†v˘aw–˜ ˜e˘a˚ ˝a¸ú†v˜ó˜˜h˜¯q˜)˘¯Ä˜4·˚˚‹˝a˜*˜ó˜@˜ÁÈ˜˚)âCfg@˚˜h˜
ÌÆo?d†v˜¡˜˜7˜◊¯ë¯›¯„˜¸ë˝a˜*˜¡˜Œ˜˚Œ˜7¸†v¯ßwﬁ˜–˜ ˜e¯Ê˜˚ ˚˜ ¸Ê¯ß˚ ¸ßd˚mı˜ ˜
˜…˜|w≥˜#˜z˜˚˜⁄¯º®¯ä˚<â¸ÀmX©D˚4!˚<˚?‚#˜!–¥£ƒ´éáL4hh>Ktò¥Å˚,#óﬁS˜'˜èí˜.Á˚˜Ñ*eR:G`«ÈÍ∂«Œ◊∑J1˚ô†v¯(˜"|wÀ˜˚˜ ¯¯%˜"éÜãÅJgp<_âÊ˚¸ßË˜ ˜®ﬂ∑∑ﬂñîäâü-†v¯}Ó˜w˜Å˜!˚˜Ë¯˘Z˚8Td w(–˜<¸}¸ã˜%À˜*˜j˜%˚*˚%¸çv˘àwj˜Î˜ ˘u˚	˚v˝à˜-}˜˜€˜
≠˜$˜`˜!¯ü˜V˚!KjnSHg¡˜ı≥≈’∫©pPò˜!˜É+‘˚˚71$˚O˚?Â(˜/˜Âÿ˜ùd†v¯?˜|wÃ˜˚˜ ˜]˜Ù¯¥¯˜Dœ˚C_rH`âÙÿ˚¸ßÏ˜ ˜ƒÿµπ—«®iE˚◊-x˜˜mÔ˜O˜¶˜˚˜˜M˜ ˚˜$Í¯ò˜g‹d∆G£çÏ»Ø¢±Œ˜0ÿ˚˚1:˚&ä˜‹é≠≠≈¬ÆhTIel:v'Ú˜â≤q<K^]NHl∞‚Ü˚˚)âÊ3˜,˜(ÔË˜-†v˜0˜¯Qw˜∆˜ ˚˜Ë¯°˜0˜<¯Q˚4˚ó¸D˚–˜´˚0˜ ˜0˚¯3ä'ä#%˚E»˜E˜∆-}ÔJv˜z‹˜˜®˜˜Q˜|¯°†uíÇ£ø˜¥Î;≈˚˚0FU˚Ä˜Ωèß£¿ ®x`t|}iÜ˚x${XRã*¸.ÀMÎ”≤ù∆…|åqçÅîp¸z˜SRS[K`q§≤ª°û“ò–òàä©úd}˜;v¯=˜˜>w»˜ ˚ ˜˜É˜#z¯’˜•˜72˜˚E]rQeâ˜ë˚ ˝a˜ŒéˆSÆªr–˜·˜˜D˚#Å*]JE@[…ÏÙ∑«◊÷∑O%-†v¯ßwò¯§¯±¯ß˚'˚¸â˚¯˚/˜T¸ß˜&˜É†v¯?˜
˚	˜
|wÀ˜ ˚ ˜˜E˜˜>˜ Î˘Ã¯˜C–˚O`qPfÁŒ_jûCF^pJgâ˜ÿ˚¸ßÎ˜ ˜◊–®Øƒ…¢n:˚“˜˜“Î”´∞…Ω•m@˚÷-†v¯ßw˜bw–˜ ¯∆˚T˜Ÿ˜N˜b˚?˚D˚]¯˚ ˝a˜ ˜<∆«˜˚xd˚Nv˜U˜˜Ÿ˜{w…˜˚˜!˜{˜#Í¯’˜§˜82˜˚AcsF^â˙ÿ˚˝vÊ˜!˜¶çå≠Rπr–ã˜·˜˜D˚#Ç)^KEÍ?\∆È˜¥∆Ÿ÷∑O$˚—†v¯EÌ‹˜·˜ ˜—¯EÌ0†øëìµ≤˜çhÄãq#XZ%_?)◊¸E˜ ¯E˜†v¯ßwï˘à˘í¯ß˚#9¸à<¯˚!@¸â8¯˚(˜)¸ß˜%›¯éﬁ¸˜"˚—†v˘qwÆ˜$˜Õ˚bd‘|®|≠_Òv˜ ã˜ã˜°˜¥ÓöÆîü∏ﬁ&˚˚0S˚*˚;˚3∆˚0˜
˚+˚—†v˘qw˜-˜$˜Ω˜û˜4R˜+˚˜0%≥@ônöjµ.¢˚ã˚ã˚x˚`'|gzleE˜	˜)≈˜1˜:˜ÉçvìÚ˜1ÚÜÚ˜1ÚßÚ˜1ÚÛÚ˜1ÚoÄ˘Ó˜?Ô:‹'&::'&‹:Ô‹‹˚J¯∞AˇÄ¸!˝n’˜¯∑:‹'&::&'‹:Ô‹‹ÔoÄ¯ ˚˘_hh`_hÆ∑∂ÆÆ∑∂Æh`Ä¸g˜˘`hh`_hÆ∂∑ÆÆ∑∂Æh_wü¯ßö˜,óíüòã˜£ó¸|ãı
˜ å
_˜™˘
endstream
endobj
88 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
89 0 obj
<</OP false/OPM 0/op false>>
endobj
97 0 obj
<</A 98 0 R/Border[0 0 0]/Rect[244.413 9.0 286.158 16.0]/Subtype/Link/Type/Annot>>
endobj
98 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
73 0 obj
<</Annots 99 0 R/Contents 100 0 R/MediaBox[0 0 612 792]/Parent 72 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 101 0 R/GS2 102 0 R>>/Font<</T1_0 29 0 R/T1_1 33 0 R/T1_10 90 0 R/T1_2 37 0 R/T1_3 41 0 R/T1_4 45 0 R/T1_5 49 0 R/T1_6 53 0 R/T1_7 57 0 R/T1_8 61 0 R/T1_9 65 0 R>>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
74 0 obj
<</Annots 103 0 R/Contents 104 0 R/MediaBox[0 0 612 792]/Parent 72 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 105 0 R/GS2 106 0 R>>/Font<</T1_0 33 0 R/T1_1 37 0 R/T1_2 53 0 R/T1_3 57 0 R/T1_4 45 0 R/T1_5 41 0 R/T1_6 69 0 R/T1_7 90 0 R>>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
75 0 obj
<</Annots 107 0 R/Contents 108 0 R/MediaBox[0 0 612 792]/Parent 72 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 109 0 R/GS2 110 0 R/GS3 111 0 R>>/Font<</T1_0 53 0 R/T1_1 33 0 R/T1_2 57 0 R/T1_3 37 0 R/T1_4 69 0 R/T1_5 41 0 R/T1_6 45 0 R/T1_7 29 0 R/T1_8 90 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 9 0 R>>>>/Type/Page>>
endobj
76 0 obj
<</Annots 112 0 R/Contents 113 0 R/MediaBox[0 0 612 792]/Parent 72 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 114 0 R/GS2 115 0 R/GS3 116 0 R>>/Font<</T1_0 33 0 R/T1_1 53 0 R/T1_2 37 0 R/T1_3 45 0 R/T1_4 41 0 R/T1_5 69 0 R/T1_6 29 0 R/T1_7 90 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 13 0 R>>>>/Type/Page>>
endobj
77 0 obj
<</Annots 117 0 R/Contents 118 0 R/MediaBox[0 0 612 792]/Parent 72 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 119 0 R/GS2 120 0 R/GS3 121 0 R>>/Font<</T1_0 33 0 R/T1_1 37 0 R/T1_2 69 0 R/T1_3 41 0 R/T1_4 45 0 R/T1_5 53 0 R/T1_6 29 0 R/T1_7 90 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 17 0 R>>>>/Type/Page>>
endobj
78 0 obj
<</Annots 122 0 R/Contents 123 0 R/MediaBox[0 0 612 792]/Parent 72 0 R/Resources<</ExtGState<</GS0 1 0 R/GS1 124 0 R/GS2 125 0 R/GS3 126 0 R>>/Font<</T1_0 33 0 R/T1_1 37 0 R/T1_2 71 0 R/T1_3 45 0 R/T1_4 41 0 R/T1_5 69 0 R/T1_6 53 0 R/T1_7 29 0 R/T1_8 90 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 21 0 R>>>>/Type/Page>>
endobj
122 0 obj
[127 0 R]
endobj
123 0 obj
<</Length 7516>>stream
1 g
/GS0 gs
0 792 0 0 re
f
0 0 0 0 k
/GS1 gs
60 41.333 492 696.667 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
0.16901 Tw 10.5 0 0 10.5 60 730.8196 Tm
[(studies cited, a longitudinal study of HR)60 (T use in the)]TJ
-0.015 Tc 0.015 Tw 0 -1.23809 TD
(Netherlands documented little change after publication of)Tj
-0.013 Tc 0.013 Tw 0 -1.2381 TD
[(the WHI findings. However)40 (, a sharp drop in the purchase)]TJ
-0.01401 Tc 0.01401 Tw T*
(of oral estrogens in late 2003 was noted, after publication)Tj
-0.02499 Tc 0.013 Tw 0 -1.23809 TD
[(of the findings of the British Million W)80 (omen Study)65 (.)]TJ
ET
BT
/T1_1 1 Tf
-0.02299 Tc 0 Tw 6 0 0 6 265.1447 682.1197 Tm
(23)Tj
ET
BT
/T1_0 1 Tf
0 Tc 0.019 Tw 10.5 0 0 10.5 70.5 665.8197 Tm
(In parallel with a decrease in the use of oral estrogen)Tj
-0.02499 Tc -1 -1.2381 Td
(and estrogen/progestin combinations, we noted an increase)Tj
-0.006 Tc 0.006 Tw T*
(in the use of tibolone, a synthetic steroid whose metabo-)Tj
-0.019 Tc 0.019 Tw 0 -1.2381 TD
(lites have estrogenic, androgenic, and progestagenic prop-)Tj
0 Tc 0.01801 Tw T*
[(erties. T)35 (ibolone has been shown to provide relief of hot)]TJ
-0.021 Tc 0.021 Tw 0 -1.23809 TD
[(flushes/sweating comparable to that provided by HR)60 (T)55 (; the)]TJ
-0.01801 Tc 0.01801 Tw 0 -1.2381 TD
[(ef)20 (fect of the drug on cardiovascular and breast cancer risk)]TJ
-0.02499 Tc 0.017 Tw 0 -1.23809 TD
[(is less clear)55 (.)]TJ
ET
BT
/T1_1 1 Tf
-0.024 Tc 0 Tw 6 0 0 6 107.115 578.1197 Tm
(13,28)Tj
ET
BT
/T1_0 1 Tf
-0.0251 Tc 10.5 0 0 10.5 122.4056 574.8197 Tm
(A)Tj
-0.02499 Tc 0.017 Tw 0.93877 0 Td
(recent clinical trial of tibolone in women)Tj
-0.01801 Tc 0.01801 Tw -6.88216 -1.2381 Td
(with osteoporosis found it to be associated with a reduced)Tj
-0.017 Tc 0.017 Tw 0 -1.2381 TD
(risk of fractures and breast cancer but an increased risk of)Tj
-0.02499 Tc 0 Tw 0 -1.23809 TD
(stroke.)Tj
ET
BT
/T1_1 1 Tf
-0.02299 Tc 6 0 0 6 86.4427 539.1197 Tm
(29)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.00101 Tw 10.5 0 0 10.5 94.5176 535.8197 Tm
[(Although tibolone is not included in the for)-25 (mulary)]TJ
0 Tc 0.04601 Tw -3.28739 -1.2381 Td
[(of Israeli HMOs, Maccabi Healthcare Services of)27.2 (fers a)]TJ
-0.02499 Tc 0.009 Tw T*
(50% discount on the purchase of tibolone to members with)Tj
0.019 Tw T*
(supplemental insurance \(86% of women aged )Tj
/T1_2 1 Tf
0 Tc 17.55806 0 Td
(\263)Tj
/T1_0 1 Tf
-0.0251 Tc 0.52382 0 Td
[(45)-244.3 (y\).)]TJ
-0.02499 Tc 0 Tw 2.44619 0 Td
(Oth-)Tj
-0.019 Tc 0.019 Tw -20.52806 -1.2381 Td
(er members may choose to purchase this drug at full price)Tj
-0.021 Tc 0.021 Tw 0 -1.2381 TD
(without the purchase appearing in the Maccabi Healthcare)Tj
-0.02499 Tc 0.00101 Tw 0 -1.23809 TD
(Services database. Therefore, we may have underestimated)Tj
0.013 Tw T*
(the degree to which tibolone has become accepted.)Tj
0.01401 Tw 1 -1.2381 Td
[(Our analysis has several limitations. W)80 (e focused on pur-)]TJ
0 Tc 0.02699 Tw -1 -1.23809 Td
(chases covered by the HMO, rather than physician pre-)Tj
-0.017 Tc 0.017 Tw T*
[(scriptions or actual drug use. Further)-25 (more, we limited our)]TJ
-0.024 Tc 0.024 Tw 0 -1.2381 TD
(analysis to purchasing behavior and did not attempt to link)Tj
-0.021 Tc 0.021 Tw 0 -1.23809 TD
(trends in utilization to health outcomes. Since our analysis)Tj
-0.01401 Tc 0.01401 Tw 24.57143 33.42857 Td
(equated a discontinuation of purchasing with cessation of)Tj
0 Tc 0.07899 Tw T*
[(therapy)65 (, we could not separately analyze the ef)20 (fects of)]TJ
-0.011 Tc 0.011 Tw 0 -1.2381 TD
(physician and patient decision-making on changes in uti-)Tj
-0.005 Tc 0.005 Tw T*
[(lization. However)40 (, because patients may choose at times)]TJ
-0.02499 Tc 0.013 Tw 0 -1.23809 TD
(not to fill prescriptions they have received, purchasing data)Tj
-0.017 Tc 0.01601 Tw 0 -1.2381 TD
(are a more reliable indicator of actual utilization than pre-)Tj
-0.013 Tc 0.01199 Tw T*
(scribing data in that patients are unlikely to continue pur-)Tj
-0.035 Tc 0.013 Tw 0 -1.23809 TD
[(c)-10 (h)-10 (a)-10 (s)-10 (i)-10 (n)-10 (g)-10 ( )-10 (a)-10 ( )-10 (drug they do not use. In addition, it is theoretically)]TJ
0 -1.2381 TD
(possible for members to purchase medications outside of the)Tj
-0.00999 Tc 0.08501 Tw T*
[(system, resulting in underestimation of HR)60 (T utilization.)]TJ
-0.02699 Tc 0.017 Tw 0 -1.23809 TD
[(H)1 (o)1 (w)1 (e)1 (v)1 (e)1 (r)41 (, prescription drug coverage with a modest copay-)]TJ
-0.034 Tc 0.024 Tw 0 -1.2381 TD
(ment \(generally 15% of the cost of the drug\) is an important)Tj
-0.01801 Tc 0.008 Tw 0 -1.23809 TD
(benefit available in the standard services that must be pro-)Tj
-0.00999 Tc 0.024 Tw 0 -1.2381 TD
(vided by all HMOs, and it is unlikely that women would)Tj
-0.035 Tc 0.013 Tw T*
(choose to pay full price for prescription medications. )Tj
-0.007 Tc 0.007 Tw 1 -1.23809 Td
[(W)80 (e defined sustained usage as a patter)-25 (n of purchasing)]TJ
-0.02499 Tc 0.004 Tw -1 -1.2381 Td
(without a break of greater than 120 days. W)Tj
-0.0251 Tc 16.45583 0.00001 Td
(e)Tj
-0.02499 Tc 0.64825 0 Td
(chose this ap-)Tj
0.006 Tw -17.10408 -1.2381 Td
[(proach, rather than a calculation of adherence to therapy)65 (, to)]TJ
-0.007 Tc 0.007 Tw 0 -1.23809 TD
(identify time points at which therapy clearly appeared to)Tj
0 Tc 0.006 Tw 0 -1.2381 TD
[(have ceased, while allowing for less than perfect adher)5 (-)]TJ
-0.022 Tc 0.022 Tw T*
(ence. Because the analysis considered a range of products,)Tj
-0.013 Tc 0.013 Tw 0 -1.23809 TD
[(and dif)18.6 (ferences in packaging and dosage make it dif)20 (ficult)]TJ
0 Tc 0.007 Tw 0 -1.2381 TD
(to establish the number of days of therapy included in a)Tj
-0.02499 Tc 0.005 Tw T*
(package, we chose the last date of purchase as the endpoint)Tj
-0.01401 Tc 0.01401 Tw 0 -1.23809 TD
(of therapy rather than adding an arbitrary number of days)Tj
-0.006 Tc 0.006 Tw T*
[(to the calculated duration of therapy)65 (. This approach may)]TJ
-0.02299 Tc 0.02299 Tw 0 -1.2381 TD
[(underestimate the true duration of therapy)65 (. However)40 (, since)]TJ
-0.009 Tc 0.009 Tw 0 -1.23809 TD
(we used the same method to calculate treatment duration)Tj
ET
0 0 0 0 k
60.5 17.75 378.5 13 re
f
BT
0 0 0 1 k
/T1_1 1 Tf
-0.024 Tc 0 Tw 10 0 0 10 60.5 23.9116 Tm
(256)Tj
ET
BT
/T1_3 1 Tf
0 Tc 5 0 0 5 84.2499 25.4116 Tm
(n)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 97.431 23.9116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_3 1 Tf
0 Tc 0 Tw 5 0 0 5 230.556 25.4116 Tm
(n)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 243.737 23.9116 Tm
[(2009 February)55 (, V)110 (olume 43)]TJ
ET
0 0 0 0 k
472.5 17.5 79.5 13 re
f
BT
0 0 0 1 k
/T1_4 1 Tf
0 Tw 10 0 0 10 476.2004 23.6616 Tm
[(www)75.3 (.theannals.com)]TJ
ET
0 0 0 0 k
60 745 234 10 re
f
BT
0 0 0 1 k
/T1_5 1 Tf
0 Tc -0.013 Tw 8 0 0 8 60 749.5293 Tm
[(BG)-250 (Silver)-25 (man and ES Kokia)]TJ
ET
0 0 0 0 k
60.62 43.118 492 17.245 re
f
0 0 0 1 K
0.5 w 
60.62 60.113 m
552.62 60.113 l
S
BT
0 0 0 1 k
/T1_6 1 Tf
-0.01401 Tw 8.5 0 0 8.5 60.6199 47.8634 Tm
(Figure 4.)Tj
ET
BT
/T1_7 1 Tf
7.5 0 0 7.5 97.8987 47.8634 Tm
(Percent adherence to oral estrogen therapy by year of initiation of trea\tment, 1999\3202005 new user cohorts, Maccabi Healthcare Services.)Tj
ET
0 0 0 0 k
60.62 65.8489 492 276.592 re
f
q
60.62 65.8489 492 276.592 re
W n
q
0 G
1 w 
/GS2 gs
/Fm0 Do
Q
Q
BT
0 g
/GS3 gs
/T1_8 1 Tf
0 Tw 5 0 0 5 285.1575 11 Tm
( at University of Canterbury Library on August 25, 2014)Tj
0 0 1 rg
/GS3 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS3 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
21 0 obj
<</BBox[0 0 611.99994 791.99994]/FormType 1/Length 62/Matrix[1 0 0 1 0 0]/Name/Fm6/OPI<</1.3<</Color[0 0 0 1(Black)]/ColorType/Process/CropFixed[0 0 8043.68115 4552]/CropRect[0 0 8044 4552]/F(sys:DOCUMENTS HW-FS1: publications:Journal art: TAP Art:TAP Feb 09 art:RRL438-4.tif)/ImageType[1 1]/Overprint false/Position[70.019 68.058 70.019 341.09799 552.62 341.09799 552.62 68.058]/Resolution[1200 1200]/Size[8200 4552]/Type/OPI/Version 1.3>>>>/Resources<</ExtGState<</GS3 6 0 R>>/ProcSet[/PDF]/XObject<</Fm7 20 0 R>>>>/Subtype/Form/Type/XObject>>stream
/GS3 gs
q
482.68039 0 0 273.10889 70.019 67.9891 cm
/Fm7 Do
Q

endstream
endobj
20 0 obj
<</BBox[-0.14506 -0.24894 1.12286 2.651]/FormType 1/Length 45/Matrix[1 0 0 1 0 0]/Name/Fm7/OPI<</2.0<</CropRect[0 0 8043.68115 4552]/F(sys:DOCUMENTS HW-FS1: publications:Journal art: TAP Art:TAP Feb 09 art:RRL438-4.tif)/IncludedImageQuality 1/Inks[/monochrome(Black)1]/Overprint false/Size[8200 4552]/Type/OPI/Version 2>>>>/Resources<</ExtGState<</GS3 6 0 R>>/ProcSet[/PDF/ImageB]/XObject<</Im4 19 0 R>>>>/Subtype/Form/Type/XObject>>stream
/GS3 gs
q
1 0 0 1 0 0 cm
0 0 0 1 k
/Im4 Do
Q

endstream
endobj
19 0 obj
<</BitsPerComponent 1/Decode[1 0]/Filter/FlateDecode/Height 1138/ImageMask true/Length 15763/Subtype/Image/Type/XObject/Width 2011>>stream
XÖÌùÕÆÎFíÁˇ,6.{q°Ï•1–ê~/’Ä˙≤≈Ωôµj5jÃùÀ4º8õF˘]Ø—ã¡T^‹Õ ~Å¡t^x·Âd°÷†Ê)â˘AJîéH1Ïë'%íøÃ»à»d}‡y%&ùŸgˆô}füŸgˆô}füŸgˆô}füŸgˆô}füŸgˆ«bÛhè w«S≤á:‹?!;€≥ë~Ÿ3:}2ˆ1CÙÚyπ†”'cßX¯Û2¶”'c_cÒE†+:}:ˆU…æ‹“Èì±oÏø-ûé˝S¡øÊO«ûÌ∑%ªñx>ˆºdˇÂØO«˛1ﬁÏ2˙ì ¢O≈ŒéÏ©$vçßäÛGvˆO˙LÏˇ^‰8πXI<˚Gˆ?¢Ç}Ωïx>ˆu¡.ûë}ΩàYƒB±}Fˆ8N{·j%ÒlÏ	Ì]∞H'ã˜dÏî‚ˆ,Ãë
<{§¢]‰	«≥±◊efüŸgˆô}füŸgˆô}füŸgˆô}füŸgˆô}füŸgˆô}füŸgˆô}füŸgˆô}füŸgˆô}füŸgˆô}füŸgˆô}füŸgˆô}füŸgˆô}füŸgˆô}füŸgˆô}füŸgˆô}füŸgˆô}füŸgˆô}füŸgˆô}füŸgˆô}füŸgˆô}füŸgˆô}füŸgˆô}füŸgˆô}füŸgˆô}füŸgˆô}füŸgˆô}füŸgˆô}füŸgˆô}füŸgˆô}füŸgˆô}füŸgˆô}füŸgˆô}füŸgˆô}füŸgˆô}f{∫èˆÚp“È3≤á:‹Gœ∆˛,EÙÛÀ~AßO∆æFÃ¿^>/c:}:ˆ%±á?ø_“È”±Ø#æÙbEßO«æ*Ÿó[:}Nˆﬂñ
}Ÿ{}˘aŸ„‡∑ˇ$A¬Hüá=›mˆ_˛*@ËöLgI∆ÕûÏÏëË;Ó©ƒ»Î˘%ªå˛(–”ç3Öë≥«´íùï£ëvΩ#3jˆEÁÂb%—è=–{≤S`èüíΩ¨Î‰z+ÒtÏ1±≥P¨ûê˝Î1cƒæYIÙcG6ˆX∑Y'	ã^∏˙{âûÏÈÿŸ”ÀY®ô
ÙdO∆ÓÛ©äˆ,Ãëp‡…ÿ*{≤úÌ≈Œr2£éÛó/Õ"MÊIŸCÕÒ¨Ï–OÀû	</ªƒ”≤ß
OÀûå∫∞ªéù=1;Ω≈|^ˆúÃì≤£.ÏÆeÁxVˆqvW≤gOÀûJ</ª¬”≤'c.nÆdgOÃ>Í¬ÓJˆ0'Û§ÏANÊIŸ°9fˆ'dœûñ}ÃÖ›’Ï
OÀûå∏∏πñù=1{4]ˆÑ‘]ÿMó=ÂxZv-·)j'Àhèl0QˆPèxXØdèÙò◊Á3˚•ÏlfüŸgˆ'äuöÏÃ˛lÏ°÷O <7ª¬ì≤#õrAÔ[øwHr
”dÀ…∏e¥ûì∫ÿ#M∆Ω{·˜åë≤áöc™Ø#cR{‡MrÅ◊3∆ ﬁa«NsLî=SòÍ´X/{‚„ô¿TŸΩa|∫Ï°7î%
ìeÁòË´X/ª?…±…≤˚ì\‰ç£eœ<Ø#s2”dO}.ÌèÜ£e˜&π—v~vˇ*VsLî›øäÕ& ÓO©ƒDŸ˝	>Uò(;2ÖivC∞≥È≤{ì‹XªÏﬁ$7÷¬.&ı∞{ì‹XªÏﬁ$7÷› Ï˛$ß9& Ó_≈fSeœ&YÿuaO}˘;Uò*ª7¡'æŒ/ª7¡3_Áåó›õ‡GZÿua˜nÃD9ôi≤{ì‹HªNÏôƒªNÏ©/éké©≤'æXñ	Lï›õ‰&ÃÓMr©¿TŸΩ´ÿÑc™ÏﬁU¨ÒW”`˜&¯…Ó]tIr3˚$ŸìúÃì≤≥úÃì≤{¸ÑŸΩIn“Ïœ éL·iŸ'ô‰:≤{W±füdíãI;∞O2…ud˜Æb'ÃÓMå£)C:vÔ*6h ;“I∞g
nvâ¶,H'¡ÓKâ¬dŸìúLøW±åtÏæWnÃ¿Œ1v_íkøätÎO#e˜%π0'”Ë≠÷üF ÓKrÌW±¡tÿ3˜´XéfjPò{⁄fuøßΩë≤'û»ï	¯CˇHŸYN∆≈.1Yvﬂ*6Uh≤{<e<Ïæü(Lñ›∑U€&ıÕíÒ∞˚|ª∞ÛÕí±ßÓ–’.¯€ÂŒhŸì÷¿˙H5«Dÿ=”◊Pÿea˜M_-0Yˆ¿√ﬁ&M&√.‡,n$º)¨Ïæ$ó*Ló=SË∑c«¶¬û∂‡<Kó®ıó—≤{º°∞k˝e¥Ïûﬂ.Ï&ƒÓIÌ¬ÆΩ9ZvCÂÊnˆU#b˜%9-0]ˆL¢_aß9¶¬û∫sVªk⁄Ω1ZvOíK¶ÀÓIrIÀ-Râ©∞{ík±'Œæ	È°Û@¡«ÓŸ™mó∞â¬É≥Ô®˛
Úpq∏Ÿ=´ÿ∞ΩS€ÍçácßyÍó=£S'ª'¡∑Ÿ€û`Ï¡.IΩ|^.Ë‘Õû*∏‹¢Ωêkı∆É±áªòÅ}ˇy”©áΩEWìVk€é}qË≈öN›Ïû$◊û=øwˆËﬂâ}Ë˜+:ı∞k2=$Ë˘˝ª≥≥’™d_n‡c˜$9Cp$}xˆ8¯m≠‡c˜$9;«C≥«ˆ_	,"Ω4…ñ7Õæ\mˆ_˛*‡eœzI Ò–ÏÎª¸ãÊ È≈In¥Ï—üÑ7í{V±ÌÔì>2˚ˆ0ﬂ%K% F:\ÇÙ=´Õ∫Ãqr±íÕ˜Hìô{ñØ¢Ç}πï±áöcJÏZˇèí}›ÅΩwÇÙq◊kämˆﬁ	˛—◊ÔÎò1ˆ"6+	/{¶‡íØ12ˆUú;W]ÿ=	~É±±G{ÊÅH8ºÏÓ$ÙLˇè¿æcAGˆˆÀ÷ª≥ıŸ;ÔQ{ì\0ÆÙﬂì=–ó∂éù›ì‰∆ï˛˚≤g
Ω^≈Nâ›ù‰2â	≥ªW±©¬ÑŸ›	>qz≈ÿŸ#gc-ˆ-ÈTÿ›	æ˝™ıá≥ª”XªÏk˝a‘Ï.Ø 3›qOwd∫vìbw'9Õ1›XÁIrô¿tsú'…•fw'πTa¬ÏÓ≠⁄dGf≤ÏÓ$«¶Õû)8ÿùY`ÙÏ©kh√úÃtŸ◊–∂ªI±;|ª∞õª;¡ké	≥ª|&0avwÇœ$&Ã≠0ç¬ÓˆTaÖ›ÏŒ$«\ç„gw&πˆéù¿ÑÿùIÆµcJLà›ô‰ZÖ]®0!vgÌ÷z=-vd
›ãõpOffü{Í ·-ˆúÃtÿ◊P¶Sfw&¯D¿¸∆Õﬁ cµé·À™ˆ2v´¸ét¬ÏÓ≠Z_9{¶–]Râ)±;ì‹ƒŸùIÆıeÖ)±;ì‹x^’ƒ§ΩŸù´ÿâ≥;W±˛›åQ≥ª∑jõ5-ˆ^	˛q˙ò¥?{¶–YÇúÃÑÿ”~¸∏ãôÀÿìÏè[–_∆Œ˙åeü¿8ˆHsÿ9∆±òπå›ô‰ò¿8
˙ÀÿùI.ëò4{¶–yÒí(Lä=uÈ¨—÷<;ª+…Mù›µäm.^öÁcgw≠bõØbv1ì^¿ÓZ≈6∑∞v1ì^¿ÓJÕ˜¥[–_»éL¢k?9ˆT°ÛéºÊò{‚H\Mühˆ≈ÿŸô#xß
ìfwz÷âD·yÿ>ë(Lä›ï‰öÖ\¢0)v◊*∂Yÿ1Öi±g
]ªHaZÏÈéL∑ùŸHaZÏIcR;äôPbZÏÆUl&0âI/bw≠b3âI≥ª|™0ivWÇO&ÕéL°kQ;∞D⁄gﬂöΩYÿŒûì}Kˆƒÿ,Ï&«Œr2›
ª…±;í\s«n`	ﬂú›ï‰MCÀ…X;ûádoÀÓJrô¿mùûåU‰;2∑ew≠bSâ€:=á]62]$&≠JD⁄Q2õ§
∑óÀ€%ô≥ßˆ
&±7"Z¬.Àô≥;<€ëπ°d
§nŒÓ®`öÖ]◊Ë”π€Ï¬$nŒÓà8MvF:§0Ö∑ewDúÊkÁÑcPâ.täÅÿ'∏1ªs,Ÿëπ5{¶9,“|3√q?qƒ‡·ÿSª”É7dœ…‹ö=±;}3¸ê+[RÎêêπ5;”
o%ø˛Øö„Ï;≤o"Õ◊U˘¢Ó¿ÓË˝[≥sÿöD◊©8Rv∏∆6Sò6ªƒ%ã¨I∞ß
ùWScO∑voÎ√Èé7πs„Xd∆jÕÒF‚€@‹Å]‡çƒ˘
¿b¥Vx¿‚ô¬≠Ÿi!◊1õ‹"…ë^ô‰ÆbGjè∂[“[ '“K·`Ïéõÿ{eYí^cè4áe>Êdﬁ.r‹ú=¥zg,D˛ÜÙ∫$w{†∫-¥>ëºW+peíãI/gG∂#cæ=«mŸâ+ì\Lzª=–gµS“˚ΩüH≠C2 ª=–g7fw%÷!êùiéNãÃåcË˘Ó‡c9ô[≥€}cX2Å°Ÿ5ô´¸ïÏÅñËÙ*6|%«—HdáÆ#Z7Oâ¡ÅÎí‹µÏi—˙Ü:Q|%'q]íãIØaOr2ÿâ¬–íIX%µπcUb“™Ùe∑FúFa«∫<L?I%¨íÿ‹qHv˚¨”’Îvyò~íHÿá$'skv˚¨ÀnÀŒ$¨“)…]ÀnÙôD’?r2√J(pÅ;…ûŸ4’dŒ˛ëìπ£hâ€≥'9cÉÊ®Œ2CÀ◊∞â¬ÌŸôä’›Ns.
W%π´Ÿ£:bµA¢:CK`õnì‹’Ï÷@jkÿÜ='sEíãIØbáV∞∞◊‹.ïú]ìπ"…]œûÌ…Ÿk7aÁ∞'9é€≥ß9?{¢pœD÷e´6&ΩéùYº+–9ŸÛ◊ÜgW∏§_ÜdÁË¬^õ˝≠‰.jå›Ë≥m≥†GjïﬂΩwºyËÃì∆˝n¬nıº¥∆6ûÖë⁄#’˚˜dØbwµ«û’m=ﬂ\Ã0á/˝ØY]’∏fœ$ì^…ûÊdºÏÕBÑq8ÿˇO'ˆfˆLr1ÈïÏÃ“√çQi|+·∏`5§~áæI.&Ωí›∂Y‹∫∆∑RÅ˜‚*ÚâÙÚ$É©hG® ó±áZ¢CŸïqtØÛRÖ´‡éåá=ŸQ˙	u∏ã8.báV0ˇ]¿æòq≥'ﬁ˜o,‘¬çô=›≥°~Ÿ3:Ωà=≥<hù∂õ)\ı‡Yê^ú‰b|≥éD/üó:Ωà=µ<h*`g◊ñÛÏ5ø«qyíãÅuÃ¿¬üótx{bπK"`_ÃhKáô6˚∑∏<…ÏÎà/ΩX—ÈEÏ∂@œÏΩŒ…8ÿ9Æ‹£¥@Wˆ˜[:ED⁄?–˚Ñ√ hM÷B,ól±+\û‰
ˆU¡˛€R·BvhÖﬁQ/qµÊ∞Àﬁ˚‡˛òò)xŸwƒøÂ
ó≤gµ!µyGì]¿ÓØˇª”%›11ı]"S€Ç˝W-aØO/Ùé‚€Õ˛KßK∫Éπ´_ÍÏø¸U ∏å›{óˆb∆√˛æ”%›¡ú˘ŸÒ±dó—ü8.Ùy[†w∞7≥üÌÃCﬂS≈¿áÌë]‡BˆP¯•πy!p·Äµ]IÏÒ™dg©ƒÖÏÅVÀä¥«%:ÖYâK˙• æ‰b%q!{∑@?ÿ˛s«‚ôÇè}Q÷6rπï∏îΩcTæAw2Åãì‹â]¨Ø`Or2Ω£ÑƒÖUK5&
ÿ˚≈sâ_«K±PlØ`gö£?ª¬Ö{∞Wn¶ùŸ7‚Ñ±°Vó≤wÙÕ!s∫d‰y+ìˇÅ=£ΩFZ¶ó≤[ﬂO\∫√Ï”≠.Õ1EÑhœ¬<©¿•Ï–
F éKG÷˜‡ß[8º«3"¥_ß¢]DEóH8p){∂'c¿ì∏xdµD'vÛùª$πòÙ =jG†gèl¶–mRìπ,…≈§∞[B*sﬁ\K∏jÁo;yO‚â·ÿ-Åû9ü?SËÔJ}ºáπ/ì¿n	ÙıΩö~#ÎÖùº«sâÅÿ-[Œı˝ä~/ \Œ‹±¯u˘ƒÄÏÊ'p≥3„o,Ø¥.Òû;±[¶ñÊ∏,5{ñß˛;wx≠ì¬nûZZ‡rvÖ´ŸùwàIá`èÃîµ±Í¢0¿ªX◊ºJˆdnŒn	Ù©ÑÉ›S/9Õ∫ÿ’'ÜcáVç]Ov¶–Iˆ§q'π¡ÿ3„(%’øÜ
YëZ•˝u≥8.‚ŒÉ±ß9ôñ∞=;Ã'R˚É\+ñô84;3∫W}ç.—êúÙzyOjÛFÖ;∞õﬂO∏VY$∆ﬂÙñÑ‘Êç;27g7ªW†…8ÜE` I¨›≤'ssvhÖæ¡¶û˛/«UXNÊˆÏô—Ω2◊oÜwÖãí‹pÏiN¶œò¯¶c˜;€Ø‚\∆§√∞õ}™‡˙çk:vèuˆ´ò£–‡ÏÊ@ü(∏~ììπZò„*Z‚Ï°Ò6Ã>&˛xUØ{Á√ÄÏ–
ÜÁr≤{R`Á^Á∏`>…ûô∫ÿ„’ˆ5ió“B‡í˘ìƒûÓ…ÙÙÍå‘!üHªÙ∫¿%I.&à=1›∆S‹| Ωºk:vÆ˘ìƒn9Z‡äiD⁄•◊.ô≤õﬂOd7ggó$πŸ°˛(·íﬂë^<%Æ,xc“°ÿçÅ>Qp]ùq\Á˚G‡·Ÿç∑I™¬8∫O’>hâí\L:{¢…8ª6i"1Du£pAíí›Ëk≈Mõ4Q¢™›ìÈù‰b“°ÿçÅæˆÍ ëpMâÀŸ´7Èú‰b“°ÿ≠‡.ŸôB˜Èÿ´◊…ÙNr1ÈPÏ–
ÓíùµFy(vé˛{C1È`Ï©i⁄UŸ£ªÎ©˚xú@Øáû=……¥ÓMjèIûzˇ*èÛ≠bc“¡ÿôÊpﬁ°¯®˜›eïk/≠˘dW≥[^DWF9'3`Ωﬂ¡±	>&åZ¡Û“^≈M$peÇ∑˙aŸÆg{	ïHLÑ›Òv&·ÑíËî‰7ŒÓ¡nÙÓ›•ê√>%:%9á√•∂∂òt8v¶9.›]∫äÙOr√≤+˙;œ˜ãä˝òtHv	˜§PË±ˆˆOâ´
ﬁaŸ°˙≤á∂Èÿ3√ìˆ,xfœlsÀ∫òqÜË>Ï}ì‹¿Ïæ@o»√Ü:˜¢^Ëõ‰b“Ÿô&”ì›ÛìÆÏ}ì‹¿Ïæäﬁ0»≠‰lÄé$ì»nLrï=¯⁄.é'∆Œr2∑gáVh˜;áÉ›äã4∆=‘∞gÜÓO=2ÖƒiåŒxˆ4'„`œ8zxÎå›≥b“!ŸM›üJ∏Rë-ı›≤„Ëô‰Üf7Õ≠D¡ÿ¶77˘›"Gœ884ª)j'ï[ÿ9ø&ûf«lÚx÷Ï
ÆÅMZ?©4õ$'ΩÆ®eÊKƒ§C≤õ}u`ôBK⁄øÏÒô9znWŒûÊdÏ≈3Ä~çK'rUﬁëˆKr1È†ÏÜ@_-h™>–µ\í∏˙’Ö¿=ÿÅæö~å+÷øCﬂR—8∫˝í‹‡Ï¶≠õJ∑W˝ˇ$üH/™‘ÎèÆ–Ô1È†ÏÅÅ=ìpºô°v“ãﬁπ‘›ËHr1È†Ï¶@ü*òÊ~«h∆r2◊Ωü0_"&ñ=m?BRÈÕ·ö›3T˜˝X€%b“aŸ√;∑
{∆·ö=W)øgnû›ËY≈2◊úËX&˜»‚ˆKœnxÑ™7¶CQﬂ$gä≤ŒKƒ§√≤°∫ib7á"OÜÍö≈ÌóàIáe7˙jqìpÙâR‹¬Ë∏DL:0{⁄æèÊp›†Íù3î∞ÁveL:0;k≥gW,W<]”•∏1ñì1È¿ÏÜ@üJ\∫Ô`ç“@ªÊ∏ª!–ß
oÀnºƒÿÅﬁ1Ì§◊'9¸#z-Ño¿›"5ÑÄö,H{eé˛…G·.Ïiã‘ìƒººuAã|E⁄=ˇ≈§C≥'9ôã"uÁZ‰iÁ‰sv¶9ÏªVÊü∞íslò.qˆˆãËjagfó∏lÖ÷5_ò.qvC†oıÜ„’M«edóËqâ[∞C+t~®NIPK\ÕÌó∏	{÷
,©Bﬂ:¯í$Á¯^¶pˆv\NÆYÆ$v&Ovu%πòtpv¶9iﬂŸÜªwMóÔ%Ì¶òtpˆv†wÏ°Z√µë£M1È‡ÏÌ˜UˆØHªÑ·j£~€ï7aáVh‹π¬˛â¥KÓS˘ÎCÔ∆§√≥g‘√ùwd\Ïôƒ Ô°]õ Z‚.ÏÌ¿≤Åõ=Qp…“NÅû£{íãIággÆq˙D⁄˛ÖÇKñ§ù:ù¥síãIág7l[ùÂ#i˚7ñdOÊÏÌ@_ëiüóÁ	À…‹ÅZ·m$ËÏã7bœvdﬁBÏsßùˇnƒûÊd˙â¬ û≠–9…≈§7`göLøEˇ0û¬z¨‰nƒﬁû\^ˆV(¢Ÿì\Lzv√˚	{NfàN'”1…≈§7`¥Bﬂ_ê¢”9∫∫DLzˆ˛ÅæÜ/ÏtÅÆã¡[±ß9ô~%ÅÑs@9ÆºLk∆§∑`ÔË3ÁDzªÚVÏÌ@ˇ<û‚û%ˆ¢•Ûe2Öª∞∑9iøµFè∑ù|⁄häIo¡ﬁ~?ëìæ-{r'ˆˆ÷çÊp{JÛ])çNóËö˚o∆ûÕŒ1ˆDˇâ¨˘ïú¬Ìä⁄uœÕÿ#≠9ÃªëÅÇInŒﬁ¨{b“õ∞áZKò_…Öçò3∞|$Ìî‰n∆8ÿ˜dn'9iß$ìﬁÑZ+ò3Lòìπb3ˆ‚=˙dOÊÏ©>¡6^3€ÿ?êﬁ¢≤∞≠‰b“€∞'ˆÛ˚D€r5Â$–ú:Ÿì‰b“€∞≥{e	©9n«N	Üló$w?ˆ ˝|Tgó∏Erµ&π˚±WäõL¿»Æ0ªÄ-…I‹âΩ1ÔŒèîJtHA-Ÿ‡jˆ⁄Ó»ûI∏Ÿì∆.,¸⁄ÀgÀn«Èú¨—•â)ËRv
'[≤˛;ƒ§∑aß¢ñ√\‹0Ö)Ë‚≈Œ¢V]w∏)ªÄπ∏aß^p•†ã«›^ﬁ‘Ôp;v*ËÃ≈Mdf∑ÂæW±¸ tÎ”≠\I.&Ω;Ù∂¬.≤å†Êp…ñ¥k∑ìın’∆§7bon[ù;[Aür’Ì˛UlLz+ˆ$'c*ÏlÏ	«@Ω^Ûm[	ìﬁäùicqc[Ã0“ÅÓ,‡Or1È≠ÿõEF&–mb~gCÃπ1{†Ã≈çÊ∏≠hûìmK-…≈§UâHá{ÇÍÏ¢È¨pîL¿¸h√≥to-…›îΩËìSW§FÈ˙“Õ/ÅV0áƒ}ÿìúLe0N]ëJòáKa0ˆ˙ΩO√°˛ñÏÿôÊ®^;'”˛∆›wdöoı{üz}˜Ÿ;∞7¬Ìπ∏a
fˆìg¿.`é˝äÏÿkäsq√vdLÏ9ôÅbçÖ]opfgäz;»√]à°ŸõÅ^∏«∑ñÇLD†´DZ¿xâ3{≤£'	u¥è8ÜfOÎåß˚⁄ÿk)»ƒ.q·|3›!∆˙cí ˙˘eΩ†”ÅŸìúL≈%éVˇª°w,◊SËﬁÔ\ìmﬂA‡ÃæY«ƒ˛Úyπ†”ÅŸY˝ˆ©ƒ±˜s2∆Y*·‰QË~o^øyª¨äÅı:‚¥ÕØË√≤WgW5º∆«Ú,À…tè6¶ôï¥Ÿ7`oz¶p™∑qv”∑é*˚**ÿó[:òΩËœ%k∆qIaié+ÀõL†≈˛€Raxˆ¥Êv°@˚	Íp
Ó9ƒqeäˇΩ@É=~Õ%ÜgO4Süò·$zÃ!_«kÅñHâ*˚∂dˇ´¿ÏLs\ô®În¨–]LÂM 6®∞oKˆ_˛ÚôN¡H”Ì;ƒ4ªÔ»tè¥bEu«‚µz^ïÏ2˙£h%‰õ-£ãl‡úCµ¯·ùqÌaIˆï=P´íù• #Ω]†Ôœ˜§C%9⁄Ω®À;¸-ŸWˆPñq^.VÉœ˜F†˜/‘7\§…Ùq;€}ÏëXE{|ˆƒÃ)ÿûñÃPIÆHÒdÏÏåóuù\o%Üggö√ƒ†`cÁp¬H∞{sZ√ÇÿY(V7a∑z	€”
ñ‰,ÂÕô˝b∆à}≥íû=–
˝FJ¬?vd˙‘VNˆ$a—W/1<ª-–€GJa∏$Gn'·`œr∂g°d*pˆ¥ﬂ√˙ñÂd˙tΩ¯H÷Œ{àÑ„ÏIœáMˆdKr0î7’X∑d˘^øƒ.ÕÌ}q+œ˜›}eŸÜª(:∆§7€£n?l®‡˚~N∆Y££g∞›ì}ˆ@+T»vdÆawcÔÚ&&Ω){=–€6ß+íìµísº†π{V≈ıç*…'“ÛÜ£ºâIoÀû‰d⁄Ø‰˛Ü‘(_ë^M¡V‡≠ÿôÊ0,U§ó…dÜ®™Ô¡^Ùö„:ˆæ+πb_Ù#Ÿ7aØÔ/û:bAjô$§&9{yìﬁñΩË3	{ ·FâÅv8c“≥g{2≠7j	áç]`hˆÍ‹ï=—dN'G'uNˆíéâDovÕÒ6Ï¨ ŒÆfg˝ŸﬁÜΩË£úå{ó:1{ËÈ
Ω◊—’'∏+{-–üÿôƒe’K@:LyìﬁòΩËOÖ™zÈÁy˜eœ*N|⁄áeÉU/ õ5Ÿ∑`gö£ï¢§óm’ˆ3&Ω5{§9ûó]†ï¡¨Î∏¬C1<{NÊÿkÅ>©æÀ
ªÀÿ5«[∞◊}R9∂%xÅ·„≠xˆtOÊ5ùèﬂëÁáS~˜˛=ŸÎÀõª∞'9ôfq„JsûtΩÏœŒﬁäùiéVqs—™‰?ˆ+≤}cé¯ä>Óœ^≠´N≈çcÍnˆ.(o>ëΩ?{†⁄ªVµ©P7ªDˇDÀµƒ∞◊˝Ÿí≥˚7¢Úı·ä≠ÏŸûÃkƒï8Ö	3{ÂÎF
éãR<ô˚≥WΩ;U8’{
fˆ ◊ádÁxv¶9⁄Œ˙ö∞íÃnD:@ysˆj†gg`ùìπ`õí^Pa5ßXLz{ˆ@+:≠tIü=¯T‡"Áìxˆj†Ø8tÎiN_ópÁj\Ùo¡ûùΩ¬V∫§˛ıúå].…Ô•ªd˜gOŒ¿ï¬Œ:·+_∑‘uñNÎ5Ú1ÈÿôÊ0d®Ã¬òTæcÖˇ∫
.dØ˝ÏNÏ’@ü	∏VW≠]ÆvÎrúÁ–ÂÂÕùÿ´[7)áØ∫©vïq˝~!{¶9ÓŒ^ı∂Ñ√W›Tª 2Â…\õ‚Ô≈ûùñë˙ÇùÌÔ'9weøê+qˆDì1˝Y¿Ïú7	;˜ggö£K≠ubW∏…‘ì_ëΩ3{mèæ:ÁπP»f?©ıGˇ!Ÿ;≥€¢óebk≠9z*ùæZ]ƒ§˜`Ø˙z‰%cË)Ì'≥tõœˇŒœìﬁÖ=5;w¢9ÃÏ
}˜"∫±üü„nÏâqÄ-\ÿç˝<ÑèÕŒ4áqÑ9LÏπVi9Ÿ1∞[=åÓ@·?Ué7µ«P°%F1ﬂmÅæ˘ ßë)áßP©å·%ÚÊÏK“©≥€˝?à¥V{íìÈ∑Ë"sÀÅèIÔ√Œ4GØóœ©%:÷¢ù¿ÿ+Åû	Ù^lõªS+åÅ=–
Ω^º3-·-or≤èœ^©ËÖ™¨Iç”Y¡[,˙b¬É∞ß{2á=ıB)IçÖõÇ◊ó4«ÿìúåâ˝Ù˜Ê‰ílø˜ã Œ4GÎu§ã=©Ä/ÄråÅ˝Ë+Ø#]Ïº>…|¥BÎïúkæ{ﬂÀûˇAŸœÅﬁºpıæKZÓ…ûÌ…zA†cY+‡è#§œû‰dΩ q¡ª€ó8üùié~ÏLKLÉ˝¸Ü1UË«Œ~ﬁæH^£û7DHLÉ˝ËŸ)Íeã”Àî¨gbpåÄ=}Eé^|ØîCë	¯j&“«g?˙Fq„*œ≤W_w~”FVG±ìÂdºCœÒËÏßäæ…hÖkVjå„—ŸœÅ>®7X=;’˛…$ËÏÁ@üIt|ß ¥ƒ$ÿOÅ>UË∏h	µ¬$ÿM∆T‹$ˆ—µ∑åjæÉicqiÖÀwÆë>:˚)–∑ä˚Ñè¸;WÂ8õ˝ËªV≈Ñ'sEQèH‚±ŸOÅæYÿ9SY÷pÛtÍÚ•7eOèOÿ,n\ﬁÈÌPÚ∞ÏIN∆¥kæzƒ≈•ùVxlv¶9ÃsXÁd.})yx/IˆëŸOÔ2âŒkñDKLÄZ°^Âú{E¬˜#œ´πú>ö˝8≠ôÊËÏ›R}≠…>2{vÙLst≠n®\ˇ@÷ÔÙ
Õû‰d™^óLÚå√ø¨è˝˙®ÏLsûT¢—ºS≈˝ßuÕ«b›£oÔV∏Ç∫i§[◊|,ˆ@+òŸC≠p›KI≠ª|ÎÌÿ_Ω7hè§V∏Ó•d“”ÈÔŒûòÏ©¬uÂE;ÖGf?z;SpÃeâ.—Ó‡Tè Œ4áô=Rp©DókÔ»>.˚k†Ô˜òHÂäl«`Ú®ÏØ[7ô¬=‹EddΩ=ÙÿÏØcìJhé>øì;ï¬C≥g{2ÂñzöVüπE‚°ŸM¶‹R◊9}vg?¸Œ+ˇÂwÔ…>&;;1hÕ—√_:~[áK≤è…˛Ëˆ¶◊Ì\±ÙÛä>ì˝5–#π'[ÅÎJªí]·QŸœA+—'ËÇ°[iá`ˇõƒ√≤gØ£Mı∑Dgˆéi!ÿeÀûúÇ]÷åÙNˆN;W¿&ÂxXv¶9N[lùŸ£.;WEaKˆ1Ÿœ[u≠Eg(pmiG	ÅøN™«c?z [9ŸÓQ≤T&:^4&Ω3˚9–Éµ¢› •ùñ9ŸeOO√G/SN˝–©¥ª’ØÍt˝«cOr2ñHÔŸó◊çüwÃŒ4«y_ôl˜()·ˇ“ÀÚÔ‹õo…~ÙÖ”sÙX
HxÂ]¯æpëúÃ≤Z·\Ëp‘ùÇ√¬ø"€-4Ï…>{%–ÉiéFıWi˜âl7vˇdäIÔŒûU∆§˘à…π_Ã#èéaQÁÙÒxÏiNÊ(H{∞wôÒGˆfØ>{®9:$ÅÀÀõÚãﬁ∫ÈçÿÏÏŒyLfÃÏÅV∞Ö∑H+\[⁄◊IZs<{5–∂Í´œ\	Ñ¶≈ø@˜/xÏYç/≠ùÈúLó∫®√¿K<{íì©åáÌ¨Ì2ùKÁádgö£J´–y?6ËU‹Wz#ˆz†OtNˆ‹VÌù´ÆëﬁªÙâIÔœ^Ÿ∫98ß@•-';@y„˝fLzˆz†oÏ`dûÅ≠}Ÿ›≈ÙØ¬£±gı–Æs≤]”XÌÀﬁŸÂË®òÙÿì⁄ÿ2≠%∫V7‰?ê/;”µT¨–µ∫!ˆˇ ;^ˆ∆^UZ;≠ùò|FstûÚ
è∆ﬁÿ´b∫:«”Zõ©`Ë|#	(<;ç≠D≠+*~Œ¥Ç˚∑=‡IlnˇVÏYçΩ˛ÇÜ™õ˜Ù·rzÖ>∂'ÛHÏâV∞9=U7ÔÈ√,4GwŸì>;´W(ı⁄;”Ô…:7"%∆ÎÛQuÇóN/Qqä!ÎúΩÿS˙xv
÷∂uG§ˇï¨+Ih…Ë†Gx!˛Gbó∞≠n¬j‰≥∞ß◊æ¡ç hè w!«]ŸÎ|â@uB◊ÏôÊË√æ'€bè$ÀÈQ^ˆåNëﬁâ]K‘÷Â®Œ~√£VãﬁTdıü{Ÿµ@õù…$°óó/Àùﬁï›¡ì∫„d¶˙îZ”GÛ&âåÿ˜üóÂ˝Ó…Æ9lÚû‘5ÓÕçÆ.õ∂-ˆTÆ#∞?k:EDzßÇ^ÎF≠¨πﬁÉëumÔ'z«ÆÍÍkbÁã@ø_—)"“˚Ù—:ßœ™/Ô…º≤'æ‚(9øì”+¥&ñ\ïÏÀ-ùﬁè=i”Ÿ9˘Ÿ…_≠–'⁄i3˚oKÖ{≤ßú Ú◊oÿ#Í<Ö≠LÏqÎa”Ïkπ˙”T64:∞óSûlèÅó ~GZaﬂÏø¸U `ßªﬂe-W>ç©Œ%v≤ﬁﬂ˜ò`Â›ﬁEK¥ÿø¸Âˇr‹—Á¨ö>Ã{’Ôj±œÓXNü}∂¬óZÏ2˙£¿}Ÿë6ú>’9YÀÜ¶qßû’/‡ÈjY∞o–öÔÚ›J‡ŒÏÕ∑È4dª≥˚˜Ú€Ú˘[¥‚º\¨$ÓœÆ9jÒhG∂>CúÚ4ÏÍ7Å6{ºï∏7{“†Kkœ¥ˆë1Ô7öÏGïΩ¨Î‰˙ÿ……´∞à/hjßñeM®–á=%[cßz^lﬂÄôÆMÿZ§˜≠ıéÀö(ßœÓÏ	Ÿ
{Ã{õïƒ›Ÿ	ØFóhÕQu˙j_ù~œ|_©›O÷ÿ√]ÚÅE?sïJ‹ùù¢õÊ∞9}H≠ö>]≥f«ÍΩÁ˘∫H…û◊Ô9€≥P2∏?;”ıaÀöë^+¯¶|N∂˚,„®≤G;‰ÅH8Óœﬁ‹∑KkÏ4ˇkÁ∂◊öˇàŒÚ´@eæø…>≠ÌΩè"[Ûy4ıO®9∫:˝gÖáaoÆdÎgÊ÷fÆ´A¬„g/<;—iÅ Ø≥ó{sû°Ã=˚˘5æhEˆQÿ≠åõváQı≤óAÉl'i¨aﬂòùÊ´Î…#Íã}ƒﬁÿ∑ycˆ÷J∂-I=›«wÙ9>v÷Hs¿u˘DÍâµ˜y„ao≠dëìˆbèà=ßœÒ±'Z+‘\X†;>nè≤ìÀ6ˆÌvå>∫œ˜„î«Ÿ≥ÊJ6O8*≤"ﬂ†èI≤7äz‚®ıEôˆd<[ô¿¯ÿõ+Y√~M™…∏3%◊
#doıâ÷
ÕaÕ…∫ßZsåèùú^”ámQﬂ© Z¿˚ïádoé¥n9}™kΩcô9#do¨””˙È°sº£öiŸƒ{#ÕQW4ºæà˝æÅO¥Ã]6
v¶µBç¥AëjÌsi⁄¬»|˝ÛàÏ-GeÍÍEÒÖÍ7å/2_ˇ<"{„ıT¶õÏ≈™”¬6u∆«NS<ßèäás¥Ú†Ñü˝›;åçΩæíMxıÃlﬁ£í¶√åÄ=©Üvf(bi∆+xC¶J5«ÿÿ°u7£áë®Oo ‘?3èΩΩm∞w›˛S#{Nµi∞#[ˇíÇó}«4}éäΩπí-ÿs≤=ŸìÇ]bdÏQ≥òKö8æ∫IWŸ%≠ü=<;9}›Yô÷ö£';Ìˆ{ 1*v0]ü‡E9ì”gï¨ªbzO£O«#b'÷∫≥ÍV(tbßÈxDÏE)+Qè Zs4+¿œd\>O/oôŒ·£,v÷p˙¢–≠˜FÈøëq±”Æ.+^S	åàΩïÊ¬÷&F%\á∆˚kÚÔ€ŸcOö\©.P<5P#«? p˙ócDÏ4\ı¡jÖøÉshÁ∏”l…ˆL`4ÏÌΩhv@i≤7'B}æó/Ò
vßáƒ§èƒû4±é√ÿÄZ°À⁄®ŸìÕéñ?G‘k˙¨ÕÉÊ‘∞ÏÜ|G·cAG#aOõ—.PD!–Ë≠9¸>TºÆH∆¬ò¢∏Æèrµ@'/íY£/òô÷Ó∑M·uGˆ¨`W{πíMÈ†∆Æ9*Ï≈óøâL+∂«8ÿ…È5ΩPF√™ÏÙÅP¬?Áy¶Ubví«c”˙ˇ56’∫Óı@Bœ™–mˇ.—;åÉΩLaçÓ–møç:u%±˜2êΩeÖ¶”kªÊAÏëV;2Ω£œ∆¿ÁÙŸ‹¬~-`}â~œ_åIçΩÎMOµ÷ç®(ä¿ÿ¸¶yi«®Î$F¿ûËF1s∆§ ‡OÛ;VÏe–—√≥†çh◊ÆuOÏ¶ø7E≤b=ü”—£≥†ÕëÏÏço⁄bHkÁ1Ÿôn«∂‘ƒ^ÑÜNS>–Â^∆'º£ìáfßQj√g¯Gòz©1ûf°›€b/#°√áfß«lÔO$a{ÑÈkZstªËwZˇëéö= √»”„KòbG∑‘Y\ócÏMT√V˘]énQdÏ–ÇF©=Ú‰∂ÌÚåæ…©pE∑°Øî1È≤gºÙe{{‡Èõ|JÏßô\‚ÖœÊÙigâéc`Ot)g°SÕa&—IR≠*èÃ^∏x£t)?}∂Ñ|>‘
.©0
ˆWØÁ®ºàË¿ƒnÏï∫ZaÏáq÷Z°Í
{∆aÒ/˚9Q<8{{‰SävâÄ•üº>?ˆ“…´EN1∫©Ñe‹´±¡¬~˛∆√≥ó[u’ óh≠åÓ|Ë§êéìhLÏÂpV‡ãÛ]§`që‹Õ>*ü?ç|NGØÛzüTÜØ1›b“Gg'ÿj∞/ˆ'ìJhC|RÏGo>ç<≈´D◊ÇµóxDbg∫Ï)G'⁄”Kˆ8&ƒéÍL´U¢9á≠ä€óØh€õ[#fOte]ìI¶-Ïa~x=≠Èx*ÏEÑ;·¶â>∏¡ÇNõ‰è¢[}ìéÇ˝@´5G…^v±ß
≠Ä«DÙr:û{9ñáTó
ºÓ·dZs4"^≤ùdÏÁ9üIîßƒñi≠9Í¡!ŸyG>&;ò.ÂœZ·U2›ﬂÅú¢Zõ%&m˛q%’ïàwf◊Ñ2hÕ“…4ÿè®gNu•Ë9»ÔHèNœ¡8¶¬~d’
GItÌ¥"â÷öÉ	@bÏGg>u¶Ï>ÇÇ›∫è76ˆ©±≤—Z^Œ4eç#ªò˚a&*õWÁVÖ?‰0•q¯Å¿ÿÃW°≥BhîTh	ÒîÏßû*#·AF»^tûÒªqtKü?{ED:bˆL#Ê—a3—◊øNG`?åÒ´îBGÁì∫–ﬂKˆàcÙÏ–ÍîËOUﬁat∞ahJŸ0ÅÒ≥gØ£y.m]ŒÄ@ˇëN¬Ùë=»«Œ~îD◊g}¶µ∞ÌZD9¿uNL:VˆˆU8PÄâCF„h…`e+«´åöΩx^]˜¸◊?PO¥Ÿä˜t4yv„◊˜Ù1ˆZ¿œéÃhdÈ£.‘ZfÖâ∞W”}^ŸµHÙ)÷æ+0!ˆb0œBtáOÙ±åÈ+'I5«´LÅù$”'˘YWŸsÄ’"˘Ω*∫.9¿ÙÒ —ÂeÇÏz~åu{™´?"ù˚q¢üÚ]É˝5º3“…±ì§∫æ¬;dÛTŸS≠i–˜¶»^y˚·µU¢è?”‰˙)«4Ÿ_AkÎ[¶+ÏSÀÔNx˝C'ê≠Ω	≤Qjı:Ó
”eÙéõ€Zë,c›¡&À≠ö·ÍøæY=IˆL†UÎÊ9Ÿâ≥'«2Fõd“Ï©’z•DO√˛ﬂûq‹MÉˇTÏç¡2vÇ~Zvd˙yŸOˇ9ŸÉˇ¨Ï≈Jáä€'e¥¬≥≤£®Îüï˝∏“yJˆäÃÏ3˚Ã>≥œÏ3˚Ã>≥œÏ3˚Ã>≥œÏ„cwÚ@t¯tÏ—û∂±¬]ƒÒ|Ï,'ˆó=£√ßcèD/üó:|>v˛º,üé}ÒE†+:|RˆÂñüé}U∞ˇ∂TxNˆ8¯u/ÒÑÏ€í]KP∫”O$˘+˚/ ˝åÏ2˙ìxBˆ’Å=ï ”O…Œ
vO¨{GziÎÇ‘Ò^úÙ6≠v¢¯5«…≈J¬ıM?›ﬂê^⁄ê^J˜;“KZOµç\o%ûî]<'{Ã"äÌV‚	Ÿ∆^∏ZI<;ÀY§øì©ƒÛ±G{ÊÅHûê}9D¬Ò|Ï›ÈÏ◊π-˚•t˝ÿÌﬂ|Kv∑≈˛L2≥œÏ3˚Ã>≥œÏ3˚Ã>≥œÏ3˚Ã>≥œÏ3˚Ã>≥œÏ3˚Ã>≥œÏ3˚Ã>≥œÏo»ÂHE¥É¶cs+ßVÛÕÏ°%LØîã÷pèå√ÿäDPk»anME∏¥Ç≠ïû*0>ï`*»CΩááùidíÌ	ÊV∫“ﬁrÅPãTEÙkknÈôHÛ¨hç8,≠íÂÅV∞∂RüÔ+ì]®ÌeOó2é√üå≠ﬂ}ëÀ%>–±·~í€mÙC(wt“Ó∑Ô©ï±‡ãÑ©ıEl6åÅqòZ#°‘bü™hç„¿|ÂËGµ^G/Èƒ…G?Jµ^DﬂI‰CŸ„û;π]≥àÈƒƒÆäV°`j•⁄∆6ˆ$E´ç=¸QRkhæ2±oóQ(¸ÏÀ'±˝»¢Ô$≤é®uÀê”±·˘•>ƒ·O‚póVk—m≈Ë§›Á¡π˛ÒÑ√‘~ë◊—w∂÷Ì:z·
&vÆ é¡éN¸Ï[qÉ¨¬≤5»È∏-Æ˛ƒ◊tbjïÎ¢uK'fˆµç}yhµ∞/É/bU∞o`b«v≥@B¡√é‡'æ⁄F?øih›n¢“°I~/„e ∞§CsÎ:0≤_ƒöZS£¸"÷´{ÛS≠—e´X»@‚¶Ï>∞ØÈ–‹z){pvr ’&˙ÿ[-qæ†[Ï+:4<·bßVs´XÆBëqXË®ıEsò[˘z˛êqEICÜùÿ√?`„‰˘\≤[.¸YîÏ[:6“-÷Åå˜=∞ˇÖ√ÿzd∞<Ûr˛ê	Xÿ£e'ˆË'æv∞øÏ‹∆~†s≥3	ÛÛãÿ¡˛ì ∫œZ¬¡niÏëÄó˝{;{°÷à[.@cGt
∆÷KˆD¿‹Á˚èøpòüJÏ?*Xûπ`∑¥Ú¿Œ·cOB{πÿ£íN
ˆV)òKüí˝'K+—˝s+/ÿÖÇ±œÂÅùØbOùÏÏªí=î∞∑æ÷fˆü,ÏI…nõMI»vÆ`ÏsQ≤3:Ù∞r≤ä∏cæ'∫H¿ÿ∏¢AÏüøÁ0”°p∞8≤[zÜweﬂáÆ8ø/Ÿm¯@tKäf∆~;≤§cc+EÚœﬂò‰#±ØB3=≥É=E…û–°õ=ÿÏ—P∞∑⁄.ê≤`OÈ–ÙÑ¡!øØÈÿ‘Z≤ˇ,a¶s∞Oµ^Ö?ò[Òâ∆<Ü<>ÛÒ√89$—YÎ∫¢ukevD∑ƒ':∂¥ÆC{®Ç¢Æ˚YÔËƒ–
¢≥∞Z£s+ˆPE]”°á]Ñ¥Zâ~ÄÇπïo∑Ã∂w°Ik±ßcKÎ:¥±À@Æ◊—g3;ıπ(V:f∫≤ïÿπ≈+∫≤3äbãÅ+ÿ[mÏäÿ‹—±È	˘°X«≠Ëƒ–´Å,Ë"{´edôEπ=±Å±œ°»%{ˆm8—≠YÙùÑ©.vznEt?*ÿZi˝˛Yòüü≤Xøáñ÷èÎËÖÔËƒÿ∫µØﬂ%äı{ˆÅtÏ€î≠±Âå„∞oKÎaﬂ∆¯¸	†ä}3˚±5˙Q¡ÿH«æç@πo„gˇ ¸Y∆q¯ìÄô˝MZ˚6˙!î∞∂2~Q0”—R”≈Nì6˙Q¬÷«¡	3˚zΩ5ªŸS-h_”∂O[¥ädoc◊2UëéÃÒ*)[iØU¬‹ö)ñ#‰0∂äL2˙≠Ä˘©{À∆ßR≈>-:±gúÌ†È∏-YŸ™,H¥*v‡ÌÏÂ˛º˘	ãû—ﬁ¬ûñ≠ÙTé÷å√ÃŒTêw`OËBÖOtlkï∞‰G-ïÎÅ%Oi¡D∞CJ«¶'≤:6∂&EkF«ñVzÊîéçOE·nèø•c7˚3øìöŸgˆô}füŸgˆô}füŸgˆô}füŸgˆô}füŸgˆô}füŸgˆô}füŸgˆô}füŸgˆô}füŸgˆõ∞/Ç}∏ˆt‘ê v°2∂–/"ÖØË∞!L1ëÚD¢›"ì¢E¿“¥$ë	œêJ‹å=‹Gª0ß£&°.[Ïa^¥`MáMé]"Së(¥9T—íJZRëŸ”≤%ì∏˚áËèåîéöÑü_˛ç≠££√ÜD?Gˇì}ƒG:l^lıÍø…è[:l∂lãñçBK÷€ˇ.ˇ*BÅñ|§_¸&ä˝S≈ã(¢£&·˜/ã≈2Z–a≥%bqº∆û≤ZÆ‘ÔÂvEáÕñ’V˝Y~ªÅ±ÂãåZ≤Ÿ˛˘À/bÉ·ŸérV≥˚íî√1btxíoph°NYöf√jπ›(µ©≤ˇ›◊_£hYo6RbKáM¬U—Rcˇ: S¥®/_ƒ∑û=(Ÿ—r±à8*˛IZ˛ÅZX≠WæA!Ô¬?{Tc_ëÏõo‰fs89»Wﬂ~ã‚óK;˚∑‘¬*∑	…-ÚüÑÿ`xˆL¢¸˝"˙WVgœHã	_∞/":j∞SÀªÂ˚˙|?û,Èy7X——)ñ~ë8¥ÏúE˛^P¨G≈Ò"2Ø-öcpv≠P>[õ˝x7;{T≤ØÈ»œŒæî!çZæÖÇÖ˝?TÿdNÏC≥zGñÿYÙo,ä8*-B+˚¢≈ûì	75œ„(9
ˆP°p4G!€ÇÔ*˝µ$Û⁄¢%Üfıû,±G/?∞ËÖ£“"Q>¡¢≈æ¡±•…h2≈”ñÏ;:2µ|ITéÊ(d◊bè˛ùâ*Z§¬†Ï©>ä v˝ÉééèqlQY—í‘ÿ]»ÆúIç=‘\ˇ®e™é]¡(º∂ê‰tP÷∆=‘≈ıD&◊G¬ﬂπÈÔ•Ï®¢ÂeœÙQ$’u˙E”„„8◊˘eK\c/9¥ÊÖW|®±G˙'˝E+ΩKT….qÊ»?2Dú8jÛùÈÔı.îZ}B ¬xm9J~l¡É≤”•OÏàx˘tïñ?ó-´6˚ñÒÇ}’bˇE{&Q∞áˆ˝ÅΩh˘ˆ	u¯ûÿwüÚÇGÅ˚°‹êù4§?û[æî-ª6˚7/ÿUã˝W≠4±G%;„8≥Îºdè8µPØ—__ŸÈ;+øòÿn¡ûÈ{D<≥À≤EµÿÛo
v4Ÿø+ÿ3ÚyVn˝ÒÃÆKvjŸ»3{D>_‹G}BI¯E+4ÿ˜Hn¬^Õq®±üÛ{ v—a#«ÖrAu›â˝ƒ
≈6ﬂ»MÌëÿ/EB√¶ ^¯v#ø≥ŒÒO1‡ä∫Õ≠‡dE±dâ6Îy¡qù=—
Â√l7Um¿±∂˘ÄÌF…”|ØÆ„@_é#Q´m÷(Íylp´övÒéΩo~ %B˝Å÷∞†√&;/◊qv˙£˙gπ•£3«∑
eÀV˝Yn6hóu(ZBâ ü—rã˛ÚÒE·Fk,¢kÆ“ó§%{ŒˆQNáv∆£b˝æ¶√{JkÓ˚Wﬂ~ã≤Ê-÷Ôˇ¨–í-äı{ PπM¿Q∂d¥~ˇãƒ‡ÏØkçhœv—ûéö{0˙{ÀæÕ°•∆˛ÍK˚D¶¢ÊøØ-ÂéŒ—◊Ísèbd∆KK&pª=´]§ÃÑﬂÌB8à›≤_óÌôH∏ë}üàîß¬Ñß0≥-)«≠ÿüyüvfüŸgˆô}füŸgˆô}füŸgˆ7dˇˇå#9:
endstream
endobj
6 0 obj
<</FL 1/OP false/SM 0.01/Type/ExtGState>>
endobj
71 0 obj
<</BaseFont/DTWGIJ+Symbol/Encoding 70 0 R/FirstChar 32/FontDescriptor 56 0 R/LastChar 202/Subtype/Type1/Type/Font/Widths[250 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 549 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 250]>>
endobj
70 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 179/greaterequal 202/space]/Type/Encoding>>
endobj
124 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
125 0 obj
<</OP false/OPM 1/Type/ExtGState/op false>>
endobj
126 0 obj
<</OP false/OPM 0/op false>>
endobj
127 0 obj
<</A 128 0 R/Border[0 0 0]/Rect[244.413 9.0 286.158 16.0]/Subtype/Link/Type/Annot>>
endobj
128 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
117 0 obj
[129 0 R]
endobj
118 0 obj
<</Length 7512>>stream
1 g
/GS0 gs
0 792 0 0 re
f
0 0 0 0 k
/GS1 gs
60 41.333 492 696.667 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
-0.01199 Tc 0.01199 Tw 10.5 0 0 10.5 60 730.8196 Tm
(new user cohorts, and \(5\) entry of tibolone as a treatment)Tj
-0.00999 Tc 0.00999 Tw 0 -1.24286 TD
(in parallel with the drop in estrogen-containing products,)Tj
-0.02499 Tc 0.013 Tw T*
[(primarily as an option for new users of hor)-25 (mone therapy)65 (.)]TJ
-0.0231 Tc 1 -1.23809 Td
(C)Tj
-0.02299 Tc 0.02299 Tw [(urrent guidelines stress that while HR)60 (T may be appro-)]TJ
-0.00999 Tc 0.00999 Tw -1 -1.2381 Td
(priate for short periods of time and at the lowest possible)Tj
-0.00101 Tc 0.00101 Tw 0 -1.2381 TD
(dose for the relief of symptoms, it should not be used in)Tj
0 Tc 0.058 Tw 0 -1.23809 TD
(women with a history of cardiovascular disease, breast)Tj
-0.02499 Tc 0.02299 Tw T*
[(cancer)40 (, uterine cancer)40 (, or venous thromboembolic events.)]TJ
ET
BT
/T1_1 1 Tf
-0.02299 Tc 0 Tw 6 0 0 6 288.1499 643.0197 Tm
(26)Tj
ET
BT
/T1_0 1 Tf
0 Tc 0.02299 Tw 10.5 0 0 10.5 60 626.7197 Tm
(Increases in the proportion of women in our population)Tj
-0.02499 Tc 0.007 Tw 0 -1.2381 TD
(who started therapy with a vaginal preparation, particularly)Tj
0 Tc 0.034 Tw 0 -1.23809 TD
(among older women, may reflect increased attention to)Tj
-0.015 Tc 0.015 Tw 0 -1.2381 TD
[(symptom relief, in concert with greater concer)-25 (n about the)]TJ
-0.01801 Tc 0.01801 Tw T*
[(long-ter)-25 (m ef)20 (fects of systemic hor)-25 (mone therapy)65 (. T)70 (otal pur-)]TJ
-0.006 Tc 0.006 Tw 0 -1.23809 TD
[(chases of oral and transder)-25 (mal HR)60 (T dropped, while pur-)]TJ
-0.00101 Tc 0.00101 Tw 0 -1.2381 TD
(chases of vaginal preparations appear to have continued)Tj
-0.022 Tc 0.022 Tw 0 -1.23809 TD
(according to previously established trends. In addition, the)Tj
-0.02499 Tc 0 Tw T*
(number of new users and the percentage of new users start-)Tj
-0.009 Tc 0.009 Tw T*
(ing therapy with an oral drug declined. While use of oral)Tj
0 Tc 0.02699 Tw 0 -1.2381 TD
[(HR)60 (T among current users appears to decline with time,)]TJ
0.054 Tw 0 -1.23809 TD
(there was an especially pronounced drop among estab-)Tj
-0.02499 Tc 0.009 Tw T*
(lished users after 2002, indicating a tendency toward short-)Tj
0.013 Tw 0 -1.2381 TD
(er duration of therapy with systemic agents.)Tj
-0.00301 Tc 0.00301 Tw 1 -1.23809 Td
(Even prior to 2002, HR)Tj
-0.0029 Tc 9.30462 0 Td
(T)Tj
-0.00301 Tc 0.85805 0 Td
(utilization in our population)Tj
-0.022 Tc 0.022 Tw -11.16267 -1.2381 Td
(appeared to be considerably lower than estimates from the)Tj
-0.017 Tc 0.017 Tw T*
(US. Our estimate of a baseline prevalence of estrogen use)Tj
-0.01401 Tc 0.01401 Tw 0 -1.23809 TD
(of 20% \(2001\) is consistent with that of a 1998 telephone)Tj
-0.02299 Tc 0.02299 Tw 24.57143 30.9619 Td
[(survey of Israeli women aged 45)-25 (\32074 years, which estimat-)]TJ
-0.017 Tc 0.01601 Tw T*
[(ed that 17% were current HR)60 (T users.)]TJ
ET
BT
/T1_1 1 Tf
0 Tc 0 Tw 6 0 0 6 468.311 721.1196 Tm
(9)Tj
ET
BT
/T1_0 1 Tf
-0.017 Tc 0.01601 Tw 10.5 0 0 10.5 473.837 717.8197 Tm
[(Despite dif)20 (ferences)]TJ
-0.007 Tc 0.007 Tw -14.84162 -1.2381 Td
(in baseline utilization between the 2 populations, the ob-)Tj
-0.013 Tc 0.013 Tw 0 -1.2381 TD
(served drop in utilization following the publication of the)Tj
-0.019 Tc 0.019 Tw 0 -1.23809 TD
(WHI findings correlates well with findings from US stud-)Tj
0.01801 Tw 0 -1.2381 TD
[(ies. An analysis of US phar)-25 (macy purchasing data estimat-)]TJ
-0.004 Tc 0.004 Tw T*
[(ed that approximately 42% of women aged 50)-110 (\32074 years)]TJ
-0.005 Tc 0.005 Tw 0 -1.23809 TD
[(were using HR)60 (T in 2001 and noted a precipitous drop in)]TJ
-0.01199 Tc 0.01199 Tw 0 -1.2381 TD
(purchases by 2003.)Tj
ET
BT
/T1_1 1 Tf
0 Tc 0 Tw 6 0 0 6 396.8231 630.1197 Tm
(7)Tj
ET
BT
/T1_0 1 Tf
-0.01199 Tc 0.01199 Tw 10.5 0 0 10.5 402.3787 626.8197 Tm
[(In that study)65 (, data were not linked to)]TJ
-0.022 Tc 0.022 Tw -8.03607 -1.2381 Td
(the identity of the purchaser; therefore, longitudinal analy-)Tj
-0.02299 Tc 0 -1.23809 TD
(sis of purchasing behavior of individuals was not possible.)Tj
-0.01801 Tc 0.01801 Tw 0 -1.2381 TD
(Data from the National Ambulatory Medical Care Survey)Tj
-0.00301 Tc 0.00301 Tw 0 -1.23809 TD
(and the National Hospital Ambulatory Care Survey also)Tj
-0.02499 Tc 0.024 Tw 0 -1.2381 TD
(demonstrated a substantial decrease in the number of visits)Tj
0 Tc 0.157 Tw T*
[(of women with HR)60 (T prescriptions between 2001 and)]TJ
-0.021 Tc 0 Tw 0 -1.23809 TD
(2003)Tj
ET
BT
/T1_1 1 Tf
-0.019 Tc 6 0 0 6 338.1274 539.1197 Tm
(19)Tj
ET
BT
/T1_0 1 Tf
-0.0209 Tc 10.5 0 0 10.5 343.8781 535.8197 Tm
(;)Tj
-0.021 Tc 0.021 Tw 0.50706 0 Td
(again, these studies were not designed to allow for)Tj
-0.02499 Tc 0.013 Tw -2.97164 -1.2381 Td
(person-level longitudinal analysis. )Tj
0.019 Tw 1 -1.23809 Td
[(In a study of HR)60 (T use among women aged 50)-110 (\32074 years)]TJ
0 Tc 0.093 Tw -1 -1.23809 Td
[(presenting for mammography)65 (, the self-reported rate of)]TJ
0 Tw 0 -1.2381 TD
(HR)Tj
-0.00011 Tc 1.32886 0 Td
(T)Tj
0 Tc 0.086 Tw 0.9468 0 Td
(use dropped 18% per quarter following the WHI)Tj
-0.02499 Tc 0.011 Tw -2.27566 -1.2381 Td
(publication in 2002.)Tj
ET
BT
/T1_1 1 Tf
-0.024 Tc 0 Tw 6 0 0 6 397.2628 474.1197 Tm
(25)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.011 Tw 10.5 0 0 10.5 404.3788 470.8197 Tm
[(T)70 (ype of therapy was not addressed in)]TJ
0 Tc 0.03799 Tw -8.22655 -1.23809 Td
[(this report. Analysis of data from a lar)20.9 (ge US phar)-25 (macy)]TJ
-0.02499 Tc 0.02499 Tw T*
(benefits management company also documented increased)Tj
-0.021 Tc 0.021 Tw T*
(discontinuation of therapy following the WHI publication,)Tj
0 -1.23809 TD
[(although switching to other for)-25 (ms of therapy was not con-)]TJ
-0.00999 Tc 0 Tw T*
(sidered.)Tj
ET
BT
/T1_1 1 Tf
-0.007 Tc 6 0 0 6 350.1498 409.1197 Tm
(27)Tj
ET
BT
/T1_0 1 Tf
-0.00999 Tc 0.009 Tw 10.5 0 0 10.5 358.6618 405.8197 Tm
(In contrast to our findings and to the American)Tj
ET
0 0 0 0 k
173 745 379 10 re
f
BT
0 0 0 1 k
/T1_2 1 Tf
-0.02499 Tc 0.013 Tw 8 0 0 8 251.5303 749.5293 Tm
[(Sustained Impact of the W)75 (omen\325)75 (s Health Initiative Findings on Hor)-25 (mone Replacement Therapy)]TJ
ET
0 0 0 0 k
167 17.75 385 13 re
f
BT
0 0 0 1 k
/T1_3 1 Tf
10 0 0 10 267.483 23.9116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_4 1 Tf
0 Tc 0 Tw 5 0 0 5 400.608 25.4116 Tm
(n)Tj
ET
BT
/T1_3 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 413.7891 23.9116 Tm
[(2009 February)55 (, V)110 (olume 43    )]TJ
ET
BT
/T1_4 1 Tf
0 Tc 0 Tw 5 0 0 5 524.3189 25.4116 Tm
(n)Tj
ET
BT
/T1_1 1 Tf
-0.024 Tc 10 0 0 10 537.5 23.9116 Tm
(255)Tj
ET
0 0 0 0 k
60 17.5 79.5 13 re
f
BT
0 0 0 1 k
/T1_3 1 Tf
-0.02499 Tc 10 0 0 10 60 23.6616 Tm
[(www)75.2 (.theannals.com)]TJ
ET
0 0 0 0 k
59 42 492 18.963 re
f
0 0 0 1 K
0.5 w 
59 60.713 m
551 60.713 l
S
BT
0 0 0 1 k
/T1_5 1 Tf
-0.00101 Tc -0.02699 Tw 8.5 0 0 8.5 59 48.463 Tm
(Figure 3.)Tj
ET
BT
/T1_6 1 Tf
7.5 0 0 7.5 95.9782 48.463 Tm
(Administration method for new users aged 45 years and older of hormone r\eplacement therapy)Tj
-0.00121 Tc 41.48446 0.00001 Td
(,)Tj
-0.00101 Tc 0.52687 0 Td
(Maccabi Healthcare Services, 1999\3202007.)Tj
ET
0 0 0 0 k
59 65.288 492 298.033 re
f
q
59 65.288 492 298.033 re
W n
q
0 G
1 w 
/GS2 gs
-0.00002 TL /Fm0 Do
Q
Q
BT
0 g
/GS3 gs
/T1_7 1 Tf
0 Tc 0 Tw 5 0 0 5 285.1575 11 Tm
( at University of Canterbury Library on August 25, 2014)Tj
0 0 1 rg
/GS3 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS3 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
17 0 obj
<</BBox[0 0 611.99994 791.99994]/FormType 1/Length 57/Matrix[1 0 0 1 0 0]/Name/Fm4/OPI<</1.3<</Color[0 0 0 1(Black)]/ColorType/Process/CropFixed[0 0 8200 4943]/CropRect[0 0 8200 4943]/F(sys:DOCUMENTS HW-FS1: publications:Journal art: TAP Art:TAP Feb 09 art:RRL438-3.tif)/ImageType[1 1]/Overprint false/Position[59 66.753 59 363.32101 550.97998 363.32101 550.97998 66.753]/Resolution[1200 1200]/Size[8200 4943]/Type/OPI/Version 1.3>>>>/Resources<</ExtGState<</GS3 6 0 R>>/ProcSet[/PDF]/XObject<</Fm5 16 0 R>>>>/Subtype/Form/Type/XObject>>stream
/GS3 gs
q
491.98004 0 0 296.5679 59 66.7531 cm
/Fm5 Do
Q

endstream
endobj
16 0 obj
<</BBox[-0.11992 -0.22509 1.12403 2.44547]/FormType 1/Length 45/Matrix[1 0 0 1 0 0]/Name/Fm5/OPI<</2.0<</CropRect[0 0 8200 4943]/F(sys:DOCUMENTS HW-FS1: publications:Journal art: TAP Art:TAP Feb 09 art:RRL438-3.tif)/IncludedImageQuality 1/Inks[/monochrome(Black)1]/Overprint false/Size[8200 4943]/Type/OPI/Version 2>>>>/Resources<</ExtGState<</GS3 6 0 R>>/ProcSet[/PDF/ImageB]/XObject<</Im3 15 0 R>>>>/Subtype/Form/Type/XObject>>stream
/GS3 gs
q
1 0 0 1 0 0 cm
0 0 0 1 k
/Im3 Do
Q

endstream
endobj
15 0 obj
<</BitsPerComponent 1/Decode[1 0]/Filter/FlateDecode/Height 1236/ImageMask true/Length 6185/Subtype/Image/Type/XObject/Width 2050>>stream
XÖÌ›]o„8ö–G£Aq/Û6bˇ_∫Aﬁüí¬^Ï›BãΩ—`å2LÓ∫˛@cG.µ*ò∫ú?–¿2»EﬂU≥–´∆‚æ∂ÛiKI™í™é√á3ä^˙M,ÒX")z∫ëów≤Ä   @ Ä   @ Ä QÑ÷8Ì”ë$aiºn’R*ëﬁì∫(Ú\KÖ q‘U1eJ*ëxó◊∫PTz1Äs¶R'©E§ âs:nÄ∆iØ⁄x“Ë¨ª ò;ƒÄ#D†Ï’(0FÑ †O÷ÛÄ1‚êâ–f&8FÑ #¯¨ñgãHrTóOÉcDê°Æã27Râ†¿‘õ•Ó§Ç1¢ê5¡Û%±1b|Ñ∂ •Ò\ï1@ Ä   @ Ä   @ Ä   @ Ä   @ Ä   @ Ä   @ Ä   @ Ä   @ Ä   @ Ä   @ Ä   däR<7@+A¨ enÙâQL$  @ Ä ≤Ä   @ Ä cÄ   @ Ä   @ Ä œ@{„t´ñà¿¯©è†¿¨ŒKm§'@ç∫(Ú\K%N ü’£LI%V óW∫Pë∏5¿I¥ â òJù§ëÑ∆iØ⁄à>π»~wHÉáΩu ¡„! ˚Ÿ	N› *ƒP>¬(∞˜ ùÏ9¿√gÇ{ _<¬≥¿^‘è4∏◊ ÌJ¿©ƒ	0wSoZ˝∞°}ò:Û%±}xîUaH˚É@ Ä   @ Ä   @ Ä   @ Ä   @ Ä ÿWÄu+ó‡YHKnke ùÏ	@ Ä ˚
†‰tN5 [AÄ2è‡ÌÒá≈G	¢–«|îÄ   @ Ä   @   @ôÄ êÄ   @Äw≤Ä   @ Ä c`è n9üà ˙Oï q úù~Úëx@Ä   @ Ä   @ Ä   %  @ Ä   @ÄÄ‡ç◊≠Z7l<5Äı;ãØ‡¶ﬁ¥™ì
∆@| ı¨,µë ìhó≥WSãØ
PyÆ•Ú4ÍYÒï|Vè2e-ÄÀ*7ÄÆ‘IjAÄ8B„¥Wmƒ Œ≈†>π∏ªª ò{ BÄ⁄] DzLú©b ØÙâ≤à†à†ﬁ<H%NÄ∆«˝4ò4~VóÖ…•ÎLpµ"§üÏíX[œæˆ≥Äq´â ¢Ìüˆ™0⁄zF XÄ   @ Ä   @ Ä  ¿< @ Ä   @ Ä   @ Ä ãèÄ   @ Ä   @ Ä eN @Ä   ﬁ…F Ä   @ åÄ ùÏ	@ Ä   @ Ä   @ HÜ ü†√`* S  @ Ä õÉD–£ﬂZDê}lA Ä   @ ‡€§Œx›™u√∆@å ”÷,u'ï8îì#î∆H%N ÌÍ¢»s-ïX|Vè2e)@Ê\^ÈBYƒ`*}¢,"(ú”ï:I-"òÄWmº UÏ ˛@ƒ‡Æ Êà i"Ôì∆À03@hW°â≤à ùÀÎàgÇIXnû§Èäêè¸in÷ñ3SJ%VÄi‹Kbp∆≠fBàÄÀ‚  @ Ä  ¿ @  –…û   @ Ä   @ Ä ˜0Aä√U1·"uKÈrCÄÁ€Ôø/‚¯Ó‘∑Ì¢Ì@ Ä   @ .R @‰ Û∞µTÄÏ#¯«Øø¸Ê/¿ØrRßÒ¸B ‡‘Å   @ Ä   @ Ä  ∫‹‡ÿÇ   @ <} §¥\H=xƒ∞é"8úÕ 2ì ZÄzVÊô  @ Ä êL  @ ¿∑G  @ Ä   L @  @ ‡‘Å   @ Ä x Û∆x›™•T"pSoñ™ì
∆@| Œ◊≥≤‘F*qX_Eûk©D⁄	zü’£LYD‡ÚJ "^ SÈe)@‚@ù§ëLßΩj„ò[7 >π»~wë‘.zÄãQ`ÓÅ&´â–fPq‘QœÎÕ≥ÄT‚h⁄∏üìS?´À¬‰RâÛ
n˜íXhå[Mm'»eqÄ   @ ` Ä ËdO Ä   /Äí`”^ƒ	¬ò∑oñ ^ yõü$  @ Ä  Äd∞îÄ áı¨$@&@ Ä   $<@ Ä Ìp §XHÈr#Ä	RHÈrCÄcÄ   @ Ä à`Œüî \ú≈AôÔ¿<úß	 	RZ	pPÊ ¿DÄ   ﬁ…F Ä    åÅΩò)≤á& ∞¯(¡sòáÛV‡å ﬁwÄ   @ `@ »ö  ¿‚£  @ Ä   Z	pPÊ ¿DÄ   ﬁajµS>m•Ç1¿º1^∑j)åÅ¯ Çõ∂f©;©`ƒ‡º°ÃçT0‚h|]yÆ•Ç1·(‡}Vè2eåÅ\^ÈBY c J SÈeåÅ(t•NR`ƒ	‡U/@‚\‹ i„5Ä≤Ó≤¨Ä¯ 4d‹ è"üPÎLY c >Ä™bígJ*ÒxD˛4ÿb÷Ê3]Jc :Ä$¥S˜íò7n5B¥C¸^Ä   @  ê_$@'{¿Ä ¯IÄ   @ HÜ K	pXœJdÄ   @ @2¡É   @ ﬂÅ   @ Ä 0Å !xÄ   @ÄSÄ   @ ¿ÑÛV¢Àé-@ Ä   @Äy  –Ä  @[œ@ Ä   @ `@Ä {‡å ﬁwÄ   @ `@ »ö  ¿‚£  @ Ä  ¿ ÄÇv ß≠T0‚–÷x›™•T0‚ò⁄ikñ∫ì
∆@å rÑ<◊R¡à`nÎ"jÄ`]^ÎLY c >ÄˇÄJ Ò§÷ôJù(`D	†+uíZ c N ØZX c‡Î ¥D∞.x˙ù`ƒyTÄ‡g'òU_{&¯ƒoÅ¨EPìØ˝0Ùî‘Íq∏ÃµT0‚ò˙o∞ ÚîÊ≠ÒΩKb#…Çà7N˚¥≈5ÄıõåLºÀ‚Î“<ÍL0â‡)wÇ  v :Ÿcd∑‰∑√à¯ÿ/ÄË;AÄ ˚∞éb$õÛΩ`) ¸YÕ$>ØÓ ¸*¡.@VÊœ¿P≤ı Ñã¶ú¨À≤Ãü’≥@∞¯
 ˚‘	Z|î #Ÿæ@+~xb Á©o∞.ø?wÄNLÍY˘ºdèëÈXó∂ûï= ‡/è∏*|q¨bjÒ( @QÊoXJ0–x|…(Ë ‡†Ã ÍzV |˜π õ€-7= “Ä∂ûSã'pK∞î‡Q<r  ¸A°[ ÷©˚Ä/xÙ+ +ÛªnnÈæl∏‡—˚Ä˚è¿ˇÑÛ”øhJl ≤°¡US0`!m;˚j ùÏ12ﬂ§\ß∫‹Ëc9—˜÷ÂÏ´uÇùÏÒŸÎK	>Ù∏ phh eæá ·‚≤ø1Bû=ãy¿’-‡∞‡p†¡Ω‰›t¸1ù†√¿U'ÿ†/u÷∞.˝ óù‡4\–øìm ,∏ Ú&≤≈
P K8îÌD$x˛≤ëu™ÀÕ@'xı0¥õ:Î∞Ï-ŒDJ	nËdèë—è6
x<l¥ËKù}Ò0XJp'¿SöX¸ #Ô¿Nê  @Ëåé†ì=FFˇ¡OÉGá=ñp@ Ÿˆˆhp+¿CoÅË;AÄ úad4D8˙INÑˆÔ∏e"tPÊwDﬂ	Ä ú #£üÃ◊„=ù DŒ8>X\∂í"ÛH∑@Ùù @ NÑ02ö"ú˝$¡Ó«|Xœ Äbü˝ep"îOÑí.7œ™≠g≈‘‚˛_éZNÑ,8
À2' Jyâ OËiQ;AŸsADs"ƒ/F}'H Ä!ååévËdNÑ¢àæ$ bê=FF˜HÄ∫ûï= <˝U·¢Ã˘Ω á¡R~7x ;AÄ °3ö"ﬂËõ!tπ˘V"Yôs@ÄRÇ=∏n¯ä_éFﬂ	Ä \FF?«ë¨Ã˘8Ãy@)ØÄ[ ÿ	Ä ù—\y“"_Òi∞ì=∏ bÄZü˝XDÿ	F†ˇ[~ƒêk˘5¿˙«@¨ ô≤à˙qx¢,Ä1Î08I-Ä1Ìp ¬E—-Ä¯:A¿bpıõù1˙¯g\%/ûü‘lVñôº¥õ˙øOæm+\. Ø«gW≈ÑÎ«zÎ—–Œ ©E?¿ß!Ä∑r¨èÚJ@iÙ;y©`¢+ˆ∆<`¢+Õ@±X›Ceå¡“‡RÁóf_˘ìle}’~vÍ√©›©@˘É≈‚RíÌÛSˇ$€Áßép7@ÆÂ«s¯∏@wÚ#fÄ´%±H“V~ƒpÁX˜=æ†ï{=æ§XÏ/¿?ﬂ¯≤b±ø xÄΩ.êç   @ Ä   @ Ä   @ ƒ†¥0€%ëWë:Ã$HıΩõ√⁄næÑÓM%;ejÂ›^…7xÿM!ıí2;e˝n´SJ•¡„.ÄåKóò7ÿ9ﬂs´<Çƒ©L‚≠b⁄§√¥—Kâ∑õrûj%ﬁ*°QÌÍ@C©i'ÒÕíò¶ˇ‹œS*\Îùl}%óÛR¡aªhyµ1À$X§PHº› •|ÓL'qJÔ¶í‡ÙÍ@â√Pjz’îÀè!ÿπóœ¢Á‹œSi∏@]hı⁄{ÏdÙkÁ≤,}”` ’PóÍÿ˙™‘oïvì Go}`Œgy∫há°‘D‚Ìè·MSU#ù8èÅ‡q¿+¯“§WK|≥îj—¯"WØÏ¶^ØR}›Éœu⁄8AµLIº’ ¶.FÍµKÜRv[ô:_Á*m<RÄ«] ùúWû.\!ÒÕR§ã¶™µJR“’Ï7“È{WLî≈N*_ß
9ØÌV⁄z¢U?Ä≠ÎU™¬n˜ïú∫"Soö›/O$U(õ8‹ê¿(OM!ïõÂ0]¨Æ·0êJñÔ »¡õbúZlófìÍ±I1©ïÜóq¢/•˙ p∫jÂ;∆@ ^}'[OIªƒÈ,9≥ôT∂q§ïïÓ@Úaïí∏ÁsY∑= ´‘ô§vp†zSo·=z iìÈ	RM⁄‡Æ+‡?@/@∫∞ìJç‡∞õ˙∞J•ˇ%a/@6ê…ç›VV√ ïzﬂJ‘◊ …0¿$mî≈ r∑|9 
	wZô≠ékáæûZHK∏3x¨Táﬁ‘è®Ç√Óß∑òZ§eq/Ä§@}¿d}^ÿMØRË˘#‰õV^;Ùv*óp∑ïÈè®JáAÄûK`› ‰Ch∞˚	m ¥ÑwŒ÷ M!qO+˝Í‡H!ìp†ï⁄b(’I∏3G®R9P·–3∞VJRÌL¬ÌVæor¯‰–ó∫?Ä…”^ ≠6©æÀ≈uæI%K	w[ô Å&C æê∞†Òÿ˝Ñk #·ù ﬁòÙÃÕ$ﬁû÷´AÄM™`∂(%HM%‹ôÔU©®rËK≠œ!óx˚cxΩËπ;Ùõ5¿µ?z'[?@;’Í¥†(á⁄aÄÛî∂ ü`í5Ä≠%ﬁN•kÄB¬ªÜÇ
.,%ﬁ˛¿§ïõÉ˜¶|oê˙M+ó§î≈Œ÷T©»9Ù•÷Á0íx˚cH÷ù†ùH‹ó∫/¿ØipÛü%ﬁ˛¿d60
¥kdÓ|`õΩï∏?’`lï˛à^ IºJfü∞zkáL‚≠A∆•v`ê8µûÏ˛î]œáæTr÷ÙŒër¨ÙÔŒ£7ı#<Foï*Yœ˙ ¸Á$2â∑pR[˜®F≠R=≥zi
›†7u÷?KûI+5>ÖN‚ùµùıL#â∑o)i•LÖ{ ÷©œ∏ˆ´ó7ﬂ
@k8Ù¶j›0=∞J°†≈˙Y t˜ß0íx˚ñJ‰â'ÌpI#©Îôw≤É´«·Ê⁄Ø^¥“¶ÕÍi0qHıº¬(9uÖëp7ï'Ô]QÔ$´«NÌÒ˝FJ¡π\*€◊a‚÷OÉµTzS◊3Ôdª¿]˚’À+6m¸˙Y©>Ät˙ﬁMJ	˚SıLYÏ|`(¥zÌ‡0ê:ıπT∂?ieÆﬁ4ªÁ~û≤Ó∞>vÖùëâ€ =©FR} -Tj]UHÿüÍ[,J£ÙuáæT.)ﬂsè´eüƒyÙß4*‹gMpuô{áûVû∫ºH?XÙ§>Ij ‡ÿ÷˛ïÑΩ© ÁF‚ùÛºL} ´îúC”ˆ\¢µ◊yÚ…c Ö
˜ô¯’ jÉù>+4°1m$ﬁIŸU™oÏ≤+KøÛ`1ê“ùT∂q[-≤pHaÓ±” ‡¶N…≤∏COjæJU∏¿Ê{ãÄπ’SΩ I'ãˇ˝ Cﬂ®–*èﬁÔ.RSáûVöFæÅô7Ë≥Y•*‹	¿Ø∆@ Ä   @ Ä   @ Ä   @ Ä   @ Ä   @Ä{ïCŸÜ^{!€nip≠$Õ–ØE†∞è *8\o,Ê°9¬ @Ç≈j/€%@é^6˚
†É«ı∆Æ *|.Ä{F U“T¯Â7ãÌ[ i4\“<Ä#4õ2ëÌ&¿‚‘b¿*¯ΩH[˝¶=ƒ%¿˚n™›ø⁄•nµ˝∑ÔŒ‹¸Öº|†º9}—j◊‡ Mñ/^©‘ÁtÉΩPKÛayu¿\˚y”ô÷»èˇı·oÚÚ¿õ◊ˇhÁøÈ•Ò.“Óe∞A…y”`Ô tgﬁ\ÃC≥|•€˘i;mßniÇüﬂ X|hÁg∫”◊VW¿˚p,,Ú'ÿ;Ä—(«Ë:ÄØ1©NõI]U>/'ÈuÄ◊{¯r°G7∏Äy∫xsúèÚIUaÔ F∫√`ï∂’©õLÊﬁeŸd˙wy˘
 i_.F£¥mp √‡‚ıálî…ü`ˇ ‘a∫†€£ó~º8Ã≤˘M µ\ËÄD Á{êÌ ÈˆË®Œ›
 ‹ ¯E/ˇ∫Ω0œ@çÆçêMééÚÒaÖ¿Ÿu F≈¸ÕËEV7∏!˘P@Ö=]8∫ 0„…—‡˝ﬂÂÂKÄÓ õß£áì€ ´+†¬>éΩ ZFÅ5¿‚ÔÚÚ%¿Ï†8Z‘Æ é÷£@ˆ, ™ upvÄBµÛ√√Z^Ÿªô`ª’	ñ´N_dVc¸N'hΩúüç^Ë∂¡’”`)3¡N…è}p© ‹ò	Æ^.ıâÒÕ·!Êìó7 gg∂Pm8˚ÛÌlºÿKÄù" *ÁÎü<ûﬂö‡g $Æ¬3∏G	qÃƒ0µà‡Y~1B Ä   û ¿ˇˆn?Ö
endstream
endobj
119 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
120 0 obj
<</OP false/OPM 1/Type/ExtGState/op false>>
endobj
121 0 obj
<</OP false/OPM 0/op false>>
endobj
129 0 obj
<</A 130 0 R/Border[0 0 0]/Rect[244.413 9.0 286.158 16.0]/Subtype/Link/Type/Annot>>
endobj
130 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
112 0 obj
[131 0 R]
endobj
113 0 obj
<</Length 6734>>stream
1 g
/GS0 gs
0 792 0 0 re
f
0 0 0 0 k
/GS1 gs
60 41.333 492 696.667 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
-0.03 Tc 0.005 Tw 10.5 0 0 10.5 60 730.8196 Tm
(45% in 2007. Most new users aged 55 years and older start-)Tj
-0.03011 Tc 0 -1.21429 TD
(ed)Tj
-0.03 Tc 0.013 Tw 1.11632 0 Td
(with a vaginal product \(62% in 1999, 82% in 2007\).)Tj
ET
BT
/T1_1 1 Tf
-0.02499 Tc 0 Tw 8 0 0 8 70.5 690.0697 Tm
[(DISCONTINUA)74 (TION/SWITCHING)]TJ
ET
BT
/T1_0 1 Tf
-0.019 Tc 0.019 Tw 10.5 0 0 10.5 70.5 669.0697 Tm
(Analysis of annual cohorts of new users of oral therapy)Tj
0 Tc 0.049 Tw -1 -1.2381 Td
(demonstrated marked variation in percent adherence to)Tj
-0.01401 Tc 0.01401 Tw 0 -1.2381 TD
(therapy with year of initiation of treatment. Oral estrogen)Tj
-0.01199 Tc 0.01199 Tw 0 -1.23809 TD
(users who initiated therapy in 2002 or later tended to dis-)Tj
-0.02499 Tc 0.013 Tw 0 -1.2381 TD
(continue therapy more quickly than those starting in earlier)Tj
-0.024 Tc 0.024 Tw 0 -1.23809 TD
(years. Of users initiating therapy in 1999, 47% had a dura-)Tj
-0.021 Tc 0.021 Tw T*
[(tion of therapy of longer than 1 year)40 (, and 33% longer than)]TJ
-0.0251 Tc T*
(2)Tj
-0.02499 Tc 0.02 Tw 0.71952 0 Td
(years. The corresponding figures for users initiating ther-)Tj
-0.008 Tc 0.008 Tw -0.71952 -1.23809 Td
(apy in 2005 were 34% and 29%, respectively \(Figure 4\).)Tj
-0.009 Tc 0.009 Tw T*
(Median duration of therapy for the 1999 cohort was esti-)Tj
0 -1.2381 TD
(mated at 319 days, compared with 178 days for the 2005)Tj
-0.02499 Tc 0.013 Tw 0 -1.23809 TD
(cohort \(p < 0.001; log-rank test\).)Tj
0 Tc 1 -1.2381 Td
(W)Tj
-0.0251 Tc 0.83877 0.00001 Td
(e)Tj
-0.02499 Tc 0.022 Tw 0.66586 0 Td
(defined switchers as women who purchased another)Tj
0.00999 Tw -2.50463 -1.2381 Td
[(f)-15 (o)-15 (r)-40 (m)-15 ( )-15 (o)-15 (f)-15 ( )-15 (e)-15 (s)-15 (t)-15 (r)-15 (o)-15 (g)-15 (e)-15 (n)-15 ( )-15 (t)-15 (h)-15 (e)-15 (r)-15 (a)-15 (p)-15 (y within 4 months of their last oral)]TJ
-0.015 Tc 0.09599 Tw T*
(estrogen purchase. According to this definition, 5.3% of)Tj
-0.02 Tc 0.005 Tw T*
(those discontinuing oral therapy switched to a transder)Tj
0 Tw 20.82577 0 Td
(mal)Tj
-0.03999 Tc 0.02499 Tw -20.82577 -1.2381 Td
(preparation, 2.2% to tibolone, and 1.1% to a vaginal product.)Tj
-0.035 Tc 0.02 Tw T*
[(Proportion switching to vaginal or transder)-25 (mal estrogen was)]TJ
-0.03999 Tc 0.02499 Tw T*
[(highest in 2002 and 2003 \(T)70 (able 1\). W)80 (omen who had recent-)]TJ
-0.03799 Tc 0.02299 Tw 0 -1.2381 TD
(ly discontinued oral therapy accounted for 19% of new users)Tj
-0.02699 Tc 0.01199 Tw 0 -1.23809 TD
(of tibolone in 2003, the first year the product became avail)Tj
0 Tc 21.95289 0 Td
(-)Tj
-0.03999 Tc 0.013 Tw -21.95289 -1.2381 Td
(able. By 2007, this figure had dropped to 12%. )Tj
ET
BT
/T1_1 1 Tf
-0.02499 Tc 0 Tw 10.5 0 0 10.5 318 730.348 Tm
(Discussion)Tj
ET
BT
/T1_0 1 Tf
0 Tc 0.099 Tw 10.5 0 0 10.5 328.5 709.298 Tm
(Changes in drug utilization guidelines can lead to a)Tj
-0.01939 Tc -1 -1.24286 Td
(n)Tj
-0.019 Tc 0.019 Tw (umber of responses in the community: cessation of treat-)Tj
-0.02499 Tc 0.008 Tw 0 -1.24286 TD
[(ment by current users, a drop in the proportion of the tar)20 (get)]TJ
-0.005 Tc 0.004 Tw T*
(population commencing use, and preference of users for)Tj
-0.00999 Tc 0.00999 Tw T*
(products perceived as posing less hazard. Several studies)Tj
-0.006 Tc 0.006 Tw T*
(have documented the substantial drop in prescribing and)Tj
-0.02299 Tc 0.02299 Tw T*
[(promotion of HR)60 (T in response to the new infor)-25 (mation and)]TJ
-0.02499 Tc 0.013 Tw T*
(changes in prescribing guidelines.)Tj
ET
BT
/T1_2 1 Tf
-0.024 Tc 0 Tw 6 0 0 6 452.3335 621.248 Tm
(7,8,18,19,25)Tj
ET
BT
/T1_0 1 Tf
-0.007 Tc 0.007 Tw 10.5 0 0 10.5 328.5 604.898 Tm
[(W)80 (e analyzed utilization of HR)60 (T products in our HMO)]TJ
-0.024 Tc 0.024 Tw -1 -1.24286 Td
(population. Our ability to link purchasing data on the basis)Tj
-0.005 Tc 0.005 Tw T*
(of a unique member identification number allowed us to)Tj
-0.021 Tc 0.021 Tw T*
(follow trends among users, thereby characterizing \(1\) new)Tj
-0.022 Tc 0.022 Tw T*
[(users, \(2\) changes in the for)-25 (mulation used to initiate thera-)]TJ
0 Tc 0.035 Tw T*
[(py)65 (, \(3\) switching to alter)-25 (nate modes of therapy)65 (, and \(4\))]TJ
-0.02499 Tc 0.01801 Tw 0 -1.24285 TD
[(changes in duration of therapy)65 (. Follow-up through Decem-)]TJ
-0.00301 Tc 0.00301 Tw 0 -1.24286 TD
[(ber 2007 allowed us to deter)-25 (mine whether the change in)]TJ
-0.013 Tc 0.013 Tw T*
[(patter)-25 (ns of utilization seen immediately after the publica-)]TJ
0 Tc 0.13699 Tw T*
(tion of the WHI findings was sustained. Our analysis)Tj
-0.02299 Tc 0.02299 Tw 0 -1.24285 TD
(demonstrated the following phenomena temporally related)Tj
-0.01801 Tc 0.01801 Tw 0 -1.24286 TD
(to the publication of the WHI findings in 2002: \(1\) a 22%)Tj
-0.00999 Tc 0.00999 Tw 0 -1.24285 TD
(drop in total HR)Tj
-0.0097 Tc 6.34133 0 Td
(T)Tj
-0.00999 Tc 0.85122 0 Td
(purchases between 2002 and 2003, \(2\))Tj
-0.015 Tc 0.01401 Tw -7.19256 -1.24286 Td
(an initial drop and subsequent stabilization of the number)Tj
-0.02499 Tc 0.02499 Tw T*
(of new users, \(3\) a major shift from oral to vaginal therapy)Tj
0 Tc 0.088 Tw T*
(among new users, but not among current users of oral)Tj
0.011 Tw 0 -1.24286 TD
(medication, \(4\) reduced duration of oral therapy among)Tj
ET
0 0 0 0 k
60.5 17.75 378.5 13 re
f
BT
0 0 0 1 k
/T1_2 1 Tf
-0.024 Tc 0 Tw 10 0 0 10 60.5 23.9116 Tm
(254)Tj
ET
BT
/T1_3 1 Tf
0 Tc 5 0 0 5 84.2499 25.4116 Tm
(n)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 97.431 23.9116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_3 1 Tf
0 Tc 0 Tw 5 0 0 5 230.556 25.4116 Tm
(n)Tj
ET
BT
/T1_4 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 243.737 23.9116 Tm
[(2009 February)55 (, V)110 (olume 43)]TJ
ET
0 0 0 0 k
472.5 17.5 79.5 13 re
f
BT
0 0 0 1 k
/T1_4 1 Tf
0 Tw 10 0 0 10 476.2004 23.6616 Tm
[(www)75.3 (.theannals.com)]TJ
ET
0 0 0 0 k
60 745 234 10 re
f
BT
0 0 0 1 k
/T1_5 1 Tf
0 Tc -0.013 Tw 8 0 0 8 60 749.5293 Tm
[(BG)-250 (Silver)-25 (man and ES Kokia)]TJ
ET
0 0 0 0 k
60.343 38.713 492 21.777 re
f
0 0 0 1 K
0.5 w 
60.343 60.2399 m
552.343 60.2399 l
S
BT
0 0 0 1 k
/T1_1 1 Tf
-0.01401 Tw 8.5 0 0 8.5 60.3427 47.9901 Tm
(Figure 2.)Tj
ET
BT
/T1_6 1 Tf
7.5 0 0 7.5 97.6215 47.9901 Tm
(Rate of hormone replacement therapy use by age group, Maccabi Healthcare\ Services, 1998\3202007.)Tj
ET
0 0 0 0 k
60.343 64.13 492 287.332 re
f
q
60.343 64.13 492 287.332 re
W n
q
0 G
1 w 
/GS2 gs
/Fm0 Do
Q
Q
BT
0 g
/GS3 gs
/T1_7 1 Tf
0 Tw 5 0 0 5 285.1575 11 Tm
( at University of Canterbury Library on August 25, 2014)Tj
0 0 1 rg
/GS3 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS3 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
13 0 obj
<</BBox[0 0 611.99994 791.99994]/FormType 1/Length 62/Matrix[1 0 0 1 0 0]/Name/Fm2/OPI<</1.3<</Color[0 0 0 1(Black)]/ColorType/Process/CropFixed[0 44.758 8200 4798]/CropRect[0 45 8200 4798]/F(sys:DOCUMENTS HW-FS1: publications:Journal art: TAP Art:TAP Feb 09 art:RRL438-2.tif)/ImageType[1 1]/Overprint false/Position[60.343 66.279 60.343 351.46201 552.323 351.46201 552.323 66.279]/Resolution[1200 1200]/Size[8200 4798]/Type/OPI/Version 1.3>>>>/Resources<</ExtGState<</GS3 6 0 R>>/ProcSet[/PDF]/XObject<</Fm3 12 0 R>>>>/Subtype/Form/Type/XObject>>stream
/GS3 gs
q
491.98004 0 0 285.28839 60.343 66.2796 cm
/Fm3 Do
Q

endstream
endobj
12 0 obj
<</BBox[-0.12265 -0.23232 1.1213 2.54381]/FormType 1/Length 45/Matrix[1 0 0 1 0 0]/Name/Fm3/OPI<</2.0<</CropRect[0 44.758 8200 4798]/F(sys:DOCUMENTS HW-FS1: publications:Journal art: TAP Art:TAP Feb 09 art:RRL438-2.tif)/IncludedImageQuality 1/Inks[/monochrome(Black)1]/Overprint false/Size[8200 4798]/Type/OPI/Version 2>>>>/Resources<</ExtGState<</GS3 6 0 R>>/ProcSet[/PDF/ImageB]/XObject<</Im2 11 0 R>>>>/Subtype/Form/Type/XObject>>stream
/GS3 gs
q
1 0 0 1 0 0 cm
0 0 0 1 k
/Im2 Do
Q

endstream
endobj
11 0 obj
<</BitsPerComponent 1/Decode[1 0]/Filter/FlateDecode/Height 1189/ImageMask true/Length 13696/Subtype/Image/Type/XObject/Width 2050>>stream
XÖÌ›œé„8û'ØZçR
¡∫mb¨~Ñ<∞^´•ˆ≤1áı`!‚ê∑©XÏº»√D [óÍfò»Cõâ:¥„—oøîÌKñ√ÚÖ≈ﬂ$)ŸV–‘«IQ›”xLò@    Ä  @ 4Ä* Cò‡n∂0¿áÄQ¢Ü á 0`ÄÒ¿íB@ ì
 )0TÄTy Ub∞ ÛN;¶a®9¿ÔòÜ	ê@%⁄a¿ ?®‰≥≈ÄÓ“¯Ÿb¿ Yâ¡Ä“≈ä–`∏&òs3\Äe ¶  @    Ä  @    Ä  @    Ä  @    Ä  @    Ä  @    Ä  @    Ä  @    Ä  @    Ä  @    Ä  †D,Z"—ÄCK‰  hÄ  @ ∏~ÄoNÈ˚ÿ¶pâ˚mëòI.√¯Õ•zñÿ,*îyà]ˆ8„6@ëöô≤yÃmôT 6œáê`™÷.ÅtPó¿L5:¡hPù†ä<Ä√`áAı8l Î{áÅD.5æt&¿Ô9Ïi(áaå‚Bi(áap‹g>ÿU·ÿdè‡ÃOˇà·¸¿9?7√∏O‹àõ7„ÅÈj ƒa¿ Jó±¡êLlãúÈ*".|Lπ›⁄O0]-¿∑€bÃtç 7~ÂÔ"NêFE¢1XÄ»dQ¡mó¯”’ƒ6C¡mó∏x'∞@.3ÊÎøºàÖøpÛnÒ¿ÙJÊÎøºà‘ƒ•‹tãúÈ⁄ w√ÕPbNÅêòá»‚ÄÔÔ |‰Ö˜¶cp8∆ê¯–C¯6Kvªm`zá b¶|¿πïßæ ?ﬁmÂúÈ›ààKıl˛º_?pÍ;ÓÔ/  !@ë~.ïÕ˘ËÀîú˙>Œ¸˜ªhº; %¿¥` -‡£yΩœˆXØ@Ô
%ÏS´ù†±¿-”ª¯.ö)ëí{õnÜÆ|ê>Œí!p,π{$Ä¶˜±Û+êK…˝#§LÔ‡1>‡¬Å	SwÄë¿ÄÚÿ}«ÕQ„ƒö 8v§Ô ±ydqÏ∏az 8›ÁÊ b N˜◊è ¿`ƒÕ	‚≤Ω` `Í ¿)∞ôq{ Éw ¿Öè;ná
0‚“ó∆© 4zê≈Ö‚Ê4q∫íw»ufQP"ÃÆ˝q{ï± F¸iÆ §"~
úiá´à`—p«eo\m¨ |∂æ¨‹'Óı®SD¬‘ÄGÁ∞£L‹-_ú.îF 8ŸqXP∫å-Nù¨ †¿(S∆√‡Sﬂ{Óùˆ0Ë…%0céïEø¥òro}Äı√†*— ¿U«ÑiπÊir‡Üi —
@bP¨_‹@c∫ﬁ	r3 å◊áAú!îA “6 ç· Ï˘Ô" } òÚ∆o» ëÉô˘àlqÄD£ ±8±∏@?Ü¡¡@l |¿ ÎÀ‚g‡,ºó gãƒbÿ  "¥Ä 0dÄæé  Ä3El0lÄÀÄ©  !¥Ä–	 26¿‡Á ≤6@l1lÄƒ! ˚p}¿†?Ä 0tÄ»aÿ ó S? 
f°π¥6¿‡á¡  ,‡0lÄM S? ¢¡8 É  ‡"√@è .3ˆ	`∆,¥Äæ¿G`√` ¯ÄÅLôpââ@ü .2
 L}¸%:¡¡œ¿‡Óô¿êJ¶ 0dÄSËÜ0¯a0 ‡ñi– LÉ(ô@ }¿p˛»4hÄæÕb¶∂¯S[¸àˆınçw
êh¥∆ò©-Z#6xß  †5r¶∂_∫`÷ bˇ˙\ µh—h˝•gÃ⁄ ∫∆⁄K‰≠ø¥¥E"ÃZ"€–2ﬁ@{Õc±h˝•ÖY¿Üñ—Ä‹¢ íˆö'‚–ÈÜñ!%≥ûŒÑ&k} ﬁPs%Ûñ_∫ aﬁ-FLg®üŒ
@"‚OiÍ[ø„¸9äÊ´rë˘¯&^)—˛4EúÚlæ¿QıÁŒô|C£«√`£°Ø (± O'Û;ëckÒôî<oûU¬7π(„OSƒ•|S|Å†*âˇÜ¡ªpà¯qÓbûé¯ì…•ÙÁ≠°¯¶xÄ‘¯”‰	gj	êæXÙ¿›sßÄg nOÄ|	P..Öûv ≤˜‹Ÿ•d2€ ‡/%5Äá≈5—12¶≥åπ≥©t’Ûö\ƒV3›™Hyb“⁄ÿ¥•òıt"f5◊¿ü %‡œ‡πóÄÁ[ˇûÑg˘;?ò¯÷Ò˚j‘≥¿™?ÁŒ˛1Ë1ÄªÁŒn!ãˆâêFÎDH6¸AO DZ3Ñïña∞ÀT8ﬂ e:?¿ÍyÆdÌS;ç÷ñQ2kù!äCüÁõ,⁄€4”∑√©ãw	†vπeÒ√DkÀ∞©EØ6 hgI,—ËäÈº o¨\"R¶AdΩπ:jƒ√‡¥y‡ =Ìzp√t^ ‡û©7 Áüú	 ∂Ë-¿òÈ‰ ù„;¶A(ç´∞Ë2h\e‡ªá>úi|„·ÈÄ : ú†‡Œy j‘èÍtÿ1ŒP2ﬂ⁄SHß√épæ€·˘:˘Ä∏>Ó∞5∏BUrsï iΩª@ß^¸ ô≈ô –OÄ‹·\ i/Œ6`_˚™û úo&»¯àÅtàÛ∏{Ó¿éπs>Ä)”†fL`»}@…4ËQ†ˆmC(òzpŒô†èΩ@/Á»ÜpæıÄóªb¶7jΩ“5†÷Ì`À5m:ˆTÁ∞8hÆp‰©0ŒêoªŒ|/Äs§R2+FLg®ˇÁ ‡„?ÊoE∆t≠˜]zA‰L◊ê	≥!ƒ¬l» ['√”π ñ? π∆π zØ I9ü¢@˝KÙõ≈YR¶M°Œp£ûæ8ú`ÑL£ v˛e…ìq8#@Ü‹`3Ä≈Ÿ \jQËÈY¥XÙ†L.(}∏"….Ù÷=a¢q>ÄyE‘ßS$mcÄ™œ¿.w;¸∑Y¡=®§¯éÈÿ√]¡¨•ïK…|cXú‡◊Ÿî{ù /ôµ≠
ÛçÀbgòT i…›Û‹¸f"õÔó
fgW 'hÒÜM7¿ú@Ê}¿4>Ä¡ŒcçÖ™3å≈‡¯£ ¿,vÓ#á3u‡ÔdO†DZa˙1rë⁄Å’1±q8@*‚–ziîÃ{ ¿Ä“Òá ∞á÷«¿%ÛÕqœtÄ» PUóÍëî¯(∏◊yx\∆”y 5’áÆ%kÁ)À∞h}@§ÒFîLg0U}ò1k∂˛y8¥ŒÑX8=2¿´¬—Ü™e´ÔÛ¨k¡∑öÒ}f—ã>`WÄ∏j*o6È◊ﬂ˛ç6˚Ã·ç3ı ãˆNÕ`1ÓµÑC◊€ƒ≥Éª(qh∞®6≠QÚ£fA3fo|”Y&BSfª §R0oÈƒ)iÑ©.á_ƒáF≥)ïÃﬁ¯çÛLÖÔôÌêµD◊Ço{òGÓä8ÏˆàL —Œ πÃòøﬁ’oáïæñ5∑H4ﬁ\7∆y ∆‹Ÿ`q=ßÚfºúO\…≤A‘ ˙–6d≠˜6[c∆„÷oäk*Û∂ap˘NÄ‹¢•ß€≠Ìf˝"h˘Ç’y”E¢F}Á?‚∂–ÿ4\»ﬁúr\ Æ7eV{‘O∞Â∆Pcırrxs iq—Q ôwvù˚7OˇE¿†Û¿ƒ·¬ ¬º˜∂ÖA5px3ritêâ¡[q.Ä’*≠®™¡J◊Æéπ≈õ¡#Íë∆Â∞Z£@ _ñ©sSﬂ
‡I≥ËÄ√FÄ÷…m&Û6 É-°d„˙P[ã18@Ê–@c˛æC˚%Æ±-2©_óêt‡;ÀŒ—¢˝‰òmã\^2¶-—ﬁ‘éPè ´W≤Fk˚.ômm÷≤50œﬂåπ‘ÂÍ;S[ü’È˜Je—ƒ‚ é©Ã◊áí}ÈŸ~TõÊ‚pÙXﬁ(Ø– óZº=<âÄK; LôNPn(ôü Ri,õ‚Œ1ŒZN˜¯6ïı±•=FL'®uFµıÄÛìOæ@∆t˙õ° »N+†[º†qrÄ_gSÓµdßäT =8epà© 
ÓÄ]Oß¿tπ>‡¥—	‡<+Bó»ªtÇg ‡/·p	Ä¨À0∏mŸ π8Ù@ú â≈% “n 'à.`–ÄMÎ'%b—á>‡R ú
9Ù¢ú1ª  ßBµoæ‹0x! éøµoﬁóz4vÜ^ÄŸ÷Ü≤:Mª2ÄMÎÎıÉÆ Í2û`Ãùã †À8x’ π√÷N.r∏⁄K ›≠ù‹è8˘Çw.êñ¸˛⁄◊∑≈ôÆ )yç3m≠‰’àÊ%»ù7„ÅÈî _Ó\¿èÉ—÷…¿”	ﬂ.PçÉ['Lß∏‘›‡rÙÉ„`nÒvåôÆ ù¡·≤∑√ó˜É)[¡ñ¡B„Z¸˝†b+ÿ“NÆ¿T≥°¡¯! ná‡:ÃÑÆ c∏@i\-@ P∂åLW∏,>ˇqK∂ÉmapçÀ‚Û˚¡. ë≈uÆ°ö§€ér∏V C¨4.∂0Í,.Ä‹°C;q∏^Ä.?Ó5§3fóÌ-.	‡«¡ÀﬁGó„`áò2ù
†‡ˆr ùê].îw9v{@zÕ €◊D+¶íŸïtØπ§µØﬂ˜L'∏‹ì°Ó„‡”â .ª–y¸ûÈ:¸8lΩRòÆ¿èÉâ¡÷µ3ç¸Â¬}Äï≈Â ˛Cf‹π @^ õu8]pq éÉ˙Ä¶SıóƒÜK±8¿•GÅÆ˜ÉJƒ·*:ﬁ*á´Ëv?%‚pù π√∞≤⁄LlÄ im  «¡a$¢1hÄn„†˘∆Õ5tïHßñ≤;@~·©p«qPâtÇ⁄@.–iTBÄ;Ó\€™|å-∫ <pÁ
‘e,.¿˚¡§ˆ+lbá+à:∏k‡8òî‹lòƒ.≈‰.n∂¸ë Gp∏8@V*@ó©pÏ2ÕÕµ§≥Ì”a%‚X[ì=∏∂a™Dn∞≠ßèÕnÆÄHsãé≠%ö)ç+à≈d›‚˜Q°Ã\ «¡¥˚ï]§ˆûõ„\¯·h‡‘åõnÒ'e∫º†Î~‹>ZÈ3M`ÚHg€gB+}¶.ã„-à‹3ª0Ä*∑œÑV„>±ﬂss§ë{f‡8∏+ÄØ˙ë:¡1w.ãŒ5v≥9ÛÎàƒf‹Ï fÛ»·z  ;ﬂÊÊqm¯~Ô yÒ=ÛùFŒ∏P‹∞˚ç˜êŒòÌﬂ«EjP›%pœùK~pÁ~„™ a∂c∏‘Oâ’· ,Â‚ ±k¸˘ö ∂Øµ]7úu( ˙p7ÿÒÈ⁄çÔ	“Érá ‰µü°kÃîÕ»,z êÌ0Mé –áı Ï3.Ó	Æ`üq–ˇôπÄ}∆¡yÁq% {çÉUÁq¯(–áyÄï∆>wáœ˙êÔ˘ÿSâ¸?nﬁ˚LºLˆÿØˇÏÄ*/–ã©0îÏ}	`—ÄX~b>`Ä}«A%RF 8Ù`Ø˚¡≈ä–˛Î£ì˛É»ÜêÌwÍPÄæÉHKf˚‹Eâéw~™–G %Ãˆåü+ı ç˝Ø¶˜>
Ï;`—Ä}«¡9@‰ÓráΩc¥Á@–ßK`ﬂqp1ìæÄ¥÷ü@˙q7®2fæ7¿Ûw=rT{è!˚ÕÖzÀ/ÃÖ4ﬁ9@$u8†’xÁ êzw¥k™±¿ÀﬂC.ê’ã]"áC ≤À§R2ﬂ7nˆ	'LÀy™øø$Äa~÷©¿
Ä¿·¬ ˛÷Á»-™.¯Ú ÒAOπ9≈| ˇ◊ø¬·¬ —a p©∆˛S·‰Ú |‘ÌpP/™±ˇ< π|'»q–·¸ ≈@,.ê.Z„˛ {,à‹sßp æc∫‡88c~Œπ–ƒåπ„"Ú'%w/8¯ı˛ˆ¿tÔ≈˘£çÉ~}<c∂?Äﬂπh¿€!fµ û∆ŒKb˜‹π ≈|ﬂa∞ y…Ïê¯1’ÿ`˘p4È@:cvÿTBcÁ©p¡ÃòÈÂJfÁúM^Ó†`ãã$¬Ïús!êÃüÀà√•b—8p.µ€T¿,;‡‚ÚS·√ê.äÿ©Y]rπ¡•Ê˜#Áà4˙≤*¸⁄!∞ÀÌå(πÌ@∂”Ô∑a.§±€Dà€ﬁ >Ó6N<ÄC T˝Á8@oûe‹`9Ó¿∆Atü
x ‹3ı‡„ ÁB3Ê; Ù©~?∏€T`‚¡zê°‹ Î@zÄÑ˘˚°D„‡Ë>ö¨ıªóàE„‡¯Sj–†v‡“ çﬂcﬂ…‡Ωp¸à≥Ùk"ƒq[…¸–ûDô¥ñ√'–´”§âˇ∆~d"/≠E≥º3@øfÇ≈‡#·ªPrÑŸN …åY á#L∫®~ƒıÓ”Ó µ7.¿÷~ëΩG)c3ÇKpô|åı8≤
ˇ¥â√ï$v9•Ôcõ¢HLı"o∞Ë@…Õq 2.ëöáÿez¶l©ëuÄí€+pŸ„,5ÛÌf çÎo©^n∞⁄¥4¢ GXyÏÎ(pŸ∂Q†è G`ﬁe–CÄ’*†‰ˆ| ?¢W  ¿1ÆÅÆ ±µË@."(π=¿á~drîk†3@˝ç §¬∞8‹qÄC†_Î\˘‘®”	c≤v˜yyÄXXß#\]ó≈{0Ô-Œê˜ mtL'àzê¸,Gπ!Í ãﬁDÏö-Œ–≥{ÅÂ Vª0á¿^Ä˘y rã˛p$¥8ÄCˇ 8:;úiË€T¯Â!ÛÛ Ùo0–8¿¨ó ÈyÊB’DËû;}òqs ;ÊNˇ ~12Ä>À@ÿgÄ+CÈæ„¬»∆Å˛É~aDÜÄ¨^≥S†ü3¡3M˚{/p¶"–À€·E∞2¿˜∏.@∆q¿`» &Øw–ÉpÈ…ØÅ~ÃNÙ†Ñà√pR—JJÓÄ” ÑÉà9»â«Å^¯€¥Ïƒ7D’≥¡1≥>Ï˝=±¡`RÒ7DÉHD°‰ﬁ óƒÊùÄÜíì.å@ıvEàK'HÿsÄÏ‰c=òwßº*ÄæÆ	ûcaå IΩ¸ﬁ Ø7—£¿¢ﬂ JÑ˘	z;~ΩÜ¿k†÷Kˇπ@ØGÅ18<›8P=ö1Î-¿Cıê–`àœó ßº&G¯ÌΩòF˚É¶N JJÊÔ ¿°}e«†5FL[„ÅâìAã”ƒƒﬂb5 hîÙâEkdL[„ûÈÑ◊¿Ñ’∂8¿ÜZ*ãv çÌÒG¶.
Lé
0cvlÄ*N7 ﬁ‡–πF◊êS]GÌííYK§*ø√Øz≤k`rÄlÄ≈MÄŸâ é6f¬0ïËtÒJ
ˆ„YëVC£îFl˝…. π∏îeıÄ=U;`∂êÕ^ ´ ù‚G¯“ ¨‰∂œ πÃ’ò']._r_Xw%Ä‘ q˛∑j]¬V˘q€g ÷ÄEÊ≤ÄØ∫åÆ˛∞ÍxçS 4boÄ™ämó@.e™Á?au	ª8⁄°S¡’=qµ} ë]È]µì¢µ:u)ÿP≤Sßπ@Œ⁄	¿°Ωs‘h€E∏Èpmyßç≈ ˜Ã0ª(Ÿ¡ZÔZ2Û}J¡Õ):¡{Óª™Ü;L‰SŸ¡˙¸¬ P“±¡Ï0ÊŒ 6=≈„’opÄ™.~%Rm{
¿÷…kÄy+Ä≈Üâ£Aßñ/W…)Œ†ﬁ –Ë‘ΩŒÊ≈l¯Çã$¶ÿ6=¿x„`ﬁ©ú-é.p elÏ6è%ÛN7√˛@%ãôTˇFÅM+>Gãd6oHã©‘u$›÷⁄ÿêSÕ~›çp@j∞=¶Û©†IÂÿÈÃˆ‡ıÕNƒ ãªMMÑ#˜É’Ω¿! y{w
Ä\◊Å√q2áΩÿ3iú	 ıój&«Ì'kUÿ	ÄÁ(Ä“Ëz§o©UG8`= ç≥Üí£~ß¯ÒˆPr¸ôI∑•Gnè¯\‡û;˚ T}Úå;gà»·ub)‚–Ä\és¶4vyö…'’≥¡=™`qx§ùn7W·g‹`ÃùVÄò©-˛¿4(π= [@u√µ{é"ø —hç[¶9 7gàé?º}	(çM5(∏9B`∞=á’~p∆ùSwÇõjñ3ÈÊ]‘io}m^øÆ∞8¿ﬂ_n §õ bªxbsæHKf+˝‡ ÀS›gÌ˜e¸’ŒøvÂ÷PÍıﬁ`˛‡e7 }	Ä| ì„4Å…õwÉô√¶ßïGP≥≠”É£ﬂT  Úˆjù†÷
7X‘oDkoÏ∞˘nê_1üwÛ0•Á}Ø∑ë¡qÔÒ∂>á£Ã∂¿˚`=ˇ 
¿«pÿPps‰~p¬¥ÄçnÒ%˘*ÄNƒ·¯w˘Ã∑‘õ…rÅ0µ8Äíìlzz‘8_á∆£%Ôñ98∆ oﬁ÷î8;™ØŸvHÛòLº@Û››ß¬x†®[ÈRˇ÷—g9%ÛmÀçc™
=7ﬂ=¿Êßöáòoº,∂.@ñ‹¨]˛28†˛s÷4Œ¿^ØGÎ”‰íõføp8¿∆©∞⁄ ê≠U‰∑:ælu≤î≤¶Ó5ØRÉ+ ÿ~$ŒØãe‹´_"ßH7ÿÊß ÿ^jl·œò©—5 ∂ø| ¸6ÊoM4ÊkÕ)‘!m`Ú÷”a∂JÊgÍ˝Âl—aºT≠¬ôÃg'ÿ`„LÏ˜˚ùj¨Ñ€Fê n ì;f= P‚∞«≈¢d‹ﬂ=<@~œÏ%.w˝≥Zﬂ§d3æÿ9™>‡ûŸK\†—méTƒa†∆≤@$cÓÙ@9t;Nƒ·%¸|UI%_Óì>DùÇßÏ=™F±ﬂX–+ÄŒëâ√
@9GŸ´'úºKÄDP`Ûﬁ/ìΩ˙ÅﬁXtÍ,¢∑U‰ãKaè60Óπ”Ä»°Îë3fU§Û≠Ï—Nz‡Ô˜vx}ãßøràFGÄyQˆ”Ï˜êi‘"ïï±†€≥€WÄ»Õ…z '¥á∆jLyıW5ˇé©•$b—˙’≠ ,&`±õì˝éÈ¬}¿¥f∞Ú∑OÄ“Xù",˚%Ì”(f5Ä‹¡ˇ©ãøZ\`˘€võ'Â"æ·¨ÑÃ√BI¡óÎëä∆kº>U.˛l—ÄZ}çÿa¿,Îø%ã~ ï_ÆGÊˇ¶∞ÄqâvËÄÔﬁ⁄"qX∞¸Õj!À(˘b=rˇ7/1aö«®? %≥N ô¥§≤ >&pË@Ùü¬º%‘zÀ'À⁄˚JﬁåÇá,£è "Ã["];—Ízûﬂ’b9+ÓêZÃz ‡oosYåÊJ6-˘§JÑ;k2›2áUÄïi≈≈ZÄf-´°Ã?∂{xπ™[ ÊÌ]£•êŒ ˘‚ı@ï∏<Äë% œ˘·Â˜,˘iK#êÄÍÌé Kÿæ  óœ≤x⁄·ß≠Ú¿ΩÓ êÆ 3~…J'xÒKÄgdYÀñK@|u€.‘F∂Gaﬁ“æö ≈=∑=ﬁ‡˛Zp˙ø∏ükˆÉ%Û6Zs€'ÄL⁄Gùsª˛˛å?ÎÍI-gÃ€∆áÄq[há~ ¨üÕ¸¢697Îç∫ @…ΩÉ>[Ù o£√C[%é	wö}√z1˜Õß*’%êqÀpÒ≥Eè¸”c?o”hoŸ8Ñ;M áfîÕá
òÄ<„ªÉ> ,*‘Äıe0æc|ªÊNÛxã ”úÃø/Â`¢—o ¥ (ÌˇÎóåA@£√úº|_R˙+‰=$˛√r±¶’pU∞`}Ëjj\©FÏ∞∑Õ•±ı¡ÛûV ı{ÅöH ﬁÂª+ã∂	î¡6Äı @#˙Pı◊3Ê;¥˛—;®7⁄◊µÅ»b-†Z,i·∂µuÿk‡\FZŒî5O⁄/é˘Ûtãk‡x–~xÉ÷ë’°=ﬁ%Äø•—hhÉQ"◊¿_¥˝L	–r]q∏*ÄTZœ‘_-oÛ`±∏* /Pr”iô…ÜÊ=¥.Å¥œëxËÜÉﬂ3 O´dﬁrΩ≥kòp[o %∑WÄú?ıà€&å´ñQ ◊‡ÔÏ2nÊ∑√u&∆òi>f:4nãØ‡ÂLïF€€ÀÜêãhlº'ò0]¿ﬂ3’#•9ÄFm®ú1ª*ÄTcÌ∫Vñ ¯‡PÔ&Ø`Tù}f–2ˆœ™E—⁄….ßÃÆ‡˚j$≥h{.ñà› †q- Ûe†Ã¢}ˆÁZr1∏.Ä‹°Ä›}+Ä≈5ËÍ^G§¨&ë©∆Ω≈[1ÕD4`OÀ˘Ò˙™˚PK ûû2à-ñØ´&C.¬w]ıÆˆØ?xﬂ ãª›%@‚¸.cV˝qQµ¸∏‡] œhê.œpÄ√Up§≠∏l#Ä≈ıƒ’VK@©¸Ω® V˙Äƒ˙èÆ`∆=æ2@&’P*≈è’“Ôñ@§õ˜¶w¿%OÊm3>6Ä÷˜ô]Äí⁄≠ﬁ0o9ædve ≠Î£%ÛñsEwÉÀbç ¸êpm ; D√∏6ı0∏.Ä√" 0Ä  @    Ä  @  Ä) Ä  @    Ä  @    Ä  @    Ä  @    Ä  @    Ä  @    Ä  @    Ä  @    Ä  @    Ä  @    Ä  @    Ä  @    Ù@ä 0p ãN πÃòØE$‚–âTØE&¬|=§Ω¯M≈(ç÷‚KÊm≈;l †@…|-báˆZ¥h¥:nph/ﬁ†{-Y|uûm '8}0Ë^K ÉñHEòo´·jÒW–ZL£Ü´≈ ﬂp¢>`SÕ”ˆb5< @òÔP‘	@XHVBâéŸ.Á/RaòHÚ_á71_H·kær‰Ú√HDÚ˙ëÛ2÷ø»}ôÛ#}ôæòÍ»Â.Àdºñπ¸v%Àbjı‰á˘ ù¨O&V˘,#ùãwId∆»˝áNâØ∂Øy„Hõ˙#´bÚï#Y¶Œd^ÃÎën^ÊºWYŒè¥jYLÌ»y’ºÀÎëÈJôrá. ,Ö¡‹‰‚Rô±
Ø JJ÷TãÿLú™>Ù5œWè¨>,îT5_=r^¶Ø˘¢≤À#}ôOÛ#”ï#/^ä)^æ›d2/ÊıH0ˇp#@’	|«Ùv∞T∆øíee2SÛsîÍ+S~˛»s)R)˘‚©:“e+G∫º:íÒz§ZÈãQı#ó≈4é\î…¯ºz‰cu$£T’ëfı€?À ”N J5ØÃÛöøV·†y$_√:¿¸œ¯a ìB5 ≠Í•Lﬂ˜4äY 4èå´6åUr˚VƒN…’^HJnﬂä¨P≤Ëu&VmÏSqÍçN–%rŒN∞:r['Ë∂]¸
%Á´EwòÏ:4h/∆‡8Û ‹mRô©Õ }öÌ<4”N ¸âJÓ]!¿ó≠"â…¯Ár≠ [gÇ±∏L‹ªπÿ¿‡mÄ‘òÎΩﬁ∫*úãS∆œó÷ˇÃ◊–¬°≠Ü:≤hâ1çñô∂´F£uGá∂‚ya¢%Ó1bæ^º≠&º{¯QÚG|œ|Ωhçhâˇ-Ò¡ˇEK1¶Ω¯Ô¸_¥ƒ˜Ì≈`˛≈÷ZNò∫¯ï≈5Ø
øê¯	∂¡p¯ÛÁ´Wœ‡ Ñ∑É»¸]Æ¸…– QuØé·T´‹ .$X¿Ø§‡˙üo†Zé∫æ@ Ë¿ˆ]Î–	Ä˜ÛÃá†¸ô+øúÃCH}ﬂÔØÃ¯b† lˇ∞.Ä‚Û$á·po∏ .Ω⁄@7ÄB`∆ù!$√‡fÿù †1lÄíy    Ä 0L (ç!‹"÷2¿" 0Ä  @    Ä  @  Ä) Ä  @    Ä  @    Ä  @    Ä  @    Ä  @    Ä  @    Ä  @    Ä  @    Ä  @    Ä  @    Ä  @    Ä  @    Ä~dp6¿}1p 7:¿xÿ ë<Ä5hÄQ 4@\|«4h •1h %É
3·â◊˚ÄÑ©-Óò⁄¬¢5"É÷8RÒõäŸÙ˛-S[¥ lÍ˛»‘ZvzSª©¯?£5b¶]ﬁﬂX¸ÑY∑y¿ÿ©Üÿπx ØÕm<p 7:¿t‡ y1pÄÃb‡ √x≥à∞S{¶é ã ¿ @    Ä  @    Ä  @     @ô®@∆ùF<Ã∏SÆVúX‘£Ù‹©G≤8∏‰~Ì}«‚˘~≥¯tQó?°•¯rá˙ì£EÒ‹_+&’ôp¿òKìƒ†.§6.π[{¥lc÷C+ázMDß˛ìD£é;?84j»oﬂ_+ﬁU≈c ˝fÒQ	)¯bµ¯r^—X/&3πht »ùíH,jπXL^$ÕöãS¨á·	‘Q1ô„¡J£~¢eƒÉYåFΩ!˘˜≥ç≈7€í/ﬁ‹HÁ≈≥™®SlÛ. ˜ëõ¶*˛‚– Hûm1Vü4Ío#}±„1_¨˛Ov:U	îF˝⁄K„œ<X}≤®k?õª±J4Í≈œîäæÿ&@U|íhãfÒè_X<´äz1˜J¡∫◊ÍLò6ƒåGOí'”4wÍ—ì46®µE{?RO∆›è¯¢^C7Nùi‘OT=}v”ëä-Ôz¥”µ‚#;/ûWpΩ¯GÁ®e,Õ◊<%èuÄâè› _làfëO‚g3Âã’ØtJs£¥QÛÿ–˚ì)¶ä/V‚&rn2äMÆQãiÚIª"Eı˜’ßGÁF£ÿ`≠¯'S¨DÛ‚-Íqó|“æGuG<Ûî&|± û≈v4é÷SæXΩ∫ú¬7ßFÕ¢µ–Î <x4äçh‘‚ÉØ°KøáE->&ü4ncÉı‚ÕîΩ{£¯JÎ≥EKÒÖRç‚#√ÉüM'Ädõ—]¸≥ûÚE‡/V›Fı∏'<òü6‚õM÷“Ö?ÿ¢ÒΩ?Å0àö≈«,û£ÁzÒ£¯ã≈zÒSßn∏W˛¶œÊû=¸ˆp ˙Ÿ4æÚ‹M ã∆eWi9≈›f«ë˘´F„D?¡Y¨XÖÿ†≠¯VÄ€Ë´CkÒ#Ó≠Ë1¶‹›ÄqÏûçC£yÄ_öp∑v¸7{C •±^C€†~¬G´ê¥ ‹©ÇªÕ‚o£Øb—êåÑªı·ayÄób&L«∏s	wÎ547H4Z DÄF†—Vºör∑Y¸& õ‹äFÄßD á Ï1∆Î›w‰ÿ	⁄tY4˙Ôi\h‘/•œ¿6ﬂÜR@l–h£ï/JÓ÷ãøÛ≈èö Ò_¸W€|_%æ¯Ù…¢1ÃÚ™Ó`'ìƒ4ÁRxt.≈ç)Ú4nH>∑åT∞÷‘'sÄ¶;ä;_¸mÛDÁ≈µ˜‹Øı’ ä
 rË‡&…ÛáÊL—π,ç-ÔO„6 µ`2Pç;≠9@&rwæ¯Ò⁄/=/MÄ…†ŸN£ÄEó{˜ê™gSpø1vEæ6áçÌ¥ }l∏ü§‹≠O@Á Mﬂx0ùrø•¯◊qmÈ∏ ph„bÉN7C•íüM„+˝ÕêÀ$iv; L[;¡,jàä9¿˜ÎÔﬂ‡£]PÊŒˇ±Qõ™¯€»6¢b á˙c´N06Ët;\&ˇ˘≥^à‰c˙◊∏¥®ˇ∫}|àl€(Û@?Œ∏__U ë≈zÒ˙ÆhÔãøÂ¡∑‹oœa«jå∫ `Ñ™Àl  ° ã˙OÅ÷âPTDv‘êX_C‹Ø’–*∏ÄEÒ"‹o‹±ån£5ÄEÒk O~' ~)∑M áDçe¢÷©pÏX√Ilç∆OëË¬©ÿ°˘K+¯©pd—,>Æ 4÷ä˜#“ò/≈OùRpX+ÜS·◊.v¬¥y0æç÷w‹ØwÇ¸âF7ëEΩÛ"¿']L˜k?E‰¸ÕP¢—8—DÛDã∆˚H¥s’è∫^ºôf%˜k]/|Ò~n≥^ºør®wΩ®nÜçNÛÄÒ$˘ŸLπø6‡Ì∞AΩ©W5,¶ä/V‹dõD£—§Õ€ae–\§L˝^d±V¸ì)–®Õ¢¯g” ®äü¶™Q
åíÁŒ n:I÷D<ÄÂGlPoãú⁄ƒ∆›è¯bµ-jT"âF£-∆ü-D4ö?QÚhßì¥1
Dæ¯'„ö UÒ*y∂˜|QsåçcÒèÕbíGÀ!¢#Ä_±qXõò‚N%ç∂8R—;ÛEΩÜ”©J–8˜à?Û‡îªÕ˜üÕ…≈+}±- ”ií<ŸÇ/j≈TuY_ÛSpÎÓwË≈)Æ-Z¨Õtæ∂jÀÃº∂(ör“Ò‡D£æ<+è~=ì£æj…eÿjùSc≠xàiÔÁã¢Î≈Ø/ä≤òjQ4·~óâêiYè¸≤xf„í˚µÂŸô?X+áFû≠àh—)gTkÔ#u±pøQs_¸:ÄK}]rãÄˆ≈Gké•_]7ä˚[~`WÍü/h‘√TFöx$E‰Zå(±’¡ø„~≠óﬂﬂY’ÙÂ˚Ï⁄¢˜≈∑=·ÑT¨◊í≈¥>ëô0Çﬂqw+@x4 @    Ä  @    Ä  @    Ä  @    Ä  .o≈üÒ1”ıDoÑsxçD„x ë∆">$Û\√†vÄà„˜LU‰&µn¯!>`y ƒÁ≈Î;ØÖ2UëÕ™oıoYlòÔÒ >¢jNãò••?];¨F,‚¿HôÊ V|ù≈(ÉZ‹01Óô™ê'1ÃK¯√_Ôè[Éí§%7õ í≥@lÛEAâ∆1 Ê•≈u Û˙N@„¿˘çVµPLæ¶˘ÅO¢	0ãÊﬂTU]ƒ¬o- e∂8>≤XèTò- õ; öq‚∞|ùŒ´ÒÚN ”òÁ*:∂ú‘†^[¶ór˝±c˚„Î  b£	≥ç ôh,îùrÁx I…l ûçÊ’PoX8Ô2É:Ä∆*@bb∆›õ ∑fr18ÄfÄZñ∫‡ø‘ Ù@¶·?ˇ7fU…:6`LìÇy‡∆a„	≥ç "ßHÁeﬂºî˙FÛjºVÆ?Vî~yÁuxÄ?˛ﬂôÕªÑÿ†X~≈+¿≠√"Ó'Ãﬁ ∞X¸√ë≤yŸ£q,è	‘x4Ø∆»°‡/6-ì")xD1ÔÒ~3h¯	‚2õô%ÄSwÃ ”DÀ®$œÑeiÛy6wπçï!ÿ°rù√ÿ∞‡"â¬âÖüÌêK¡ú ¨
˚k§Û.nÏPÎ+Dﬂl6S3Uï+çﬂÍ?óÖ?˛S$.∑π·%`·FwÃÎ „©‚w∆%26∆"Â…X»Øf*´ ƒ/∏ÅÁpoÔ	‡≤ôÀ/—Wy‚ﬂÔ†DæàÃ|øu{´~Jûün∆)ﬂ‡0xÁ”ÿ§"¢«<{?çF˛Jø¨¥U ˛j\·†$ñ™M›ﬁqS]t.©æò wÈ(˘ÙI.+p7NRül¸ÂoÊ€[‡•íÛ(£gÎ>⁄‹¡ìQöÍ‰Iû~˝˘ŸaOÄT‰[êô€ëR…„≥∆ÌXï OoÍ≥ƒf¬{ ¨õN'j‰Ë‹J>?¨¥’Ä‰È˘≥õ:¯ﬂXØdR(ëØ¬wÔ∆£ëz˙Y.ù·√8M~"Ä˘ª˝Õ∫/ï\DÙhùC„t|3QZ=˛ÌÈÁ«gã=2ëﬂ*Ä‹‹±&	æå«H3qësØsŒ>Ñ'V÷}º'£Í*˘ª»/üûü ¿„g{W@˝dí_§åÕ¯éoœRë_E<¿Ìçä~÷à¨ØÚmˇ‰ßˇdøöè/ï\"ÎúkLÄq¢UÙ∑Á_¢Ø˚|[ å3<~µ@e‚"Á^‘ ≤≈«ª±J5‡O"øƒø>¥ ®‰˘Ò≥ùŒ†xJı ”uÄÈ‰ˆF≈?D#`<äˇ9≤±˛ßo_çsx©‰ ∂ŒE÷‚(∆7wâæ¡oœ?=~5ÿ¿-.ÅLîJ‰KIZ$ˇ*ﬂ¨√⁄%@ )¶”L|ƒvBã⁄ ‰˘˘≥ô&@DÄDº„€/ó¿Ø"ö3‡—à—,CAÕ*ÄDOø}Á–ºx’¿Xåëc5¯˘'˘j∞‡Ú9@.Í&[‚#4ÄøXáñ> ^™¿ xà,¨¥Î _E4§ç^“%¿›∑gq/ïl‹`e"‰5K|5YØD¯G)ôØÕ=Œ-œd|úà|uº¨˛6˙*ëAdUda˝ÑAça0≤*-n¸gâÜ¬Ùvq	Lˇ«ìÜCs"∂Œ≈R¿M«jÏ‹_bÉÉ 4*ÄüÊ y û¯¿„Ä±∞à¨‚%`ﬂ P5Äü"ê?8l òΩ®»ï
±¡!7C¬∞…ø#—˛ﬂ√ï_q+wØ5ÄI·O|Ã#ÃPOÊÂûˆe‹fŒc~3ëCd’”ˇç-†Ä¨¸o(ÖDa:&Äã¸…¬°y/?ZÁ√`¢¥z¥e¢cÉ ‚íoHåØÕ¯6≠æm ~ä<Ó£œŒ~æcbÉF«¬w¯ç
‡”'åë´	`íˇÖ
@·nÇª¿óEÕª¡¯Ÿ:«™⁄)\1Vi™ì'S&&68x= ≤Ò/e,œå”≤ö¡°@aî;U¶≈bA$Ê|‘††LÒbróõX8iØj¥õ‰_f±|*ë"õÒﬂ(˛$ñ%gæøCsA$ˆù `≈A†¸TX?∞÷ ‡# …sÈ™©∞Ü√ÄBIÍS·®D¨—
è<ëBL\&R]m Òøî±¸<c˚»äjx¢ºòπsXπ¨Jf†Lê[‰≈›Mu3ƒ¶x(¿2˛]tˆX,óòöã¢>æ„‚÷L~E W~R“ÏTfÃˇE¨r,Áã7jöU¸´ è™ïïÑ8éì\yM-Vø‹°∫%aöØ∏å7Œ¯ô∆Q F±Fßp∑Ã∫tØ⁄akåçû<πÌZïku3ÎË∞@iÙ çN±º∆∑∞b—·[ôı@ïÃ:≠!9t–ÿ–QÛ I◊™dõä∆vˆÇY? ¬„Ò  Æ	‡ˇ‰È&Q
endstream
endobj
114 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
115 0 obj
<</OP false/OPM 1/Type/ExtGState/op false>>
endobj
116 0 obj
<</OP false/OPM 0/op false>>
endobj
131 0 obj
<</A 132 0 R/Border[0 0 0]/Rect[244.413 9.0 286.158 16.0]/Subtype/Link/Type/Annot>>
endobj
132 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
107 0 obj
[133 0 R]
endobj
108 0 obj
<</Length 7237>>stream
1 g
/GS0 gs
0 792 0 0 re
f
0 0 0 0 k
/GS1 gs
60 41.333 492 696.667 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
-0.02499 Tc 10.5 0 0 10.5 60 730.348 Tm
(Results )Tj
ET
BT
/T1_0 1 Tf
0.011 Tw 8 0 0 8 70.5 709.348 Tm
(ANNUAL PURCHASING)Tj
ET
BT
/T1_1 1 Tf
0 Tc 0.08701 Tw 10.5 0 0 10.5 70.5 688.148 Tm
(Purchases of oral estrogen replacement preparations)Tj
0.03 Tw -1 -1.25714 Td
(among women aged 45 years and older peaked in 2001)Tj
0.097 Tw 0 -1.25714 TD
(and dropped steadily from 2002 onward. Purchases of)Tj
-0.015 Tc 0.015 Tw T*
[(transder)-25 (mal estrogen lagged substantially behind those of)]TJ
0 Tc 0.04201 Tw T*
(oral estrogen in all years, peaked in 2002, and dropped)Tj
-0.02499 Tc 0.02299 Tw T*
[(thereafter)55 (. V)110 (aginal estrogen products accounted for a rising)]TJ
0 Tc 0.03 Tw T*
(percentage of estrogen purchases\321from 5% in 1999 to)Tj
-0.02299 Tc 0.02299 Tw T*
(18% in 2007. Likewise, tibolone accounted for an increas-)Tj
0 Tc 0.10201 Tw T*
(ing percentage of oral drugs purchased\321from 12% in)Tj
0.011 Tw T*
(2003, when it was first introduced in this population, to)Tj
-0.0166 Tc T*
(29%)Tj
-0.017 Tc 0.017 Tw 2.033 0 Td
(in 2007 \(Figure 1\). In 2001, 20% of women aged 45)Tj
0 Tc 0.007 Tw -2.033 -1.25714 Td
[(years and older had made at least one purchase of HR)60 (T)75 (.)]TJ
-0.00101 Tc 0.00101 Tw T*
(This figure dropped by 29% to 14% in 2003 \(p < 0.001;)Tj
ET
BT
/T1_2 1 Tf
0 Tc 0 Tw 10.5 0 0 10.5 60 516.5481 Tm
(c)Tj
ET
BT
/T1_3 1 Tf
6 0 0 6 65.6288 519.8481 Tm
(2)Tj
ET
BT
/T1_1 1 Tf
-0.013 Tc 0.013 Tw 10.5 0 0 10.5 68.5523 516.5481 Tm
(\), and further to 10% in 2007 \(Figure 2\). The most dra-)Tj
0 Tc 0.082 Tw -0.81451 -1.25714 Td
[(matic changes in utilization patter)-25 (ns occurred between)]TJ
-0.02499 Tc 0.013 Tw 0 -1.25715 TD
(2001 and 2003.)Tj
0 Tc 0.116 Tw 1 -1.21905 Td
(During the period from January 2001 to July 2002,)Tj
0.172 Tw -1 -1.21905 Td
(women aged 45 years and older made an average of)Tj
0.166 Tw 0 -1.21904 TD
[(14,793 purchases of oral HR)60 (T per month; this figure)]TJ
-0.007 Tc 0.007 Tw 0 -1.21905 TD
(dropped to 8982 for the period from August 2002 to De-)Tj
-0.01801 Tc 0.01801 Tw T*
(cember 2003. ARIMA analysis of monthly oral HR)Tj
-0.0184 Tc 19.83248 0 Td
(T)Tj
-0.01801 Tc 0 Tw 0.84252 0 Td
(pur)Tj
0 Tc 1.27796 0 Td
(-)Tj
-0.021 Tc 0.021 Tw -21.95297 -1.21905 Td
(chases from January 1998 through December 2007 identi-)Tj
-0.022 Tc T*
(fied significant seasonal and autoregression components \(t)Tj
-0.0233 Tc T*
(=)Tj
-0.02299 Tc 0.02299 Tw 0.79059 0 Td
(8.5 vs t = 28.9, respectively; p < 0.001\), as well as a sig)Tj
0 Tc 21.16238 0 Td
(-)Tj
0.01401 Tw -21.95297 -1.21906 Td
[(nificant ef)21.5 (fect of the period of purchase \(after vs before)]TJ
0.12801 Tw 24.57143 33.87133 Td
[(July 2002, t = \320)-25 (2.8; p = 0.007; model r)]TJ
ET
BT
/T1_3 1 Tf
0 Tw 6 0 0 6 492.6687 733.897 Tm
(2)Tj
ET
BT
/T1_1 1 Tf
0.12801 Tw 10.5 0 0 10.5 499.635 730.5969 Tm
(0.97\). Mean)Tj
0.07001 Tw -17.29857 -1.21905 Td
[(monthly purchases of vaginal HR)60 (T products rose from)]TJ
T*
(1)Tj
0.06 Tw 0.46485 -0.00001 Td
(197 for the period from January 2001 to July 2002 to)Tj
-0.02 Tc 0.02 Tw -0.46485 -1.21905 Td
(1287 for the period from August 2002 to December 2003.)Tj
-0.0096 Tc T*
(H)Tj
-0.00999 Tc 0.009 Tw [(owever)40 (, while ARIMA analysis of monthly purchasing)]TJ
0 Tc 0.095 Tw 0 -1.21906 TD
[(of vaginal products for the entire study period \(1998)-90 (\320)]TJ
-0.021 Tc 0.021 Tw 0 -1.21905 TD
(2007\) revealed seasonal and autoregression components \(t)Tj
-0.0069 Tc 0 -1.21904 TD
(=)Tj
-0.007 Tc 0.007 Tw 0.807 0 Td
(7.7 vs t = 17.6, respectively; p < 0.001\), period of pur-)Tj
-0.01401 Tc 0.01401 Tw -0.807 -1.21905 Td
[(chase had no ef)20 (fect on purchasing volume in the model \(t)]TJ
-0.0251 Tc 0 -1.21905 TD
(=)Tj
-0.02499 Tc 0.013 Tw 0.77639 0 Td
(0.821; p = 0.413, respectively\). )Tj
ET
BT
/T1_0 1 Tf
0.011 Tw 8 0 0 8 328.5 587.3969 Tm
(NEW ESTROGEN USERS)Tj
ET
BT
/T1_1 1 Tf
-0.01401 Tc 0.01401 Tw 10.5 0 0 10.5 328.5 566.6469 Tm
(In 1999, a total of 9394 women were identified as new)Tj
-0.011 Tc 0.011 Tw -1 -1.21429 Td
(users of estrogen therapy \(excluding tibolone\). The num-)Tj
-0.005 Tc 0.005 Tw 0 -1.21428 TD
(ber of new users per year declined to 8266 in 2003, then)Tj
-0.02299 Tc 0.02299 Tw 0 -1.21429 TD
(rose to 10,352 in 2006. Although the number of new users)Tj
0 Tc 0.26199 Tw T*
(stabilized, the type of treatment used by new users)Tj
-0.009 Tc 0.009 Tw 0 -1.21428 TD
(changed markedly with time. Among new users in 1999,)Tj
0 Tc 0.065 Tw 0 -1.21429 TD
[(60% started with oral, 10% with transder)-25 (mal \(patch or)]TJ
-0.028 Tc 0.02299 Tw T*
[(g)-5 (e)-5 (l)-5 (\))-5 (,)-5 ( )-5 (a)-5 (n)-5 (d)-5 ( )-5 (3)-5 (0)-5 (%)-5 ( )-5 (w)-5 (i)-5 (t)-5 (h)-5 ( )-5 (v)-5 (a)-5 (g)-5 (inal preparations. By 2007, the pro-)]TJ
-0.011 Tc 0.006 Tw T*
(portions of new users starting with each of these delivery)Tj
-0.021 Tc 0.01601 Tw T*
[(methods were 24%, 8%, and 61%, respectively)65 (, represent-)]TJ
-0.02 Tc 0.015 Tw T*
(ing significant changes in use of oral and vaginal products)Tj
-0.026 Tc 0.021 Tw T*
(\(p < 0.001, )Tj
ET
BT
/T1_2 1 Tf
0 Tc 0 Tw 10.5 0 0 10.5 364.166 426.3969 Tm
(c)Tj
ET
BT
/T1_3 1 Tf
6 0 0 6 369.6545 429.6969 Tm
(2)Tj
ET
BT
/T1_1 1 Tf
-0.0262 Tc 10.5 0 0 10.5 372.4979 426.3969 Tm
(,)Tj
-0.026 Tc 0.021 Tw 0.46869 0 Td
[(Pearson\325)55 (s r for trend\). Seven percent of new)]TJ
-0.005 Tc 0.026 Tw -5.65897 -1.21428 Td
(users in 2007 started treatment with tibolone \(Figure 3\).)Tj
-0.03 Tc 0.00999 Tw T*
(Choice of delivery method varied widely with age. In 1999,)Tj
-0.01801 Tc 0.01199 Tw T*
[(78% of new users aged 45)-25 (\32054 years began treatment with)]TJ
-0.02499 Tc 0.02 Tw T*
(oral medication; this figure dropped to 50% in 2003 and to)Tj
ET
0 0 0 0 k
173 745 379 10 re
f
BT
0 0 0 1 k
/T1_4 1 Tf
0.013 Tw 8 0 0 8 251.5303 749.5293 Tm
[(Sustained Impact of the W)75 (omen\325)75 (s Health Initiative Findings on Hor)-25 (mone Replacement Therapy)]TJ
ET
0 0 0 0 k
167 17.75 385 13 re
f
BT
0 0 0 1 k
/T1_5 1 Tf
10 0 0 10 267.483 23.9116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_6 1 Tf
0 Tc 0 Tw 5 0 0 5 400.608 25.4116 Tm
(n)Tj
ET
BT
/T1_5 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 413.7891 23.9116 Tm
[(2009 February)55 (, V)110 (olume 43    )]TJ
ET
BT
/T1_6 1 Tf
0 Tc 0 Tw 5 0 0 5 524.3189 25.4116 Tm
(n)Tj
ET
BT
/T1_3 1 Tf
-0.024 Tc 10 0 0 10 537.5 23.9116 Tm
(253)Tj
ET
0 0 0 0 k
60 17.5 79.5 13 re
f
BT
0 0 0 1 k
/T1_5 1 Tf
-0.02499 Tc 10 0 0 10 60 23.6616 Tm
[(www)75.2 (.theannals.com)]TJ
ET
0 0 0 0 k
60.351 38.316 492 21.7789 re
f
0 0 0 1 K
0.5 w 
60.351 59.845 m
552.351 59.845 l
S
BT
0 0 0 1 k
/T1_0 1 Tf
0 Tc -0.01401 Tw 8.5 0 0 8.5 60.3506 47.5952 Tm
(Figure 1.)Tj
ET
BT
/T1_7 1 Tf
7.5 0 0 7.5 97.6294 47.5952 Tm
[(Purchases of hormone replacement therapy by type among women aged 45 yea\rs and older)55 (, Maccabi Healthcare Services, 1998\3202007.)]TJ
ET
0 0 0 0 k
60.351 64.747 492 275.927 re
f
q
60.351 64.747 492 275.927 re
W n
q
0 G
1 w 
/GS2 gs
/Fm0 Do
Q
Q
BT
0 g
/GS3 gs
/T1_8 1 Tf
0 Tw 5 0 0 5 285.1575 11 Tm
( at University of Canterbury Library on August 25, 2014)Tj
0 0 1 rg
/GS3 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS3 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
9 0 obj
<</BBox[0 0 611.99994 791.99994]/FormType 1/Length 61/Matrix[1 0 0 1 0 0]/Name/Fm0/OPI<</1.3<</Color[0 0 0 1(Black)]/ColorType/Process/CropFixed[0 0 7554 4598.96484]/CropRect[0 0 7554 4599]/F(sys:DOCUMENTS HW-FS1: publications:Journal art: TAP Art:TAP Feb 09 art:RRL438-1.tif)/ImageType[1 1]/Overprint false/Position[77.805 64.747 77.805 340.67401 530.91199 340.67401 530.91199 64.747]/Resolution[1200 1200]/Size[7554 4610]/Type/OPI/Version 1.3>>>>/Resources<</ExtGState<</GS3 6 0 R>>/ProcSet[/PDF]/XObject<</Fm1 8 0 R>>>>/Subtype/Form/Type/XObject>>stream
/GS3 gs
q
453.22159 0 0 275.9888 77.805 64.6852 cm
/Fm1 Do
Q

endstream
endobj
8 0 obj
<</BBox[-0.17167 -0.23438 1.17866 2.63531]/FormType 1/Length 45/Matrix[1 0 0 1 0 0]/Name/Fm1/OPI<</2.0<</CropRect[0 0 7554 4598.96484]/F(sys:DOCUMENTS HW-FS1: publications:Journal art: TAP Art:TAP Feb 09 art:RRL438-1.tif)/IncludedImageQuality 1/Inks[/monochrome(Black)1]/Overprint false/Size[7554 4610]/Type/OPI/Version 2>>>>/Resources<</ExtGState<</GS3 6 0 R>>/ProcSet[/PDF/ImageB]/XObject<</Im1 7 0 R>>>>/Subtype/Form/Type/XObject>>stream
/GS3 gs
q
1 0 0 1 0 0 cm
0 0 0 1 k
/Im1 Do
Q

endstream
endobj
7 0 obj
<</BitsPerComponent 1/Decode[1 0]/Filter/FlateDecode/Height 1150/ImageMask true/Length 18438/Subtype/Image/Type/XObject/Width 1888>>stream
XÖÏΩMè‰8ön˘(ïÂ"Æ3ó—h/c˛Ñ∏`⁄/⁄ òÛOb–€¡K4pØÂÂb ÄõF˘∂Wañw—∏≈ø∏ætlÔ‚¢í 6‰"ï(ïﬁ˚í˙0ôπ˘W∏πõô§◊Éî(Q2ë|˘æ/Î£å2 (£å2 (£å2 (£å2 (£åÚxÚú”P‰ê”»:≤é¨#Î»:≤é¨#Î»:≤é¨#Î»:≤é¨#Î»:≤é¨#Î»:≤é¨#Î»:≤é¨#Î»:≤é¨#Î»:≤é¨#Î»⁄÷Ô0÷9Ü√ZpkTp6÷ò8k≤É¨ëâsa•ïe§±kíò§êNYe±QVIª&¬»\Ò_Ê∞QVEª&“Lêßiûoñ5#á]e¶HßÓ»•õfÕ9ﬂ-˘≠I·fnfß˝gç<Îƒ>´√.≤Úí£6Õ™»b˜X3˜¨ívêı◊«`§±{¨'dkVQÖ^€à©jXe¡zl˚3´lX7ÍÁîú’b∞;¨ÓqY#Éb}[¢3Ücáùaù∏©ˇ€4´F£¶Çº¬ˆYßÈqû∫t≥¨X∞ Ç3˛%á-Klß«åößõeUÀ¨qŒŸv}∫BÊ Òü≈fY%ß∆\‰åár¡Ÿv}∫B5¨6Àz¿©q4º%Ur÷ÀÿZG#ô≥Å∞™™{˚÷hWüä5´}d5kb—Æ¥aÚP∂Ë)ÎÖ¡`X?Z _sBV-6}g=‡ƒK8g~æZÙìµö∞RÉ≥ 8T§—gV•¡ìCeKhÙî52‡qk¡¨}∑5XY¥˝⁄g÷∞Œ‰“gà~Ó7kLÅµ‡ÒÁﬁ≤
N$ˆ|Q¡≤‹ü˜ìU√ˇ_¡	"ZΩdïÊ»/3ƒß»√‘uË/Î±g-˘s¯©k—_÷ÎJµáÛµ∫â3º‡±[ﬁÎFYÉF™÷ú)'àèa‡∏±%N8±ÂÔçæ≤ÜÖ¶++'fÕÖAüY≥“˜Îã‡ΩÉu6÷ÈIœY'ú∏KO8Ví[Ñå{∆™8˘·˚-*E‹Á5'ÉÎŒ¥^`2Ë/´‘¿QË”iœmD≈1¸
À©
Qp÷[›X#ÓNﬂØ%g=eıû¸–5ëCΩ´>G_YÖÖWI6v®lQŒ«~≤&a©â¸âÈ)´‡‰√áqÆ(èú
k—sVixeïe≈ZÌÍ$úz»™[Lä∫¨;'áú6b49é¿d§c'âÆDèY…≥/≠VêÎ7kDäà»Üıª)bçôı∏b›π¯¶Y"U¨°Qâ7Ù˙ùba'#ø€,™*fú˙ ™¡yÕzR«b˙…*		Ø≠5kVß˛Õ◊“≥ñ“
ÌgÏ	˙…ÍıpXπKcì¯CoÁ´ﬂ∆qHÚ YŸ˝loÏı;≈
rëÛnçá¨Y˚∫æ≤Úı˛[ÅD£˜¨ xVˆÈ¯‹œ\çjlsÍ°ˇÍYO¯lÈùâA„:rÎÙgùh[oXøÊ‘J≈öïú!∂‡ÓvËÎßV¶úZVû∆9gΩaUú:Ú¢eM¯¥‡¨?¨^,=´JŒ*V
ß}a%ø∂‰)Áıå=<ˆì5vﬁú"Ùâ’¬OŒº‡ºfEéƒ›ƒ¨Ωaç»°bçjV^iá:\a–÷ÑrŒØ‡ÆD¨=kÃ¶¢EÂ˛Ùãµ‡pE‚º|æ∆¶¢EÕ™—VŸh⁄ö!HÅ»÷sﬂÊkÀÜm≈*†‚¢ˇ y/Y•¡*Îøpﬁ≥˘⁄uÂ≤∞ëS‡Ó#ÎWú|g:?U-|‰~∞∆’ös
Ú
5kLÄ¯ê{eK4>πwÿ´M¬ç‰å˙¬Z€à¬ÉÜ5#9w¸∫Í˜~∞f´¨äLîW¨Q8Ó´F≈˙A¯?=´$ÁíàO!®‰º/cX£f5 >{V¡v≥HAπ'∫I£ä¢Ω3ıˆˆp3_!˙»öH”∞≤ü€G÷0RõP≈ÚÑ⁄ºû∞úµˆa†[¢ﬁ¿Îk‡Z?∏Íºﬁ∞~èõ'29ÙÜµçàøÇ≤-+ga=cU>xX;±A“Fi)Éﬁ∞∆k¡ákQïŸà“ËkbP± ,÷&p°—õ5Á‘z˝§jVi±¬*4zó¯d«A√jçQ´¨}bDÕÍOÉn‚To∏£7¨M∞k;)+8ÎÑû˙’Ø⁄˚5®Ì_Úß≠…ÿ∑˘jÉø
ø&"∫‘ü	ßΩbç8µrƒiqG◊±oÈY;˚7ÎﬁÌø&9Ê¥l4ëy…Yˆ 5ˆúUX,§ùím»âlæ ˙Õﬁ≤Jáé√Ÿr»â\±:ÜgBc?Y€e3,.±Fãn+VA\'&BÎÏÇƒ&r“Úü¡]Y≥Ç≥v« 1hﬂÊ*÷ÑúÔÛfÄgú:æ¡∂$1ûUÒÓÃ⁄ Ñ≈≈BX‘Ú,ˆ¨∂‡.µ¿b}mYÉ-ä4±KΩ‰weÌ,õ^Î≤"ÚèÜGæq|E£KáJ¶úv@Kì∏ÙòQÔÃ∫P9+¨&∞ 5¨áúvÄUfù∫©Kªm∫Ö’`±¬‰Õ¸ç-‰kA|éå§≈ä≈±›1¸[ì87s3;Ω++/õ]÷zZ&.∏‚ÎåÑ¡ä≈±]÷»Ãù¥˜`]√Õ¸9DÁø¢u◊∂À:ô[i’≤JrMYx÷ƒ˘WÁÇ”.∞ﬁìïWŒZV€Ã_UrÊ„·±¡™úˆìï°¶|¨mâÜ5#Œ|<<±∏vÔcÀ¨G-+è¬;©nÆv¬«⁄Fl∆p8ºB'Ã‘Yÿ∞¨ÈΩYyF÷}ËmˇZ7Ò¡Të•,ÁlôUc7XÁ-Î›˝úà4ZüŒèixV˚Çì–Y¡≈ı˝lï’ÂÓ~¨<c2hY+6œ:Û¨ÜBy=´≈VY©t37ª+/õ	Y¥ªÀ™⁄S&2'Ã*◊≥^U[OŒz/ë7é*Ó¢’ED˙‹ØÔÉí∫Ü’a´¨(R∂˝Ô¡äÁº¨Ê|¨Ø,Í5Ásà7AI-k3á]√¸Î¡ÕIÓÃ:©b,Õ†TPªµ'˛J|ï5sÿ›§
ÃïSˆæ˙±™bg´|ßQÖ+˘∞Ï’÷GŒŸˆE1´è¡(Éª≤û¨∞
©—YVØ≤FMÌ˝ã≠ïj1_#ç∆T»ö∏Ö∆ä∑PræØ¨ÇªR£”Ø ‚l≈„Â|/YO´8aª%º~ﬂy˛ô?Y
ûiÏ'Îq≥Á∏{xëÖxƒa˙¬Ê§√äô‡cLs^ux2Á\X?Ü#áΩc9¥˝˙ÇO<kXÖ√ïHÁu¨|ˇX3ã™Àﬁjµrö±K~¬ƒâ≈ukNÏ∞w¨SePuÎ[0kUö∞ÂÔ˚56Xg˚…π`éf∫ r´M8]{ÕÍπZVWù˘kœ9]1Œ⁄}ºΩa˝ÜÚ8?i¬eRiDé˚Œ‡ÜçÏﬂö3	`œöî|Zô/c*xN\øo∞¨ œπ< ßƒß!DÍ◊œ¢ÅZµ·¥w¨Y≈ZºXa-ofç9Ì+x$5{:#ÛV˛^b?‰6÷»/.pPö=XÉ.´ ¸vù¢¨19‘VSF+è·©$ì\Xf-¯‚ı‚∞/¨	1ô D’Zˆ≈gälry+k∞6ˆÉU¯≈≈eﬁ`&á∞Ÿÿq$Ç≈EÁÆG¨í¬™Í◊”åXT∞˚òî»Å'¨∂SèX˝£ÍMWÌY3b…[ s‹ ë√Æ»!ßõ$∞FF5kéÔWÀ‡°_#ã€ƒa_X√|ç≠ Ç .˚ò"yJñ£=íCN7I–√+€^&ú !â™~ÓkL.E‚¸|ç+÷˙EDG|÷#÷ÀÇ˚µ≤ıπÏÂÑS`ß˙¡—ÓQÎ◊Wî\Ó≤ñ@¶ëº7ËÎ;Bd@.Dâ¨íº÷ ºÌtìÃ±?cXíB|©ëì$(h«]ùYàKáõÑkÌKøñíx»‘rÑ©‘@BnBh‚“·&)8Ì+rIUî©í„™ìAÿΩJ.ˆèı{¨EÄ‡‘ŒVœVû≥…ã˝cuX'Âú?„ñ≤bÕ≈•€ßùcΩ∆#a÷D#Ë)ã™_™@Á7À;»ú≠e°ÇC5_ÉLÉI˚hK‘Òﬂ€XSNÕì{À*÷çG¡FÉ·c8T◊4ZœÄ4ˆëUÆk∑¨ã~Ω¬j∞¨äÆ≤öÑC£Ay‘◊–ZêÂÕ!Ò]eÕ»bkÎ -∆µCÀ N‹$SN;«J‰pïU∑Æ‹Çµ‡¨˛>r∫Öıò”~∞ä+ÜèC≤∏¢‹≠¨ã ªŒ∫“1_ãc±8Iã X‹3÷µÛïÂ%9Ä–À¨¬ â∆ﬁçaE7ÀÑU≥F÷[8wñUgÎ]NU\YfÌÃ◊}ç#ﬁ¿™QMÊz¬∫öK~^≤`µƒ≥u}≈=c-8[„}
›∞ œ‰ÎH‚lœYôÎJ∏©¶ì‰≥:vËªTë∆N*ü{¯t◊∞YÕJaq2ËH…iÔXsŒVY˘ö4hW%Ú]JKÒUrÏ·µq	ç÷⁄ “´¨±øtÉÃ8ÌÎÌ÷£RlWXŸÁ√Míq⁄=÷í”Ú6XﬁÔ`›î¨≤ä•“ﬁ≤∆À˚D≥.Î&yÎå”Ó±sZ»—B3r™YsfUK£VQŒ˘ûÈ&O∑L.ÚØ¯$ÑÑõ1ÏòUÆƒ ˜Õñ‡¥<¢e!4¨<Q…Ò∏%ˆùUj¥ZHáeSï“ ë=AÉ%=◊≤ÌØ»_€_÷D#&ÌŸ,ªÜUï¬s≈>Î´∞ºlö0f=⁄uç"ti‰p=º¨6Ë¢.´»+€ ‚ÎÎnÍ¶Œ™ïswπ∞ûvª1qﬁ«[ë€Ï&…iÁXøÆ[U‘¨y√j—`Yˇ!Vé[XßùcÖ“≥±®dïS¯1L|•´û!8]Yúˆïï˜4¸6≥z›D|e!Ω`ÂÊ^≠(o|∏ï¨»ß}õØu´ø’(ôUQ≈:GGÉ\+_+úvéı€Ø9Î•g‰öòãN,X5ˆU:¨«úÇ‰<kBÇ®ƒJ¿"—Ë´«™ly?_crHú_sê˘lˇªu=kµ]Óæä´ÿwÊ≥kU”≥>˜>ö∫‰Dd2á^≤s‚êIFŒ”Ed•Ê],‹◊ıj¯6úvéı(÷ 2Ô∑0+;n T›8„ÙÂ™Ip⁄9V$@ÊùπÃ"q»bæÚ@È∏O;ƒ*åè)ùìÊÒÀ¨iTÒ¶ôA“`GYc˙»àû’≤a|√^l˙5°œåH±MJlÇUhÏË|Ù+idëÑ⁄ï≥ËÑ5z†õ,Ç5\0MÇK“®ºqá∞Ó‚˙9‘¨ıÊÜ"É´õï§±ˇ¨U$TQyPè⁄¨	öâÇ≥vˇ ¢/¨í
ŒÎ(øC•IKŒ˙¿˙gVA·∞ÃJúµë¥ˆ˛˛±N9kÊ´k¨±`Uù9ö¯˚˜íDcWXO8´‰˚»yW->R∑Û5kî‘ÚøÎöc∞+¨ƒY3>ù£6ƒÅŸfPdPfãk…˘ΩX-vDdg|V¨6±GÃ⁄‹äà,˙¡j–eeÉ?vâ=Ê1,Í.(´¡Œ∞Z,≥≤BNÃ	˚3≠=Lù:AwÌ-´C›}Ä0e÷'›aF_ÆáwGd€vØ|Yæ	›ÎY€∞pVO\/AwÌ©(*8Ô∞Vb
áÊ{p÷‹ÏÙÒ˛≤
ãÖº‡ÑW®YKŒÈÙÒ≥\#IS%hN{*ÚÍÆ‰%¨9gçÃ8ÌèƒF⁄g–’M±¡<‰ïfj.˚9Í∞ê	ß{˛∂'âQN:≈¿“˙
ÓboV>o≈‚!?g±≈ak2ßÚ,œ÷≥NNµ?ﬂ–ßµÿ&Î<Mè”4Oπ2Xeùù@¯Û∞*É4ù∫©Û¨á§±ƒj∏[à⁄ﬂ‹÷ﬂ2´õπôùz÷L£ÀfÕôı%6¶
±=â<´¥5´2®‰†]gî€°`˝√Y≠¥™bïı4ÊTüπû≤
ç∫79’T¡áû∞Œ;¨úU¨Îl¬}gçl√*æPÕV≈˘¬÷è4zÀ*Î˘˙,¯[÷ûõdML√⁄∆˝ï˛:ÿıRWæyb±©5«b´¨⁄µkß‡™ı$58æd6…Í∞MV	7sÀ¨dQ±ö7åŒ-˙¡:[àµçáZ±h˙’≥∆-˙¡:eÉ8O+÷*ÇVmIy÷*ú\Ùaæä<√ÔÛ„¸˜-k
e›$´I,6ˆi-∂ËÁîY°ú≤ ÇYõ≠»r á6F∫A÷ÌÜòä,oc0uøJ*è˘–ƒ€∂;Kj›ƒ¨%vSÂêSÀÒô–g˝eT0kl–ƒH¯ÿSV÷√% ,¶ıä(±1±ÿ-÷ò\…¨'®V	•±©5«a◊X/à;3[ëŸ$kµ®ÌÎÁÃzF™¨aç’Ë!´‰úm•∑dêïa_¿†á¨äsfdAtSÎ˜ÙnæVÃ$96Ñı7®∑îz®áU–ElÊ±w“]ïsﬁªıuÇÿbï5°ÇÛÕâ∆é¨9âÿπ):¨ÇJŒ7¶›÷T‰møj<
kÏ∞¨Q.»íX7ÆŒ‚t#{uª¡Z™íYøÊd%ræ∂·~ù¢~Ì∂Y àM¬ÑYU|-Ë¶Õ±2grﬂ2´ "ÌY57i¡ -‹ê+’Êæ‹√lDbı+uƒT‰k¥9VˇJ9ªaKëù eP!9_€¨çË_πXÃvÄÅ5vpxVÖ≈.∞2Íöñ(ç.Ø’◊‹Vç+ÅUç≤f¥éıÄ”Üd∫;c8£u¨ºª)ôy›§±+∫)≤x<°›Ys$}†»!»Û«pH| ´‰„NÿMoÀ&&$cãMKÃsU|≤ˆpl}§?¨4±√ÊYÌŒÿ˛q·h¨Çá›È
@X<"kéGò_ó»ô—‚—Ê´¢ë¡n∞æ‚5¡°“√0ÿ<ÎN(·ä’÷∏oKúÔÎc6G>ÊÀÔœ=Ê0Û∫I¶|≤¨1=¢óê€["4á4kÔ≈€™‡ìcçÍ„Fc˛l#Ó"´∑]≈ˆ/¯∏cÛıQX3ΩKÛµ’√è¬™4vhÕi◊◊!∞f9g^~“ÿº1°±K¨ °^56ø¿r⁄!ViQ9˝ïäU‘„Õ†Ô¨Ì–Uè!˘å≥a˝äS•§C
≈Ÿé∞.lúF!oRæGëÒa«X£f°›®Alwí5n®ç::n'«0;úoö5ﬂ)›¥à!<Î.≠9è 9Ï"Î£åaXÏ"Î£Ë¶≥õuÕŸQ÷«±%xã#·|◊X3áGêÿ
çùc}€?±;·?≠∞>Jõ˜(Ô} Î£å5≈˝™±s¨	ßÕ≥ÓÊ|}ú]…H?„√0X9Öu¬i(¨;j7ç¨#Î›E ÷´‘â¡0X#“â≈0Xc“¬b¨…Ä˙5!fæ&ÉYsbá¡∞F9ga≈ÄX„í≥ëµw¨Çt‰0÷ÿa 1≤±√»⁄7V";Ü5≤kFCYs2rL,ú,ÜcK»n¬`Ïaæ√@¸◊¢rÎ^p+ˇC Èâ%6“VxVÃ=ÓsúÈKb§ìN9eÒD¨/=Î%ü>±H3Mè”„<Õüä5ÑaáˇÒÙ¨5MÛÙ	YSdo∂¿™L:u·Ô	YŸ¯@O-ø5Ûâõπôù>%kDDO-ëôK'≠zZ÷òYs>>5+ì>9k2 VAD¿z(i€˝*ær"â»aõ¨¢‡O!ô$"ãm≤>ŸŒleÕôÿß]_Oº÷ÿÎƒÕ‹”≤Œ˙y+¨È4ü∫có>!Î7	]láï-ˇ4u˘≤≤-a∂¿*rïgyÊ2á'e’ô∆ì˚9•t )´,ûîJc¨V2È≥ñêΩè≠5Úå”Xß!ƒáC‡Gc8¨ÉaU#kY36“bÉ¡∞&É`•b0¨ÒfŒ@X9:<VéJhﬁ ƒ`X≤Êâ5Ã◊Å∞=<÷∞æ…Fƒ˜éÌÔ0ˇ’Ú§ı};Ñåk¢á√˙ï_x¬ƒa8¨Y_G÷ëud›3÷#NCaùr
Î	ßëudY˜ÉuHkŒ»:≤é¨#Î.≤
NCaïúÜ¬™4F÷>éaçqæˆêuHkŒ∞XcÉ∞Õn—÷ƒ" ;ÙüU8‰ú≥æ≥ 
Rúıõ51™?)K.ıú’f9cä∏‘s?«Cf¸è4˙ﬁØƒê˛Ùùıí!#ˇè,zŒü1kLv¨àôUêk>Ñ˘ä÷Mää!Ëa\Úö3÷òòSqí%ózæÊêÁ‰$
.ı‹n"r‰êË}ºâ>1'9ƒz3•7Ü'≠ETp©ﬂ¨ùù3´¡o.ıõïÕ%°^o≤c.Ä5& {âû≥FDNöò◊÷ÙùµÍWøkFÜYëcä¨9,ßÿúÑUî!^pÆ—w€øhX•Fﬂ}∫úÁléóC`çÎbÊçMˇYayçe÷ƒ
çæ≥z{¢bÂ≥ﬁ≥FT¥ª∞}gç©D<VAÑ‰Ã`(¨¬b8¨√aeU¨1›ƒ¶bÏ0VeUÏ–VoK$4VA:v ´≤Ï≤õ»b¨ÜC1÷{˝g>ƒÊ0ÑıuP¨!tÍ0≤>FÏ“IÎˇ∞VØõ^ÒiXsÂ¸∂√ kf||9Nèsˇ∑%V∂%ûnG'ù¶«iÍ“-±≤çàåè/8=´[bıªíôÊ·Ößaùπôùnâ5*ò’ å¸¨©ìVmçï7%!-á˘Ù—eñ€≠≤ŒÂÿï’xäıuª¨ﬁûn¨¡0X^z,ûíU\‹Üz¢íM
á'0“⁄˘∫=VbV÷QèØáU√∫≠1Èå
>{t=(ù¥€[_ÉÈDZ=IøŒ'nÊ¶€fïOƒ¨ƒt¨l˚≥‰€Úsj›Ù4kNVdyÊ2á-≤ÚV<≈ö„’∞≤ÿ´∑%û FîVi∞UQ˚[´>7‰ì¯tª¿˙ë◊WÉA∞&ÁFΩ≥Îi©N-¡
A2±
ÎèÉaeK"∂k¸‘Zxã¨9Ö5&ÔzeæúEóúÉU2ÎîèCaùÒqÛµ|∫Mÿ–MCaçxÕ´ånBf1î5ô¡`X•∆pX9Ω¬0Xüq≤´˜uû÷’Ÿ.k¡Ÿ@Xìí≥Å∞>Ò.«VY%iÖıâw9∂ ö—•|+Y°1V'Ü¬ö+ãÅÃW*2áÅËaﬂ≥|2àıï• ^bv€â)ü˜ﬁfT"†‡ÛÅ∞F‹µΩgç~eT‚-;>Ô;+>3*q˜jÙü’[%Ä5Ûké$ã∞™ím	E`ïEñsÁÊ|⁄{Vë´b(¨âì%è·A∞∆Vî¨õ¿iéõäaËañ∂%Ü¡:eQc¨~ãù≥Å∞™∫_ª-è˝˛;±f’Ãù£Ô¨Y¶<Ó:ª¨R#L€◊˙ÃŸL¡≥û=nÄb˚¨q>Â<Dd>zÕZL9Ø£ä˝fm:Së¡pX-˙≠õöŒTD‰–Û~5∞
´ãÍ1¸®∆ƒ!ß-á&ò5Ác`uË5´†"¨~«√"Ê≥ﬁ≤J*x'&∞É˛≤**=+˜(ùRœYπ_}Ó (!Â–Î˘Z± 2¶û≥&a°Q9ÔÄY3_ÍÒ˙
 „0Ò?1kD%ó˙ÀjÅàR„w&Êì˛≤ÇæaVùπ_x8Ô/´ÜdƒˇƒßÅU£ø¨k&F¸üˆûu∆¨<MﬂiÙ?gVûØ¡ç}ﬁs›‰-	œj†K…«≥ #r`÷◊T(>ˆòïQ0üÂôAøY%Q·Y-92Ë7´ *É /»°ﬂ¨…«ä5g‰–g÷»∆?y÷"N¬`Ó/kL—i`U%DœY∂¸…èa≈ÓN8È/´¨Ö˜HÄ5
Î+[ä¢Á¨“≥∫‡≤3kÅ>≥*“>÷ƒ:äLÍ/k∆∂Rf™~ç…ΩeıNé‘∫)"á»°Ø¨‹ùÃ '‹¡Ãõ£⁄‡È/Î3>Ò∂Ñè'ü˜ì5å·J!!,.ySfJ!≠¥ bótSµ–Ú‡ïé◊ llÈŒïÛÿ•5ßjôûªE˘·2¡qöÊ)√ù±%8NÄ≈R?o"Jô2¨Kw«FlÊgd∞4.)‹‘ˇÌéüSp∂§ó6«:±3;›_›°+ﬂ9lå5®·Èé≤∆EF^rNUÒn«Xa±‰π◊∫)*8{(kæk¨+Q
U≥ñú=îı/;ŒJ’îTááÕW’∞zõlY´Â0Ã*÷ùÏWAøT¨íár¢—gVI?7¨¬‡Å¨n∑÷◊UÎ¯W‚É7§≈√X'nÊ¶;ÃZT5£ · ÊΩXßÈ‘ªtgYÛL£fÕr>Y‚úÓ.«l˘ßiæ;~Œ*´ìı¶´∑5ÓÛ≤\ÂôÀvU79	pLFëã®ƒ™u`pù´∫ÓeŒ´ae±´ké ¥◊√1ü/l,*yŒi©9]}ôïVi∞´vì 5D`’Xq¯0«ö~Ã4ˆ ∂∂∫C…îı–lCi¨‹e=√ˇÆˆc¯D{∆g»,c≠aızQ]Ì«à,ˆé'èH_ùØÇµU\∆ˆJ?∆‰∞¨)†£™˚.ØËa…WJV˚Ò÷MØùd˝ëç=dæ≤æzVAßºBÀ^pæo¨<O‘ Ω[tV’V¡¨í®∏“è“ƒ{∆ö8X—Á?·àœB®∑—M ≥äï~¨XÉ=eïD	'|Êı.ßjÕ…àÔVl´¨¬aO«∞¢Á§=É◊Ãµ-AûU∂’˘*ˆå’w´ ù—˘[zﬂ@‘6"±Ÿeç¸‡îœˆéïg§!:KË≤bçÎ5&´Y´~lXmxÇÔ˙lœX#ûñ‚=ëM»ÔÓƒæﬂj#C≥.È·ƒÒEÿ
‚lÔX›´Ö†·FIÃì√ÇïÔ˘˚—~≤Z$ØS˘.vê°ﬂ´ "Ì{~°Ñ˘^fèÛG¿˛±$<"ç§¿ÍnD)êÑh9uXUÈ˝û˝dùFA!µ¨™bç˚s9í2Û¨ﬂïòï˜Dˆëı‹¯Ä )∞˙IZ±ŒSﬁØU≥9,±>gg™oø¨ò˙iË}"Á’k‚µUÅ⁄¨r¿stwßM–†íU{«zÏm°jnZf’ûïŸ´üû„%⁄’òL√*∞¨¸Çá-1´gÒ∂Ñ"æD&π¥®ù˙´‰Y°4ˆL7y÷)báà≠„YºfŒ*VÜ;sìŒ^t5Ü%9Vbô¡~±‚≥û]‰mƒ–oa(õØÅ·ﬁ:Ö*◊∞∆&£ ë≈~±∆%ìñÄ≤◊Tç—ÃzVÅD√è⁄¨ªMƒì8Ïâ\ê{¡ˆà5)Ò≠g{Â˜^7qïªœJùfhHn÷úƒ÷˜îœ¯¬±ä≤RP!‰˝{ÁY§©X≈E^æÇYcºSâSƒ¨o®»∞W¨≤¨Têø °H+∆"∂£t‚YΩÛ&…!1·õÁFíÉÚkî∆>±™í≥oQkûäµ∂V—AXæ
?uc#»b"(Ë‰=bÕ<k´es:U’¥|Ü¯œûï
.qﬂÊ>dÓuô∂Ä Úá=b%Úaï.Î;
Ò'ŒjGµbU>Pl˝œ&r!à»aèX#‚5’¢ã¯£*k75åŸèR‰¸ ›˘
ÕéN|Ö}ä#z˚◊b¡~©©®lFè§R`•Çö≠Y~î|≠˝â˚x“Ö¡"ÜÍÓ1Ñõy"HrQ8‰< }ƒ<≥ëÊ+› „^Ùkmﬁ7¨≥≤”„îiU9? $q¸¢gb"*∞oÛı£√Ç’œœë…ràzZzèˆ#E%˜´;Aˆ¸¶@¡g{≈}rXﬁ(™eï«l•õb∫¯Ö+÷(/˘ÆgUü¸˝˝aa^e—XåØ≠X∞*™◊ú®‰!Ï«p˘Í’ÇUæ%á}≥%¨“@0Îqe÷∞»|ï (Ï¡|Ò≥ä∞ÃÓìç»$ôF√Í#·‹”ïπ§ào"sºÕWCD G¬ˇ3 ÒF„Îf„golˇºŸó´KIXHÚ(Ï4ÛÕ–Îﬂ)Øá‚∞»@i–nËÌèOÁ⁄}πä5c¥n´$áK˘·ÎYCYZ¥µ˚„´õ ∫≠…YÖŒÙ¨:¨Ø^Öëˇ($˙“°›Äﬂ÷H#!áéÁNÃ sSW·àÑìgµÏøJ“»™°-‘5ówbShx√mJ™~6b≥ˇbòUëzπ≤ó˜-> Œ+≠Ï«®Å0©üØì∑¨ü5«`2œ| {ŒöëÅ‘¶⁄_] ë¬ëÀ»y;
a Ï'´o}ã$‡YC˜£Û$Kî˚˜œhÏyøz÷gk∆_†3∏=kFŒ€À’ ÿGV¥MÕÍP/3 aÈ{p¯8qä¨ “û’bY;ÎkßªÑEwÊ‡b+¬.H3˜í’`ÖUT„x=+œn÷\˚»⁄±ïüaªâA˜{‰º-¿;î~!*ˆ∏_ª∂?qÊ˚◊`Â{8‘;]ï-ëë¡^≤fú6b†7XãÄ\T>^; ˆéu∆©ùñ’®÷X/‹ß b1 ˆéu—6&⁄ä≥µ2Ø}:Qrv˚˚vY"á*jÃŸuB£ ˚ÃäW®¨É´ﬂ¡ûpŒùŒ© {Õ⁄®cÉ´À∞´Xª†¨änfÖEOX3r∏Öın∫nÑ»aÎåÛa∞F}dÕ»a#Îı^Ë&ã°∞Æ]sz *Hc(¨ÎmDi–CVÔ¶ÆaµË!´wS◊hgã≤z7u´CY_bùÖ·–G÷ı!8á°∞∆!®6÷Ñ
Œá¡*®‰|dYG÷˝–M√aç§áád7Å,√öÜUiÜUr
Îß°∞ˆ3∂6≤é¨#Î»:≤é¨#Î»˙‰bÖFÄ5r“J´,¡™rÂî√ Xcwú¶yÍ˜Azœö∏îa]:V7ıC`s7q3;ÎdnΩûé¨=3ñƒz4 ÷¥eï{-Ûñµˇ˝:$V"7 ˙J‰≠¶a∞fEzÏb#ıíÁÉ`ù{ÔU9Ç’´·aƒ%ù0BKç!∞)é8≤é¨#Î»:≤é¨#Î»:≤é¨#Î»:≤é¨#Î»:≤é¨#Î»:≤é¨#Î»:≤é¨#Î»:≤é¨#Î»:≤é¨#Î»zÉDDaçâF÷ëudYG÷ëıâXÂ´§ëudYG÷ùaïDÉaU√b•ÇYÉå¨#Îû≤ñ	gam%∞**8Ô/k–¬√dÂ˘k1Vá~±˙∞∞¢ë’°Á¨/>FÑUÑ+˝gµ`ƒÅ∞_YG÷}c≠e®¨Y{z»Fqáµ°ΩaÂ°⁄∞
"›g÷å¨h˚πΩi÷ó¯
˛ﬂ˜xzVÊyR÷#<„±X<%+^£®fıàèÃÊ˛ilèï;ÿ·±Yq‚a"klëuI/?´çu¢S>≥	gΩfeD`~¿Ÿc≥2IŒá€Y_SÂ»VAƒw.ÈøﬁÇ5‘ıD◊ﬂy4VûøÅï6…z4aΩ`¡@GúmÅµ7∞˙ 9 ™2ﬂ}òLéxAwxÅÉ9∂¬ö3íE∑∆£±§… yçM,6«öQŒ˘≤Êb=+ó5Ó&/,“¯ÀíXf-0GÃ'O¡Z°aÕàáı0∞æƒäÍ∑‹≤¿j$¨≥V1“eV/Ç∂™ÜË≤.F∆Úå€l#sÑòãVVÒ&t_ŒÍ˚I6Ì»Ç∆FXóÁÔùX}Ñ4∂ëôz˚∑}ØÛ∏4ò·ÀYEN‡≥äïÀ€bçÕ”òÌ§	&ﬁ÷èÙ+¸{ÃN¬Ø≤x˝Æˆx¨	ï´†Ódr÷:HæÜ5#{uE÷bí∏D{[?÷s>…\ï4H˘YQ≈*iuøı¨DN\˘)|6Héù„yd1+—ÆJ∆øËî4¬Í≤Õ∞&Ù`÷Ã )ßÚ¢ƒQdò·8¢OÁÔàﬂøË›≤fT)Kﬂ .>òuÅºûUt_M‰D∑\osjDøñJ+˛ls∏C†åÈ#Ö–N‚ﬂFˇàé*´˛p+è˛∫´¨Ã°:sQ‹ìµzÒ≤ö†ç"ÇCzÑ$¢Ñœ≥¸ÆVã¥“*˛√m¨Ç:/(˘¬Ç’≥\ºÅïØ_/í∏3ÓÀØ¿Ìˆøeˇ¶≈ÒÒõÛS™§î¥ÚëïS9'áõY˝õT>ã Ôv∂Â¿V¯ãX√Zõ{±z1∏ûU√"saX∏åıëıŒMÙÈ”O¥$÷yz|ú¶©ør´„´ìtï’7Ÿâ´¨`Õ%ó_±bg¨u#&IﬁÒ-Ú-ä>pΩqhÂª4=ŒSóﬁëu5úêZ√⁄îØ6˘v÷e)˘vÕZó}Kπ©Sÿÿàz)Ø∫!>7mΩµ¨H›ÃMÌtc¨ãQÆ(4A>Ñï¯ˆ2´ÉwQπgÁâp¡Z$ß»ËF÷âù›ÃöÖ-¶µ¨±ÎõÏƒÉYeXàªÛO±.<˛F`˝D˛3oW—™Ñ˙-´¥ÍfV∫Ü’p∫Ü5‚toV´Ë:VMm€üFQÅCÈoº¶V$WãËFV+og≠⁄r≥X˘•¨¢~–/ìÎ_‹eMtXÖ“íË=uE«ú-À£∞:˘•¨ç>¨ãØcçMXìåd◊çñXŒñ•‡∑7ßkY}jWSá˚≤≤|9k®7VwTå∂ä∫ÚWt•M¸ˆÖ[T≥ ÇãÌWvÿ´ìt´¨÷e¥ *;m∏¬∑¨ù1¸•¨·&?6´p)óEg7±&Ê¨◊\˛÷6‡xwVÈ~À≈e˘oŸM¨BªâõmúïüÈ∞j‹)¶lT≈*Ë
kGØ6¨ [)+ÚÅ€Ù˜tÎnÍˇ¬È]Y5ßÜ5¥éÇjV‹]T≈ä∫7≥fÖ§uﬂˇœú≠gù!=vï=¨∫lá ‡Ê¸ÀXŒCKqwë¡Ês®€p-k˝”w”ó¸ÆZé¡nNû{¶6å‘∞6·˚•7wgœzVì’¨\≠ÛKwﬁq®€–˘≈´†”	—/|ºe≈_jAñ´\πÃ°√öëC≈öTM^˛e–›X≥ÊçdmÑﬂÎfôµêM\B5-„‰PmUàäµ~3_±®k‹Åwï98_e5äÆg˝@7âo√Vï#¥‘hY%’¨äñg'?∑éï°Ãz‘.7≤˛DwﬂríñXó¥`¡9$’&sFK¨°%+¨ãèÚÂ¨áL{-´St/÷\Tm 'ÈN¨uıkX%mñı r¯K¨»hı≈wî\p9IÙpV$DN.X˘¡Ö˚VYºƒ2kµﬁ~)kxë§ÎYóg«≤N√5.6≥6Ù_ŒùYX\ëóuõjÔL—Ó±™{≥∆,÷®,~’B3*z÷˜DÎX9ÔlU|âÌ‡Â~8ç∫Ú=æ˝Ú≠ppZ/¸ë7¬™âÆà‹Î!ûùLçÆº¬À»?e¥2º8uá5ß≈r∏˚¨_AË√!¯¥íXHÁ6·wft≥eîQá5WT/ó,wauäûñ5F¢èNƒè|Zø… /é~µ±ÊwﬁœÀ®√Í$›èµµ¨oeΩ*Ÿ5oæë4∂â˛·”;÷W3˘gù	∫Éy‰õ ?€∞uY=ﬂ∫Öu1”õUG61ü?“Ø:∞æ¨Ûô$}|GÁøÁüøë54µ∏éU>ÎHdﬁ[yÒÒ5˘1ûß¯J\¸ß£Âc¯ø“ˇ˙M¨äc®Î˚ıfQ¥÷ãK7˘èÏ%Ê6—˛t">ùPÊc¯ø“œ¸Î7±J rOXÒ˜ø‰GY…æe*√ﬂƒÔË›)ôn2∫¢-÷†[VC˛ é≤*ö˛ﬁG ~<íI[q£ˇxJD6Qt≠pãÍ1\ô‚-´ŒæîıßGfï•$nﬁ,˘Qù‡Jπ—ÙÅºI†Ë&÷RT∫	]V‹Ò/Ïëò≥*Òÿ¨¢TD≥¯Cv˙„7ä2™⁄0Qt≠†⁄Ä7ôÔWq÷IËü\∞:ı®¨/Ö`c}¸Ûá‚PÚiF’ÿö*ZéÆ[IDÖ(ƒÇU≠ŒWçªô•\Ω	3∆|®c.Ú1XøEm	ß¸z"˜Ígn˛LíiX)œ®˙$ÔAgÛ…QΩ'¨Qõlú◊M≈ΩXjVç ¨OÓ’]∏~AEXFÉLëÛÎπïëqøÛ^õ"√çÆ@Nù≠E™X·D≈ Õ≈™’z_Vçöïè˜zAGj/ç<„Ñÿ",£Af(2" Á•sED’≠ ∫‡tïµTNPÕ p¨·9ŒÔıÇµ¨±A´Ü8!v`9·‰’!˛B˛èé¢\P5™ÍVt∂ëK®&Ñôë_åh√¨‚A¨ßö’¢mäO.ñ∫ïYıì8<é™¡Ïá3gÀZ‚Ø√àµ5kzŸœW<Ñ’+7ç≥FjVá´¨QÕJ‹^bñÉì∏PT˘î·Ró5+áO`TêA˝Ê+ìWÆ\®˜4p÷2≤®‘m`c±<b5 ë'Ñ3ﬂ∑XüùƒîQ≈öp∂2Q=kôë∆¬c∆≥Æ}¡YÙe‰Ù,ÑC∏‚ò’ÄÀ<"m:)»3ê¢Üç[–ıŸ
Øn=kkÒh¥¨€gç)v*h˙±bÕ, œ:â…ÿ(¨ˇ^~˘C}≤ŒgÛ¨:!ãñá≥]bM(	à%ú,¯»Ù~”ƒ¬€ø	&	}Œc„gúóœÔòÁ ∂)gV~ºVÊƒŸ5Ûı>·º≤û◊¨y≈z‰Y…¡è¡DKAÏcﬂZ/~Wü‘ˆí"
à‹|q#:¨%g+Á`}àpÚ†A±|äÚÍ$MÚ¯5π©g˝`2"÷Ç÷∑6à:•ïmSç÷ö·Øo≈:÷á»!ß…ÑS0æëk‰ù¬íOpúÒ≥∞BNTÎ1÷•g≠√¨2ºne?=kƒ©Që’“"p®B;üE¡ˆÒ°eÚâ ŸÇï>8Zïô6¯yî˘¨™|•‰≥›ÙÙ¨!"V≥j¿qkå »7ÓÄõ…Úˇb‚;Èëø»y3/!â»˘{VEZÍæ¢FµS7(õÀOÕ˙ÌíΩ´4"ûWÃJ‰'>ùCµ<æÂ-Î◊äàVY[jNñ√Ó™s˘IYè™(}÷5kFKûíóèV›û1ÎÅ"ŒWL∆Híº¬∫=1ÿ
k
+¯ëeVÉ∏≠…(∏ä—˘Üµ÷’*hÖUëÆhbŸk„ÌOŒ˙UÂŒ'5*ªàÏ∑¨nUÚäjNÕiáï$y÷≈£»ªoµJ≤XÀjÒ‰¨IÂö’¨âCDˆ()„˜T…ôŒ®ísNÕzÚ7ú5ÚGZ∂ı:˝vÎ5óôU◊LÊ  ∞∆TIJ>Q%gWˆº9≠D?WXñ®.Ø
ë√√Âû¨B{V´ Ã ﬂ%yíPYftNÕ¿4úVÂ/‰",£°Ô˛ÄÑè¥–≥Î5RmI=k§Qâ4‹ìpä°^`.Ú‰-Ãºà≥´](©æU≥ñÈ≠ˆüÖ(«›Xü¥_cçö’"¶◊.„∆˘p‡íﬂÄÍSd‘∏.ÇB•Òb('ä Ω⁄ç;<¶tYø«µ”‘¢eMËÏW"o“™t+gµ!!®÷ƒ5´À ».Y
∏µ_7œÍpÎ, B{óäì® zGVnÚ’S-®÷Eeı-‹¥¿|ôµ	+Ì´∞œ0Â#2Aãàeu∫ *©a≠«∞*º9"∑ ÍMΩÎXù¿ûµ≤›ÉƒúñÕ⁄‡–x$«≠Ø5≥VDÑäÇ∏ZÊ¸Ø
_n~˘…Y}·™|√â◊S°O¯¯ö:¨W]≥ö5¡Œö’(™˙’"ÿ
TYxiG™ªO…Zp∆ÚÆTPπ“ƒﬂˇ,¯_∑±÷PD>kuzæqf∞9‰¥¬örj‰+vπè<¬ﬂShhΩHÆY|M◊Ù´A#Lˇﬁ`Î¨Iheª≈T]ÉÚen.qÁpC˝l\T‰≈d2]~Ã◊¨N¬$Ô∞
~è≈÷YE…KŸà^å–û5 pÉ=Å§%Ò~v¯íÚ´ ¢˙uﬁﬂ≥Ë≤Œ±]÷Ø€†Nƒ¨±FâFòå}∏òºÿπg}G+˝ êmÄ∫ççâÊ VºƒˆX#?-3“•2râF`µÚå.J|§0˚ú§Z¨§.´üñ®ß©F=Ü9oY∫¨S>nç’÷ZCFªƒ†f•÷ﬁ°_ù§Zå†Œ|]√∫$9tYüÛqK¨Û»˙–gFÙ≥∏Ωosa´∞“œ‰•fmghmﬂV‚w¯[÷ı‰ßr£Ï/Œ∑∆ö∆÷áπ›°≈‹^Y∂€(»N…V~IDŒ’Ï^¨∏Ëú?5Îaî'ŒáπÌû¡∑óO:¨À‚*ãNëÛlY∑◊ÆauXhá≠±N£"Ò€iÔπÌ‰ Ú''<ÀÏ?ÁUõ‘™√∫^2ˇmZEÂ∞5÷YT*øùVıYÇo˘I)u	ó—÷∏ŸÿWDù˘ªãrÿkøö5ÁmôåºzUlˇÊ|≤  q√*ä†à»}¡°rÿ´b≤‰U+à–ä*9ß◊ÊCΩ∆(™D«‰DR…˘˝EYlçïàíS™‰ùQ‘»ß≈4≠°;õ›_&ô¡vYﬂæ£&£5Aõb%Ém…o†·Äb≠CÎDã:¿`V?ﬂ∑%íZ±»Ë—fmÿÿ/¯ÙÀ%&áù`ÂÏ6V˘P÷ÚàÛ≠≥∫ÎY™¯
}±˙≠‰D˛úè[gıÜÓÃåÇÌ‡YÛ/_jö0á»¯∏}÷à3"s÷Q¡h6
â‹CYc≠\¬«Ì≥2îÔ√
π◊ãË-ë{0´Q6Ê„÷YΩkV·±ô€ô®K¨ﬁ∏K¨LWkÊnT>´í9ilïµà»áR\gST“Çuì¢∂…™((•0	πõU≤Æ€"kasVGæ*[Ai"áMã®hK¨Ã÷∫°Ç»ó¡Wà6Œﬁæµ˘ c∂/"jø<ë√∆Y˘◊∂&NO»*∑…z»i¡ZèÈGú2ª√˙ÿÍ°‡l´¨O'Y;Czœ—)ÁCa}´1÷ÑbÉ°∞ñë≈`XÒ=¬oS?5k¡Ÿ X#Ìw?¬jÜ√
ó8Öu> ÷£ƒb(¨áâ¡PXgaM&úÑ5˛gŒ¬9l+\jLë'/íW≠O‚åˇüÁFEˇ- +ıﬂ·ˇäù0ˇ÷¸áËü˚¬¸-äÿæ˙ç˛˜Q~Ú¿¸ó˘¡ø“'?¯oå¬yÙﬂ˘A¸˛gı‡ˇÓ_tdˇ⁄óüÛÉˇ/∂$ôÉÔ◊<ˆl8é
ﬂƒJ¶7Rg8ˆe•g°l$“ÿ
+ıq‰£y§zP°åÚòÀ¸`‘>h˝É«|ﬂ
.ˇêÛ/nErˇÀ§‹vn–yd=¡1Cﬂ≤îÀ·ÜÛeŸ-[_ë‰ÕÉå*b∂T±}PË)~ˆø∏q©ÿ¢`VÓÆF›s\ç·ô≥¬¯~„≤– ó}ásôóÔÛ†Ø}¸ëq+bßû5*„\8©	ÖöôÊrbO\>ëñ≥øn$<òï)cnª4Y˜¡\˝ì∏∂z–˘)*¸É*<h•…‚¸ã[d=˚ê¸Û$˝áãÛ7”©ª|ˇ)˘ëÀˆó7∏<ˇ›˚èoúMÌÁ˜¶˜√≈«‰GëN›œgß’ÉﬂÑ?øˇîÉ©˝ÂÕ_˛›˚À∑¸‡oÌœgƒ·d˛ˆ„€2·_‹"Î˘€”…t˙ÍÚÕ˘Èdí˛pÒÛ˘©8<rø^ûø˝√·<˝|y∆å≥Ù≥Ω|{8ô¶ÓÁ≥ìÈú?Œ€S~p^?¯ÊÚ¸4ôÜﬂ¸a2O?_ûù3ÛëG9K›Á≥Û"÷ÿäDÅıê™ù÷å(° oJôKÚR
ß,Ω£ Üﬁí¬ÂÑ§Sˆj%—k™Ôs∑ÒëÂ¨N˝¬'~ó>3Õã_ÛFØ¡Y'‹ﬂ“¨,c>˙&ô‰-Oø,#/‘ŸÎ\ëó"¶S´(êàüTøAç π∞Úy˘dïÕπ»a{¨íz)#ÎX+=,Œ9=˘}Aó>ˇ„§Ã~¯Àœ?ùf2/?:ˇ„iëˇr˘”áR˝óﬂ}˛tIÚOø˝ı„œt˙iR¸ÓW:ˇÂ√…oã¨~◊† À_˝Éexú¯¡_ˇıíﬁ˝§“_>ˇtn#·9^BC?√º¬˜q(øåB˘å/ÉÔ|˘Î™*6ö’´Úã™\?¯å/Øe=£§êyv¡˙W —{JXgñﬁê‡rˆûı´Ãï•˜\ñé+æ-EÆ›È¡BYÆ(JÈ2À™.∫¬Zïø´Xø]jÚ◊\61æ
¨∏ñ’ﬂ_fıÆ⁄àSœZô?JST$π4ô.c6†î…*ªâoƒÖp≤≤õÑvS‚§≠Ì¶˙AQ=ËÔÛ~ë7¬ÉØÎ≥ÿnè5}B{ÿ¯Ì÷XS`¬^JsNBìπe«ﬁœÒM>é¨oÚåÀVhâ¥jÚ1ª7|c‚Ù>‹â?	ÚG0ÇÎÛÉ˛ç≥∆œÒ^†öÀ[cUﬁW/Ç _}·Ü˙rVuèÚ˝Ë-w °b.B≈{?àt{¨U\"MˆÓã0**óö¸7Ê§”dy+≠{PY ÛGe˝∂}–ﬂ_√Z«õÊòGÊ G¸g.zó˚ |Öá"‚™Èn©âå’`cÙcñÙæ˙!ˇ÷‹?¯,¯Ê⁄?8èuı†Mêgùﬂ»˙≠orÑoÆc˝∫bÂˆ¡˚∞Çoáp˚[|ˇ¸/±|ÕÈ[‡+˛eˇKÄˆoæØöÙù’É®öË¸A¬ÉUCi©¨´¡ø¯ÆjÚ∑’ã¸´æ„m˙æ~ë‘ãˆø©ZÄÍAÑ6|’˘£å2 (£å2 (£å2 (£å2 (£å2 (£‹$ˇÀq•—ëÔxKK;t‰kic*w%OÛIWæÕ¸”6.¯ºïØÑ„ßèëÒ˘B˛èíü/—ëoîIlîGdpµ*ˇ‚’™…r’5õX;n!3hÂÛ	2-m“ykÇÂ˘ ±—y	nÇéZ9ƒ~⁄%%óöü“âÃ˘ßJ~3Zô„í[KÉîKµ‡yf∑+&É´Uª≠j™ÊÇ,neç\B¸Œn’‘≥íÕrŸi´¿AñÀ")#“hGÖç~"æ@∂À:≈ø#´ú,q©˘V:Q¸tLØ…†ï˘i£üµ"qHNÊæ≤A+Æ™öÒ{π¥Z5È\œ*ﬁæ9ªp÷W≥Ë≥Kèg.-XÛ„√i"‚3Éˆy˝Iº9◊61Ë∞˛ÌÖKÁáS)4:¨«3!‚≥◊÷Ooﬂ_ÿ‘-≥˛∆Â”©±FóµÆ:È¥™©z¿M¡Õ"Lí8ôÑwp±Ó¨ØN"õÁ”ô‡b-
n:ùà‰ÌôE`„?%oﬂº∑N¥R‡oçsÈt2I4⁄VÈ$ùLDÚÊÃ:t&˚ß¯Ï=WÊm%√oÏÒt6Ybçôµ™:Ì∞Ü™«\â¡Õ"M"úåœ__tXπel”|2\lﬂ:±3ﬂ¸∑Ø-⁄oe„ˇ¡.åìÌ∑*;Ì¯√»√D£˝V:ô”o.çC˚≠ÚË_£K√ïª
á3Âìº—XTu¯◊Ë“p’ÙÄã´Uu¢q≥(√¨ì¯\6)õxV√ÉÂ∏Û¬°ô§bíº}m—~+ˇS|˙˙“‰ †˝V˛s7M≈7±F˚≠Ù¡wì‰4∫–÷ˇ?∫4nïu™¿[ç≈gu—ˇ]öœvö>√’™Zh‹∆*§õDÁ¯lS.∂∏,c}d'i¢—y+<k¸ˆµ≈Ç5—Òiti“Ã†√Í0∑Ãä%÷	ì”»¬°»#]öœv⁄QÆÒJ¿OOì∑]÷∫Í´U'SfÂ‚çÚ∑Ê‡ﬂ∏Cf˝°ÀöFÔº¬˙Û[SqøÖE#ø±	f’Èˇf–6‡üπÜ≥\πÀ˙7˙êY˘√tYüÂº}©Xb≈OxâÈ\L„∑%óö™Æ©˙:UÁ\ıÄY'\∫E?G`˝Ïz82ì+¨¬¡yr∏ƒV\Í£ÿ†£á-òuŒ˜4z¯ì√¯∞±≈B«:>”?òCës©˝©ó8¨ƒ•V7U≥•™sÆz0çıåK∑≥N‚s8≤Xf5È5¨`—eX√}^À:ı¨¬`ÖıÃ°\H+Vç%÷Û¿Zp©[’q’ª≥ævô¡*´c=¨—eM+VáÎ3àÉu¨Åui}=ƒtˇ¨4Ë≤&o<Î$ÂR ˜ ßo∫¨…[_ıx¬•NUXß\∫Öıºæûøw‰∞`çı$≤y>[fMë_e=Äº Ÿ¯"∞J.µ¨G8¨¬a¡öhXßK¨.r‡ml∞`M¥X√ZW’«\∫ùU$gÔ?ªúãÀ¨Èl&5:_0rÎXgkXMÚ>∞Œ∏‘aÕ+:¨êÒ÷ÿÄ»¢√
ô¯™©‡Rß™U;œ_«zƒÔ†˜ÙŸvÍ¶	&†\ïí4oµâΩ:_Q\eçç|X.µ¨iÏ¬|EŒ≈Î,∞¶)ó:?eÊkXgâüØ©‡“¢™0ÓÓ¨±g5´¨ﬁÚÀ¨¬\’√áQ.pÖU+÷úK-Î<±áWXü·$ K∫…OyÄŒO¡†®™
.-U=ò∆∫Û¸¨¯’Ã˛ûOñYÂN˛˝¢—aï:ÿÀ¨±—•IcÉ.Î	Ï4±CóUò√¯4≤Hπÿ∞D9ÿ)ó 
ÃöËŒO1k]ïõ∑®˘™~}ÕπtÎK8DwÖGúuﬂ
´X#ãkb◊±´EóUÍ√‰4≤À¨±ãÕÁ5¨ﬁnZaÂ™⁄€àÀ¨'òO∏™√≠¨s∞n:}aé∏ÿ∞
L"õ:÷√\Z∞„XLí∑Ø-:¨Bã◊ó&è:¨Ø‹ÙHç.´¬$9Â )[÷ƒƒ∆π)r.- 
x#˜4≤Ë∞÷US¡•Â™≥D;‹çıÌÎ{ƒ≈Üı ∞ÊÏr©}+≥Æ˙9ë=í:y}a]l∞`M"«~é–Ë∞æ:a÷∑oŒå√Çu“∞¶\Z ‰kXõ™]?ß≠
ã;≤æø∞]›t‡Y]>ùp©˚VÔøæ93X∞¶<–ﬂº_eÂ¡Î“ÈDra¡ ﬂj’EŒ„"æ∞.Eó5~Ô‡}eÒ∆`¡Í´æÁ™”	ó⁄™Ø´™∞∏ï’2´àœﬁªúãÎÑY/löŒ&\Í≤Úƒ8çœñX„s˝Ÿ∆V¡¨©õL%ñXÖåœﬂ\8,±F6uÀ¨Øëº5XbU'3.≠T=Ä≈]XBZ≤á˝˙jî9óo•¬Gvñ„Ms≈$Æ,Xr ä\u™&Øï˛iÆåÎ…±.£Ï2k\˝T‹yÆ©*
.u™Ê°Uw`µqÅô≈2k¶•ã∂FÃ*\:Æ∞ñ\96∏¬ÍÆ∞∆ETb)8Ë2≠ÃR—≥˙üäàK]VÎ´v{†Æ .∑≈(£å2 (£å2 (£å2 (£å2 (£å2 (£å2 (£å2 (£å2 (£å2 (£å“9‰tEbNïÃ±ˆæFW,ÏæL8]ëD£áõÔ{âlïvSûsÍ≤∆Dwc]öh∞|èØ9.Ï.≥p∫k ¨Yö˚ØÍoˆŸÓ2´‚¥ÜıÄ”Z÷ƒ`k&{d>€]f˝_ÌùΩn‹8«GP¡&0€È5÷»zïºAúŒ.G.T®Ã‚GπXlô7HFpnGpv2‘~ŸÜS‹·
%ﬁˇä\~HZ˝Dj8‘~9ˇÎ
ñSAOsfÑ«Jp4D¿xò6eà¨Õò5ÜÁXsœ≤ZÜgÏ∞Mt[Jx∆¨©C—à2MX›?CéÔ…URñøm(GÜ®ú!‚,H®∂∆C$ÆîxlãÜ‹˙oÔ4?3Y5◊XçÉ‹é	K-ıò˜"\√CVYK§„!û°[ vÏÖ]K“äáYiïb!€•Ò ˝6≥ÿ®*Üã;ñA¨|⁄Ê≠àÊx_≠j®î A©=8Q K3(´Ù≠¥ëf•?:ë—b¬˜¸zë≈FùXS∫0ûx∏$kolûÙ√ı;Ê}µä¯æ
°
m0µ-–Ω ¸°vx(Èæ•û∫Ü`^¨ñ‚Q*+ï je«j¯¬x∏‚KŒÃgì'ƒ◊ö+÷+N"kÉ¶ˆâàl∆{˛Heá%uH0SV=∫ü±˛e≤ÑË	Î5%°™b˙Ñïﬁb©¨ÿyÇôıar2*käód«'}∏`^s#Yd’X9∞ñ§Wk∞ï´ˆ·âµ¿ÀŒóx'se-) Í±F€dÂ»⁄J∏≠vøÎ4ú2 ƒ>ú≠2M∆ú„e5_ÕdëUs0˘¢1º	]ê4‡˜MÌ!é6¡ŒG¸∏Î√w3ıõ"ÎbëiÍË#œWºLøöœ;VÕ¡â5Mÿ¶ Z◊N~™m⁄≥zò©?ú–Z¨≤Z„ôïıã›∑´Ê`WÌAY´*¯4‡˜∫ˆ0πó◊{÷‘w‘„¬\Á9}OŸ3¨+ÛÂÊ”£>|d›<b›ÕsÍÔ˚æo€ÔÊß\CÙ'€ÙÄı÷;eç>¢m”ÆA´◊§⁄Ÿ&8Õ_«^»µÍ#"O´ÕÚæÑk»éÒp¨fb}+©Tß1Á‘Ækà¨ïáÈæ€+ça$A›ï[#Õ–ˇwô@Rd÷g÷ﬂêuÉRîäáó¢D4:Î¨≥Œ:Î¨_^? ∏⁄<<
endstream
endobj
109 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
110 0 obj
<</OP false/OPM 1/Type/ExtGState/op false>>
endobj
111 0 obj
<</OP false/OPM 0/op false>>
endobj
133 0 obj
<</A 134 0 R/Border[0 0 0]/Rect[244.413 9.0 286.158 16.0]/Subtype/Link/Type/Annot>>
endobj
134 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
103 0 obj
[135 0 R]
endobj
104 0 obj
<</Length 12100>>stream
1 g
/GS0 gs
0 792 0 0 re
f
0 0 0 0 k
/GS1 gs
60 41.333 492 696.667 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
-0.021 Tc 0.021 Tw 10.5 0 0 10.5 60 730.8196 Tm
[(promotion of most types of hor)-25 (mone therapy by manufac-)]TJ
-0.02499 Tc 0.013 Tw 0 -1.23809 TD
(turers also decreased.)Tj
ET
BT
/T1_1 1 Tf
-0.02299 Tc 0 Tw 6 0 0 6 144.5524 721.1196 Tm
(18)Tj
ET
BT
/T1_0 1 Tf
-0.008 Tc 0.008 Tw 10.5 0 0 10.5 70.5 704.8947 Tm
(Studies have documented substantial reductions in the)Tj
0 Tc 0.002 Tw -1 -1.23095 Td
[(use of HR)60 (T in the US and other countries subsequent to)]TJ
-0.00301 Tc 0.00301 Tw 0 -1.23095 TD
(the publication of the WHI findings.)Tj
ET
BT
/T1_1 1 Tf
-0.002 Tc 0 Tw 6 0 0 6 211.8567 682.3447 Tm
[(7,8,19)-24 (-)-1 (2)-1 (4)]TJ
ET
BT
/T1_0 1 Tf
-0.00301 Tc 0.00301 Tw 10.5 0 0 10.5 237.4737 679.0447 Tm
(These studies)Tj
0 Tc 0.024 Tw -16.90226 -1.23095 Td
[(took a range of approaches to estimate changes in HR)60 (T)]TJ
-0.00301 Tc 0.00301 Tw T*
[(use. Analyses of phar)-25 (maceutical marketing data and na-)]TJ
-0.017 Tc 0.017 Tw T*
(tional patient care surveys highlighted the marked drop in)Tj
-0.02299 Tc 0.02299 Tw T*
(prescribing of oral estrogen and estrogen/progestin combi-)Tj
0 Tc 0.005 Tw T*
(nations that occurred after July 2002, while noting little)Tj
-0.02499 Tc 0.02499 Tw T*
(change in the use of vaginal preparations. The data used in)Tj
-0.019 Tc 0.009 Tw T*
[(t)-10 (h)-10 (e)-10 (s)-10 (e)-10 ( )-10 (analyses were not person-level and did not allow for)]TJ
-0.02499 Tc 0.015 Tw T*
(direct estimates of population use rates.)Tj
ET
BT
/T1_1 1 Tf
-0.024 Tc 0 Tw 6 0 0 6 216.2902 578.9447 Tm
(7,8,19)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 10.5 0 0 10.5 232.9182 575.6447 Tm
(Cross-sectional)Tj
-0.034 Tc 0.024 Tw -16.4684 -1.23094 Td
(surveys in the context of trials or routine medical care docu-)Tj
-0.019 Tc 0.009 Tw T*
(mented utilization at selected points in time but did not al-)Tj
-0.01199 Tc 0.002 Tw 0 -1.23094 TD
(low for longitudinal analysis.)Tj
ET
BT
/T1_1 1 Tf
-0.011 Tc 0 Tw 6 0 0 6 179.2658 540.1697 Tm
(21,22,25)Tj
ET
BT
/T1_0 1 Tf
-0.01199 Tc 0.002 Tw 10.5 0 0 10.5 202.1977 536.8697 Tm
(Person-level drug pur-)Tj
-0.033 Tc 0.02299 Tw -13.54264 -1.23095 Td
[(chasing data of)15.4 (fer the opportunity to quantify purchases and)]TJ
0 -1.23095 TD
(describe users at specific points in time as well as the ability)Tj
-0.035 Tc 0.013 Tw T*
(to track changes in therapeutic regimens over time.)Tj
ET
BT
/T1_1 1 Tf
-0.034 Tc 0 Tw 6 0 0 6 256.7463 501.3947 Tm
(20,23)Tj
ET
BT
/T1_0 1 Tf
0 Tc 10.5 0 0 10.5 70.5 485.1697 Tm
(W)Tj
-0.0018 Tc 0.86201 0 Td
(e)Tj
-0.002 Tc 0.002 Tw 0.69208 0 Td
(examined HR)Tj
-0.00191 Tc 5.44853 0 Td
(T)Tj
-0.002 Tc 0.85905 0 Td
(use among female members of an)Tj
0 Tc 0.26401 Tw -8.86167 -1.23097 Td
[(Israeli HMO from 1998 through 2007 to deter)-25 (mine)]TJ
0.005 Tw T*
[(whether changes in the extent and patter)-25 (ns of use of the)]TJ
-0.004 Tc 0.004 Tw T*
(treatment occurred subsequent to changes in prescribing)Tj
-0.02499 Tc 0.013 Tw T*
(guidelines for this class of medications. )Tj
ET
BT
/T1_2 1 Tf
0 Tw 10.5 0 0 10.5 60 405.5446 Tm
(Methods)Tj
ET
BT
/T1_0 1 Tf
-0.00999 Tc 0.009 Tw 10.5 0 0 10.5 70.5 384.6196 Tm
[(W)80 (e used the phar)-25 (macy purchasing records of Maccabi)]TJ
-0.00301 Tc 0.002 Tw -1 -1.23095 Td
(Healthcare Services to examine use of estrogen replace)Tj
0 Tc 21.95304 0 Td
(-)Tj
-0.011 Tc 0.011 Tw -21.95304 -1.23096 Td
[(ment therapy \(oral, transder)-24 (mal, and vaginal products\) in)]TJ
-0.02499 Tc 0.015 Tw T*
(female members aged 45 years and older)Tj
-0.0251 Tc 15.46544 0 Td
(.)Tj
-0.02499 Tc 0.46484 0 Td
(Maccabi Health)Tj
0 Tc 6.02267 0 Td
(-)Tj
-0.00101 Tc 0.00101 Tw -21.95294 -1.23096 Td
[(care Services is Israel\325)55 (s second-lar)20 (gest HMO, providing)]TJ
-0.02 Tc 0.02 Tw T*
(medical and preventive services to approximately 1.7 mil)Tj
0 Tc 21.95298 0 Td
(-)Tj
-0.00301 Tc 0.00301 Tw -21.95298 -1.23095 Td
(lion members, 25% of the Israeli population. During the)Tj
-0.01801 Tc 0.01801 Tw T*
(study period, the total population of HMO members grew)Tj
0 Tc 0.00999 Tw T*
[(from 1.3 million to 1.7 million, while the number of fe)8 (-)]TJ
-0.02499 Tc 0.007 Tw T*
(male members aged 45 years and older grew from 150,000)Tj
0.013 Tw T*
(to 251,000. )Tj
-0.022 Tc 0.022 Tw 1 -1.2381 Td
[(The patient infor)-25 (mation systems of Maccabi Healthcare)]TJ
-0.02499 Tc 0.006 Tw -1 -1.2381 Td
(Services are fully computerized and capture visits to hospi-)Tj
-0.007 Tc 0.007 Tw 0 -1.23809 TD
(tals, physicians, and other health professionals; prescrip-)Tj
-0.017 Tc 0.017 Tw 0 -1.2381 TD
(tion drug purchases; laboratory testing; and imaging stud-)Tj
-0.009 Tc 0.009 Tw T*
[(ies. A)75 (vailable data regarding prescription drug purchases)]TJ
-0.02499 Tc 0.02499 Tw 0 -1.23809 TD
(include identification numbers for the patient and prescrib)Tj
0 Tc 21.95287 0.00001 Td
(-)Tj
-0.021 Tc 0.021 Tw -21.95287 -1.2381 Td
(ing physician, date and place of purchase, and drug classi)Tj
0 Tc 21.95292 0.00001 Td
(-)Tj
-0.013 Tc 0.01199 Tw -21.95292 -1.2381 Td
[(fication number)55 (. Drug classification numbers identify the)]TJ
-0.02499 Tc 0.02 Tw T*
(drug name, active ingredient\(s\), dosage, route, and number)Tj
-0.01601 Tc 0.01601 Tw 0 -1.2381 TD
[(of units per package. W)80 (e searched the phar)-25 (macy purchas-)]TJ
-0.011 Tc 0.011 Tw T*
(ing database for all purchases of products in the category)Tj
0 Tc 0.13499 Tw 0 -1.23809 TD
[(of hor)-25 (mone replacement therapy)65 (, comprising: \(1\) oral)]TJ
0.02 Tw 0 -1.2381 TD
[(medications, including estrogen-)-75 (only and estrogen/pro-)]TJ
-0.00101 Tc 0.00101 Tw T*
(gestin combinations, \(2\) vaginal preparations, including)Tj
-0.00999 Tc 0.00999 Tw 0 -1.23809 TD
[(estrogen creams and suppositories, \(3\) transder)-25 (mal prod-)]TJ
-0.02299 Tc 0.02299 Tw 0 -1.2381 TD
(ucts, including estrogen patches and gels, and \(4\) tibolone,)Tj
-0.00259 Tc 24.57143 65.09048 Td
(a)Tj
-0.00301 Tc 0.002 Tw 0.69134 0 Td
(synthetic steroid that has been available in Israel since)Tj
-0.02499 Tc 0.02499 Tw -0.69134 -1.23809 Td
[(2003, but is not included in the drug for)-25 (mulary that by law)]TJ
0.013 Tw T*
(must be supplied to HMO members. )Tj
-0.022 Tc 0.022 Tw 1 -1.21905 Td
[(W)80 (e used 3 separate approaches to assess the overall im-)]TJ
-0.005 Tc 0.005 Tw -1 -1.21905 Td
[(pact of changing knowledge regarding HR)60 (T on purchas-)]TJ
0 Tc 0.02299 Tw 0 -1.21905 TD
(ing. First, we calculated total annual purchases of these)Tj
-0.022 Tc 0.022 Tw T*
(types of medications by category and used these figures to)Tj
-0.02299 Tc 0.02299 Tw T*
(calculate purchase rates and to examine time trends. In ad-)Tj
0 Tc 0.026 Tw T*
(dition, we studied changes in the frequency with which)Tj
-0.02499 Tc 0.011 Tw T*
[(women commenced therapy)65 (, as well as changes in the type)]TJ
-0.01401 Tc 0.01401 Tw T*
[(of product \(ie, oral, transder)-25 (mal, vaginal\) they used when)]TJ
-0.022 Tc 0.022 Tw T*
[(starting therapy)65 (. A new user was defined as any woman in)]TJ
-0.007 Tc 0.007 Tw T*
[(the tar)20 (get age group who made an HR)60 (T purchase after at)]TJ
0 Tc 0.02699 Tw T*
(least 1 year with no such purchases. The first drug pur-)Tj
-0.024 Tc 0.024 Tw T*
[(chased in the year was used to deter)-25 (mine the type of estro-)]TJ
-0.02499 Tc 0.013 Tw T*
(gen therapy used to start treatment. )Tj
0.005 Tw 1 -1.21905 Td
(As a third indicator of changes in attitude toward the use)Tj
0.00101 Tw -1 -1.21905 Td
[(of estrogen therapy)65 (, we examined the rate at which users of)]TJ
-0.009 Tc 0.009 Tw T*
(oral HR)Tj
-0.00909 Tc 3.07919 0.00001 Td
(T)Tj
-0.009 Tc 0.85178 0 Td
(medication discontinued treatment or switched)Tj
-0.017 Tc 0.01601 Tw -3.93097 -1.21905 Td
(to another type of product. For the purposes of this analy-)Tj
-0.02499 Tc 0.015 Tw T*
(sis, we defined discontinuation as 120 days without an oral)Tj
-0.005 Tc 0.005 Tw 0 -1.21906 TD
(medication purchase, even if the patient later began pur-)Tj
0 Tc 0.03 Tw 0 -1.21905 TD
(chasing again. W)Tj
-0.00011 Tc 6.89314 0 Td
(e)Tj
0 Tc 0.72351 0 Td
(calculated duration of therapy as the)Tj
-0.021 Tc 0.021 Tw -7.61665 -1.21905 Td
(number of days elapsed from the date of the first purchase)Tj
-0.02499 Tc 0.022 Tw T*
(to the date of the last purchase, for any period with a break)Tj
-0.01401 Tc 0.01401 Tw T*
(of less than 120 days between purchases. Switching from)Tj
-0.01199 Tc 0.01199 Tw T*
(oral therapy was defined as a purchase of another type of)Tj
-0.015 Tc 0 Tw T*
(HR)Tj
-0.01511 Tc 1.2989 0 Td
(T)Tj
-0.015 Tc 0.015 Tw 0.84586 0 Td
(within 120 days of the last oral drug purchase. Each)Tj
-0.019 Tc 0.019 Tw -2.14477 -1.21905 Td
(patient entered the analysis of discontinuation and switch-)Tj
T*
(ing only once, regardless of how many times she resumed)Tj
-0.02499 Tc 0.013 Tw T*
[(and discontinued therapy)65 (. )]TJ
0 Tc 0.021 Tw 1 -1.2381 Td
(Analysis of switching and discontinuation of therapy)Tj
-0.00101 Tc 0.00101 Tw -1 -1.23809 Td
(was limited to women who made at least 2 purchases of)Tj
-0.00999 Tc 0.00999 Tw 0 -1.23809 TD
(oral medication during the study period. W)Tj
-0.01041 Tc 16.79185 0.00001 Td
(e)Tj
-0.00999 Tc 0.68346 0 Td
(used autore-)Tj
-0.015 Tc 0.015 Tw -17.47531 -1.2381 Td
(gressive integrated moving average \(ARIMA\) time series)Tj
-0.008 Tc 0.008 Tw T*
[(analysis to assess trends in monthly HR)60 (T purchases over)]TJ
-0.02499 Tc 0.019 Tw T*
[(the period of the study)65 (. ARIMA analysis included an inter-)]TJ
-0.01801 Tc 0.01801 Tw T*
(vention variable to indicate purchases occurring after July)Tj
0 Tc 0.117 Tw T*
(2002, when the WHI findings were widely published.)Tj
-0.005 Tc 0 Tw 0 -1.2381 TD
[(Pearson\325)55 (s )]TJ
ET
BT
/T1_3 1 Tf
0 Tc 10.5 0 0 10.5 360.3714 229.4196 Tm
(c)Tj
ET
BT
/T1_1 1 Tf
6 0 0 6 366.0799 232.7196 Tm
(2)Tj
ET
BT
/T1_0 1 Tf
-0.005 Tc 0.005 Tw 10.5 0 0 10.5 371.674 229.4196 Tm
[(tests were used to evaluate changes in HR)60 (T)]TJ
-0.017 Tc 0.017 Tw -5.11181 -1.23809 Td
(population purchasing rates and in the proportion of users)Tj
-0.011 Tc 0.011 Tw T*
[(commencing therapy with dif)20 (ferent treatment modalities.)]TJ
-0.02499 Tc 0.002 Tw 0 -1.23809 TD
(Life-table analysis was used to assess the impact of the cal)Tj
0 Tc 21.95293 0.00001 Td
(-)Tj
-0.006 Tc 0.006 Tw -21.95293 -1.2381 Td
(endar year in which treatment was started on duration of)Tj
-0.019 Tc 0.019 Tw 0 -1.2381 TD
[(therapy)65 (. Follow-up for purposes of life-table analysis con-)]TJ
-0.007 Tc 0.007 Tw 0 -1.23809 TD
[(tinued through December 31, 2007. W)82.2 (omen who died or)]TJ
0 Tc 0.032 Tw T*
(left the HMO within 120 days of their last purchase, as)Tj
-0.009 Tc 0.009 Tw 0 -1.2381 TD
(well as women whose last purchase was within 120 days)Tj
0 Tc 0.033 Tw 0 -1.23809 TD
(of the last possible follow-up date, were censored from)Tj
0.00999 Tw 0 -1.2381 TD
(analysis as of the date of the last purchase. All analyses)Tj
0.15199 Tw T*
(were conducted using SPSS version 14.0 \(SPSS Inc.,)Tj
0.118 Tw 0 -1.23809 TD
(Chicago, IL\). This project received approval from the)Tj
-0.024 Tc 0.024 Tw 0 -1.2381 TD
(HMO Helsinki Committee for Research Involving Human)Tj
-0.02499 Tc 0 Tw T*
(Subjects.)Tj
ET
0 0 0 0 k
60.5 17.75 378.5 13 re
f
BT
0 0 0 1 k
/T1_1 1 Tf
-0.024 Tc 10 0 0 10 60.5 23.9116 Tm
(252)Tj
ET
BT
/T1_4 1 Tf
0 Tc 5 0 0 5 84.2499 25.4116 Tm
(n)Tj
ET
BT
/T1_5 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 97.431 23.9116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_4 1 Tf
0 Tc 0 Tw 5 0 0 5 230.556 25.4116 Tm
(n)Tj
ET
BT
/T1_5 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 243.737 23.9116 Tm
[(2009 February)55 (, V)110 (olume 43)]TJ
ET
0 0 0 0 k
472.5 17.5 79.5 13 re
f
BT
0 0 0 1 k
/T1_5 1 Tf
0 Tw 10 0 0 10 476.2004 23.6616 Tm
[(www)75.3 (.theannals.com)]TJ
ET
0 0 0 0 k
60 745 234 10 re
f
BT
0 0 0 1 k
/T1_6 1 Tf
0 Tc -0.013 Tw 8 0 0 8 60 749.5293 Tm
[(BG)-250 (Silver)-25 (man and ES Kokia)]TJ
ET
BT
0 g
/GS2 gs
/T1_7 1 Tf
0 Tw 5 0 0 5 285.1575 11 Tm
( at University of Canterbury Library on August 25, 2014)Tj
0 0 1 rg
/GS2 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS2 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
105 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
106 0 obj
<</OP false/OPM 0/op false>>
endobj
135 0 obj
<</A 136 0 R/Border[0 0 0]/Rect[244.413 9.0 286.158 16.0]/Subtype/Link/Type/Annot>>
endobj
136 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
99 0 obj
[137 0 R]
endobj
100 0 obj
<</Length 11370>>stream
1 g
/GS0 gs
0 792 0 0 re
f
0 0 0 0 k
/GS1 gs
60 44.116 492 464.685 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
27.357 0 0 27.357 58.4855 488.6202 Tm
(P)Tj
ET
BT
/T1_1 1 Tf
-0.008 Tc 0.11099 Tw 10.5 0 0 10.5 76.625 501.6202 Tm
(rior to 2002, estrogen replacement)Tj
0.157 Tw 0 -1.23809 TD
(therapy was widely recommended)Tj
-0.033 Tc 0.004 Tw -1.58333 -1.23809 Td
(for the relief of menopausal symptoms, as)Tj
-0.02699 Tc 0.019 Tw T*
(well as for the prevention of osteoporotic)Tj
-0.01199 Tc 0.004 Tw T*
(fractures and heart disease.)Tj
ET
BT
/T1_2 1 Tf
-0.011 Tc 0 Tw 6 0 0 6 170.3076 452.9202 Tm
(1,2)Tj
ET
BT
/T1_1 1 Tf
-0.01199 Tc 10.5 0 0 10.5 180.1393 449.6202 Tm
(Numerous)Tj
-0.02699 Tc 0.019 Tw -11.44184 -1.23809 Td
(observational studies had indicated a car-)Tj
-0.008 Tc 0.082 Tw 0 -1.2381 TD
[(dioprotective ef)20 (fect of postmenopausal)]TJ
-0.02699 Tc 0 Tw 0 -1.23809 TD
(hor)Tj
0.02 Tw 1.27639 0 Td
(mone replacement therapy)Tj
-0.02 Tc 10.24444 0 Td
[(\(HR)60 (T\), al-)]TJ
0 Tc 0.033 Tw -11.52083 -1.2381 Td
(though an increased risk of stroke was)Tj
-0.017 Tc 0.01601 Tw 0 -1.2381 TD
(also observed.)Tj
ET
BT
/T1_2 1 Tf
0.009 Tc 0 Tw 6 0 0 6 117.8154 387.9202 Tm
[(3-)24 (5)]TJ
ET
BT
/T1_1 1 Tf
-0.01601 Tc 0.01601 Tw 10.5 0 0 10.5 128.2904 384.6202 Tm
[(Prior to 2002, HR)60 (T)1 ( )1 (u)1 (s)1 (e)]TJ
-0.02499 Tc 0.024 Tw -6.50385 -1.23809 Td
(in the US was widespread, although esti-)Tj
-0.007 Tc 0.007 Tw 0 -1.23809 TD
(mates of population rates of use varied.)Tj
-0.0051 Tc 0 -1.2381 TD
(A)Tj
-0.005 Tc 0.05701 Tw 1.01925 0 Td
(telephone survey conducted in 1995)Tj
-0.007 Tc 0.002 Tw -1.01925 -1.23809 Td
(estimated that 37.5% of US women be-)Tj
-0.005 Tc 0.013 Tw 0 -1.23809 TD
(tween the ages of 50 and 74 years used)Tj
0 Tw 0 -1.2381 TD
(HR)Tj
-0.08 Tc 1.31886 0 Td
(T.)Tj
ET
BT
/T1_2 1 Tf
0 Tc 6 0 0 6 81.9924 309.9202 Tm
(6)Tj
ET
BT
/T1_1 1 Tf
10.5 0 0 10.5 89.809 306.6202 Tm
(T)Tj
-0.005 Tc 0.217 Tw 0.53577 0 Td
(wo studies extrapolated from)Tj
0.246 Tw -3.37472 -1.23809 Td
(drug purchasing data suggested rates)Tj
-0.03 Tc 0.01801 Tw 0 -1.23809 TD
[(among women aged 50)-107.8 (\32074 years of 33%)]TJ
-0.005 Tc 0.01199 Tw T*
(and 41% in 1995 and 2000, respective-)Tj
0 Tw T*
(ly)Tj
0 Tc 0.70265 0.00001 Td
(.)Tj
ET
BT
/T1_2 1 Tf
-0.004 Tc 6 0 0 6 69.9504 257.9202 Tm
(7,8)Tj
ET
BT
/T1_1 1 Tf
-0.005 Tc 0.005 Tw 10.5 0 0 10.5 79.9857 254.6201 Tm
(Use of HR)Tj
-0.0051 Tc 4.18137 0.00001 Td
(T)Tj
-0.005 Tc 0.85581 0 Td
(among Israeli women)Tj
-0.00101 Tc 0.00101 Tw -6.94058 -1.2381 Td
(during the same time period appears to)Tj
-0.034 Tc 0.024 Tw T*
(have been less prevalent than in the US; a)Tj
-0.01601 Tc 0.006 Tw 0 -1.2381 TD
(1998 telephone survey of Israeli women)Tj
-0.00999 Tc 0.186 Tw T*
[(aged 45)-25 (\32074 years estimated that 17%)]TJ
-0.035 Tc 0.00101 Tw 0 -1.23809 TD
[(were current HR)60 (T users.)]TJ
ET
BT
/T1_2 1 Tf
0 Tc 0 Tw 6 0 0 6 154.1407 192.9202 Tm
(9)Tj
ET
BT
/T1_1 1 Tf
-0.035 Tc 0.00101 Tw 10.5 0 0 10.5 159.1992 189.6202 Tm
[(HR)60 (T use among)]TJ
-0.017 Tc 0.017 Tw -9.44754 -1.2381 Td
[(Israeli women aged 50)-110 (\32074 years attend-)]TJ
-0.00999 Tc 0.00999 Tw 0 -1.2381 TD
(ing family-practice clinics was, not sur-)Tj
-0.02499 Tc 0.013 Tw 0 -1.23809 TD
[(prisingly)65 (, somewhat higher)40 (, at 27%.)]TJ
ET
BT
/T1_2 1 Tf
-0.02299 Tc 0 Tw 6 0 0 6 202.149 153.9202 Tm
(10)Tj
ET
BT
/T1_1 1 Tf
-0.024 Tc 0.024 Tw 10.5 0 0 10.5 70.5 137.6201 Tm
[(The W)80 (omen\325)55 (s Health Initiative \(WHI\))]TJ
-0.009 Tc 0.009 Tw -1 -1.2381 Td
[(findings questioning the safety and ef)20 (f)1 (i)1 (c)1 (a)1 (c)1 (y)1 ( )1 (o)1 (f)1 ( )1 (l)1 (o)1 (n)1 (g)1 (-)1 (t)1 (e)1 (r)-24 (m)]TJ
-0.02499 Tc 0.02499 Tw T*
(estrogen therapy for prevention of chronic conditions were)Tj
-0.004 Tc 0.004 Tw 0 -1.2381 TD
(published in July 2002.)Tj
ET
BT
/T1_2 1 Tf
-0.058 Tc 0 Tw 6 0 0 6 157.1152 101.9202 Tm
(11)Tj
ET
BT
/T1_1 1 Tf
-0.004 Tc 0.004 Tw 10.5 0 0 10.5 165.3588 98.6201 Tm
(In response, the US Preventive)Tj
-0.007 Tc 0.007 Tw -10.03417 -1.23809 Td
[(Services T)71.1 (ask Force and several professional groups and)]TJ
-0.008 Tc 0.008 Tw 24.57143 3.87234 Td
[(health maintenance or)20 (ganizations \(HMOs\) changed their)]TJ
0 Tc 0.047 Tw 0 -1.23809 TD
[(guidelines for the use of HR)60.9 (T)75 (, reaf)20 (fir)-25 (ming its value for)]TJ
-0.02 Tc 0.02 Tw T*
(treatment of menopausal symptoms but deemphasizing its)Tj
-0.022 Tc 0.022 Tw 0 -1.2381 TD
(use for prevention of chronic conditions.)Tj
ET
BT
/T1_2 1 Tf
-0.021 Tc 0 Tw 6 0 0 6 480.5013 90.5797 Tm
[(1)-1 (2)-24 (-16)]TJ
ET
BT
/T1_1 1 Tf
-0.022 Tc 0.022 Tw 10.5 0 0 10.5 496.6095 87.2797 Tm
(It was recom-)Tj
0 Tc 0.062 Tw -17.01042 -1.23809 Td
(mended that symptomatic treatment be provided in the)Tj
-0.01801 Tc 0.01801 Tw T*
[(lowest ef)20 (fective dose and for the shortest time period pos-)]TJ
0 Tc 0 Tw T*
(sible.)Tj
ET
BT
/T1_2 1 Tf
0.002 Tc 6 0 0 6 340.4535 51.5797 Tm
(17)Tj
ET
BT
/T1_1 1 Tf
0 Tc 0.039 Tw 10.5 0 0 10.5 349.4885 48.2797 Tm
[(In parallel with changing attitudes toward HR)60 (T)75 (,)]TJ
ET
0 0 0 0 k
157.5 17.75 394.5 13 re
f
BT
0 0 0 1 k
/T1_3 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 267.483 23.9116 Tm
[(The Annals of Phar)-25 (macotherapy    )]TJ
ET
BT
/T1_4 1 Tf
0 Tc 0 Tw 5 0 0 5 400.608 25.4116 Tm
(n)Tj
ET
BT
/T1_3 1 Tf
-0.02499 Tc 0.013 Tw 10 0 0 10 413.7891 23.9116 Tm
[(2009 February)55 (, V)110 (olume 43    )]TJ
ET
BT
/T1_4 1 Tf
0 Tc 0 Tw 5 0 0 5 524.3189 25.4116 Tm
(n)Tj
ET
BT
/T1_2 1 Tf
-0.024 Tc 10 0 0 10 537.5 23.9116 Tm
(251)Tj
ET
0 0 0 0 k
60 562 492 106.556 re
f
BT
0 0 0 1 k
/T1_5 1 Tf
-0.02499 Tc 0.011 Tw 16.8 0 0 16 60 640.9177 Tm
[(Use of Hormone Replacement Thera)10 (p)35 (y)80 (, 1998\3202007: )]TJ
0 -1.5 TD
[(Sustained Impact of the W)90 (omen\325)79 (s Health Initiativ)20 (e Findings)]TJ
ET
BT
/T1_0 1 Tf
10.5 0 0 10 60 580.9177 Tm
(Barbara G Silverman and Ehud S Kokia)Tj
ET
0 0 0 0 k
60 17.5 79.5 13 re
f
BT
0 0 0 1 k
/T1_3 1 Tf
0 Tw 10 0 0 10 60 23.6616 Tm
[(www)75.2 (.theannals.com)]TJ
ET
0 0 0 0 k
60 715.5309 492 21 re
f
0 0 0 1 K
0.5 w 
60 720.417 m
552 720.417 l
S
BT
0 0 0 1 k
/T1_5 1 Tf
0 Tc 0.011 Tw 13 0 0 13 60 727.6668 Tm
[(W)88 (omen\325)78 (s Health)]TJ
ET
60 60.25 m
294 60.25 l
S
BT
/T1_0 1 Tf
-0.02499 Tc 8.5 0 0 8.5 60 48 Tm
(Author information provided at the end of the text.)Tj
ET
0 0 0 0.14999 k
239 149.46 313 359.3409 re
f
BT
0 0 0 1 k
/T1_6 1 Tf
-0.007 Tc 0 Tw 7 0 0 7 251 486.4172 Tm
(BACKGROUND)Tj
ET
BT
/T1_6 1 Tf
0 Tc 10 0 0 10 301.8243 486.4172 Tm
(:)Tj
ET
BT
/T1_0 1 Tf
-0.005 Tc 0.005 Tw 8.5 0 0 8.5 307.4643 486.4172 Tm
[(T)37 (rials of hormone replacement therapy \(HR)18 (T\) for prevention of)]TJ
0 Tc 0.049 Tw -6.64286 -1.29412 Td
(chronic disease in postmenopausal women have suggested that the risks of\)Tj
-0.01801 Tc 0.01801 Tw 0 -1.29411 TD
(treatment outweigh the benefits. The publication in 2002 of the W)Tj
0 Tw 27.82727 0 Td
(omen\325)Tj
-0.0182 Tc 2.61402 0 Td
(s)Tj
-0.01801 Tc 0.75966 0 Td
(Health)Tj
-0.02499 Tc -31.20096 -1.29413 Td
(Initiative \(WHI\) study sparked a rapid decline in HR)Tj
-0.0251 Tc 21.29108 0.00001 Td
(T)Tj
-0.02499 Tc 0.83835 0 Td
(purchases among American)Tj
-22.12944 -1.29412 Td
(women. )Tj
ET
BT
/T1_6 1 Tf
-0.036 Tc 7 0 0 7 251 428.4172 Tm
(OBJECTIVE)Tj
ET
BT
/T1_6 1 Tf
0 Tc 10 0 0 10 288.4204 428.4172 Tm
(:)Tj
ET
BT
/T1_0 1 Tf
8.5 0 0 8.5 293.8027 428.4172 Tm
(T)Tj
-0.0251 Tc 0.47499 0 Td
(o)Tj
-0.02499 Tc 0.01801 Tw 0.80207 0 Td
[(examine the impact of the WHI findings on patterns of HR)18 (T use in)]TJ
0.011 Tw -6.31267 -1.29412 Td
(Israeli women.)Tj
ET
BT
/T1_6 1 Tf
-0.02 Tc 0 Tw 7 0 0 7 251 403.4172 Tm
(METHODS)Tj
ET
BT
/T1_6 1 Tf
0 Tc 10 0 0 10 285.0153 403.4172 Tm
(:)Tj
ET
BT
/T1_0 1 Tf
-0.01401 Tc 0.01401 Tw 8.5 0 0 8.5 290.5646 403.4172 Tm
[(W)18 (e linked purchases of estrogen preparations from 1998 to 2007 by)]TJ
0 Tc 0.036 Tw -4.65466 -1.29411 Td
(female Israeli health maintenance organization members aged 45 years and\)Tj
-0.015 Tc 0.015 Tw 0 -1.29412 TD
(older to membership data. For each year)Tj
-0.0148 Tc 17.51954 0 Td
(,)Tj
-0.015 Tc 0.54114 0 Td
(we calculated total annual purchases)Tj
-0.02499 Tc 0.009 Tw -18.06068 -1.29412 Td
(and rate of HR)Tj
-0.0251 Tc 6.15992 0 Td
(T)Tj
-0.02499 Tc 0.84763 0 Td
(utilization, characterized new users by age and mode of therapy)Tj
0 Tc 26.71464 0 Td
(,)Tj
-0.02499 Tc 0.011 Tw -33.72218 -1.29413 Td
(and examined rates of switching between modes of therapy)Tj
-0.0253 Tc 24.95467 0 Td
(.)Tj
ET
BT
/T1_6 1 Tf
0 Tc 0 Tw 7 0 0 7 251 345.4172 Tm
[(RESUL)74.3 (TS)]TJ
ET
BT
/T1_6 1 Tf
10 0 0 10 283.1476 345.4172 Tm
(:)Tj
ET
BT
/T1_0 1 Tf
8.5 0 0 8.5 290.6659 345.4172 Tm
(T)Tj
0.215 Tw 0.55591 0 Td
(wenty percent of women aged 45 years and older purchased)Tj
0.166 Tw -5.22249 -1.29412 Td
(estrogen products in 2001, versus 10% in 2007 \(p < 0.001; )Tj
ET
BT
/T1_7 1 Tf
0 Tw 8.5 0 0 8.5 489.7402 334.4172 Tm
(c)Tj
ET
BT
/T1_6 1 Tf
5 0 0 5 494.4053 337.1672 Tm
(2)Tj
ET
BT
/T1_0 1 Tf
0.166 Tw 8.5 0 0 8.5 497.1848 334.4172 Tm
(\). V)Tj
0 Tw 1.64768 0 Td
(aginally)Tj
-0.019 Tc 0.019 Tw -30.6106 -1.29412 Td
(administered products accounted for a rising percentage of purchases, fr\om 5%)Tj
-0.011 Tc 0.011 Tw T*
(in 1999 to 18% in 2007. An increasing percentage of new users aged 55 ye\ars)Tj
-0.02299 Tc 0.02299 Tw T*
(and older started with a vaginal product \(62% in 1999, 82% in 2007\). A\fter 2002,)Tj
-0.02 Tc 0.02 Tw T*
(new users of oral therapy discontinued use more quickly than those who s\tarted)Tj
-0.00301 Tc 0.00301 Tw T*
[(oral therapy before 2002. T)37 (ibolone accounted for an increasing percentage of)]TJ
-0.02499 Tc 0.011 Tw T*
(oral drugs purchased \(12% in 2003, 29% in 2007\). )Tj
ET
BT
/T1_6 1 Tf
0 Tc 0 Tw 7 0 0 7 251 254.4171 Tm
(CONCLUSIONS)Tj
ET
BT
/T1_6 1 Tf
10 0 0 10 302.7154 254.4171 Tm
(:)Tj
ET
BT
/T1_0 1 Tf
0.07899 Tw 8.5 0 0 8.5 309.0773 254.4171 Tm
[(The WHI findings had a rapid and sustained impact on HR)18 (T)]TJ
-0.008 Tc 0.008 Tw -6.83262 -1.29412 Td
(utilization in a large population of Israeli women, including a sharp de\crease in)Tj
0.007 Tw 0 -1.29411 TD
(the rate of use, particularly of oral preparations, as well as reduced d\uration of)Tj
-0.01199 Tc 0.01199 Tw 0 -1.29412 TD
(therapy and increased use of vaginal preparations and tibolone as first \choices)Tj
-0.02499 Tc 0.011 Tw T*
(for treatment. )Tj
ET
BT
/T1_6 1 Tf
-0.036 Tc 0 Tw 7 0 0 7 251 196.4172 Tm
[(KEY)-377.8 (WORDS)]TJ
ET
BT
/T1_6 1 Tf
0 Tc 10 0 0 10 292.8581 196.4172 Tm
(:)Tj
ET
BT
/T1_0 1 Tf
-0.02499 Tc 0.011 Tw 8.5 0 0 8.5 298.1792 196.4172 Tm
(hormone replacement therapy)Tj
-0.0251 Tc 12.6089 0.00001 Td
(,)Tj
-0.02499 Tc 0.51687 0 Td
[(Israel, pharmacoepidemiology)74 (.)]TJ
ET
BT
/T1_8 1 Tf
-0.0251 Tc 0 Tw 8.5 0 1.80673 8.5 251 181.4172 Tm
(Ann)Tj
-0.02499 Tc 1.96763 0 Td
(Pharmacother)Tj
ET
BT
/T1_0 1 Tf
8.5 0 0 8.5 322.581 181.4172 Tm
(2009;43:251-8.)Tj
0.011 Tw -8.42129 -1.76471 Td
(Published Online, 3 Feb 2009, )Tj
ET
BT
/T1_8 1 Tf
0 Tw 8.5 0 1.80673 8.5 361.7747 166.4172 Tm
[(www)55.2 (.theannals.com)]TJ
ET
BT
/T1_0 1 Tf
-0.0251 Tc 8.5 0 0 8.5 433.7303 166.4172 Tm
(,)Tj
-0.02499 Tc 0.011 Tw 0.51686 0 Td
(DOI 10.1345/aph.1L438)Tj
1 g
/T1_9 1 Tf
-0.278 Tc 0 Tw 1 0 0 1 -1000 1792 Tm
( )Tj
ET
BT
0 g
/GS2 gs
/T1_10 1 Tf
0 Tc 5 0 0 5 285.1575 11 Tm
( at University of Canterbury Library on August 25, 2014)Tj
0 0 1 rg
/GS2 gs
-7.94899 0 Td
(aop.sagepub.com)Tj
0 g
/GS2 gs
-8.11398 0 Td
(Downloaded from )Tj
ET

endstream
endobj
49 0 obj
<</BaseFont/EYSPAI+GillSans-Bold/Encoding 46 0 R/FirstChar 32/FontDescriptor 48 0 R/LastChar 213/Subtype/Type1/Type/Font/Widths[278 0 0 0 0 0 0 0 0 0 0 0 271 0 0 0 552 552 552 0 0 0 0 552 552 552 271 0 0 0 0 0 0 0 0 0 0 0 604 0 833 333 0 0 0 0 0 0 0 0 677 604 719 823 0 1167 0 0 0 0 0 0 0 0 0 531 0 500 583 552 302 542 583 271 0 0 271 958 583 594 583 0 448 427 406 583 510 0 0 510 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 500 0 0 0 0 271]>>
endobj
61 0 obj
<</BaseFont/JTWRAJ+Helvetica-Oblique/Encoding 58 0 R/FirstChar 32/FontDescriptor 60 0 R/LastChar 119/Subtype/Type1/Type/Font/Widths[278 0 0 0 0 0 0 0 0 0 0 0 0 0 278 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 667 0 0 0 0 0 0 0 0 0 0 0 0 0 0 667 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 556 0 500 0 556 0 0 556 0 0 0 222 833 556 556 0 0 333 500 278 0 0 722]>>
endobj
65 0 obj
<</BaseFont/QDTYHD+Helvetica-Bold/Encoding 62 0 R/FirstChar 32/FontDescriptor 64 0 R/LastChar 32/Subtype/Type1/Type/Font/Widths[278]>>
endobj
62 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space]/Type/Encoding>>
endobj
64 0 obj
<</Ascent 750/CapHeight 717/Descent -205/Flags 262178/FontBBox[-170 -227 1001 963]/FontFile3 63 0 R/FontName/QDTYHD+Helvetica-Bold/ItalicAngle 0/StemH 0/StemV 140/Type/FontDescriptor/XHeight 737>>
endobj
63 0 obj
<</Length 313/Length1 313/Subtype/Type1C>>stream
  QDTYHD+Helvetica-Bold   @¯ ¯¯¯¯˚>˚w˙}˙W
 ãã
 ãã      ≤   Äçï002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Helsinki is a trademark of Stream Technologies Inc.Helsinki BoldHelsinki      ¸wü¯ßö˜,óíüòã˜£ó¸|ãı
˜ å
_˜™˘
endstream
endobj
58 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 46/period 65/A 80/P 97/a 99/c 101/e 104/h 108/l/m/n/o 114/r/s/t 119/w]/Type/Encoding>>
endobj
60 0 obj
<</Ascent 717/CapHeight 687/Descent -194/Flags 32/FontBBox[-214 -224 1198 931]/FontFile3 59 0 R/FontName/JTWRAJ+Helvetica-Oblique/ItalicAngle 0/StemH 0/StemV 88/Type/FontDescriptor/XHeight 737>>
endobj
59 0 obj
<</Length 1421/Length1 1421/Subtype/Type1C>>stream
  JTWRAJ+Helvetica-Oblique   E¯ ¯¯¯¯˚:˚t˙|˙7
 ã
 o
 ãã      ¸  !¨  l Äà002.001Copyright © 1994-1997 Stream Technologies Inc. All Rights Reserved.
 Helsinki is a trademark of Stream Technologies Inc.Helsinki    " O  1 I B S N D P U F X  M T    < ~ Å √ ˝â¬!s∫ÎHÜñ´%ú†v˜d‚¯:wô˘˘ ˚ò˘a˚˚†˝aÓ÷˜d˜≥“˚d!˜ª˚r˜˜–ç-†v¯^€|wÃﬁ8‰˜è‚Ù¯Ä˜˜˜IŒ˚EZpM_âÙ’8¸üÏ‰˜∞˜¿ÃÂ’≠`.˚÷¸ú†v˜¬ﬁ˜é›·Ì˜ÁÓ˘¯ò˜6€˚˚◊˝aÌ˜¬˜u˜··˜(â6Y_+˚U˜é˜XÈºb;-†v¯_€˜FwÃ„˜è‚¯˜˜˜
KÕ˚HbtLYâ˜ú3˝a„˜±˜¬ Î–™f:˚È-|‘[v˜âÕ˜8‘Ø‰L€˜Ö„6‡µ¯§Àá~ÉäÑvÉî°˜¡Ê@¬˚˚HT˚
Ñ€—ï∞©Ÿ÷∑kSi{wlá˚$yπ$~SQ.0ÕOÌ◊√§«ƒˆQë§t√ûñçî°∫˚%˜HK>Q5Qf´ø¿Ø©ÿî˜òÜä≥ü˚—†v¯PÈ|wÿ›9„˜ﬂ¯PÊç~ÑåáQamB]â„9¸üË„˜ƒ‹√∆Ÿ˜K†v¯_⁄|wÃﬁ8„˜q„˜n„ˆ˘î˜˛˜KŒ%Lp|EJ≈o^¶IGYoNcâˆ’8¸üÓ„˜±Ù¡–ﬂæ´fO˚˛„˜”Ÿ¡…ŒÃ´c:˚Ê˚*{ÿ¯"⁄©È˜†‡7ﬂË¯q˜L7<y]_I1Z“˜˜¬’Áœ±h>ö‡˜}GÃ˚˚)*˚˚?˚8Á ˜"˜€÷˜ô-}◊¯$◊ÆÊ˜ƒÊ¯ù˜ö˜7'˜˚#˚#'˚˚7˚8Ó˚˜$˜$Ó˜˜80˚P=..PŸ˜˜∆ŸËË∆=˚¸Ñ◊¯’ﬂ„˜ï–mezó®˜Áﬂ’7˜&3˚&EA—˚Ï?¨g–úôåë≥-|◊˜@—˜/€≥Ë˜¥‚8ÊÙ¯ò˜}˜V:˜˚%˚1.˚ ˚K˚6Á'˜*¯˜ÿ»˜
ß4J{YeC.W√˜ÜÙ˜∏—˚∏Ïî«≈›Ô∞@;è”†v¯üwõ˘I˘Y¯ü4 ¸.â&¯.)&¸.â'¯.,˜+¸üÂÒ¯)çÙ¸)Ê¸ãı‚Û˜Sı#!¸@†v˘awŒ„˜/˘a3˝a˚*|÷˜2ŸV÷˜$◊´ﬂGﬂ˜y‡D„’¯c˜2‘c± ¶ˆ4°<üyòã±∑µ® ‹±pNê‡˜ ÇF√˚˚=J%I≥a›wŸrﬁv†}ãdW]k@2d©ŸÅ7éTíqùp´\”oÊã˜ãﬁ–ãÛu°¯üö˜)õôü˜°ñ¸}ö◊
„
_˜™˘
endstream
endobj
46 0 obj
<</BaseEncoding/MacRomanEncoding/Differences[32/space 44/comma 48/zero/one/two 55/seven/eight/nine/colon 70/F 72/H/I 82/R/S/T/U 87/W 97/a 99/c/d/e/f/g/h/i 108/l/m/n/o/p 114/r/s/t/u/v 121/y 208/endash 213/quoteright]/Type/Encoding>>
endobj
48 0 obj
<</Ascent 716/CapHeight 682/Descent -221/Flags 262176/FontBBox[-177 -230 1167 929]/FontFile3 47 0 R/FontName/EYSPAI+GillSans-Bold/ItalicAngle 0/StemH 0/StemV 145/Type/FontDescriptor/XHeight 728>>
endobj
47 0 obj
<</Length 2969/Length1 2969/Subtype/Type1C>>stream
  EYSPAI+GillSans-Bold   A¯ ¯¯¯¯˚E˚zè˙5
 ãã
 ãã       Q±  s }ãîCopyright (c) 1990 Adobe Systems Incorporated. All Rights Reserved.Gill Sans is a trademark of The Monotype Corporation Plc.Gill Sans BoldGill Sans  %  6 T F  P G ) S N O 3 Q M B D U 5 I Z     o     4 V J E * 8  W ' H '   A î Ê È0w®ËWôÏE^ŒQs≥ﬂ!rıY¶«]ù÷0Iäπﬁ		–¸˜AÇ˜"¯πw—˜>˜Í˜>¯⁄˘>¸˚8\1)D∆Ì¯˚>¸˚g˜#/˜Z˜O˜.Ÿ˜v¯˚sÇÏ˜ûvæ·∞˜Í˜¯¯H£[`ïQ˚>R6˚+˜yóãHvp~`T\ûü\%Äü“t’˜œ¡Î˜.˚yçãæ´¨èû®…d )Ç·˜◊·∞˜*˜_˜¯í˜#ZG^zQ0Sª›Ü˜ﬂ˜<í˚Í˚˚"&'˚!˚$Ù-˜6Ø‚ã»ﬁ˚‘˜{Àë∞∞ƒ√±eLë¸SÇ·˜«·∞˜/˜f˜/¯¡˜z˜E˚& ˚˚˚9˚1˚%˜,˜+Ò˜1√˜K˚/è&gSGTXÆ˜Û∂º ‘™O1˚†v˜˛Ó˜˜Çw‹˜%Ë˜v¯a®»Æü∏õñäÜ±ÿ˜	Ëéueëo˚	6D˚tI(Õ˚˛˜%˜˛ÕÓ˜K†v˜®˜˜¶wÿ˜>˜Ë˜>˘â˘>˚>˚¶˚Ë˜¶˚>˝>˜>˜®˜Ë˚®˜>˚^†v˜‚˜ÇwÀ˜%∞˜e¯a˚%¸a˜%˜[–‡´≠Ω¿¢§Ås±≥˜a™rñnãS[^+`â˜»†v¯	ÏÇw ˜%˜[˜%˜[˜%º˜d¯a˚%¸a˜%‹˜…µÆ±°±∂∏r@˚•˜%˜ªæ¨≤¶µ¿´fI˚¢˜%˜ºÙ@–"FVnFOÕkU´;npÜÄpºqqzrtH†v¯	„3Ï«˜%˜A˜%ÿ˜a¯a˚%¸a˜%∏˜Ωƒ±¶ûØ¥™pJ˚≠˜%˜π˜+¥CP^uV]¶†v˜©˜˜/˜◊˜>˜K˜C◊˘>˝>˜>˜©ºÁ¶˚˚&‘˜O+˜\vﬂEÆŸØ≤√ã÷ãÒ8È˚ ã˚˚·À¨qXQ]w\1H˚ev˜qÏ˜õv∞È-Úƒ˜%˜[˜'ˆ˜^¯a˚%˝G˜%˜ëw≠∑¥˜ÂÏ˜(Ó˜-Ò˚Yb|ib0ßØ¢î™–≥X35_UDnqî†n¸†v˘>w ˜%˜d˘>˚%˝>˜%˚Ç·˜ºÏ¨˜'˜˜%¯ß˜siÄâÅ|Çî¢˜f<≤˚BHxfO˚
∫πÕ©≈ üi`à˚UO:u˚Q¬T’Ωπô±√fï¢|ª≤ƒù£≥˚t⁄usn~pqv°¶π¥ü·™˚*ÇÚ˜óv™ˆ≥˜/¯c˜sKlÉh8T¡›‹√ø‚Ø∑Äw±˜ ù[Oó\˚,˚'˚!˚$Ù-˜6ººï†≈˚àÇˆ˜úÓŸ˜%¯¯a˚<˜%y˚U˚loÕ˚Z˚ﬁ_Î∏±ì†æÙwdoÑm^q®∏˜R˜<–†v¯¡˜˜ß˜>˘H˘>˝,˚˜ã¸¡˜>¯¡˜ãH†v¯ ı˜hw…˜%˜@˜%˜c˘>˚%˝>˜%˜∫º≠®†≠∏©kF˚õ˜%˜∫˜6æ7R\sVaâ˚ ˚\v˘>wå¯ê¯ë¯a˚,#˚Å*˜Å˚/˜H¸˚˚º˜.¸óvÍ˜Ω˚=ÌïŸ„ÔŒb∫P\hj]fõuÆ}ë[uTnq)†v˘>w˜Z˜+˜Ò˘>˚+˝>˜+)óv˜é˜˜b˜Ω˜&˜.˜,˜Ç˜;˜˜WÀÛ•⁄ãﬂ˜+˚˚)%˚˚˜!˜≠œ˜hPk`_\lµ»«¨∂∏∫®cK)ÇÔ˜jÏ˜QÔª˜,˚˜&˜˜&˚˜,Ï¯z¯ç„IÌ˚&˚8A˚I£b«dÚFkiT<˚Á8˜˜ Â‹˜’i√GÆÏ¬¨ßªÀÏ˚&ÜNtfdcr∞∆≈£Æ≤¥¢kPÚò˚ƒKmb^\l∂ÕÀ©¥∫π©aH˚*†v˜9˜Ö¯î¯é˜Ω¸î˚¯î)ã˜¯A˜˜“˜,¯ç˜˚p˜˜/ ˜	·˜9‘˚JWy\A˚#¿¬»´ªæ≥^VVyYS6Z@F'C3x¯W)Ç˜¯P˜∑˜,˜3˜,¯è˜Ï˜]>˜&˚-˚+˚˚{˚bÿ˚$˜2˜4œ˜-˜\˚,ñ˚"Ä-HMx◊˜˜îÍ“…úB˚)óv¯ø˜À¯W˜∂˜W˜ä˘?ì¸W˚˜ê¸Ç˜B˜˜Bª˜B`˜¯a[dd[[≤dªª≤≤ªªd≤[†˚º[dd[[≤dªª≤≤ªªd≤[]Ç˜¯V˜∂˜C˜@˜C¯™˘∞5Fõ?˚2%=˚
˚â˜Ô¥ã˚chtJ@O¢Ã)˚'hœ∆l˜˜,˜◊˜˜Ç˚ÔnãÚ≠≤°»≈∆z_ÓHÇÏ3„¯	w«˜%˜A˜%x¯˜%¯a˚&∏˚∫^|ci_eh¢Ã˜±˚%˚ª˚ŸSÊ≈∏°¿π¸†v¯awÂ˜4¬˜4˚,˜%Ë˜d¯a˚%¸a˜%0B˘G_gg__Øg∑∑ØØ∑∑gØ_HÇÏ3„˜±Ï˜hwÆ˜'˜Y˜%º¯†˘>˚%˚Öûddïa˚/)˚!˚Á%˜º±ò¨¥|f˜%º˚%˜pmrÄlG`√ﬂÁ∂¿‘•≠|†˚—†v˘>w›˜>˜ê˘>˚>˝>˜>¯ôóv˘Gwäê¯€¯H˜h¸Q‘˜ø˘G˚H˚4¸˚C¯˚˚C¸˚5¯˚H˜¿˝G‘¸†v¯$v˜Ãw∑˜JΩ¯ÌïŸ„ÔŒb∫P\hj]fõuÆ}ë[uTnq˚ óv¯jwç¯é˜kÇ‹˜h¯j˚.(˚í)˜í˚/]†v˜¨˜˜,˜◊˜>¯∂˘>¸j˝>˜>˜¨˜¿˜˚¿˜,˜¿˚ ˚z·˜ˇ a¿ ˇ GaHˇ I·Hˇ õ˝pÏ5·ß˜˚˜1˜˜˜%˜ÚÄ¯¶¯a˚¶˚:c˚RÒ@6—[∆ÇâpÖR~Zj§y™ÇâÙ@%qvYdNøB˜V˜)Íªˆ¢ÑØm©Ò@?ÿ˚D]¿¡˜[››ÚÄ§§úÆ¥¶Ñ°{ßÕÍÄ˚ÌB∫Ø∞ªΩ¨fa[fc]]e±∏Ù@˜\¸lcpK>aûÆ≠µ†œ”¥yjÇî˘>î˚zî˜äó˜Ÿí¸∆îÓ
å
yXO	˜™˘
endstream
endobj
101 0 obj
<</OP true/OPM 1/Type/ExtGState/op true>>
endobj
102 0 obj
<</OP false/OPM 0/op false>>
endobj
137 0 obj
<</A 138 0 R/Border[0 0 0]/Rect[244.413 9.0 286.158 16.0]/Subtype/Link/Type/Annot>>
endobj
138 0 obj
<</S/URI/URI(http://aop.sagepub.com/)>>
endobj
84 0 obj
<</CreationDate(D:20090130163019Z)/Creator(QuarkXPress\(tm\) 6.52)/ModDate(D:20140825201611-07'00')/Producer(QuarkXPress\(tm\) 6.52)/Title(Layout 1)/XPressPrivate(%%DocumentProcessColors: Black\n%%EndComments)>>
endobj
xref
0 139
0000000000 65535 f
0000042030 00000 n
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000095906 00000 n
0000142924 00000 n
0000142411 00000 n
0000141766 00000 n
0000000000 00000 f
0000120263 00000 n
0000119750 00000 n
0000119106 00000 n
0000000000 00000 f
0000105618 00000 n
0000105109 00000 n
0000104480 00000 n
0000000000 00000 f
0000079976 00000 n
0000079463 00000 n
0000078821 00000 n
0000000000 00000 f
0000000000 00000 f
0000000000 00000 f
0000001838 00000 n
0000058184 00000 n
0000058762 00000 n
0000058559 00000 n
0000057538 00000 n
0000031819 00000 n
0000032500 00000 n
0000032295 00000 n
0000015119 00000 n
0000023731 00000 n
0000024164 00000 n
0000023957 00000 n
0000016187 00000 n
0000027763 00000 n
0000028197 00000 n
0000027989 00000 n
0000015801 00000 n
0000022344 00000 n
0000022633 00000 n
0000022430 00000 n
0000016878 00000 n
0000189400 00000 n
0000189860 00000 n
0000189648 00000 n
0000185744 00000 n
0000064109 00000 n
0000064599 00000 n
0000064386 00000 n
0000057104 00000 n
0000022888 00000 n
0000023182 00000 n
0000022982 00000 n
0000016599 00000 n
0000187532 00000 n
0000187900 00000 n
0000187689 00000 n
0000186332 00000 n
0000186842 00000 n
0000187142 00000 n
0000186929 00000 n
0000186691 00000 n
0000017701 00000 n
0000018113 00000 n
0000017898 00000 n
0000017032 00000 n
0000096451 00000 n
0000095963 00000 n
0000001942 00000 n
0000069317 00000 n
0000069638 00000 n
0000069923 00000 n
0000070254 00000 n
0000070574 00000 n
0000070894 00000 n
0000001882 00000 n
0000002044 00000 n
0000002118 00000 n
0000002399 00000 n
0000000016 00000 n
0000193171 00000 n
0000000097 00000 n
0000042329 00000 n
0000042354 00000 n
0000069059 00000 n
0000069117 00000 n
0000017612 00000 n
0000002668 00000 n
0000002693 00000 n
0000042071 00000 n
0000042129 00000 n
0000042174 00000 n
0000042273 00000 n
0000069162 00000 n
0000069261 00000 n
0000174295 00000 n
0000174321 00000 n
0000192908 00000 n
0000192967 00000 n
0000161852 00000 n
0000161879 00000 n
0000174032 00000 n
0000174091 00000 n
0000134450 00000 n
0000134477 00000 n
0000161528 00000 n
0000161587 00000 n
0000161648 00000 n
0000112293 00000 n
0000112320 00000 n
0000134126 00000 n
0000134185 00000 n
0000134246 00000 n
0000096889 00000 n
0000096916 00000 n
0000111969 00000 n
0000112028 00000 n
0000112089 00000 n
0000071226 00000 n
0000071253 00000 n
0000096565 00000 n
0000096624 00000 n
0000096685 00000 n
0000096731 00000 n
0000096832 00000 n
0000112135 00000 n
0000112236 00000 n
0000134292 00000 n
0000134393 00000 n
0000161694 00000 n
0000161795 00000 n
0000174137 00000 n
0000174238 00000 n
0000193013 00000 n
0000193114 00000 n
trailer
<</Size 139/Root 83 0 R/Info 84 0 R/ID[<41826E465C66F8DA921D21131FEE9C78><6ECBDF72D21DB2110A00E90910000000>]>>
startxref
193399
%%EOF
